



# MAPS

MULTIDISCIPLINARY ASSOCIATION FOR PSYCHEDELIC STUDIES

## Investigator's Brochure

SPONSOR	Multidisciplinary Association for Psychedelic Studies (MAPS) 3141 Stevens Creek Blvd #40563 San Jose, CA 95117
PRODUCT	3,4-methylenedioxymethamphetamine (MDMA)
DATA CUT-OFF DATE	01 October 2021
VERSION DATE	18 March 2022
EFFECTIVE DATE	01 April 2022
EDITION	14th Edition
REPLACES	13th Edition (dated 22 March 2021)

## Table of Contents

<b>List of Tables</b> .....	<b>5</b>
<b>List of Appendix Tables</b> .....	<b>7</b>
<b>List of Figures</b> .....	<b>8</b>
<b>List of Abbreviations</b> .....	<b>9</b>
<b>1.0 Summary</b> .....	<b>11</b>
<b>2.0 Introduction</b> .....	<b>13</b>
<b>3.0 Physical, Chemical, and Pharmaceutical Properties and Formulation</b> .....	<b>16</b>
<b>4.0 Nonclinical Studies</b> .....	<b>18</b>
4.1 Nonclinical Pharmacology .....	18
4.1.1 Primary Pharmacodynamics .....	21
4.1.2 Secondary Pharmacodynamics .....	23
4.1.3 Safety Pharmacology .....	24
4.1.3.1 Central Nervous System.....	24
4.1.3.2 Cardiovascular System.....	29
4.1.3.3 Respiratory System .....	29
4.1.3.4 Hepatic System .....	30
4.1.3.5 Renal System .....	30
4.1.4 Pharmacodynamic Drug Interactions .....	31
4.2 Pharmacokinetics and Product Metabolism in Animals .....	31
4.2.1 Absorption.....	32
4.2.2 Distribution .....	32
4.2.3 Metabolism .....	33
4.2.4 Elimination.....	34
4.2.5 Pharmacokinetic Drug Interactions.....	34
4.3 Toxicology .....	35
4.3.1 Single-Dose Toxicology Studies.....	35
4.3.2 Repeat-Dose Toxicology Studies.....	36
4.3.3 Genotoxicity.....	38
4.3.4 Carcinogenicity .....	39
4.3.5 Reproductive and Developmental Toxicity .....	39
4.3.6 Other Toxicity Studies .....	41
4.3.6.1 Immunological Effects.....	41
4.3.6.2 Mechanistic Studies .....	42
4.3.6.3 Abuse Potential .....	43
<b>5.0 Epidemiological and Naturalistic Evidence Summary</b> .....	<b>44</b>
5.1 Serious Reports of Incidents, Mortality, and Morbidity .....	45
5.1.1 Thermoregulatory Disorders .....	48
5.1.2 Cardiac Disorders.....	48
5.1.3 Metabolism and Nutrition Disorders.....	49
5.1.4 Hepatobiliary Disorders .....	50
5.1.5 Blood and Lymphatic System Disorders .....	50
5.1.6 Injuries, Poisonings, and Procedural Complications.....	51
5.1.7 Gastrointestinal Disorders.....	51
5.1.8 Respiratory, Thoracic, and Mediastinal Disorders.....	51
5.1.9 Psychiatric Disorders .....	51
5.1.10 Nervous System Disorders.....	52
5.2 Cognitive Function and Performance .....	53
<b>6.0 Effects in Humans in Clinical Settings</b> .....	<b>55</b>
6.1 History of Use in Clinical Settings .....	55
6.1.1 Phase 1 Studies .....	61

6.1.2 Phase 2 Studies .....	61
6.1.2.1 Study MP-1 .....	62
6.1.2.2 Study MP-8 .....	62
6.1.2.3 Study MP-12 .....	62
6.1.2.4 Study MP16 .....	63
6.1.2.5 Other Phase 2 Studies .....	63
6.1.3 Phase 3 Studies .....	64
6.1.3.1 Study MAPP1 .....	64
6.1.4 Non-PTSD Indication Phase 2 Studies .....	66
6.2 Pharmacology in Humans .....	66
6.2.1 Pharmacokinetics and Product Metabolism in Humans.....	67
6.2.1.1 Absorption.....	68
6.2.1.2 Distribution .....	68
6.2.1.3 Metabolism .....	68
6.2.1.4 Elimination.....	70
6.2.1.5 Pharmacogenomics .....	71
6.2.1.6 Pharmacokinetic Drug Interactions.....	71
6.2.2 Pharmacodynamics .....	73
6.2.2.1 Primary Pharmacodynamics .....	73
6.2.2.2 Secondary Pharmacodynamics .....	74
6.2.3 Physiological Effects .....	75
6.2.3.1 Central Nervous System.....	75
6.2.3.2 Cardiovascular System.....	78
6.2.3.3 Hepatic System and Other Laboratory Values.....	79
6.2.3.4 Renal System .....	80
6.2.3.5 Immune System .....	80
6.2.3.6 Reproductive System .....	81
6.2.3.7 Cognition and Performance .....	81
6.3 Efficacy of MDMA Across Populations.....	82
6.3.1 PTSD.....	82
6.3.2 Social Anxiety in Autistic Adults .....	86
6.3.3 Anxiety Associated with Life-Threatening Illness .....	87
6.3.4 Alcohol Use Disorder .....	87
6.4 Safety of MDMA in Humans.....	87
6.4.1 Adverse Events .....	88
6.4.1.1 Commonly Reported Reactions from Early Phase Studies.....	88
6.4.1.2 Spontaneously Reported Reactions from Early Phase Studies .....	89
6.4.1.3 Adverse Events Summary.....	98
6.4.1.4 Serious Adverse Events of Suicidality.....	110
6.4.1.5 Serious Adverse Reactions.....	112
6.4.2 Suicidal Ideation and Behavior.....	113
6.4.2.1 C-SSRS in PTSD Studies.....	113
6.4.3 Vital Signs.....	119
6.4.3.1 Body Temperature .....	119
6.4.3.2 Cardiovascular System.....	122
6.4.4 Cognition and Performance .....	132
6.4.5 Abuse Potential .....	134
<b>7.0 Summary of Data and Guidance for the Investigator .....</b>	<b>144</b>
7.1 Pharmacology .....	144
7.2 Toxicology .....	145
7.3 Safety in Humans.....	146
7.3.1 Adverse Events .....	146

7.3.2 Suicidal Ideation and Behavior ..... 147  
7.3.3 Immunological Effects ..... 148  
7.3.4 Hepatic Effects and Other Laboratory Values ..... 148  
7.4 Risk Assessment and Mitigation..... 149  
7.4.1 High Level Risks..... 149  
7.4.2 Medium Level Risks ..... 149  
7.4.3 Low Level Risks ..... 152  
7.4.4 Minimal Risks ..... 153  
7.5 Reference Safety Information for Regulatory Reporting..... 154  
**8.0 Conclusions..... 155**  
**Appendix..... 156**  
**References..... 204**

## List of Tables

Table 1: Summary of Completed Nonclinical Toxicology Studies .....	19
Table 2: Pharmacokinetic Constants for Plasma MDMA After Various Routes of Administration to Humans or Animals .....	34
Table 3: Summary of Published Morbidity and Mortality Reports .....	46
Table 4: Summary of Completed Sponsor Supported Trials with MDMA <sup>A</sup> .....	57
Table 5: Summary of Ongoing and Planned Sponsor Supported Trials with MDMA .....	59
Table 6: Demographics of Participants in MAPP1 Study of MDMA-Assisted Therapy .....	65
Table 7: MAPP1 Exposure Table .....	66
Table 8: List of All Abnormal Clinically Significant Changes in Laboratory Values in Two Participants from MP-2.....	79
Table 9: Average ALT Values at Baseline and 2-Month Follow-up After Two Dosing Sessions in Participants from MP-1.....	80
Table 10: Relative Incidence of Spontaneously Reported Reactions at Any Severity During Dosing Sessions in Sponsor-Supported Phase 2 PTSD Studies of MDMA-Assisted Therapy MP-1, MP-2, MP-4, MP-9, MP-8, MP-12 (N=105) .....	90
Table 11: Relative Incidence of Spontaneously Reported Reactions During Telephone Contact on Day 1-7 After Dosing Sessions in Sponsor-Supported Phase 2 PTSD Studies of MDMA-Assisted Therapy MP-1, MP-2, MP-4, MP-8, MP-9, MP-12 .....	92
Table 12: Adverse Events by Body System Organ Class (MedDRA 17.1) At Any Severity among Participants with PTSD in Sponsor-Supported Phase 2 Studies of MDMA-Assisted Therapy .....	99
Table 13: Severe Adverse Events by Body System Organ Class (MedDRA 17.1) among Participants with PTSD in Sponsor-Supported Phase 2 Studies of MDMA-Assisted Therapy .....	105
Table 14: MAPP1 Treatment-emergent Adverse Events Related to MDMA <sup>A</sup> .....	107
Table 15: Treatment-emergent Adverse Events with a Prevalence of 5% or Greater by Body System Organ Class (MedDRA 17.1) among Participants with PTSD in MAPP1 Study of MDMA-Assisted Therapy .....	108
Table 16: Serious Adverse Reactions in Sponsor-Supported Studies of MDMA-Assisted Therapy Across Indications.....	112
Table 17: C-SSRS Suicidal Ideation and Serious Ideation Reported During Screening, Dosing Sessions Including Integrative Sessions, and Post-treatment for PTSD Studies MP-4, MP-8, MP-9, MP-12, MP16, MP17 and MPVA-1 <sup>A</sup> .....	115
Table 18: MAPP1 Suicidal Ideation and Behavior Measured by C-SSRS .....	117
Table 19: Pre-Drug, Peak, and Final Body Temperature (°C) During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored Studies of PTSD (MP-1, MP-2, MP-4, MP-8, MP-12).....	120
Table 20: Predose, Interim, and Endpoint Body Temperature (°C) Across Dosing Sessions in MAPP1.....	121
Table 21: Pre-drug, Peak, and Final Systolic Blood Pressure During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored Studies of PTSD (MP-1, MP-2, MP-4, MP-8, MP-12).....	123
Table 22: Pre-drug, Peak, and Final Systolic Blood Pressure During Dosing Sessions in Controlled Hypertension Participants in MAPS-Sponsored PTSD Study MP-8.....	124
Table 23: Predose, Interim, and Endpoint Systolic Blood Pressure Across Dosing Sessions in MAPP1.....	125
Table 24: Pre-drug, Peak, and Final Diastolic Blood Pressure During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored Studies of PTSD (MP-1, MP-2, MP-4, MP-8, MP-9, MP-12).....	126

Table 25: Pre-drug, Peak, and Final Diastolic Blood Pressure During Dosing Sessions in Controlled Hypertension Participants in MAPS-Sponsored PTSD Study MP-8..... 126

Table 26: Predose, Interim, and Endpoint Diastolic Blood Pressure Across Dosing Sessions in MAPP1..... 127

Table 27: Pre-Initial Dose, Post-Initial Dose / Pre-Supplemental Dose, and Final Blood Pressure in MDMA Sessions by Dose and Age Bracket in MAPP1 ..... 128

Table 28: Pre-drug, Peak, and Final Heart Rate During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored Studies of PTSD (MP-1, MP-2, MP-4, MP-8, MP-9, MP-12) ..... 130

Table 29: Predose, Interim, and Endpoint Heart Rate (Beats Per Minute) Across Dosing Sessions in MAPP1 ..... 131

Table 30: Neurocognitive Function – RBANS Mean Total Scores at Baseline, Primary Endpoint, End of Stage 1, and End of Stage 2 for MP-1, MP-4, and MP-12..... 133

Table 31: Neurocognitive Function – PASAT Trial 1 and Trial 2 Mean Raw Total Scores at Baseline, Primary Endpoint, End of Stage 1, and End of Stage 2 for MP-1, MP-4, and MP-12 ..... 133

Table 32: Summary of Ecstasy Use History and Subjective Effects of MDMA Among Healthy Volunteers in Controlled Studies Conducted Without Sponsor Support ..... 135

Table 33: Summary of Selected Effects in Controlled Clinical Studies Comparing MDMA and Stimulants Among Healthy Volunteers Conducted Without Sponsor Support ..... 139

Table 34: Pre-Study Ecstasy Use Compared to Ecstasy Use Based on Long-term Follow-up Questionnaire After All Participants Received Two to Three Blinded or Open-label Active Dose MDMA-Assisted Therapy for Treatment of PTSD ..... 142

Table 35: Serious Adverse Reactions for the IMP Considered Expected for Safety Reporting Purposes ..... 155

## List of Appendix Tables

Appendix Table 1: Summary of Investigator-Initiated Trials with MDMA.....	156
Appendix Table 2: Pre-Drug, Peak, and Final Body Temperature (°C) During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored MAA-1.....	172
Appendix Table 3: Pre-Drug, Peak, and Final Body Temperature (°C) During Dosing Sessions with Placebo or Full MDMA Dose in MAPS-Sponsored MDA-1 Study.....	172
Appendix Table 4: Pre-drug, Peak, and Final Systolic Blood Pressure During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored MAA-1 Study.....	172
Appendix Table 5: Pre-drug, Peak, and Final Systolic Blood Pressure During Dosing Sessions with Placebo or Full MDMA Dose in MAPS-Sponsored MDA-1 Study.....	173
Appendix Table 6: Pre-drug, Peak, and Final Diastolic Blood Pressure During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored MAA-1 Study.....	173
Appendix Table 7: Pre-drug, Peak, and Final Diastolic Blood Pressure During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored MDA-1 Study.....	173
Appendix Table 8: Pre-drug, Peak, and Final Heart Rate During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored MAA-1 Study.....	173
Appendix Table 9: Pre-drug, Peak, and Final Heart Rate During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored MDA-1 Study.....	174
Appendix Table 10: Summary of Lifetime and Baseline Positive and Serious Responses on C-SSRS for Study MAA-1.....	174
Appendix Table 11: C-SSRS Positive and Serious Responses During Dosing Sessions and Integrative Session 1, Day 2 Phone Call, and Day 7 Phone Call Post-Drug for Study MAA-1.....	175
Appendix Table 12: C-SSRS Positive Responses at Endpoints After Treatment for Study MAA-1.....	176
Appendix Table 13: Summary of Lifetime and Baseline Positive and Serious Responses on C-SSRS for Study MDA-1.....	176
Appendix Table 14: C-SSRS Positive and Serious Responses During Dosing Sessions and 1-Day Post-Drug for Study MDA-1.....	177
Appendix Table 15: C-SSRS Positive Responses During Telephone Contact Following Dosing Sessions for Study MDA-1.....	178
Appendix Table 16: C-SSRS Positive Responses at Endpoints After Treatment for Study MDA-1.....	178
Appendix Table 17: Prevalence of Spontaneously Reported Reactions During Dosing Sessions and Telephone Contact on Day 1-7 After Dosing Sessions in Sponsor-Supported Phase 2 Study MAA-1.....	179
Appendix Table 18: Prevalence of Spontaneously Reported Reactions During Dosing Sessions in MDA-1.....	185
Appendix Table 19: Relative Incidence of Spontaneously Reported Reactions During Telephone Contact on Day 1-7 After Dosing Sessions in MDA-1.....	186
Appendix Table 20: Adverse Events by MedDRA (V. 17.1) System Organ Class (SOC) among Autistic Adults in Sponsor-Supported Phase 2 Study of MDMA-Assisted Therapy MAA-1.....	190
Appendix Table 21: Adverse Events <sup>A</sup> by MedDRA (v 17.1) System Organ Class (SOC) among Participants with Anxiety Associated with a Life-threatening Illness in Sponsor Supported Phase 2 Study of MDMA-Assisted Therapy MDA-1.....	191
Appendix Table 22: Highlights of MDMA Clinical Pharmacology and Cardiac Safety.....	193
Appendix Table 23: MDMA Salt to Active Moiety Conversion Chart.....	203

## List of Figures

Figure 1: Chemical Structure of MDMA.....	17
Figure 2: Metabolism of MDMA in Humans .....	69
Figure 3: Least Squares Mean Estimates of Change in CAPS-IV from Baseline to Post 3 <sup>rd</sup> Dosing Session .....	83
Figure 4: Least Squares Mean Change in CAPS-IV from Baseline to Long-Term Follow-Up .....	84
Figure 5: Change in Mean CAPS-5 Score from Baseline to Primary Outcome .....	85
Figure 6: Treatment Response and Remission for Treatment Groups .....	86
Figure 7: MAPP1 Participants Reporting Suicidal Ideation on C-SSRS by Visit .....	118



## List of Abbreviations

Ach	Acetylcholine
AE(s)	Adverse Event(s)
ALT	Alanine Aminotransferase
ARF	Acute Renal Failure
AVP	Arginine Vasopressin
BDNF	Brain Derived Neurotrophic Factor
bpm	Beats per minute
°C	Degrees Celsius
CAPS	Clinician Administered PTSD Scale
CBCT	Cognitive-Behavioral Conjoint Therapy
CBF	Cerebral Blood Flow
CBT	Cognitive Behavioral Therapy
CL	Renal Clearance
CL/F	Oral Clearance
cGMP	Current Good Manufacturing Practice
CNS	Central Nervous System
COMT	Catechol-O-methyltransferase
C-SSRS	Columbia Suicide Severity Rating Scale
CSO	Concerned Significant Other
CTproAVP	Stimulating Secretion of Copeptin
DAT	Dopamine Transporter
DEA	Drug Enforcement Administration
DBP	Diastolic Blood Pressure
DMF	Drug Master File
DNA	Deoxyribonucleic Acid
DSM-5	Diagnostic and Statistical Manual of Mental Disorders, 5 <sup>th</sup> Edition
ED	Emergency Department
EKG	Electrocardiogram
EMDR	Eye Movement Desensitization and Reprocessing
ESR	Erythrocyte Sedimentation Rate
FAERS	FDA Adverse Event Reporting System
FDA	Food and Drug Administration
fMRI	Functional Magnetic Resonance Imaging
G-CSF	Granulocyte-colony Stimulating Factor
GD	Gestational Days
HCl	Hydrochloride
HHA	3,4-Dihydroxyamphetamine
HHMA	3,4-Dihydroxymethamphetamine
HMA	4-Hydroxy-3-methoxy-amphetamine
HMMA	4-Hydroxy-3-methoxy-methamphetamine
HPA	Hypothalamus-pituitary-adrenal
HPMC	Hydroxypropylmethylcellulose
HR	Heart Rate
IB	Investigator's Brochure
IL	Interleukin
IMP	Investigational Medicinal Product
IND	Investigational New Drug
LD <sub>50</sub>	Lethal Dose in 50% of Cases
LSAS	Liebowitz Social Anxiety Scale
LSD	d-Lysergic Acid Diethylamide

MAO-A	Monoamine Oxidase A
MAOI	Monoamine Oxidase Inhibitor
MAPS	Multidisciplinary Association for Psychedelic Studies
mCPP	meta-Chlorophenylpiperazine
MDA	3,4-Methylenedioxyamphetamine
MDMA	3,4-Methylenedioxymethamphetamine
mmHG	Millimeters of Mercury
MRI	Magnetic Resonance Imaging
mRNA	Messenger Ribonucleic Acid
MW	Molecular Weight
nAChR	Nicotinic Acetylcholine Receptors
NET	Norepinephrine Transporter
NK	Natural Killer
PASAT	Paced Auditory Serial Addition Task
PET	Positron Emission Tomography
PFC	Prefrontal Cortex
PMA	Paramethoxyamphetamine
PMMA	Paramethoxymethamphetamine
PTSD	Posttraumatic Stress Disorder
RACT	Risk Assessment and Categorization Tool
RBANS	Repeatable Battery for the Assessment of Neuropsychological Status
RSI	Reference Safety Information
SAE(s)	Serious Adverse Event(s)
SAP	Statistical Analysis Plan
SAR	Serious Adverse Reaction
SBP	Systolic Blood Pressure
SERT	Serotonin Transporter
SIADH	Syndrome of Inappropriate Antidiuretic-hormone Secretion
SNRI	Serotonin and Norepinephrine Uptake Inhibitor
SPECT	Single Photon Emission Tomography
SRR	Spontaneous Reported Reaction
SSRI	Selective Serotonin Reuptake Inhibitor
SUD	Subjective Units of Distress
SUSAR	Suspected Unexpected Serious Adverse Event
TEAE	Treatment-emergent Adverse Event
TNF- $\alpha$	Tumor Necrosis Factor-alpha
URTI	Upper Respiratory Tract Infection
VHD	Valvular Heart Disease
VMAT2	Vesicular Monoamine Transporter 2
WBC	White Blood Cell Count
5HT	Serotonin
8-OH-DPAT	8-Hydroxy-2-(di-n-propylamino)tetralin

## 1.0 Summary

The Multidisciplinary Association for Psychedelic Studies (MAPS) is a United States (U.S.)-based non-profit research and educational organization supporting research of the therapeutic potential of 3,4-methylenedioxymethamphetamine (MDMA). MAPS is the sponsor of clinical trials of MDMA-assisted therapy<sup>1</sup> for patients with chronic psychiatric disorders such as Posttraumatic Stress Disorder (PTSD), social anxiety, and anxiety related to terminal illnesses. In 2014, MAPS formed the MAPS Public Benefit Corporation (MAPS PBC), a U.S.-based wholly owned subsidiary of MAPS that has been delegated the responsibility of trial organization for all research studies within the MDMA Clinical Development Program. In 2017, MAPS initiated the establishment of MAPS Europe B.V. in the Netherlands as a second wholly owned subsidiary of MAPS. MAPS Europe B.V. is the designated sponsor for studies in the European Economic Area.

MDMA-assisted therapy is an experimental treatment that combines psychotherapeutic techniques with administration of MDMA under direct observation as a pharmacological adjunct that enhances therapy. Prior to placement on the Drug Enforcement Administration's (DEA) list of Schedule I substances, MDMA was administered to thousands of people in psychotherapeutic practice outside of clinical trials. This Investigator's Brochure (IB) provides information on the pharmacology, safety, and efficacy of MDMA. The information presented in this IB summarizes results from published research studies of MDMA conducted by groups outside of the sponsor, sponsor collected data, and published studies and case reports of people who use Ecstasy, unregulated material represented as containing MDMA. In this document, 'MDMA' will be used to refer to drug of known purity used in a controlled setting and 'Ecstasy' will be used to describe drug-related information gathered from epidemiological settings.

PTSD is a psychiatric disorder that may occur following a traumatic event such as war, disaster, sexual abuse, violence, terrorism, and accidents [1]. Epidemiological studies estimate the lifetime prevalence of PTSD in the U.S. adult population is estimated between 6.1% and 9.2%, while worldwide lifetime prevalence of PTSD ranges from 1.3% to 12.2% [2, 3]. PTSD reduces quality of life and can affect physical health [4, 5]. Evidence based psychotherapies and pharmacotherapies exist, but may be difficult to tolerate [6-8], and are ineffective for many individuals with PTSD, with an estimated 40 to 60% of patients remaining symptomatic and meeting diagnostic criteria even after receiving treatment [8-10]. In addition, available pharmacotherapies used to treat PTSD may have problematic side effects and generally require long-term and/or consistent use to maintain effectiveness [7]. Novel interventions are needed to better treat people with PTSD. MDMA-assisted therapy might also serve as a tolerable treatment that requires only a handful of administrations with lasting treatment effects.

MDMA is a ring-substituted phenethylamine also known as methylenedioxymethamphetamine. MDMA is structurally similar to, but functionally distinct, from amphetamines. MDMA is a chiral molecule and the hydrochloride (HCl) salt of racemic anhydrous MDMA is under development for marketing. The drug product is formulated as a white crystalline powder compounded with excipients and placed in capsules. The HCl salt of MDMA is readily water soluble and hydrophilic. Due to a wide range of responses to identical dosing [11], the sponsor's

---

<sup>1</sup> The treatment modality name "MDMA-assisted psychotherapy" has been updated to "MDMA-assisted therapy" which more appropriately reflects the standard terminology for psychological treatments in the PTSD field, though MDMA-assisted psychotherapy is still accurate and both names may appear in documents as this change is implemented.

human trials use fixed doses equivalent to between 1 and 4 mg/kg MDMA HCl (active doses in studies range from 75 mg to 225 mg). Onset of MDMA effects occurs 30 to 60 minutes after oral administration [12, 13], peak effects appear 75 to 120 minutes post-drug [11, 14-16], and duration of effects lasts from 3 to 6 hours [14, 15, 17], with most effects returning to baseline or near-baseline levels 6 hours after drug administration. The elimination half-life of active doses of MDMA is 7 to 9 hours [18].

The pharmacokinetics of MDMA in humans has been characterized using oral doses of up to 150 mg MDMA HCl, and disposition follows nonlinear pharmacokinetics. Metabolism of MDMA results in N-demethylation to 3,4-methylenedioxyamphetamine (MDA). The parent compound and MDA are further O-demethylated to 3,4-dihydroxymethamphetamine (HHMA) and 3,4-dihydroxyamphetamine (HHA), respectively. Both HHMA and HHA are subsequently O-methylated mainly to 4-hydroxy-3-methoxy-methamphetamine (HMMA) and 4-hydroxy-3-methoxy-amphetamine (HMA). These four metabolites, particularly HMMA and HMA, are known to be excreted in the urine as conjugated glucuronide or sulfate metabolites [18].

MDMA concomitantly promotes release, inhibits reuptake, and extends duration of serotonin, norepinephrine, and dopamine in the synaptic cleft to increase serotonergic, noradrenergic, and dopaminergic neurotransmission. MDMA is a triple monoamine reuptake inhibitor, and similar drugs in this class have been found to exert potent anti-depressant activity with a favorable safety profile in clinical trials [19, 20]. MDMA produces anxiolytic and prosocial effects through release of the monoaminergic neurotransmitters, with the greatest effect on serotonin, followed by norepinephrine and dopamine [21-25]. Subjective effects of MDMA can include increased compassion for self and others, reduced defenses and fear of emotional injury, and making unpleasant memories less disturbing while enhancing communication and capacity for introspection [26-29]. These factors taken together provide the opportunity for a corrective emotional experience in the context of therapy. Many of the therapeutic effects of MDMA-assisted therapy are evident within a short period of treatment, often after the initial session.

Increased feelings of interpersonal closeness, changes in social perception, and reduced anxiety might make MDMA a suitable pharmacological adjunct to enhance therapy for treatment of anxiety disorders, such as PTSD, social anxiety, and anxiety associated with other conditions.

MAPS completed a pivotal Phase 3 clinical trial (MAPP1) in 2020 demonstrating the efficacy and safety of MDMA-assisted therapy for treatment of PTSD [30]. In this randomized, double-blind, placebo-controlled, multi-site study, participants with severe PTSD were treated using divided doses of 80 mg to 180 mg MDMA HCl. Therapy in conjunction with MDMA was statistically superior for PTSD treatment as measured by a decrease in CAPS-5 severity scores from Baseline to 2 months after three blinded dosing sessions in comparison to therapy paired with an inactive placebo. These findings are supported by the sponsor's earlier Phase 2 clinical trials to develop the medical use of MDMA-assisted therapy for patients with chronic PTSD [31]. Large placebo-subtracted effect sizes, indications of efficacy in a Phase 3 trial, and favorable safety outcomes led to the approval of MDMA for the treatment of PTSD as a Breakthrough Therapy Designation (BTD) by the FDA in 2017 for expedited drug development [32]. A long-term follow-up of participants at least 12 months later found a low relapse rate and that benefits outweighed risks associated with treatment [33].

As of October 01, 2021, with 358 individuals exposed to MDMA in the development program across various indications and at least 1,441 participants in MDMA research studies conducted without sponsor support (for a total of at least 1,799 individuals), the sponsor has observed an acceptable risk-benefit ratio for MDMA-assisted therapy. There have been no unexpected Serious Adverse Reactions (SARs) to date and Serious Adverse Events (SAEs) have been rare. As of

March 01, 2022, a single expected SAR (increased ventricular extrasystoles), has been reported in MAPS-sponsored clinical trials. The most prevalent Treatment-emergent Adverse Events (TEAEs) related to MDMA in the pivotal Phase 3 trial MAPP1 were muscle tightness, decreased appetite, nausea, hyperhidrosis, and feeling cold [30]. Safety findings from MAPP1 were comparable to the Adverse Events (AEs) profile reported in the pooled Phase 2 analysis [31]. Most AEs were mild to moderate in severity, lasted no longer than 7 days, and did not require any treatment.

Of note, no increase in suicidality was reported in the MDMA group (see [Section 6.4.1 Adverse Events](#)). Safety findings for other indications were explored in a Phase 2 social anxiety study in autistic adults (N=12, MAA-1) [34, 35], and a Phase 2 anxiety study in participants with a life-threatening illness (N=21, MDA-1). (See [Table 4: Summary of Completed Sponsor Supported Studies with MDMA](#))

Data from MAPS studies and other researchers' published literature support that MDMA produces sympathomimetic effects that include transient, self-limiting increases in heart rate (HR) and blood pressure that were well-tolerated by healthy volunteers [11, 13-15, 36-42]. Similar transient effects were observed in Phase 2 and Phase 3 studies in participants with PTSD [30, 31]. Most people did not experience elevations that exceeded those seen after moderate exercise. Risks posed by elevated blood pressure were addressed by excluding candidates with a history of cardiovascular, cerebrovascular disease, or with pre-existing uncontrolled hypertension, and by regularly monitoring blood pressure and pulse throughout dosing sessions. Common reactions from MDMA reported in the literature and clinical trials were transient and diminished as drug effects waned during the session and over the next one to seven days.

MDMA may reduce responsiveness to changes in water/salt balance after normal and increased water consumption [43]. MDMA is also a mild immunosuppressant [44]. However, the clinical relevance of this observation is not clear as a review of infections, particularly upper respiratory tract infections (URTI) in the time of the COVID-19 pandemic did not reveal an increase in the MDMA groups compared to placebo (see [Section 6.4.1.3 Adverse Events Summary](#)).

PTSD is a serious, chronic, life-threatening condition that afflicts a substantial number of individuals who are more likely to exhibit increased risk of suicide, psychiatric comorbidities, cardiovascular disease, and functional impairment. Those who suffer from PTSD are often insufficiently treated with available therapies. In MAPS' clinical trials to date, MDMA has been well-tolerated and has reduced symptoms of PTSD. In summary, results from clinical studies to date suggest a favorable risk/benefit profile among PTSD participants treated with a two to three-session MDMA-assisted therapy, which also included follow-up non-drug therapy sessions. Therefore, MDMA-assisted therapy might be a novel treatment option with the potential for sustained improvements after only a handful of sessions.

## 2.0 Introduction

MDMA is not a novel compound. It was first synthesized and patented by Merck in 1912 [45] and is currently not covered by a patent. MAPS holds the Drug Master File (DMF) and an Investigational New Drug (IND) file for MDMA with the U.S. Food and Drug Administration (FDA). After MDMA was rediscovered by the chemist Alexander Shulgin in 1976 [46], he and his colleagues provided initial reports of its pharmacology, with 80 mg to 160 mg MDMA HCl required to produce desired subjective effects in humans [47, 48]. MDMA was found to robustly influence human emotional status in a unique way [48] without adversely affecting physiological functions or perception, such as visual perception or cognition [12, 14, 16, 17].

MDMA possesses a complex pharmacological profile that is dominated by its effects as a monoamine releaser and reuptake inhibitor, with additional effects on limiting neurotransmitter production and degradation. Its prominent effects on serotonin differentiate it from amphetamine and methamphetamine, which primarily act on norepinephrine and dopamine pathways [21, 49]. In the Merck Index, MDMA resides in the Entactogen class [50]. Entactogens contain a ring-substituted amphetamine core, belong to the phenethylamine class of psychoactive drugs, and are described as promoting acceptance and compassion for self and others, changing recognition and response to emotions, and increased interpersonal closeness [27, 51-53]. In comparison to anxiolytics, antidepressants and atypical antipsychotics, steady state levels in blood are not required for MDMA to function as a catalyst to therapy.

Shulgin and Nichols were the first to report the effects of MDMA in humans [48]. Reported effects of MDMA include enhanced feelings of closeness to others, well-being, and insightfulness [54-56]. MDMA was used in the 1970s and 1980s to enhance therapy for individuals, couples, and groups to treat various psychological disorders, including moderate depression and anxiety [55, 57-59]. It was also found to be useful in reducing physical pain secondary to certain kinds of cancer [58]. No formal controlled clinical trials of safety and efficacy were conducted at the time [55, 60].

During the early 1980s, increasing numbers of people began using MDMA, sold as 'Ecstasy', outside of therapeutic contexts [61]. In the U.S., an estimated 6.8% of people aged 12 years and above reported using 'Ecstasy' (material represented as containing MDMA) at least once in their lifetimes [62], and an estimated 4% of Europeans aged 15 to 64 reported lifetime Ecstasy use [63]. MDMA was added to the list of Schedule I controlled substances in the U.S. in 1985, defining it as a drug with a high potential for abuse and no accepted medical use [64, 65]. Classification as a Schedule I controlled substance, combined with the early research in animals and recreational users, hampered clinical research for medical uses of MDMA until the 1990s. Adverse reports following use of Ecstasy have raised safety concerns regarding MDMA administration, including hyperthermia [66-68], changes in serotonin transporter (SERT) density, and impaired memory and executive function [69-73]. However uncontrolled studies of Ecstasy use and nonclinical animal studies at doses significantly greater than the therapeutic dose range of MDMA yielded findings that are open to an array of interpretations [74, 75]. The vast majority of publications on Ecstasy users are retrospective reports in polydrug-users who are using drugs of unknown purity and quality [76, 77].

Initial human studies from the 1990s focused on physiological effects of MDMA from a safety perspective, and current investigations have examined the effects on attention, prosocial effects, memory and brain activity, and human drug discrimination. Findings from an initial sponsor-funded study indicated that MDMA-assisted therapy could be conducted safely in people with chronic PTSD who had failed first line treatments [78]. This was demonstrated in a chronic, treatment-resistant PTSD sample in a sponsored placebo-controlled study (MP-1) [79], which demonstrated durable improvement in PTSD severity. In this study, MDMA had no deleterious effects on cognitive function or safety pharmacology laboratory results when given on two occasions, spaced 1 month apart. In addition, placebo-controlled Phase 1 clinical trials confirmed that the active doses of MDMA produce an easily controlled state characterized by euphoria, increased well-being, sociability, self-confidence, extroversion, transient increases in anxiety, and minor alterations in perception [12, 14-16, 80-84].



MAPS has completed ten Phase 2 and one Phase 3 investigations of MDMA-assisted therapy for treatment of PTSD (see [Table 4: Summary of Completed Sponsor Supported Studies with MDMA](#)). The pooled Phase 2 efficacy results in PTSD participants indicate that MDMA-assisted therapy administered in a controlled clinical setting demonstrated that the treatment was safe and efficacious among patients with moderate to severe PTSD [31, 33]. Durable improvements in PTSD symptom severity were found at least 12 months after the last dosing session in 91 participants who received a therapeutically active dose of MDMA in these studies, and 67% did not meet PTSD diagnostic criteria per CAPS-4 assessment [33]. Though the interpretation of long-term results might be limited due to a lack of a blinded control group at this time point, the results suggest significant durable improvement in PTSD symptoms that lasted for at least 12 months for many participants following MDMA-assisted therapy. A report from a pilot study of a combination of MDMA-assisted therapy with a form of conjoint cognitive behavioral therapy geared toward dyads is now complete (MPVA-1) [85]. The findings from two open-label studies (MP16 and MP17), testing the modality of MDMA-assisted therapy in PTSD in two multi-site clinical trials to assess the feasibility of scaling across 14 North American sites demonstrated that the observed treatment response to MDMA-assisted therapy can be scaled and replicated by newly trained therapy teams across multiple sites [86]. These Phase 2 clinical studies in participants with PTSD supported the design of Phase 3 clinical studies for treatment of PTSD with MDMA-assisted therapy [87]. Ongoing Phase 2 studies include three investigations of MDMA-assisted therapy for people with PTSD: one in U.S. veterans (MPVA6), a multi-site study in Europe (MP18), and an open-label safety extension crossover study among Phase 3 participants (MAPPUSX). Long-term follow-up studies examining durability of response to therapy with MDMA or placebo among recent Phase 2 and 3 study participants are also underway (MPLONG and MPELONG). The studies taking place in Europe are intended to prepare sites in Europe for Phase 3 studies. Planned Phase 2 studies include an open-label feasibility and safety study of MDMA-assisted group therapy for the treatment of PTSD in veterans (MPG1) and an open-label Expanded Access Program of MDMA-assisted therapy for treatment-resistant PTSD patients (EAMP1).

The first Phase 3 randomized, double-blind, placebo-controlled MDMA-assisted therapy trial, MAPP1, was completed in October 2020, with 90 participants treated in at least 1 blinded dosing session at fifteen study sites in the U.S., Canada, and Israel (see [Table 4: Summary of Completed Sponsor Supported Studies with MDMA](#)). This trial demonstrated that PTSD symptoms were significantly attenuated by MDMA-assisted therapy and confirmed findings seen in Phase 2 studies. MDMA as an adjunct to supportive therapy was statistically superior for PTSD treatment in CAPS-5 severity scores from Baseline to 2 months after three blinded dosing sessions in comparison to therapy paired with an inactive placebo [30]. This finding was supported by a positive secondary efficacy result in reducing clinician-rated functional impairment, as measured by the Sheehan Disability Scale (SDS). There were no new safety signals found in MAPP1 compared to the previously observed IMP safety profile, including no increase in reported adverse events of special interest in the categories of suicidal ideation or behavior, cardiovascular, or abuse potential in the MDMA group as compared to the therapy with placebo control group. Responder analysis indicated that at the primary endpoint, 88% of participants in the MDMA group had a clinically significant improvement with 67% of participants no longer meeting diagnostic criteria for PTSD, compared to 62% with clinically significant improvement and 32% with loss of diagnosis in the placebo group. There are ongoing Phase 3 studies, including a confirmatory Phase 3 clinical trial (MAPP2), encompassing a sample of participants with moderate to severe PTSD. An additional Phase 3 study is under development in Europe (MAPP3) and will investigate MDMA-assisted therapy for people with at least moderate PTSD (see [Table 5: Summary of Ongoing and Planned Sponsor Supported Studies with MDMA](#)).

Additional Phase 1 MDMA research studies supported by the sponsor include a randomized, placebo-controlled, double-blind study of the effects of MDMA on startle response (MPVA-4) completed in 2020 [88], an ongoing placebo-controlled, double-blind crossover study to assess the psychological effects of MDMA-assisted therapy and to expand the knowledge of therapists training to conduct MDMA-assisted therapy research (MT-1) and a planned open-label companion study (MT2), a planned study of the effects of fasting on MDMA pharmacokinetics (MPKF), and a planned study of MDMA pharmacokinetics in healthy volunteers and people with impaired liver function (MPKH), deferred as a post-marketing commitment (see [Table 5: Summary of Ongoing and Planned Sponsor Supported Studies with MDMA](#)).

Based on clinical experience with PTSD, MAPS is currently exploring additional indications for this treatment that share anxiety as an element or feature of the condition, or that may benefit from a greater ability to confront emotional thoughts and memories. Two studies have been completed exploring the use of MDMA-assisted therapy for social anxiety in autistic adults [89] and MDMA-assisted therapy to address anxiety associated with a life-threatening illness [90]. A planned Phase 2 investigation of the safety and effectiveness of MDMA-assisted therapy for treatment for people with eating disorders is also underway (MED-1).

This IB presents available nonclinical and epidemiological data on MDMA and on data collected from sponsor-initiated studies through October 01, 2021. The addition of these data has confirmed the improved benefit/risk profile of MDMA-assisted therapy over therapy with placebo in a larger sample size and with an adequate and well-controlled study since the last edition of this IB.


### 3.0 Physical, Chemical, and Pharmaceutical Properties and Formulation

MDMA is the short form of the name 3,4-methylenedioxyamphetamine. The International Union of Pure and Applied Chemistry (IUPAC) nomenclature is (RS)-1-(benzo[d][1,3]dioxol-5-yl)-N-methylpropan-2-amine, and the United States Adopted Name (USAN) is midomafetamine hydrochloride.

MDMA is structurally similar to, but functionally distinct from, amphetamines and mescaline. MDMA, also known as 3,4-methylenedioxy-N-methylamphetamine and N-methyl-3,4-methylenedioxyamphetamine, has the chemical formula of C<sub>11</sub>H<sub>15</sub>NO<sub>2</sub>.

MDMA is a chiral molecule, possessing two enantiomers, S(+)-MDMA and R(-)-MDMA, with S(+)-MDMA being more potent than R(-)-MDMA [91, 92]. Research in humans to date and the majority of nonclinical studies have used racemic MDMA, or an admixture containing equal amounts of both enantiomers. The current manufacturing process is using achiral methods and produces racemic MDMA. The sponsor is developing the racemic anhydrous hydrochloride salt of MDMA for marketing. The salt of MDMA is readily water soluble with a pKa of 9.9 [93].



**Figure 1: Chemical Structure of MDMA**

MDMA doses in sponsor-supported early Phase 1 and 2 studies are fixed within the initial therapeutic dose range of 75 mg to 125 mg MDMA HCl, rather than dosing by body weight, based on initial publications information and lack of linear dose response with behavioral effects in Phase 1 and sponsor-supported studies [11]. The clinical dose tested in Phase 3 trials is a divided dose ranging from an initial dose of 80 mg to 120 mg MDMA HCl and a divided dose of 120 mg to 180 mg MDMA HCl, which is equivalent to 1.1 mg/kg to 1.8 mg/kg based on the initial dose for a 70 kg person. As previous sponsored studies and most non-sponsor supported clinical and animal studies list the dosage strength of MDMA as a hydrochloride (HCl) salt, dosage strength is reported throughout the IB as MDMA HCl. Both HCl salt and active moiety values are listed for doses used in clinical studies conducted by the sponsor in [Appendix Table 23: MDMA Salt to Active Moiety Conversion](#).

In November 2018, the sponsor released a clinical batch of Investigational Medicinal Product (IMP) at the dosage strength of 40 mg and 60 mg MDMA HCl, manufactured according to current Good Manufacturing Practices (cGMP), and all subsequent sponsored studies follow this standard. Up to 36 months stability data at 25°C/60%RH and up to 6 months data at 40°C/75%RH are available on the drug substance batch of MDMA HCl used to manufacture this clinical IMP batch. No significant degradation has been detected under any of these conditions.

MDMA (as hydrochloride salt) in the form of off-white crystalline powder is compounded with the excipient mannitol and the lubricant magnesium stearate. The blend is then encapsulated in hydroxypropylmethylcellulose (HPMC) capsules of 40 and 60 mg MDMA HCl. Placebo to match consists of mannitol and magnesium stearate.

A new clinical batch was released in October 2021. Stability data are available on the current cGMP batches and cover up to 6 months under accelerated storage conditions 40°C/75% RH, up to 36 months under long term storage conditions 25°C/60% RH in cold form aluminum blister packs, and 24 months under long term storage conditions 25°C/60% RH in HDPE wide mouth bottles with HDPE SecuRx child resistant closures. The stability protocols for storage under long-term conditions (25°C/60% RH) in cold form aluminum blister packs are complete for the 60 mg MDMA HCl capsules whereas the stability protocols for the 40 mg MDMA HCl capsules in cold form aluminum blister packs are still ongoing and will be running up to 60 months. The stability protocols in HDPE bottles are also ongoing and will be running for up to 36 months. To support evaluation of stability under more extreme temperature deviations during shipping, the stability of the capsules has been studied for 1 week at both -20°C and 50°C/75% RH. No degradation was observed.

The most current stability results for 40 mg and 60 mg MDMA HCl capsules (equivalent to 34 mg and 50 mg of MDMA) after 36 months or 24 months storage at 25°C/60% RH in aluminum blister strips or HDPE bottles respectively show no evidence of change in appearance, assay, or impurities in the capsules. Moisture remains at a low level and there is no trend of dissolution data. All results comply with specifications.

Optimization of the API synthetic route has been conducted to manufacture the Phase 3 cGMP MDMA HCl and a high yielding process that reproducibly provides material within the specifications has been achieved [94]. Following the manufacture of a small-scale batch (5 L) in August 2020 and a commissioning batch in October 2020, three consecutive process validation batches were manufactured with this optimized manufacturing process at the commercial scale (50 L) in November 2020. This cGMP API material was used to manufacture the new cGMP IMP batch of 40 mg and 60 mg MDMA HCl capsules released in October 2021. Based on the available stability data, a shelf life of 36 months and retest date April 2024 has been assigned to this clinical drug product batch with recommended storage at ambient temperature up to 30°C.

MDMA HCl does not require special conditions for storage. Drug product capsules are produced under cGMP. The capsules are packaged in aluminum cold-formed blister strips or in HDPE bottles. The containers are typically placed in a safe at room temperature in a dry, clean, well-ventilated space at temperatures between 15 to 30°C. Short-term deviations between 5 to 30°C are allowed based on available stability data.

As a Schedule I controlled substance, MDMA is stored and handled in compliance with relevant federal or national, state, provincial and local regulations. License holders are responsible for administration and dispensing of the MDMA for approved uses only. They are responsible for ensuring that it is stored securely in accordance with the requirements of the U.S. DEA and other relevant international regulatory authorities.

## 4.0 Nonclinical Studies

### 4.1 Nonclinical Pharmacology

Findings from nonclinical animal and *in vitro* research are presented. Research into the pharmacological, physiological, or psychological effects of MDMA began in the 1950s, when the U.S. Army administered MDMA to guinea pigs, monkeys, mice, rats, and dogs as part of a military research program, possibly intending to develop chemical incapacitants or means of enhancing interrogation [95]. Investigations of the pharmacology, functional effects, and toxicity of MDMA in animals have generally included injections of large and often repeated doses of MDMA that are not human-equivalent doses. Studies of MDMA have been conducted in primates and rodents. Primate species studied include baboon, macaque, rhesus monkey, and squirrel monkey, and rodents include mice and rats. Studies of circadian rhythm have occurred in hamsters [96]. Beginning in the mid-2000s onwards, reports re-examining these effects have questioned the applicability of allometric interspecies scaling models for MDMA [74, 97, 98].

MDMA possesses a complex pharmacological profile that is dominated by its effects as a monoamine releaser and reuptake inhibitor. Its prominent serotonergic effects differentiate it from amphetamine and methamphetamine, which primarily act on dopamine and norepinephrine [21, 49]. MDMA also has a complex profile from a pharmacokinetics perspective and has been demonstrated in multiple animal models to follow nonlinear pharmacokinetics, with increased doses resulting in disproportionate increase in exposure to the parent compound (see [Section 4.2 Pharmacodynamic and Product Metabolism in Animals](#)). Additionally, MDMA exhibits pharmacodynamic drug interactions with other drugs commonly used in psychiatry. In the

following sections, the pharmacology of MDMA is presented based on nonclinical animal studies from both primary literature and sponsor conducted studies.

A full listing of completed nonclinical studies conducted by MAPS is available below ([Table 1](#)).

**Table 1: Summary of Completed Nonclinical Toxicology Studies**

Species	Type of Study	Findings (when available) and Notes	Study Code/ Completion Date
Rat	28-Day General Toxicology	↓ weight gain ↓ ♀ urine pH, blood: BUN, Glu, Creatinine, LDH, (♀,♂) Cl ↑ (♀,♂) WBC, Phos (trend)	EMD-SC-002/1986[99,100]
Dog	28-Day General Toxicology	↓ weight gain 9, 15 mg/kg ↓ testicle size ↑ prostate size Deaths at 15 mg/kg	EMD-SC-001/1986[99,100]
<i>In vitro</i> bacteria	†Genotoxicity Ames test	Negative for mutagenic activity ± metabolic activation	01244001/2020
<i>In vitro</i> CHO cells	†Genotoxicity Chromosome Aberration test	Negative for clastogenic activity <i>in vitro</i> ± metabolic activation	01244004/2020
Rat	†Genotoxicity <i>In vivo</i> Micronucleus Evaluation by Oral Gavage	Negative for clastogenic activity and disruption of mitotic apparatus <i>in vivo</i> at MTD 100 mg/kg/day x 2 days, single housing	2884-016/2020
<i>In vitro</i> HEK-hERG	†hERG Channel Inhibition patch clamp assays per ICH S7A/S7B	Negative: IC <sub>50</sub> of 206 µM (~170x over clinical C <sub>max</sub> ); Hill coefficient=1.1	191028.NB Q/ 2020
Rat	†Pilot Prenatal Developmental Toxicity Study	Well tolerated by time-mated ♀ at 20 mg/kg/day p.o. GD6-17, no effect on ovarian/uterine implantation, mean gravid uterine weights, or fetal body weights. No external malformations or developmental variations in any fetus at GD21 TK: No systemic accumulation with repeated daily doses	2884-005/2020
Rabbit	†Pilot Prenatal Developmental Toxicity Study	Well tolerated by time-mated ♀ at 10 mg/kg/day p.o. GD7-19, deaths at 15 and 20 mg/kg/day. At tolerated dose, no effect on ovarian/uterine implantation, mean gravid uterine weights, or fetal body weights. No external malformations or developmental variations in any fetus at GD29. TK: systemic accumulation with repeated daily doses	2884-006/2020
Rat	†Reproductive Toxicology: Fertility/Early Embryonic Development Study	NOAEL dose 10 mg/kg/day p.o. for maternal, paternal reproductive performance and fertility Mortality at (n=1,♂) D57, (n=1,♀ euthanasia due to tail injury) D15 10 mg/kg/day [not MDMA-related]	2884-003/2020
Rat	†Reproductive Toxicology: Embryo-Fetal Development Study	NOAEL 15 mg/kg/day p.o. for maternal and developmental toxicity at GD17 C <sub>max</sub> 1330 ng/mL, AUC <sub>0-24hr</sub> 10900 hr*ng/mL	2884-004/2020

Rabbit	†Reproductive Toxicology: Embryo-Fetal Development Study	<p>NOAEL 10 mg/kg/day p.o. for maternal and developmental toxicity at GD19 C<sub>max</sub> 603 ng/mL, AUC<sub>0-24hr</sub> 2920 hr*ng/mL</p> <p>(♀) NOAEL 25 mg/kg/week p.o. Day0-22 C<sub>max</sub> 1490 ng/mL, AUC<sub>0-10hr</sub> 10700 hr*ng/mL</p> <p>(♂) NOAEL 20 mg/kg/week p.o. Day0-22 C<sub>max</sub> 1100 ng/mL, AUC<sub>0-10hr</sub> 4590 hr*ng/mL</p> <p>Mortality at 25 mg/kg (n= 2 ♂) on Day 2 &amp; (n= 4 ♂) on Day 16</p> <p>No MDMA-related CNS neurotoxicity observed in expanded neurohistopathology through MTD</p> <p>Myofiber degeneration in skeletal muscle associated with mononuclear cell and neutrophil infiltration</p> <p>↓ (♂) food consumption 25/20 mg/kg Wk 2</p> <p>↓ (♂) weight gain 25/20 mg/kg Wk 1-2</p> <p>↓ (♀) weight gain 25/20 mg/kg Wk 1</p>	2884-007/ 2020
Rat	†Extended Single-dose 28-Day Neurotoxicology Study	<p>Clinical observations were transient, trending toward resolution 24 hrs post minimal subclinical dehydration</p> <p>↑ salivation, red material around nose (♂) ≥ 7.5 mg/kg, (♀) 25 mg/kg,</p> <p>↑ activity, hypersensitivity to touch (♂) 25/20 mg/kg (♀) ≥ 7.5 mg/kg,</p> <p>↑ (♀) hypersensitivity to sound and piloerection 25mg/kg,</p> <p>↑ (♂) aggression 25/20 mg/kg,</p> <p>↑ (♂,♀) stereotypy 25/20 mg/kg</p> <p>↑ (♂) penile protrusion, anogenital swelling +/- sperm plug (n=2) 25 mg/kg D1</p> <p>TK: C<sub>max</sub> approx. dose proportional, AUC<sub>0-10hr</sub> &gt; dose proportional</p> <p>No systemic accumulation or reduction with repeat weekly doses, no sex effect</p> <p>Dose includes HCl correction factor</p>	2884-001/ 2021

Dog	†Extended Single-dose 28-Day Neurotoxicology and In Vivo Cardiovascular Study	<p>(♀, ♂) NOAEL 4 mg/kg/week p.o.            Day 0-22 C<sub>max</sub> 219 ng/mL, AUC<sub>0-8hr</sub> 983 hr*ng/mL            Mortality at 9 mg/kg (n=1 ♀) &amp; 12 mg/kg (n=4: n= 2 ♀, 2 ♂) on Day 1            No MDMA-related neurotoxicity observed in expanded neurohistopathology through MTD            ↓ (♂) body weight 12/9 mg/kg/week Wk 1, ↓ (♀,♂) weight gain through Wk 4 ≥ 2 mg/kg/week            Clinical observations were transient, trending toward resolution 24 hrs post            ↑ (♀,♂) salivation, injected sclera, hypersensitivity to touch, emesis ≥ 2 mg/kg/week            ↑ (♀,♂) activity ≥ 4 mg/kg/week            ↑ (♀,♂) dilated pupils, aggression, hypersensitivity to sound, vocalization, trembling, closed eyelids, stereotypy, audible breathing, coughing, cold skin 12/9 mg/kg/week            ↑ (♀) ocular discharge (n=1) 12 mg/kg D2            TK: C<sub>max</sub> &amp; AUC<sub>0-8hr</sub> appr. dose proportional, no systemic accumulation with repeat weekly doses, no sex effect            ECG: no effect on QT/QTc interval            Dose includes HCl correction factor</p>	2884-002/ 2021
-----	---	--	-------------------

† =Studies conducted by Charles River Labs

#### 4.1.1 Primary Pharmacodynamics

Most effects of MDMA likely arise directly from monoamine reuptake inhibition and release, and indirectly from activation of downstream monoamine receptors and subsequent secretion of neuromodulators oxytocin and arginine vasopressin (AVP). MDMA binds primarily to membrane-bound monoamine transporters, which remove monoaminergic neurotransmitters from the space between neurons, known as the synaptic cleft. MDMA appears to alter the conformation of the transporters, enabling monoamines to diffuse out of the neuron rather than being actively transported into the presynaptic neuron [49, 101-103]. MDMA prevents the reuptake of serotonin, and to a lesser extent, norepinephrine and dopamine, and facilitates release of these neurotransmitters [49, 104-106]. The selectivity of MDMA for specific monoaminergic neurotransmitters is species-dependent and cannot solely be attributed to differences in binding affinity for specific reuptake transporters observed *in vitro*, as described below. In *in vitro* studies, MDMA was also found to compete with monoamines for sites on the vesicular monoamine transporter-2 (VMAT2), suggesting MDMA also promotes active release of monoamines from vesicular stores, in addition to inhibiting reuptake [107-109].

MDMA can inhibit monoamine oxidase A (MAO-A) *in vitro* at high concentrations, which preferentially degrades serotonin, and leads to accumulation of extracellular serotonin in the synaptic cleft [110, 111]. Inhibition of MAO-A may have played a role in fatalities and medical emergencies seen after combining Ecstasy with monoamine oxidase inhibitors (MAOI) in epidemiological settings [112, 113]. Spurred on by prior reports hypothesizing that apparent greater serotonergic toxicity of MDMA in primates, as compared to rodents, could be attributed to greater SERT affinity [114], researchers specifically examined affinity in cells transfected to express human monoamine transporters [106, 115]. These studies found that even though binding affinity of MDMA for the human norepinephrine transporter (NET) exceeded the affinity for SERT and dopamine transporters (DAT), serotonin was preferentially released over norepinephrine and dopamine [106], which may account for primarily serotonergic effects of MDMA. On the other hand, in rodents MDMA affinities for transporters are ordered as SERT>NET>DAT [116]. MDMA does not have as strong an affinity for the DAT as methamphetamine [21].

The ability of MDMA to stimulate release of pre-synaptic serotonin, norepinephrine, and dopamine in multiple brain regions and inhibit reuptake has been well documented [117]. *In vivo* microdialysis and voltammetry results show significant enhancement of serotonin, and to a lesser extent dopamine following MDMA administration, a response attenuated by various transporter inhibitors. MDMA-stimulated serotonin and dopamine release has been measured in the striatum, nucleus accumbens, prefrontal cortex (PFC), and the hippocampus of freely moving rats [118-122], including after administering 0.32 to 3.2 mg/kg MDMA HCl [122]. Female rats exhibited longer duration of nucleus accumbens dopamine, and longer duration of serotonin after 1 and 3.2 mg/kg MDMA HCl. In addition, enhancement of Acetylcholine (ACh) release has been demonstrated in the PFC, striatum, and hippocampus by both a dopaminergic and serotonergic dependent mechanism [123, 124]. The subjective and physiological effects of MDMA are produced by the dynamic interaction of these transmitter systems on numerous brain networks that modulate learning and memory, emotion, reward, attention, sympathetic/parasympathetic activity, and neuroplasticity.

In addition to carrier-mediated monoamine release, MDMA has affinity *in vitro* for specific serotonin, norepinephrine, acetylcholine, and histamine receptors, although the concentrations tested may not translate to standard human MDMA doses [24, 125-127]. An *in vitro* binding study comparing MDMA with several drugs that include cathinone derivatives suggests that contrary to an earlier report of low affinity for 5HT<sub>2A</sub> serotonin receptors, MDMA may have significant effects at the receptor [25]. MDMA likely modulates 5HT<sub>1A</sub> receptors indirectly through serotonin release, though it is possible that MDMA may also act as a partial 5HT<sub>1A</sub> agonist in some brain areas [128]. Findings from other studies suggest that MDMA shares qualities with 5HT<sub>1A</sub> agonists. Early studies in rats suggest that pharmacological activation of 5HT<sub>1A</sub> receptors reduce anxiety and aggression [129, 130], and some drug discrimination studies suggest that the 5HT<sub>1A</sub> agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) at least partially substitutes for MDMA [131-133].

Findings from drug discrimination studies in rats suggest dose-dependent differences in the role of the serotonergic versus the dopaminergic system, with rats trained on 1.5 mg/kg MDMA HCl recognizing Selective Serotonin Reuptake Inhibitors (SSRIs) as similar while rats trained on 3.0 mg/kg recognized amphetamine as similar, and rats trained on both doses recognizing 5HT<sub>1A</sub>-related compounds as similar. Training with 1.5 mg/kg but not 3.0 mg/kg MDMA HCl resulted in considering higher doses of a 5HT<sub>2A</sub> agonist as similar [134]. The same research team determined that dopamine antagonists interfered with the stimulus properties of amphetamine, but not MDMA [135].



#### 4.1.2 Secondary Pharmacodynamics

MDMA has been shown to have a diverse array of secondary pharmacodynamics in animals. Both enantiomers of MDMA enhance Ach release in the PFC [124, 136] and promote changes in GABAergic systems that correlate with sociability [137]. There is some evidence that 5HT<sub>2B</sub> receptors are involved in stimulating increased locomotor activity in mice, reported in studies administering 20 mg/kg [138]. At least some direct or indirect effects of MDMA on serotonin receptors may alter GABA uptake in the ventral tegmental area of rats [139]. An *in vitro* study found that S-MDMA showed signs of competitive interaction with the alpha-4 beta-2 nicotinic receptor which are implicated in learning [140], while R-MDMA did not produce this effect [141].

Infusion of serotonin in the rat brain stimulates secretion of oxytocin into peripheral blood via activation of 5HT<sub>1A</sub>, 5HT<sub>2C</sub>, and 5HT<sub>4</sub> receptor subtypes, as well as AVP secretion via activation of 5HT<sub>2C</sub>, 5HT<sub>4</sub>, and 5HT<sub>7</sub> receptor subtypes [142]. MDMA was shown to increase oxytocin and AVP secretion in rats [143] through a 5HT<sub>1A</sub> mechanism [144, 145]. MDMA also promotes norepinephrine release through reuptake inhibition, which is an additional pathway that can contribute to oxytocin secretion and may control emotion regulation. Both oxytocin and AVP are implicated in the widespread regulation of behavioral aspects of mood and act on different target organs to modulate physiological functions in the periphery [146]. Drug-discrimination and pre-pulse inhibition studies in rats lacking a SERT gene confirm the importance of the serotonin transporter in the interoceptive effects of 5 or 10 mg/kg MDMA HCl, and its enhancement of pre-pulse inhibition [147].

In rats, 10 or 20 mg/kg doses of MDMA HCl elevated serum corticosterone (a rodent cortisol analog) and prolactin [148-150], with elevations lasting up to 4 hours after dosing, and with hormone levels attenuated by a 5HT<sub>2A</sub> serotonin receptor antagonist. Given the dosage used was five to 10.7 times larger than an active dose in humans, it is unclear if this response is analogous to elevated cortisol in humans or whether it reflects a different process. Administering 1 to 3 mg/kg doses found that R(-)-MDMA, but not S(+)-MDMA, significantly increased prolactin levels in rhesus monkey plasma, suggesting that at least the R(-) enantiomer of MDMA can influence endocrine signaling at doses relevant for studies in humans [23]. Fluoxetine attenuated prolactin release after administration of racemic MDMA, and fluoxetine and a 5HT<sub>2A</sub> antagonist attenuated prolactin release after R(-)-MDMA, indicating that prolactin release is associated with serotonin release and indirect action on 5HT<sub>2A</sub> receptors by R(-)-MDMA [151].

MDMA has been shown to have significant effects outside the central nervous system; namely on the cardiovascular, osmoregulatory, and immune systems. MDMA has been shown to cause increases in blood pressure and heart rate in small mammals and primates. These effects are possibly controlled through increased sympathomimetic activity via beta adrenergic receptors [102, 152, 153]. For further information on the cardiac effects in animals see [Section 4.1.3.2 Cardiovascular System](#). MDMA has also been shown to effect water regulation by activation of the AVP system [154], thus explaining the increased thirst seen in humans. For more information on the mechanism of the osmoregulatory effects of MDMA see [Section 4.1.3.5 Renal System](#). Additionally, MDMA has been observed to have some mild immunosuppressant effects in animals. Possible mechanisms include central regulation via the HPA axis and suppression of various circulating cytokines and interleukins. For more information see [Section 4.3.6.1 Immunological Effects](#).

### 4.1.3 Safety Pharmacology

Safety pharmacology studies are defined as those studies that investigate the potential undesirable pharmacodynamic effects of a substance on physiological functions in relation to exposure in the therapeutic range and above. The purpose of the safety pharmacology core battery is to investigate the effects of the test substance on vital functions. Safety pharmacology studies were conducted with the racemic mixture of the parent compound, as the finished product formulations for clinical usage do not substantially alter the pharmacokinetics and/or pharmacodynamics of the active substance.

Intravenous MDMA doses that cause lethality in 50% of the cases, known as the LD<sub>50</sub>, are 97 mg/kg MDMA HCl in mice, 49 mg/kg in rats, 14 to 18 mg/kg in dogs, and 22 mg/kg in monkeys [95]. LD<sub>50</sub> may vary across strains, sexes, and housing conditions [155-157]. For example, LD<sub>50</sub> in mice housed together is 20 mg/kg, which is considerably lower than in isolated animals [158, 159]. Considerable variation across studies in environmental factors, that are often underspecified in published reports, contribute to challenges in extrapolating findings in animal studies to humans.

The majority of these studies employed multiple dosing regimens to account for the shorter drug half-life in animals compared to humans, with doses ranging from 5 mg/kg to 20 mg/kg, via s.c., i.p., p.o., or gavage administration. Frequently, doses are administered at regular intervals of two to four times per day. Other regimens employ these doses once daily for 5 or 7 days. Doses were selected through use of simple dose conversions or allometric scaling, a method of modeling human equivalent doses in other species [160]. Comparison of pharmacokinetic parameters requires consideration of route of administration for dose conversions between species (see [Table 2 Pharmacokinetic Constants for Plasma MDMA After Various Routes of Administration to Humans or Animals](#)).

#### 4.1.3.1 Central Nervous System

Most nonclinical research with MDMA has focused on the CNS effects on serotonergic neurons, while other studies have examined changes in neurohormones or effects on neuroplasticity. It appears that single doses of MDMA HCl (2.5 mg/kg s.c. in squirrel monkeys, 7.5 mg/kg i.p. in rats), approximately 1.5 to 2x of a single human equivalent dose of 100 mg to 150 mg MDMA HCl based on exposure levels, correlates with regional reduction in brain serotonin for 2 weeks or more [97] but does not increase validated markers of neurotoxicity associated with neurodegeneration [98]. Monkeys allowed to self-administer MDMA for an 18-month period had no reductions in brain dopamine, slight reductions in brain serotonin, and no chemical markers of neuronal injury [161]. One report detected a reduction in N-acetylaspartate to creatine ratio, which the authors considered a sign of neuronal injury, although no decreases in brain serotonin were detected after administration of two 1 mg/kg doses of MDMA HCl to rhesus monkeys for 2 days [162].

Studies in rodents and primates suggest that repeated chronic exposure to high doses of MDMA have the potential to reduce regional serotonin, damage serotonin axons and cause neurotoxicity [102, 114, 163-168] and promote apoptosis in the hippocampus after 5 or 10 mg/kg i.p. MDMA HCl given daily for a week, but not after 2.5 mg/kg i.p. [169]. Serotonin syndrome is defined as an excess of serotonin in the CNS causing a suite of specific signs and symptoms that can require intervention [170-172]. Repeated doses of 10 mg/kg administered s.c. and i.p., but not 2 mg/kg, produced signs of serotonin syndrome in rats at supratherapeutic doses, but neither dose reduced total serotonin levels in the brain 2 weeks after drug administration. When observed, serotonin syndrome severity correlates with MDMA plasma concentrations [74]. MDMA appears to alter



regulation of serotonergic signaling in the rat brain without producing damage to serotonin axons, based on transient reductions in forebrain (striatum, hippocampus, and cortex) serotonin and SERT protein levels, in the absence of indicators of CNS neuronal injury/degeneration [75]. MDMA doses that produced substantial, long-lasting reductions in serotonin and other serotonergic markers did not reliably provoke astroglial or microglial changes. This study subsequently found that 4 x 10 mg/kg s.c. MDMA HCl in rats reduced gene expression of VMAT-2, TPH-2, and SERT, in the absence of axon terminal degeneration and the presence of acute reactive synaptogenesis [75]. A long-term chronic dosing study in monkeys that counted rates of different types of neural progenitor cells (NPCs) combined with immunohistochemistry detected signs of reduced neurogenesis, but no signs of apoptosis, in the hippocampi after an intermittent regimen of ascending doses of MDMA HCl from 0.5 to 2.5 mg/kg approximately every 2 weeks for up to 10 months [173].

In a MAPS-sponsored pilot repeated dose 13-day toxicity study (EMD-AT-001), testing increasing doses ranging from 25 mg/kg to 300 mg/kg MDMA HCl, no changes were found in the brain tissue of treated rats compared to controls. The subsequent definitive GLP 28-day repeated dose toxicity study in rats [100] found vacuolar changes in the brainstem adjacent to the trigeminal nuclei in 1 of 10 animals receiving 50 mg/kg/day of MDMA HCl and similar changes in 5 of 10 male rats receiving 100 mg/kg/day [100]. No changes were observed in female animals. The definitive 28-day repeated dose toxicity study in dogs [174] also found possible changes in the CNS of MDMA-treated dogs with doses of 3, 9, and 15 mg/kg/day, however the effect was not dose-dependent, suggesting that they could be background events. These possible changes included white matter changes, neural malacia, and cellular infiltrates of the cerebrum. Neural chromatolysis was observed in the brainstem. The pathogenesis of these changes was unknown. Serotonergic axons can be resistant to silver staining [75], providing an alternate explanation for these inconclusive findings.

A MAPS-sponsored follow-up repeat dose neurotoxicity study administering Sprague-Dawley rats 40 mg/kg or 80 mg/kg of p.o. MDMA HCl twice a day for 4 days showed no morphological brain changes (EMD-SC-003). Neurochemical brain changes related to MDMA administration included a 50% decrease in serotonin (5-HT) and 5-Hydroxyindoleacetic acid (5-HIAA) at both dosing levels. This decrease was apparent both 2 and 4 weeks after exposure. A temporary 34% decrease in homovanillic acid (HVA) was observed in the 80 mg/kg group at 2 weeks after treatment. Four weeks after treatment the HVA levels had returned to normal. These findings indicate that repeated high dose administrations of MDMA 2x per day over 4 days produce long-term reductions up to 4 weeks later in 5-HT and 5-HIAA in the rat while having no apparent effect on the dopaminergic system [174].

These studies were supplemented with MAPS-sponsored definitive GLP follow-up Extended Single-Dose Neurotoxicology studies in the rat and the dog to conclusively study neurotoxicity with modern experimental methods (see [Table 5 Summary of Ongoing and Planned Sponsor Supported Trials with MDMA](#)). In Study 2884-001, Sprague-Dawley rats were administered 0, 2, 7.5, 20/25 mg/kg p.o. MDMA (with correction factor for HCl salt) once weekly for 4 weeks. There was no evidence of CNS lesions at any dose level based on expanded neurohistopathology through the MTD. In Study 2884-002, beagle dogs were administered 0, 2, 4, 9/12 mg/kg p.o. MDMA (with correction factor for HCl salt) once weekly for 4 weeks. This study also found no evidence of CNS lesions at any dose level, based on expanded neurohistopathology through the MTD. An interim necropsy was performed on selected animals at Day 2 to examine single-dose effects and the remaining animals were necropsied at Day 29, 7 days after the last dose, to examine repeat-dose effects. Both studies did not find MDMA-related evidence of CNS neurotoxicity based on routine hematoxylin and eosin staining and expanded neurohistopathology including brain and spinal cord tissue (Luxol fast blue/cresyl violet, Bielschowsky's silver stain,

FluoroJade B, GFAP immunohistochemistry, Iba1 immunohistochemistry), sciatic, tibial, peroneal and sural nerves (Luxol fast blue/periodic acid-Schiff), and tibial and sural nerve cross-sections (Osmicated Spurr resin-embedded toluidine blue). On this basis, the risk of CNS neurotoxicity with the intended clinical dosing regimen appears to be minimal.

### **Motor Activity**

MDMA produces some repetitive behavior in rodents, but not to the same degree as psychostimulants. MDMA has been shown to increase locomotor activity [145]. Rats on MDMA walk around a cage perimeter, interpreted as an indicator of thigmotaxis, which is a sign of anxiety [102]. However, it is notable that a 2007 publication failed to find thigmotaxis in rats given 5 mg/kg MDMA HCl [175]. Increased locomotion in rodents after MDMA may be regulated in part by 5HT<sub>2C</sub> and 5HT<sub>2B</sub> receptors, possibly through indirectly regulating dopamine and serotonin release [138, 176], and at least one study reported that blocking alpha1 adrenergic receptors reduced locomotor activity after 5 mg/kg MDMA HCl [175]. Rhesus monkeys did not exhibit increased locomotor activity after receiving up to 2.4 mg/kg MDMA HCl [177].

### **Behavioral Effects**

Several dose-dependent differences on behavioral tests in rats given MDMA have been reported, including increased anxiety-related behaviors thought to be associated with serotonin syndrome [178], and decreased social anxiety at 5 mg/kg i.p. [145]. Rats given 7.5 mg/kg MDMA HCl, equivalent to four times the dose tested in humans, exhibited increased anxiety in the elevated plus maze [179], while rats given 15 mg/kg MDMA HCl, equivalent to eight times the dose tested in humans, exhibited reduced anxiety on the maze. A study in mice reported that doses from 0.5 to 20 mg/kg MDMA HCl produced anxiogenic responses on the plus maze [180]. A study in rats of the effects of four different doses of MDMA HCl given daily for 1 week, found reduced anxiety with 1.25 and 2.5 mg/kg and increased anxiety with 5 and 10 mg/kg [169]. Lower doses used in these studies are comparable to dose used in human research and nonmedical settings. However, sample sizes used in the study were small. Rats given higher doses also reduced aggressive behavior as well as social investigation. Mice placed in the forced-swim test, an animal model with high predictive validity for antidepressant action, exhibited less immobility after acute doses of 2.5, 5, and 10 mg/kg MDMA HCl, considered an indicator of antidepressant activity [180].

Some researchers have proposed that behavioral tests of anxiety may instead be measuring risk-taking behavior, or impulsivity [181]. The possibility of sex-specific effects cannot be ruled out, given the high prevalence of all-male samples [182, 183]. Preclinical data in animals suggests that the profile of neurotransmitter release observed after MDMA administration may increase the risk of mania in some individuals [184], although mania has not been reported as a side effect of MDMA or Ecstasy in humans. Conflicting findings on anxiogenic and anxiolytic dose-dependent effects of MDMA have been reproduced in clinical trials.

A behavioral study measuring the effect of a single dose of 10 mg/kg MDMA HCl in mice following social defeat detected additive effects on measures of memory, anxiety, and depression, 1 to 10 days after drug administration. Social defeat and MDMA both affected passive avoidance and object recognition memory, and the combination of the two produced greater memory impairment. Social defeat and MDMA also increased immobility in the tail suspension test, and increased motion and increased tendency to remain in the center of the open field [185]. Administering an additional 5 mg/kg MDMA HCl in the open field resulted in slower speed in mice that underwent social defeat and received MDMA. Social defeat lowered body temperature, however, when immediately followed by MDMA, body temperature increased and blood cortisol

decreased, and the authors refer to this as evidence for stress enhancing impaired cognition and depression-like behavior after MDMA. However, they did not employ a test of direct effects of corticosterone, and it is possible that social defeat and MDMA could produce independent effects.

Morley and colleagues observed rat behavior after receiving 5 mg/kg MDMA HCl, noting that this dose correlated with prosocial behavior, such as lying next to each other [145]. Subsequent studies suggest that MDMA increases prosocial behavior in rats by elevating oxytocin in the paraventricular nucleus through 5HT<sub>1A</sub> receptor agonism, with the oxytocin increase arising from the indirect effects of MDMA on 5HT<sub>1A</sub> receptors via serotonin release [144, 186, 187]. There have been no human pharmacological challenge studies combining MDMA with 5HT<sub>1A</sub> agonists, while 5HT<sub>1A</sub> antagonists have negligible effects on subjective or physiological effects of MDMA in humans [84, 188-190]. As a result, it is unclear whether the rat behavior is analogous to human reports of increased feelings of empathy or interpersonal closeness while under the influence of MDMA [17, 191-193]. Pitts and colleagues reported observing greater prosocial effects of MDMA when compared with the psychostimulant methamphetamine in squirrel monkeys [194], confirming rodent findings in primates. The effects were seen with racemic MDMA and with each enantiomer, and they were dampened by administration of a 5HT<sub>2A</sub> receptor antagonist. MDMA appears to have prosocial effects on animals less closely related to humans, including octopuses and zebrafish [195, 196]. The study in octopuses examined the octopus serotonin transporter gene, determining that the receptor that binds MDMA is conserved across species.

### **Coordination**

The effects of MDMA administration on coordination has been tested in primates and rodents. Rhesus monkey coordination was tested in a 4-day repeated dose regimen, receiving a high dose of 10 mg/kg [197]. It was found that MDMA acutely disrupted bimanual motor coordination in rhesus monkeys following MDMA administration. These effects on bimanual motor coordination were apparent for a week following high dose MDMA administration and returned to baseline at the 1 week mark [197].

The effects of MDMA on fine-motor coordination of baboons has been studied in a single arm, single-dose (0.32 to 7.8 mg/kg, spaced 5 days apart) study [198]. Fine-motor incoordination was not observed in the fine-motor task, but rather a dose-dependent delay in initiating the task was observed. It should be noted that 6 months prior to this study, the baboons in question had been used extensively for toxicology studies of both GABA-A allosteric modulators (chronic administration) as well as self-administration of cocaine, ethanol, and five distinct sedative compounds [199]. These confounding factors could potentially reduce the validity of the results as it was undocumented whether they resulted in any chronic effects, such as dopaminergic disruption.

Coordination was also ascertained in mice in a repeated dosing regimen using a repeated dose regimen twice daily, 3 or 30 mg/kg for 4 days [200]. The effects of MDMA administration on coordination in the mouse was measured using the road test. The mice were tested 24 hours and 48 hours post MDMA administration. Unlike the rhesus monkeys, mice showed no apparent disruption of motor coordination following MDMA administration [200].

### **Sensorimotor Reflex Responses**

The effects of 20 mg/kg MDMA HCl on the startle reflex in rats has been tested in a 10-day repeated dosing study [201]. It was observed that MDMA acutely affects the magnitude of the acoustic startle response, while having no long-term effects on the startle response. It was

furthermore found that pre-pulse inhibition (unlearned suppression of the startle response) was profoundly reduced in rats exposed to MDMA, both acutely and long-term [201].

In order to evaluate MDMA's effects on bruxism, specifically jaw-clenching, the effects of MDMA on the jaw-opening reflex was tested in rats, both in a single and repeated dose regimen (20 mg/kg MDMA HCl once or same dose, twice daily for 4 days) [202]. It was found that single-dose administrations of MDMA exerted an inhibitory effect on the jaw-opening reflex. For repeated administrations this effect was amplified and found to be mediated by enhanced noradrenergic inhibitory mechanisms that are responsible for regulating the jaw-opening reflex [202].

### **Body Temperature**

Rodents have generally been used to study the hyperthermic effects of MDMA. Rodents have a much smaller body mass and do not perspire but use their tail to regulate body temperature, which has a large surface to volume ratio, and is perfused with many blood vessels for thermoregulation. Since thermoregulation is different in rodents and humans [203], findings may have limited applicability to humans. MDMA doses that are moderate to high elevate body temperature and disrupt thermoregulation in mice [102], and doses of MDMA HCl in the 1 to 2 mg/kg range only cause a slight increase in body temperature [204]. Rats given doses of 10 mg/kg MDMA HCl (s.c. and i.p.), but not 2 mg/kg, experienced increases in body temperature correlated with levels of the active metabolite MDA [74, 205]. A study of rats receiving subcutaneous injections of 1 and 3 mg/kg MDMA HCl demonstrated minimal effect on brain hyperthermia using thermal couplers installed in the nucleus accumbens, and in another study, in the striatum [206], however ambient temperatures of 29°C and social interaction during group housing had a potentiating effect on malignant hyperthermia at 9 mg/kg (s.c.) [207]. MDMA effects on body temperature are susceptible to changes in ambient temperature in rodents, with high ambient temperature significantly increasing body temperature in mice and rats, and low ambient temperatures reducing it [159, 208, 209]. A study in rats found that age-dependent increase in severity of body temperature elevation after 2x5 mg/kg MDMA HCl, with 20-month old (aged) rats exhibiting significantly higher body temperature than young (40 days old) rats [210]. The aged rats in this study also exhibited more signs of brain and liver toxicity than younger rats. The MDMA-induced impairment in thermoregulation is caused, at least in part, by peripheral vasoconstriction in the tail, an effect mediated by brain neurotransmitter activity [211, 212]. The exploration of the translation of this finding to elderly humans is ongoing.

High doses of MDMA also produce significant elevations in body temperature in primates [97, 213, 214]. At doses closer to those humans ingest [215], monkeys exhibit only slight to moderate elevation in body temperature [177, 216]. In contrast to findings in rodents, primates, including humans, are not susceptible to changes in ambient temperature when given MDMA, exhibiting slight to moderate increases in body temperature regardless of the temperature of the environment [177, 215, 216], though at least one study found that the ambient temperature influenced the effects of 1.5 mg/kg i.v. MDMA HCl on body temperature in monkeys, with lower body temperatures seen after MDMA administered in cool temperatures and higher body temperatures in another group given MDMA at warm temperatures [217]. Findings in rodents do not extrapolate well to primates in this area. Given that the thermoregulatory effects in rodents are highly dose-dependent, most physiological effects in humans seen after MDMA administration suggest that a controlled environment and moderate doses are sufficient to mediate physiological complications associated with hyperthermia, including cardiovascular, osmoregulatory, neurological, and immunological effects.

#### 4.1.3.2 Cardiovascular System

The sponsor has completed an appropriately controlled, *in vitro* IKr Assay (commonly referred to as a human Ether-à-go-go-Related Gene (hERG) assay) per ICH S7A and S7B. Final results from the cell patch clamp measure found an IC<sub>50</sub> of 206 µM and a Hill coefficient of 1.1 for MDMA at near-physiologic temperature (33°C), with a 170-fold ratio over the expected unbound MDMA plasma concentration in clinical exposure at 2 mg/kg p.o. [218]. These results demonstrate that MDMA has minimal risk of QTc prolongation or *Torsade de Pointes* (TdP), which is one of the most critical types of arrhythmia associated with sudden death. In comparison, SSRIs are known to carry low to moderate risk of QTc prolongation, including available PTSD medications paroxetine and sertraline [219, 220].

The sponsor has completed an *in vivo* cardiovascular substudy as a part of the GLP Extended Single-Dose Neurotoxicology study administering beagle dogs with 0,2,4, 9/12 mg/kg p.o. MDMA (with correction factor for HCl salt) once weekly for 4 weeks (Study 2884-002). The dog is commonly used to investigate cardiac electrophysiology in a manner that will extrapolate to humans in terms of which cardiac ion channels contribute to cardiac repolarization and to the duration of the action potential. All animals in all groups received an electrocardiographic (ECG) examination pretest, and all survivors predose and 1-2 hours postdose on Day 1 and prior to terminal necropsy (study days 2 and 27). Standard ECGs (10 Lead) were recorded at 50 mm/sec. The RR, PR, and QT intervals, and QRS duration were measured and recorded using an appropriate lead. The Principal Investigator for electrocardiographic analysis interpreted the electrocardiograms. Heart rate was calculated from the number of ECG complexes in 10 seconds. QTc was calculated using Van de Water's correction. There was no effect of the oral administration of MDMA on qualitative or quantitative ECG parameters in this study.

*In vivo* assessments of cardiovascular effects of MDMA in animals detected increased sympathomimetic activity, as seen in humans [102, 153]. An injection of 2 mg/kg MDMA HCl elevated heart rate in rabbits [152]. Ten mg/kg MDMA HCl produced a relatively larger increase in heart rate in rats than in blood pressure, an effect possibly controlled by beta adrenergic receptors [153]. The researchers found that MDMA has both pressor and depressor effects, acting through adrenergic receptors [221-223]. Another study in rodents also suggests that norepinephrine may play a role in cardiovascular effects [224], findings that have been more intensively investigated in humans [225-228]. Given the affinity of MDMA for the NET, it is possible that the cardiovascular effects of MDMA could be partially attributed to norepinephrine signaling in the peripheral nervous system.

Injections of 20 mg/kg MDMA HCl in conscious rats assessed by radio telemetry (10.7 times the equivalent dose in humans) found that MDMA caused a prolonged increase in blood pressure [222]. In the same study, MDMA was found to produce mild isotonic contractions of aorta and vas deferens vascular tissue in anesthetized rats, but could also inhibit prejunctional contractions evoked by stimulation [222]. *In vitro* work in human internal mammary artery suggests that contractile effects may increase at high temperatures (40°C versus 37°C) and that some metabolites may contribute to this effect [229].

#### 4.1.3.3 Respiratory System

MDMA causes serotonin reuptake inhibition and carrier-mediated release of serotonin which causes indirect agonism of serotonin receptors and has known sympathomimetic effects. Animal studies show that serotonin agonism increases respiratory drive via actions at 5HT<sub>1A</sub>, 5HT<sub>7</sub>, and 5HT<sub>4A</sub>, although these studies may not translate well to humans [230]. MDMA does not have detectable affinity for the mu opioid receptor. Two published clinical studies with MDMA found



there were no significant effects on body temperature measured at tympanic membrane, respiratory rate, or blood oxygen saturation by pulse oximetry [11, 215]. Finally, the definitive GLP 28-day repeat dosing studies in the rat (2884-001) and the dog (2884-002) found no effect of MDMA on respiration rate.

#### 4.1.3.4 Hepatic System

MDMA is primarily processed through the hepatic route, with 50 to 75% being metabolized. Standard toxicity studies EMD-SC-001 and EMD-SC-002 failed to find liver damage after MDMA administration in rats or dogs after 28 days of daily exposure [99]. In a sponsor-supported pilot dose range finding study of Sprague-Dawley rats (EMD-AT-001), toxicity was assessed in a 13-day increasing dose regimen [231] from 25 mg/kg to 300 mg/kg p.o.. This study found significant elevations of the liver toxicity markers alanine aminotransferase (ALT) and aspartate transaminase (AST) in male rats. Despite a rise in these markers, gross pathology and microscopy of liver tissue failed to show any liver damage [231]. In a sponsor-supported definitive GLP 28-day repeated dose study of Sprague-Dawley rats (Study 2884-001), toxicity was assessed in a single-dose arm after 25 mg/kg p.o. MDMA (dose includes HCl correction factor). A marked increase in AST and ALT with a mild increase in alkaline phosphatase (ALP) and total bilirubin was found in a single animal that was found recumbent with decreased activity and hunched posture on Day 2 and subsequently euthanized, 24 hours post-dose. These were consistent with a hepatobiliary effect and correlated with the microscopic finding of liver necrosis. Moderate increases in triglyceride and cholesterol also indicate a lipid effect. Microscopically, there was extensive acute liver necrosis that was the likely proximate cause of death. Otherwise, there were no MDMA-related effects on gross findings or organ weights in the single-dose Day 2 or repeat-dose Day 29 animals in pathology or organ weight assessments for the remaining animals. Although direct hepatotoxic effects are unlikely, MDMA carries a rare risk of idiosyncratic hepatotoxicity, which is also seen in other marketed medications [232].

#### 4.1.3.5 Renal System

Renal clearance of MDMA is between 8% to 11% of the parent compound. All metabolites of MDMA in urine were detected as glucuronide and sulfate conjugates. Acute symptomatic hyponatremia is associated with the syndrome of inappropriate antidiuretic-hormone secretion (SIADH) involving raised antidiuretic-hormone, also known as AVP [233]. SIADH refers to disorders related to water and sodium balance characterized by the impairment of urinary dilution and hypotonic hyponatremia in the absence of renal disease or other identifiable non-osmotic stimuli known to activate the release of AVP [234]. MDMA is known to cause central release of both oxytocin and AVP through indirect effects of serotonergic signaling as previously described, and this activity indicates that it is not accurate to attribute the osmoregulatory effects of Ecstasy to SIADH, but rather this should be characterized as a pharmacological effect on AVP secretion. AVP plays a key role in osmoregulation and is released upon a change in plasma osmolality [235]. AVP is also involved in the response and adaptation to stress, through its effects on the HPA axis [235]. The rise in AVP does not seem to be part of a generalized stress response, but results from an indirect pharmacological effect compounded by excessive fluid ingestion [236].

AVP is a key regulator of water balance in the body, and has antidiuretic actions when acting at its V2 receptor subtype in the kidneys [237, 238]. In 28-day repeated dose studies, the only renal change observed microscopically was mild to minimal hydronephrosis, which the researchers attributed to treatment-related polyuria (abnormally large urine production). Gross pathology revealed enlarged urinary bladders (most likely polyuria-related) in some animals and were deemed potentially treatment-related. MDMA can influence water regulation by activation of the AVP system, as shown in several animal studies. A study of isolated *in vitro* rat hypothalamus

initially reported AVP and oxytocin release after MDMA and its metabolite HMMA [154]. *In vivo* drug-discrimination studies in rats suggest that AVP receptors are involved in producing interoceptive effects of MDMA [146]. When 10 mg/kg i.p. MDMA HCl was administered at 30°C ambient temperature to male Wistar rats, MDMA induced expression of Fos, a marker of neural activation, in the supraoptic nucleus, a brain region important for osmoregulation and a key mediator of oxytocin and AVP release [239]. This finding suggests that MDMA can affect the renal system in rats at high doses administered at warm ambient temperatures. However, due to <20% renal clearance of the parent compound, a renal impairment study is not planned.

#### 4.1.4 Pharmacodynamic Drug Interactions

MDMA has been shown to interact with numerous CNS active compounds in animals, with effects on behavior, neurotransmitters, gene expression, and thermal regulation among others. When given with moclobemide, a reversible inhibitor of monoamine oxidase A, 10 mg/kg i.p. MDMA HCl has been shown to cause statistically significant increases in 5-HT outflow and body temperature in rats [240]. Caffeine (10 mg/kg) has also been shown to increase MDMA associated hyperthymia in rats when given with 2.5 mg/kg MDMA HCl. Increased hippocampal 5-HT loss was also seen in the caffeine treated animals, which the authors stipulate may result in increased MDMA toxicity [241].

Although previous statements have highlighted deleterious pharmacodynamic drug interactions of MDMA with other CNS active agents, potential for increased efficacy is also possible with concomitant administration with these agents. MDMA efficacy for depression (in a mouse forced swim test) has been shown to be synergistic with non-effective doses of mephedrone, a synthetic amphetamine derivative [180].

Some CNS active agents have been shown to decrease MDMA adverse effects in animals. Both mirtazapine, a direct serotonin antagonist, and fluoxetine, a selective serotonin reuptake inhibitor, have been shown to reduce MDMA related hyperthermia in rats [242]. Interesting both mechanisms, serotonin blockade and serotonin reuptake inhibition, were shown to have this effect. Other authors have shown that chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA in rats [243]. Note that the pharmacodynamic interaction of MDMA with fluoxetine is complicated by also being accompanied by a pharmacokinetic interaction, as both drugs are substrates and inhibitors of CYP2D6 [244]. Although these effects seem positive, they need be balanced by the possibility of lower efficacy for the primary indication of PTSD when given concurrently.

#### 4.2 Pharmacokinetics and Product Metabolism in Animals

For context, it is important to note that MDMA clinical pharmacology differs from many other drugs in psychiatry in that it does not require reaching of steady state for onset of effect like SSRIs, Serotonin and Norepinephrine Uptake Inhibitors (SNRIs), and other common drugs. In clinical trials MDMA is given in single-dose sessions consisting of an initial dose followed by a supplemental dose administered 2 hours later, followed by abrupt discontinuation. MDMA's pharmacology is complicated by non-linear pharmacokinetics, which has been observed in multiple mammalian models. Due to the nonlinear characteristics of MDMA, bioavailability is likely incomplete and variable across doses (see [Section 4.2.1 Absorption](#)). MDMA has been shown to be primarily eliminated by hepatic metabolism with minimal renal contribution in animals (see [Section 4.2.3 Metabolism](#) and [4.2.4 Elimination](#)). MDMA has also been shown to have pharmacokinetic drug interactions with many drugs used in psychiatry, as both the perpetrator and victim compound due to its metabolism though and autoinhibition of CYP2D6 (in humans), a common metabolizing enzyme of many CNS agents (see [Section 4.2.5](#)

[Pharmacokinetic Drug Interactions](#)). Additionally, MDMA has been shown in nonclinical studies to have a large volume of distribution and high CNS penetration (see [Section 4.2.2 Distribution](#)). A summary of the pharmacokinetics of MDMA across multiple mammalian species is available in [Table 2](#).

#### 4.2.1 Absorption

At doses of 2 mg/kg, MDMA is rapidly absorbed by rats by both oral and subcutaneous routes of administration, with an observed  $T_{max}$  of  $0.56 \pm 0.31$  hours by the oral route. At higher oral doses of 10 mg/kg a slightly shorter  $T_{max}$   $0.31 \pm 0.13$  hours was observed in rats [74]. Although no robust IV MDMA data is available to the sponsor at the time of writing this edition of the IB, Baumann and colleagues measured IP exposure of MDMA in rats in their 2009 article. At 2 mg/kg the p.o. to i.p. ratio of MDMA AUC can be calculated to be 0.37. This calculated relative bioavailability of 37% can be thought to approximate the absolute bioavailability of MDMA in rats. Note that at doses of 10 mg/kg in rats, the p.o. to i.p. relative bioavailability increases to 65%. At low doses, sex effects on exposure have been observed in rats. This effect dissipated at 5 mg/kg and is not expected nor observed in higher mammals or humans [155].

In squirrel monkeys, Mueller and colleagues observed an oral  $T_{max}$  of 1 hour at 1.4 mg/kg and as long as 1.3 hours at 10 mg/kg [245]. At doses of 7.4 mg/kg p.o. to i.p. relative bioavailability can be calculated of 68% [97]. Mechan and colleagues also observed increased exposure to MDMA upon repeated dosing, further illustrating MDMA's nonlinear pharmacokinetic characteristics. A 2011 article from Mueller and colleagues observed a prolonged  $T_{max}$  of 7.1 hours at 5 mg/kg in baboons, a result not seen in other non-human primates [246].

Additionally, see [Table 2](#) for a list of exposures across multiple mammalian species.

#### 4.2.2 Distribution

MDMA has been shown to be partially bound to plasma proteins in mammals. The mean unbound fraction of MDMA in plasma was measured in rabbits by De Letter and colleges to be  $63\% \pm 3$  ( $n=6$ ) at a concentration of 400 ng/ml [247]. *In vitro* plasma-protein binding of MDMA in mice is lower than in rat and human serum, in which it is approximately equal [248]. This indicates that the same dose of MDMA in mice will have more active drug available in serum than in rats and humans. Mice were shown to have lower plasma protein binding *in vitro* compared to rats and humans, and only mice exhibited stereoselective plasma protein binding [248].

The volume of distribution of MDMA at 1 mg/kg was observed to be 7.41 to 7.52 L/kg in rats [155]. From Baumann and colleagues' published noncompartmental data, the volume of distribution is 4.43 to 9.52 L/kg in rats.

Work from De Letter and colleagues has identified a 2-compartment model of MDMA pharmacokinetics in rabbits. The total volume of distribution at steady state was reported to be 4.9 L/kg. A central compartment of 1.9 L/kg was elucidated by the model, suggesting a large peripheral compartment in rabbits, leading to a biexponential half-life ( $\alpha$ - $t_{1/2}$  of 5 minutes and a  $\beta$ - $t_{1/2}$  of 63.5 minutes). The authors also observed some accumulation of MDMA in the vitreous fluid of rabbits [247].

MDMA has been shown to have high distribution into the CNS compartment. Scheidweiler and colleagues observed a significantly higher AUC of MDMA in the striatum of mice across doses



from 10 mg/kg to 40 mg/kg. Striatum to plasma ratios were observed from 6.5 to 12.4, illustrating MDMA's high CNS penetration [249].

Additionally, MDMA has been shown to distribute into amniotic fluid and the fetal brain in pregnant rats after a single 15 mg/kg SC injection. Although amniotic drug exposure was shown to be lower than in maternal plasma, fetal brain MDMA and MDA exposure was shown to be much higher than that observed in maternal plasma [250]. The volume of distribution of neonatal rats is comparable to adult rats and has been reported to be 4.61 to 4.83 L/kg [251].

#### 4.2.3 Metabolism

MDMA is metabolized via two hepatic pathways in rodents (see [Figure 2](#) for a comparison to human metabolism). In the major pathway in rats, MDMA is O-demethylated by cytochrome P450 CYP2D1 and 3A2 to form HHMA, which is O-methylated to generate HMMA by catechol-O-methyltransferase (COMT). In the minor pathway in rats, MDMA is N-demethylated by CYP1A2 and 2D1 to form MDA, which is an active metabolite. MDA is O-demethylated by the same enzymes as MDMA, with subsequent metabolism by COMT. Metabolites of MDMA are excreted in urine as glucuronide and sulfate conjugates. MDMA and metabolites have shorter half-lives in rats than humans at comparable doses based on plasma  $C_{max}$  values. Rats tend to form more MDA and glucuronide-conjugated metabolites than humans [252]. As MDMA dose increases above 2.5 mg/kg subcutaneous (s.c.) or intraperitoneal (i.p.) in rats, a larger percentage of the administered dose is shunted to the N-demethylation pathway, resulting in greatly enhanced formation of MDA [205]. Comparison of metabolic pathways between rats and mice given 10 mg/kg i.p. MDMA HCl indicate that 49.1% of MDMA is metabolized through the HMMA pathway in mice versus 72% in rats, and 18.3% of MDMA is metabolized through the MDA pathway in mice versus 28% in rats based on AUC ratios to MDMA. MDMA HCl at 10 mg/kg was also found to be eliminated more rapidly in mice (0.4 hours, i.p.) than rats at (1.1 hours, s.c.) [74, 249].

To address questions of the applicability of interspecies scaling models and nonlinear pharmacology of MDMA, a study examining MDMA and metabolites in rats given 2.5, 5, and, 10 mg/kg s.c. found that MDMA metabolism is nonlinear in rats, with 2.5 mg/kg producing plasma  $C_{max}$  levels approximating those seen in humans receiving between 75 and 100 mg [18, 205, 253]. Injections of 2 mg/kg s.c. or i.p. in rats were found to be similar to oral administration of 100 mg MDMA HCl in humans based on plasma MDMA and metabolite concentrations [74]. Based on plasma values, a dose of 3 mg/kg i.p. MDMA HCl administered in mice was comparable to a single oral dose of 100 mg in humans [254]. Studies in rats and mice provide compelling evidence of nonlinear pharmacokinetics, likely due to saturation of metabolic enzymes, determined by greater than expected AUC values for MDMA and MDA after subsequent MDMA doses, while AUCs for HHMA and HMMA remained lower than expected [205, 249]. For example, when comparing the AUCs of the 2 mg/kg s.c. data to the 10 mg/kg s.c. from Bauman [74] and Concheiro [205] respectively, the AUC observed at 10 mg/kg is 1.89x higher than expected from the 2 mg/kg study. This is consistent with nonlinear pharmacokinetics observed in humans (described later in [Section 6.2.1 Pharmacokinetics and Product Metabolism in Humans](#)) and is likely due to autoinhibition of the CYP450 system.

MDMA exposure, half-life, and other parameters are summarized below in [Table 2](#) for rats, mice, squirrel monkeys, and humans.

**Table 2: Pharmacokinetic Constants for Plasma MDMA After Various Routes of Administration to Humans or Animals**

MDMA HCl	C <sub>max</sub> (ng/ml)	AUC (h•ng/ml)	T <sub>max</sub> (h)	t <sub>1/2</sub> (h)	References
<b>Rat<sup>A</sup></b>					
2 mg/kg i.p.	210±108	163±56	0.14±0.08	0.80±0.16	[74]
2 mg/kg s.c.	196±50	304±65	0.75±0.29	0.79±0.14	[74]
2 mg/kg p.o.	46±15	61±42	0.56±0.31	0.77±0.11	[74]
10 mg/kg i.p.	2257±131	3432±278	0.13 ±0.04	1.08±0.14	[74]
10 mg/kg s.c.	1130±138	3146 ±514	1.10±0.22	1.27±0.39	[74]
10 mg/kg p.o.	966±49	2226±301	0.31±0.13	1.62±0.41	[74]
2.5 mg/kg s.c.	164.1±47.1	272.1±71.6	0.6±0.2	1.1±0.9	[205]
5 mg/kg s.c.	370.8±41	879.1±133.2	0.9±0.6	0.9±0.1	[205]
10 mg/kg s.c.	893.9±90.7	2879.9±491.5	1.1±0.4	2±0.6	[205]
<b>Mouse<sup>B</sup></b>					
3 mg/kg i.p. <sup>C</sup>	369.8	---	0.17	0.6	[254]
10 mg/kg i.p.	1109±87	1233±53	≤0.3	0.4	[249]
20 mg/kg i.p.	2152±82	2611±86	≤0.3	0.6	[249]
<b>Squirrel Monkey</b>					
1.4 mg/kg p.o.	100.2±51.5	340.3±248.4	1±0.4	1.8±0.9	[245]
2.8 mg/kg p.o.	312.7±92.8	1314.2±581.5	1.1±0.4	2.1±0.8	[245]
5.7 mg/kg p.o.	723.6±228	3866.2±891	1.3±0.9	2.6±0.7	[245]
10 mg/kg p.o.	1594.5±295.6	12,839.2±2144.6	1.3±0.9	4.2±1.5	[245]
7.4 mg/kg s.c.	1227±167	5006±528	---	3.5±0.9	[97]
7.4 mg/kg p.o.	773±157	3408±821	---	3.1±0.5	[97]
<b>Human</b>					
1.0 mg/kg p.o.	147±10	1389±119	2.3±0.2	7.2±0.6	[246]
1.6 mg/kg p.o.	292±76	3485±760	2.4±0.6	8.1±2.1	[253]
1.6 mg/kg p.o.	254.7±60.4	3070.6±673.4	2.4±0.6	8.4±1.6	[255]
2.0 mg/kg p.o.	442-487	5133-5232	1.5-2.0	6.9-7.2	[18]

#### 4.2.4 Elimination

Although hepatic metabolism is thought to be the major route of elimination across mammalian species, MDMA and its metabolites have been shown to be present in urine of rats for as long as 48 hours after a single 20 mg/kg MDMA HCl dose [256]. Additionally, De Letter and colleagues have shown that at intravenous doses of 1 mg/kg only 6% of the MDMA dose given rabbits was found unchanged in urine [247].

In contrast to most small molecule drugs, MDMA has been shown to have rapid clearance on the first day of life of rats treated with 20 mg/kg of MDMA HCl. Peculiarly, MDMA clearance has been observed to rapidly decrease from 1.26 L/h/kg to 0.81 L/h/kg by day 11 of life in rats [251].

To date, there is no known well controlled animal study quantifying excretion of MDMA into breastmilk.

#### 4.2.5 Pharmacokinetic Drug Interactions

MDMA has been shown to effect the absorption, distribution, and metabolism of tramadol in rats, leading to decreased half-life and an increase in exposure at relatively low MDMA HCl doses 0.5 mg/kg [257]. The data from this study suggests that the interaction involved both CYP2D6 and CYP3A4 specificity. MDMA has also been shown to interact with methamphetamine in rats, leading to increased exposure to both MDMA and methamphetamine with concurrent exposure

[258]. The authors of the study warn that interactions with other amphetamine derivatives and CYP2D6 substrates are likely.

MDMA is also likely to interact with many approved psychiatric drugs. Upreti and Eddington described the complicated interaction of MDMA with fluoxetine in rats [244, 259]. The authors showed that pretreatment of rats with fluoxetine resulted in an increase in MDMA (1.4-fold) and MDA (1.5-fold) exposure in both brain and plasma. Additionally, the elimination half-life was increased for MDMA (2.4 vs. 4.9 h) and MDA (1.8 vs. 8.2 h) with fluoxetine pretreatment. As MDMA and fluoxetine are both substrates and inhibitors, and interact with (or metabolized by) the same enzyme, CYP2D6, this profound increase in MDMA exposure was to be expected. The authors also partially ruled out P-glycoprotein as a potential site of drug-drug interactions with MDMA [244]. It is likely that other CYP2D6 substrates or inhibitors used in psychiatry (such as duloxetine, amitriptyline, doxepin, fluvoxamine, paroxetine, or trazadone) may interact with MDMA in small mammals.

### 4.3 Toxicology

MDMA has been studied in single-dose (see [Section 4.3.1 Single-Dose Toxicology Studies](#)) and repeat-dose toxicology studies (see [Section 4.3.2 Repeat-Dose Toxicology Studies](#)). The sponsor has also completed *in vitro* and *in vivo* safety studies addressing genotoxicity (see [Section 4.3.3 Genotoxicity](#)), fertility and early embryonic development (see [Section 4.3.5 Reproductive and Developmental Toxicity](#)), and embryo-fetal development with toxicokinetic analyses.

Independent nonclinical studies support that MDMA possesses abuse potential, but much less than structurally related compounds, such as amphetamine (see [Section 4.3.6.3 Abuse Potential](#)). Overall, sponsor conducted studies have shown MDMA was well tolerated with no mortality or significant toxicologic findings after p.o. administration to rats (<150 mg/kg) and dogs (<9 mg/kg) when single-housed. Completed sponsor-initiated toxicology studies are summarized in [Table 1](#).

#### 4.3.1 Single-Dose Toxicology Studies

In a sponsor-supported single-dose study of Sprague-Dawley rats (EMD-AT-001), 10 rats per sex were exposed to 300 mg/kg p.o.. Of these, 40% per sex died, and 12 survivors were euthanized 3 days later [231]. The single-dose oral LD<sub>50</sub> was estimated at 322 mg/kg, which is 6x higher than the LD<sub>50</sub> for i.p. injection. These findings show that MDMA administered orally at 300 mg/kg (approximately 100 to 150x the accepted human therapeutic dose), resulted in marked adverse clinical reactions, including death; with physiological and morphological changes in the kidney (hydronephrosis), and possible testicular tubular changes. No evidence of histologic brain damage was found in the survivors using Cresyl violet, Luxol fast blue, and Bodian's silver stain in standard histopathology assessments.

Single doses between 5 and 100 mg/kg have been administered in rodents. Single doses in this range have transient effects on serotonin depletion [74, 205, 255], likely due to reversible inhibition of tryptophan hydroxylase [260-262], which prevents additional serotonin from being produced and released. A study of the long-term effects of a single dose of 5.7 mg/kg MDMA HCl on estimated SERT sites in the brains of squirrel monkeys reported reduced SERT sites in some frontal, temporal and parietal areas [263]. The plasma C<sub>max</sub> of 725 µg/L in squirrel monkeys was 3x greater than what is observed in humans after a single dose of 100 mg MDMA HCl [252, 264, 265].

### 4.3.2 Repeat-Dose Toxicology Studies

In order to establish the Clinical Development Program for MDMA, 28-day repeat-dose general toxicity studies were conducted in both sexes of Sprague-Dawley rats (53 male, 52 female) (0, 10, 50, 100 mg/kg MDMA HCl oral gavage) and dogs (12 male, 12 female) (0, 3, 9, 15 mg/kg/day MDMA HCl oral dosing with gelatin capsules) [99]. The initial highest dose was set at 18 mg/kg/day but after the death of one female dog, the highest dose was subsequently reduced to 15 mg/kg/day. Dosing was once daily for 28 days. This research was performed within the U.S., which is a member of the Mutual Acceptance of Data (MAD) program, and studies were conducted in compliance with GLP based on available standards in 1986. Both sexes of dogs administered 9 and 15 mg/kg/day of MDMA HCl and rats receiving 50 and 100 mg/kg/day gained less weight than controls and the 3 mg/kg/day group, with significant differences in food consumption observed as early as the first week which were no longer significantly different by the third week for the rats and the fourth week for the dogs. Gross observations at necropsy in the dog possibly related to MDMA included reduced testicular size for one of three dogs receiving 9 mg/kg/day and one of three dogs receiving 15 mg/kg/day and prostatic enlargement in two dogs receiving 15 mg/kg/day. No gross lesions were seen in the rats at necropsy. Blood chemistry and urinalysis values were unremarkable in the dog. Clinical pathology findings showing a trend to decrease with dose in the rat were urinary pH, blood urea nitrogen, glucose, creatinine (females), lactate dehydrogenase (females), and chloride, in contrast total white blood cell count (WBC) and phosphorus showed a trend to increase with dose. Histopathological examinations showed mild, diffuse atrophy in the two dogs with reduced testicular size. Mild, focal atrophy was furthermore observed in the testes of one additional dog from the 15 mg/kg/day group. The two dogs with grossly enlarged prostates showed hyperplasia of the prostate. The silver stain for neurohistopathology was inconclusive in both the rat and the dog studies. These were interpreted as potentially MDMA-related effects as they were only seen in MDMA dosed animals and not in vehicle treated animals. In the rat, effects were observed in 5 of 10 male rats administered 100 mg/kg/day (none were observed in females). Although inconclusive, these potential effects were interpreted as vacuolated lesions apparent in the fiber tracts of the brainstem adjacent to the trigeminal nuclei. In the cerebrum of the dog, these effects included floccular changes of white matter, focal neural malacia and focal cellular infiltrates. Neural chromatolysis was observed in the brainstem. However, the authors noted that it is difficult to extrapolate the findings due to the low sample size (three dogs per sex per group).

In a MAPS-sponsored pilot dose range finding study of Sprague-Dawley rats (EMD-AT-001), oral toxicity was assessed in a 13-day increasing dose regimen [231]. The initial dose started at 25 mg/kg and was increased by 25 mg/kg on a daily basis until 300 mg/kg was reached. Adverse reactions were observed in all doses above 25 mg/kg and included hyperexcitability, uncontrolled urination, piloerection and bulging eyes. Tremors, muscle spasms, impaired movement, convulsions, and death were observed in the highest of dose levels, in the range of 150 and 300 mg/kg. Blood chemistry analyses suggested possible liver and kidney damage in animals receiving higher doses, however, gross pathology and microscopy found no treatment-related damage to the liver. The only renal change observed via microscope was mild to minimal hydronephrosis, which the researchers attributed to treatment-related polyuria (abnormally large urine production). Minimal tubular atrophy was seen in the testes of 3 of the 20 treated male rats, suggesting a possible relationship between high dose, repeated MDMA treatment and minimal testicular atrophy in the male rat. Gross pathology revealed reddened lungs and enlarged urinary bladders (most likely polyuria-related) in some animals and were deemed potentially treatment-related. Histopathological observations of brain tissue revealed no signs of brain damage in any of the treated rats.

These studies were supplemented with MAPS-sponsored definitive GLP follow-up Extended Single-Dose Neurotoxicology studies in the rat (Study 2884-001) and the dog (Study 2884-002) to conclusively study neurotoxicity with modern experimental methods at doses covering the MTD (see [Table 5 Summary of Ongoing and Planned Sponsor Supported Trials with MDMA](#)). An interim necropsy was performed on selected animals at Day 2 to examine single-dose effects and the remaining animals were necropsied at Day 29, 7 days after the last of four weekly doses, to examine repeat-dose effects. Both studies did not find MDMA-related evidence of CNS neurotoxicity based on routine hematoxylin and eosin staining and expanded neurohistopathology including brain and spinal cord tissue.

In Study 2884-001, 28-day repeat-dose general toxicity studies were conducted in both sexes of Sprague-Dawley rats (10 male, 10 female per dose per arm) (0, 2, 7.5, 25/20 mg/kg MDMA HCl p.o.). Oral administration of 25mg/kg/dose of MDMA HCl was not tolerated in male rats, resulting in mortality of 6 of 20 study males. Clinical signs preceding euthanasia (n=1) included decreased activity, hunched posture, partially closed eyes and lateral recumbency. Clinical signs associated with oral administration of MDMA HCl (observed at 7.5mg/kg/dose and above, depending on the sign) varied by sex and included salivation, increased activity, red material around the nose, hypersensitivity to touch, hypersensitivity to sound, piloerection, stereotypy (head weaving), and aggression. Changes in FOB endpoints were consistent with the clinical signs and included changes in endpoints related to activity/arousal, sensorimotor, neuromuscular, autonomic, and physiologic endpoints, most apparent 1 hour post dose and trending towards resolution at 24 hours post dose. Weekly oral MDMA administration resulted in decreases in mean body weight gain in animals administered 25/20 mg/kg/dose between Days -1 and 14 for males and Days -1 and 7 for females. This correlated with decreases in mean food consumption in males administered 25/20 mg/kg/dose between Days 7 and 14. Changes in clinical pathology associated with MDMA administration included minimal decreases in mean urine volume and/or elevated urine specific gravity and increased total protein, albumin and globulins which was indicative of minimal subclinical dehydration in both sexes at 25/20 mg/kg/dose. Microscopically, MDMA-related changes were noted in the quadriceps, soleus and gastrocnemius skeletal muscles on Days 2 and 29. These findings included myofiber degeneration in the quadriceps (males  $\geq 7.5$  mg/kg/dose and females  $\geq 2$  mg/kg), soleus (25/20 mg/kg/dose males  $>$  females) and rarely in the gastrocnemius (25/20 mg/kg/dose males only) with infiltrations of mononuclear cells/leukocytes and/or neutrophils to varying degrees depending on muscle type (quadriceps $>$ soleus $>$  gastrocnemius). The basis for the difference was suspected to be related to a difference in myofiber type in the soleus muscles of rats. At terminal necropsy within 7 days after the last of four weekly repeated doses, myofiber degeneration was observed at a much lower incidence in the soleus muscles and rarely present in the gastrocnemius muscle (males only). It is possible that these observations indicate some level of repair or adaptation, as a low incidence of myofiber regeneration was also found at the MTD. Exposure of MDMA and active metabolite MDA as measured by  $C_{max}$  and  $AUC_{(0-10hr)}$  generally increased in a dose proportional to greater than dose proportional manner across the dose range with no notable differences in exposure related to sex and no evidence of accumulation or reduction in exposure after repeat administration. Taken together, weekly MDMA administration for 28 days (4 total doses) via oral gavage was tolerated in Sprague-Dawley rats up to 25 mg/kg/dose in females and 20 mg/kg/dose in males. Due to the lack of any adverse findings or mortality after reducing the dose level in males, the NOAEL is determined to be 25 mg/kg/dose in females and 20 mg/kg/dose in males which correlated with Day 22 systemic exposures of 1490 ng/mL and 10700 hr\*ng/mL ( $C_{max}$  and  $AUC_{0-10hr}$ ) in females and 1100 ng/mL and 4590 hr\*ng/mL ( $C_{max}$  and  $AUC_{0-10hr}$ ) in males. The risk of CNS neurotoxicity is minimal, however microscopic findings in the rat include a risk of neuromuscular inflammation in skeletal muscle in the periphery at human equivalent doses. An *in vitro* study reported MDMA activates nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction, inducing calcium ( $Ca^{2+}$ ) transients and increasing acidification in



myofibers, potentially leading to generalized denervation which precedes myofiber degeneration [266].

In Study 2884-002, 28-day repeat-dose general toxicity studies were conducted in both sexes of beagle dogs (3 male, 3 female per dose per arm) (0, 2, 4, 12/9 mg/kg MDMA HCl by oral gavage). Oral administration of 12mg/kg/dose of MDMA HCl was not tolerated resulting in mortality of 4 dogs and one dog at 9 mg/kg/dose. Clinical signs preceding euthanasia included severe hypersensitivity to sound and touch, salivation, vocalization, aggression and (in the single animal administered 9 mg/kg/dose) unconsciousness. Clinical signs associated with oral MDMA were most prominent on Day 1 (generally resolving within 24 hours of dosing), diminished at subsequent dosing intervals and included increased salivation, injected sclera, hypersensitivity to touch and vomitus/emesis/retching at  $\geq 2$  mg/kg/week; lacrimation/ocular discharge (yellow or green; which was observed in a single 12 mg/kg animal during ophthalmoscopic exams on Day 2), and increased activity at  $\geq 4$  mg/kg/week; and dilated pupils, aggressive behavior, hypersensitivity to sound, vocalization, trembling, partially/completely closed eyelids, stereotypy/abnormal head movements (jerking and side to side), audible breathing, coughing and cold skin at 12/9 mg/kg/week. Changes in the FOBs were consistent with the clinical signs and included changes in endpoints related to activity/arousal, sensorimotor, neuromuscular and autonomic endpoints that are consistent with clinical observations described above. Changes were generally similar between the sexes and were most apparent at 1 hour post dose on Day 1 with a majority of changes trending towards resolution by 24 hours post dose. A majority of the changes in FOB endpoints observed on Day 1 were also observed on Day 22. Oral MDMA administration resulted in a reduction in mean body weight during Week 1 and an overall decrease in mean body weight gain through the dosing phase in males administered 12/9 mg/kg/week. Post dose decreases in food consumption were observed at all dose levels (including controls) predominantly during Week 1, however, this decrease in food consumption did not translate into a body weight effect in any dose level except 12/9 mg/kg males. Following weekly oral gavage administration of MDMA, exposure (mean  $C_{max}$  and  $AUC_{0-8hr}$ ) of MDMA and MDA increased with increasing dose in an approximately dose proportional manner from 2 to 9 mg/kg, with no apparent increase from 9 to 12 mg/kg (N=1) on Day 1 and increased with increasing dose in an approximately dose proportional manner from 2 to 9 mg/kg on Day 22 with no evidence of accumulation or differences in sex. Systemic exposure ( $AUC_{0-8hr}$ ) to MDA appeared similar to the systemic exposure of MDMA on Days 1 and 22. Taken together, weekly oral administration of MDMA for 4 weeks (4 total doses) was tolerated in dogs up to 4 mg/kg/week. Due to the mortality/early termination at 12 and 9 mg/kg/week, the NOAEL for this study is determined to be 4 mg/kg/week which correlated with peak and cumulative exposures of 219 ng/mL and 139 ng/mL ( $C_{max}$ ) and 983 hr\*ng/mL and 897 hr\*ng/mL ( $AUC_{0-8hr}$ ) for MDMA and MDA, respectively.

#### 4.3.3 Genotoxicity

A sponsor funded *in vitro* bacterial reverse mutation Ames assay was conducted for MDMA by Charles River Labs. This GLP compliant study was completed April 2020. Four tester strains of Salmonella typhimurium (TA1537, TA98, TA100, and TA1535) and one Escherichia coli strain (WP2 uvrA) were used for mutagenicity testing. After a range finding assay, MDMA HCl was tested at 100, 250, 500, 1000, 2500, and 5000  $\mu$ g/plate using the plate incorporation method. Precipitates and cytotoxicity were not observed in any strain with or without metabolic activation. Additionally, criteria for a negative response (via Ames assay) were met for all tested strains with and without metabolic activation. These data support the conclusion that MDMA is negative for mutagenic activity in Salmonella typhimurium and Escherichia coli.

A sponsor funded *in vitro* genotoxicity chromosome aberration test in Chinese hamster ovary (CHO) cells was conducted for MDMA by Charles River Labs. This GLP compliant study was completed April 2020. Chinese hamster ovary cells cultures were treated with MDMA, positive control, or vehicle control in the presence and absence of an Aroclor™ 1254-induced rat liver S9 microsomal fraction (for metabolic activation). After a range finding assay, MDMA was tested at range of 60 to 240 µg/mL. No statistically significant test article-related increases were observed in the mean percent of cells with aberrations. Additionally, no statistically significant increases in polyploidy or endoreduplication were observed. MDMA was considered negative for inducing structural aberrations in Chinese hamster ovary cells with and without metabolic activation under the conditions of this test system. These data support the conclusion that MDMA is negative for genotoxic activity in CHO cells in the presence and absence of metabolic activation.

A sponsor funded GLP-compliant *in vivo* genotoxicity micronucleus study was conducted for MDMA in male Sprague Dawley rats in April 2020. The vehicle control (Nanopure Diamond ultrapure water) or the maximum tolerated dose of 100 mg/kg MDMA HCl were administered orally via gavage once daily for 2 consecutive days. Bone marrow was harvested approximately 24 hours after the last dose was administered for the vehicle and test article groups. The positive control (cyclophosphamide; stock slides prepared in WIL-99737) was administered orally via gavage and harvested approximately 24 hours after dose was administered. MDMA did not produce statistically significant or dose-dependent increases in the %MN-PCEs in male rats at any dose level as compared to the vehicle control. No bone marrow cytotoxicity (decreases in PCE:TE ratio) was noted in any male rats at any 3,4-methylenedioxymethamphetamine hydrochloride dose level. Group mean values for %MN-PCEs and PCE:TE ratios for the vehicle and positive controls were within 95% historical control intervals obtained by Charles River Skokie, demonstrating the acceptability of the assay with the following exception. The %MN-PCEs for the positive control male rats (2.91) produced a higher response when compared to the 95% historical control interval (0.13 to 2.59). This demonstrated a more robust positive response. Therefore, MDMA was negative for clastogenic activity and/or disruption of the mitotic apparatus under the conditions of this assay.

#### 4.3.4 Carcinogenicity

Based on negative genotoxicity studies, there is no cause for concern of carcinogenic risk of MDMA and carcinogenicity studies have been waived by regulatory agencies. No tumors were reported after daily 28-day repeated dose toxicology studies of MDMA in rats or dogs described in [Section 4.3.3 Genotoxicity](#).

#### 4.3.5 Reproductive and Developmental Toxicity

Preliminary teratological studies in rats (N=12 per dose) given 0, 2.5, or 10 mg/kg MDMA HCl by gavage on alternate gestational days (GD) 6 to 18 found no abnormalities in gestational duration, litter size, neonatal birth weights, or birth defects (N=10 litters per dose), despite statistically significant reduction in maternal weight gain at 10 mg/kg [267]. These results are in contrast to physiological abnormalities resulting from prenatal methamphetamine and d-amphetamine exposure in mice and rabbits [268].

The sponsor has completed a definitive GLP study of the effects of MDMA on Fertility and Early Embryonic Development to Implantation in both sexes of rats. In this study, males were dosed once daily for 28 days prior to pairing and continued to euthanasia. Females were dosed 21 days prior to pairing and continued through GD 7. The copulatory interval (days to mating) in the MDMA-treated groups ranged from 3.5 to 3.9 days. Euthanasia was conducted at GD13. MDMA-related clinical observations included hypersensitivity to touch, salivation, vocalization,

red material, and red discolored wet hair around the nose and/or mouth and were not considered adverse. MDMA-related decreases in body weight, body weight gain, and food consumption were expected pharmacological effects based on repeat-dose studies described in [Section 4.3.2 Repeat-Dose Toxicology Studies](#). Mean prostate gland weights decreased in all MDMA-treated groups relative to controls, however this did not affect fertility or overall health of the animals. The NOAEL dose was demonstrated to be the highest dose level evaluated  $\leq 10$  mg/kg/day (supratherapeutic dose) in both sexes for fertility and reproductive performance.

The sponsor has completed a pilot prenatal developmental toxicokinetic study in time-mated female rats in order to optimize dose selection for definitive GLP reproductive toxicology studies (see [Table 1: Summary of Completed and Planned Nonclinical Toxicology Studies](#)). Rats were dosed on gestations days (GD) 6 through 17. Five dose levels were tested 0 mg/kg/day (vehicle control), 2.5 mg/kg/day, 5 mg/kg/day, 15 mg/kg/day and 20 mg/kg/day MDMA HCl by gavage (N=5 each). MDMA-related clinical observations of salivation, as well as decreases in mean gestation body weight, body weight change, food consumption, adjusted GD 21 body weight, and adjusted GD 6 to 21 body weight change were observed at all dose levels. MDMA-related decreases in mean gestation body weight and body weight change in comparison to controls were observed at all dose levels evaluated. At 15 mg/kg/day, mean body weight was statistically lower than controls on GD 9 (-8.8%) and 12 (-8.4%). At 20 mg/kg/day, mean body weight was statistically lower than controls on GD 9 (-10.6%) and 12 (-8.9%). MDMA was tolerated at dose levels  $\leq 20$  mg/kg/day when administered to time-mated female rats once daily via oral gavage from GD 6 to 17. No effects of MDMA at these dose levels were noted on mortality, clinical observations, or maternal macroscopic observations. Likewise, no MDMA-related effects were noted at dose levels  $\leq 20$  mg/kg/day on ovarian and uterine implantation data (mean number of corpora lutea, implantation sites, viable fetuses, resorption sites [early, late, and total], litter size, and mean pre- and post-implantation loss indices), mean gravid (pregnancy) uterine weights, or fetal body weights. No external malformations or developmental variations were noted in any of the fetuses evaluated on GD 21. As expected from prior literature, the AUC/Dose ratio increases with higher doses, indicative of non-linear pharmacokinetics. Systemic exposure ( $AUC_{0-12hr}$ ) to MDMA did not appear to change following repeated administration of MDMA, indicating lack of systemic accumulation in rats despite daily dosing. Pilot dose range finding developmental toxicity studies found no adverse developmental effects in rats at 20 mg/kg/day by gavage.

The sponsor completed a pilot prenatal developmental toxicokinetic study in time-mated female New Zealand White Hra:(NZW)SPF rabbits in order to optimize dose selection for definitive GLP reproductive toxicology studies (see [Table 1: Summary of Completed and Planned Nonclinical Toxicology Studies](#)). Rabbits were dosed on GD7-19 at 0 mg/kg/day (vehicle control), 2.5 mg/kg/day, 5 mg/kg/day, 15 mg/kg/day and 20 mg/kg/day (N=6 each). MDMA-related mortality was observed at 15 and 20 mg/kg/day. Two females died on GD 7 following a single dose of MDMA at 20 mg/kg. Due to excessive toxicity at 15 mg/kg/day the dose level was lowered to 10 mg/kg/day beginning on GD 9 and the remainder of the 20 mg/kg group was euthanized. MDMA was tolerated at dose levels  $\leq 10$  mg/kg/day when administered to time-mated female rabbits once daily via oral gavage from GD 7 to 19. No effects of MDMA at these dose levels were noted on mortality, mean gestation body weight, or maternal macroscopic observations. No external malformations or developmental variations were noted in any of the fetuses evaluated on GD 29. As expected from prior literature, the AUC/Dose ratio increases with higher doses, indicative of non-linear pharmacokinetics and possible systemic accumulation in pregnant rabbits. Pilot dose range finding developmental toxicity studies found no adverse developmental effects in rabbits at 10 mg/kg/day by gavage.

The sponsor has also completed a definitive GLP embryo/fetal developmental toxicology study in time-mated female New Zealand White Hra:(NZW)SPF rabbits. Rabbits were dosed on GD7-19



at 0 mg/kg/day (vehicle control), 2.5 mg/kg/day, 5 mg/kg/day, and 10 mg/kg/day (N=22 each). MDMA was well-tolerated at dose levels  $\leq 10$  mg/kg/day. No MDMA-related effects were noted on maternal survival, mean gestation body weight, ovarian and uterine implantation data (mean number of corpora lutea, implantation sites, viable fetuses, resorption sites [early, late, and total], litter size, and mean pre- and post-implantation loss indices), mean gravid uterine weights, adjusted GD 29 body weight, or maternal macroscopic observations at any of the dose levels evaluated. Likewise, no effect of MDMA was noted on fetal sex ratio, fetal body weights, or fetal external, visceral, or skeletal examinations. No adverse MDMA-related effects were noted on clinical observations, body weight change, food consumption, and adjusted GD 0-29 body weight change at any of the dose levels evaluated. MDMA-related clinical observations of dilated pupils and ears cold to touch were noted in all treated groups. Additional findings noted at 5 and 10 mg/kg/day included hypersensitivity to touch and rapid breathing. At 5 and 10 mg/kg/day, mean gestation body weight gain was decreased in comparison to controls (statistically significant at 10 mg/kg/day). Adjusted GD 0-29 body weight gain at 5 and 10 mg/kg/day were lower than controls. Mean food consumption at 10 mg/kg/day was also statistically lower than controls. These findings were all expected pharmacological effects of MDMA and were therefore not considered adverse. Following daily oral gavage administration of MDMA to pregnant rabbits,  $AUC_{0-24hr}$  values for MDMA increased with increasing dose in a slightly greater than dose proportional manner on GD 7 and increased in an approximately dose proportional manner from 2.5 to 5 mg/kg and in a greater than dose proportional manner from 2.5 to 10 mg/kg GD 19. Systemic exposure ( $AUC_{0-24hr}$  values) to MDMA increased following repeated administration of 5 and 10 mg/kg MDMA HCl to pregnant rabbits. Following daily oral gavage administration of MDMA to pregnant rabbits,  $C_{max}$  and  $AUC_{0-24hr}$  values for MDA increased with increasing dose in a greater than dose proportional manner on GD 7 and GD 19. Systemic exposure ( $AUC_{0-24hr}$  values) to MDA increased following repeated administration of 2.5, 5, and 10 mg/kg MDMA HCl to pregnant rabbits. Systemic exposure ( $AUC_{0-24hr}$  values) to MDA was 1 to 3 times greater than the systemic exposure to MDMA on GD 7 and GD 19. Based on the results of this study, the NOAEL for maternal and developmental toxicity was considered to be 10 mg/kg/day, the highest dose level evaluated, with a maternal MDMA  $C_{max}$  of 603 ng/mL and  $AUC_{0-24hr}$  of 2920 hr\*ng/mL on GD 19.

#### 4.3.6 Other Toxicity Studies

##### 4.3.6.1 Immunological Effects

MDMA may act as a mild immunosuppressant in rodents, with no evidence of immunotoxicity in repeat-dose toxicology studies described in [Section 4.3.2 Repeat-Dose Toxicology Studies](#). Only a trend towards a dose-dependent increase in white blood cells were noted in the dog study, which could be related to an increase in cortisol secretion induced by MDMA. Single-dose MDMA administration at 5 mg/kg in rats is associated with impaired macrophage activity as evidenced by inhibition of tumor necrosis factor-alpha (TNF- $\alpha$ ) secretion for 12 hours post-drug [269]. In mice injected with 10 mg/kg MDMA HCl for 5 days, increases in epithelial tissue of cytokines interleukin 1-alpha (IL-1 $\alpha$ ), granulocyte-colony stimulating factor (G-CSF), and interleukin 3 (IL-3) were found, while decreased serum levels of many cytokines were reported [270]. MDMA decreased neutrophil oxidative bursts and phagocytosis and increased the number of circulating neutrophils while decreasing the number of lymphocytes. Incubating photoreceptor-generated cells with 0.5, 1 and 2  $\mu$ M MDMA HCl activated macrophages and leading them to release proinflammatory cytokines [271]. MDMA also increased hypothalamus-pituitary-adrenal (HPA) axis activity through a noradrenergic pathway in the hypothalamus [272]. MDMA also suppresses interferon- $\gamma$  secretion and signaling in mice [273]. Interestingly, MDMA was shown to reduce inflammation and airway reactivity in a mouse model of allergic asthma, suggesting that 10 mg/kg MDMA HCl (i.p.) could have beneficial immunomodulatory effects in cases of

heightened inflammation [274]. A microarray study found that mice self-administering MDMA at moderate doses had transcriptional changes in many genes related to immune and inflammatory responses as well as neuroplasticity and learning [275], suggesting that immunosuppressant effects of MDMA at clinically relevant doses could be beneficial in the treatment of psychoneuroimmunological disorders such as PTSD [276]. There have been no publications reporting an increased occurrence of tumors or infections associated with MDMA administration to date, so these cell-mediated effects are unlikely to relate to immunotoxicity.

#### 4.3.6.2 Mechanistic Studies

Epigenetic modifications, including deoxyribonucleic acid (DNA) methylation, demethylation, and histone acetylation, are thought to be involved in dynamic regulation of memory reconsolidation in the adult nervous system and play a role in memory formation [277]. Early childhood adversity and trauma is associated with transcriptional silencing of the brain-derived neurotrophic factor (BDNF) gene through DNA methylation, which can either be a risk factor in development of PTSD or a result of having PTSD in adulthood [278]. Epigenetic effects on BDNF and other gene expression is one possible hypothesized mechanism by which MDMA in combination with training in animal studies modeling anxiety disorders, or therapy in humans, exerts its therapeutic effects.

The social effects of MDMA may also include setting-dependent acute social sensitization and extension of a critical period of increased sociality in mice. MDMA may sensitize mice to social interactions with unfamiliar mice via setting-dependent sensitization [279]. After an initial dose of MDMA HCl (7.8 mg/kg) in the company of an unfamiliar mouse, a subsequent dose produced greater social interaction. The same effect did not occur when preceded by a social setting, or with MDMA in a nonsocial setting, and the effect can be antagonized by blocking 5HT<sub>2A</sub> receptors. Adult mice exhibited a greater desire to be with another mouse 2 days after receiving MDMA HCl (10 mg/kg) [280], re-opening a critical period for learning social reward that generally declines during adulthood. This effect appears tied to upregulation of oxytocin receptors in the nucleus accumbens. These effects may support posited therapeutic effects in humans, such as increased rapport with therapists and greater ability to have fulfilling interpersonal relationships.

A series of studies examining neuritegenesis, a marker of neuroplasticity, found that MDMA and classic psychedelics stimulated neurite growth [281], with this BDNF-dependent effect blocked by 5HT<sub>2A</sub> antagonists. MDMA was more effective than ketamine in promoting neurite growth. These findings may lie behind some of the therapeutic effects of MDMA, such as enhanced fear extinction learning, greater sensitization to prosocial effects and or re-learning or re-opening experiencing social reward, but behavioral effects were not specifically tested in this report.

MDMA given before training persistently enhanced fear extinction learning in mice through a BDNF-dependent mechanism [282], which could be a possible mechanism of action for MDMA in combination with therapy as a treatment for anxiety disorders. The dose of 5.6 mg/kg was approximately two times a human equivalent dose based on exposure, but these findings were the first biological evidence of a lasting effect of MDMA administered in combination with training on lasting attenuation of anxiety-related behavior in mice. MDMA HCl (1 mg/kg, 2.5 and 5 mg/kg, not 1 or 10 mg/kg), given alone or with nicotine, enhanced consolidation of recall for a passive-avoidance task, a different type of fear memory [180, 283]. A fear extinction study in rats funded by MAPS failed to replicate an enhancement of fear extinction, finding instead that 3 and 5 mg/kg MDMA HCl administered prior to training impaired fear extinction learning, while MDMA administered during reconsolidation produced persistent reduction in fear [284]. These

results highlight species-specific differences between rats and mice among translational mechanistic studies attempting to simulate results observed in clinical trials.

A number of research teams have studied the effects of MDMA on gene expression in rodents [285-290]. Many of these reports used 10 to 20 mg/kg MDMA HCl. Toxicity was not observed at these doses, and effects were broadly indicative of changes in memory and cognition. Particularly of interest for treatment of PTSD, one study found downregulation of the gene for several glutamate receptor genes, several calcium transport genes, and the cannabinoid receptor CB1, among other effects [286]. Another study found that MDMA influenced genes of proteins known to regulate glutamatergic signaling and are associated with neuroplasticity and learning, as well as processes involved in memory consolidation in serotonergic neurons [275]. These studies also report an increase in expression of genes that regulate the GABA transporter [285], which is expressed in GABAergic neurons indirectly regulated by glutamatergic afferent neurons. Serotonin-transporter knockout mice did not display some of these changes in gene transcription, suggesting that serotonin release is required for this activity [285]. In the acute period 24 to 48 hours after MDMA exposure, a study in rats found 33 to 70% upregulation of BDNF messenger ribonucleic acid (mRNA) transcripts in the frontal cortex, with a time-dependent decrease, up to 73%, of BDNF transcripts in the hippocampus [291]. The frontal cortex and hippocampus are both regions known to play a causal role in memory retrieval and reconsolidation in animals and humans [292], mediated in part through GABAergic signaling [293]. Changes in transcription do not always correlate with functional consequences in proteins levels. BDNF has been shown to have multiple functionally distinct splice variants which have tight temporal and spatial control in an activity-dependent, stimulus-specific manner [294]. However, MDMA produces a durable enhancement of fear extinction in mice, an effect mediated by an MDMA-associated increase in BDNF expression specifically in the context of fear extinction training, supporting that gene expression changes after MDMA are functionally relevant [282].

Examining rat brains after repeated MDMA administration for 2 weeks detected a sharp drop in SERT expression [295], suggesting a compensatory downregulation in response to repeated high doses of MDMA. A study in rats found repeated administration of MDMA HCl at 1 or 5 mg/kg weekly for 4 weeks increased transcripts for 5HT<sub>1B</sub> receptors in various brain regions and 5HT<sub>2C</sub> receptors in the cortex and hypothalamus, likely due to serotonin depletion and subsequent need to increase serotonin receptor availability [296]. Increased levels of gene transcripts regulating extracellular signaling in mice were also reported after MDMA [297]. Serotonin may play a more significant role than dopamine in transcription changes mediated by MDMA [296]. Mouse brains examined 8 hours after 8 days of self-administration or non-contingent administration detected increased transcription of genes related to inflammation and immune modulation in both groups and transcription of genes related to neuroadaptation in mice self-administering MDMA [275]. Transcripts in these studies were assessed 8 to 10 hours after the last of repeated MDMA administrations and it is unclear whether these changes reflect residual acute effects of the MDMA, or changes related to repeated MDMA administration. Findings in rats were confirmed in humans receiving a dose of 75 mg MDMA HCl in the therapeutic dose range, which found increased expression of the SERT gene following MDMA when compared with placebo [298]. Increased SERT gene expression after MDMA was associated with decreased arousal and increased fatigue. Taken together, these nonclinical studies support a plausible mechanism for the therapeutic actions of MDMA administered in a single-dose regimen.

#### **4.3.6.3 Abuse Potential**

Nonclinical studies support that MDMA possesses some abuse potential, though to a much lesser degree than amphetamine. A number of studies have investigated the abuse liability of MDMA in animals through paradigms of drug seeking, drug discrimination, and withdrawal. Mice, rats, and

monkeys self-administer MDMA, indicating that MDMA has rewarding properties in animals [299-302]; however, the rate and response-acquisition of self-administration is much lower than other drugs of abuse, such as cocaine or heroin. Rodent studies found that training attempts at self-administration required an increased training dose of 1.75 mg/kg for acquisition over a 5 week period [301, 303-305]. Research that used the ability of a drug to impact the rate of intracranial self-stimulation (ICSS) as a measure of abuse liability compared the impact of 0.32, 1, or 3.2 mg/kg MDMA HCl pretreatment in male and female rats. At the 3.2 mg/kg dose, MDMA increased responding for ICSS when the rate of responding for ICSS was low, and reduced seeking ICSS when rate of responding was very high in both sexes [122].

Physical dependence and drug withdrawal were investigated by treating rats with 10 mg/kg i.p. MDMA HCl twice daily for 5 days. When compared with rats trained to self-administer cocaine, MDMA-trained rats were less likely to return to self-administration after a period of abstinence [300]. Results in a study in mice showed that they did not exhibit aversive/dysphoric or anxiogenic behaviors after treatment, indicating that high doses of MDMA do not induce classical symptoms of physical dependence [306]. Monkeys choose to self-administer MDMA in doses equivalent to or only slightly higher than doses used by humans [299], but typically reduce their MDMA intake over time. While monkeys work hard to obtain MDMA, they work harder to obtain other psychostimulants, such as cocaine or methamphetamine [304, 305]. Taken together, results in animals suggest that the abuse liability of MDMA is low to moderate.

Nonclinical drug discrimination studies investigating the discriminative stimulus effects of MDMA as either hallucinogenic or stimulant have reported inconsistent findings, indicating that psychoactive effects of MDMA are not expressly hallucinogenic or stimulating [307]. Two-way discrimination studies with MDMA are not specific enough to assess the complex pharmacological profile of MDMA and lead to low accuracy and mixed results. In three-way discrimination studies, MDMA has discriminative stimulus effects that are more serotonergic, with minimal involvement of dopamine. One such study found that lysergic acid diethylamide (LSD) produced dose-dependent increased substitution for MDMA while neither cocaine nor 2,5-dimethoxy-4-bromoamphetamine (DOB) substituted for it [308].

Administering MDMA to amphetamine-trained rats suggests that dopamine plays a role in stimulus properties, but blocking serotonin receptors interfered with recognizing MDMA, while administering dopamine receptor antagonists did not do so [309]. A higher dose of 3 mg/kg may have a greater dopaminergic component, while 1.5 mg/kg may have more of a serotonergic component [134] in drug discrimination studies in rats. Serotonin 5HT<sub>1A</sub>-acting drugs were treated similarly to both 1.5 mg/kg and 3 mg/kg MDMA HCl [134]. Drug discrimination studies in SERT knockout rats supports a key role for serotonin release in producing the subjective effects of 1.5 mg/kg MDMA HCl [147]. The ratio of serotonin to dopamine release are likely to influence stimulus characteristics of MDMA in animal models, and these studies lead to the definition of a unique class of drugs called the Entactogens, which are clearly distinguishable from hallucinogens and stimulants. Discrimination research in a sample of monkeys trained to discriminate cocaine from saline and tested with cathinones, amphetamines, and MDMA and MDA, suggested that the greater serotonergic effects of MDMA are at least partially related to the methylenedioxy structure [310].

## 5.0 Epidemiological and Naturalistic Evidence Summary

Evidence exists for intentional human use of MDMA in the late 1960s [46] and there are records of a police seizure of MDMA in the early 1970s [311]. An estimated 500,000 doses of MDMA were administered in a psychotherapeutic setting prior to MDMA being in Schedule I [46, 312]. MDMA was administered to thousands of people prior to scheduling and many continue to use

Ecstasy around the world in various non-medical settings [61, 193, 313-315]. In this IB, 'Ecstasy' refers to material assumed to be MDMA used in naturalistic settings, however when used in these uncontrolled settings, the drug may not contain any MDMA and is likely to be of limited purity. It may contain other substances along with or instead of MDMA, and when present, the amount of MDMA can vary widely [316-318]. These synthesized tablets may also be cut or mixed with other psychoactive substances. Substances found mixed with MDMA have included amphetamine methamphetamine, dextromethorphan, paramethoxymethamphetamine (PMMA), paramethoxyamphetamine (PMA), cathinones, ketamine, caffeine, and ephedrine [318, 319]. Most studies rely on self-reported use and do not attempt to confirm that material contained MDMA. Retrospective studies, epidemiological settings and case reports of morbidity and mortality in Ecstasy users are summarized in [Section 5.1 Serious Reports of Incidents, Mortality, and Morbidity](#).

It is important to note that the vast majority of non-clinical epidemiological studies are retrospective comparisons of people who have previously self-administered Ecstasy, a study design that is unable to eliminate the possibility that one or more predisposing factors may lead to repeated Ecstasy use [76, 315, 320]. Samples are often selected on the basis of moderate to heavy self-reported Ecstasy use, with very few studies conducted in samples reporting the levels of moderate exposure seen in clinical trials. Many of these studies have compared people reporting use of Ecstasy with non-Ecstasy using controls, mostly as a means of detecting long-term effects of Ecstasy use, and do not appropriately match samples for polysubstance use. Findings are considered cautiously with respect to their degree of relevance for safety in clinical trials.

### **5.1 Serious Reports of Incidents, Mortality, and Morbidity**

Numerous serious events, including fatalities, have been reported in humans after Ecstasy use in unsupervised and uncontrolled settings. These events are relatively rare given the widespread prevalence of Ecstasy use (an estimated 4% of people, or roughly 13.7 million people, ages 15 to 64 in Europe to 6.7%, of people ages 12 and older in the US) [321, 322]. The UN World Drug report concluded that an estimated 20.5 million people (0.4% of the global population) had used 'Ecstasy' at least once in in 2018 [323]. These include hyperthermia (potentially arising from "serotonin syndrome"), psychiatric problems, hepatotoxicity (secondary to hyperthermia), cardiac disorders and hyponatremia [77, 321, 324-326]. Set and setting likely play a role in the development of some Ecstasy-related adverse outcomes, such as vigorous exercise, lack of attention to somatic cues, and too little or too much hydration combined with pharmacological action on oxytocin and/or AVP resulting in hyperthermia or hyponatremia [327, 328]. A systematic search of medical literature was conducted using the PubMed database in April, July, and October 2021 using the terms "MDMA" and "methylenedioxymethamphetamine." Further examination of the literature was conducted to include specific classes of report, such as clinical trials, case reports, epidemiological studies, intended to capture relevant primary literature. The reports of serious morbidity and mortality where MDMA was detected in plasma or other fluids are summarized in [Table 3](#) below.

Most Ecstasy-related emergency department admissions are the result of people experiencing anxiety or panic reactions after use and were treated with supportive care [325, 329, 330]. An extensive systematic review reached similar conclusions concerning the frequency and nature of emergency department admissions, though also noting that owing to complexities of nonmedical and recreational use, the researchers found it hard to establish a lethal dose [77]. However, a pair of case series drawn from two different events suggests a general relationship between estimated dose and number of emergency department admissions after exhibiting seizures, unresponsiveness or hyperthermia, with both series reporting high doses of MDMA (230 and 270 mg) in sample tablets or capsules [331, 332]. Post-mortem hyperthermia due to a deadly



intoxication by Ecstasy was found in a 19-year old female. Toxicology results showed the presence of MDMA with a lethal blood concentration of 4.52 mg/mL and detection of cannabinoid with a blood concentration to 0.7 ng/mL. The MDMA concentration was 8.96 mg/mL in the bile and 129.7 mg/mL in the gastric content. The blood alcohol concentration was 0.8 g/L [333]. As is the case with fatalities associated with reports of Ecstasy use, medical emergencies after Ecstasy use are more likely to occur in men [325]. Individuals consuming Ecstasy with pre-existing conditions are at increased risk when consuming drugs of unknown purity, identity, and dose in uncontrolled settings.

**Table 3: Summary of Published Morbidity and Mortality Reports**

Body System	Reports	Morbidity Reports	Mortality Reports	Total Reports
Thermoregulatory Disorders (MedDRA “Body Temperature Conditions” under “General Disorders and Administration Site Conditions)	Hyperthermia, Hyperpyrexia, (sequelae incl. Rhabdomyolysis, seizure, Hypoglycemia)	138 [66, 331, 334-351]	46 [66, 172, 331, 334, 346, 352, 353, 333, 354]	184
Cardiac Disorders	Cardiac valve disease, Ventricular fibrillation, Cardiac arrest, Arrhythmia, Myocardial infarction, Generalized tonic-clonic seizure, Acute coronary syndrome, Myocardial necrosis, Cardio-respiratory arrest, Cardiomyopathy	16 [355-364]	13 [334, 365-371]	29
Metabolism and Nutrition Disorders	Acute renal failure, SIADH, Urinary retention, Hyponatremia, (sequelae of cerebral oedema, Acute renal failure), Diabetic ketoacidosis (MDMA+alcohol)	19 [372-384, 385]	7 [355, 386-391]	26
Hepatobiliary Disorders	Acute fulminant hepatitis, Liver disease, (Sequelae: Disseminated intravascular coagulation)	4 [363, 392-394]	5 [395-399]	9
Blood and Lymphatic System Disorders	Aplastic anemia	3 [400, 401]	1 [402]	4
Injuries, Poisonings, and Procedural Complications	Anaphylactic shock, Facial rash eruption, swollen lip (allergic or mechanical injury), uvular angioedema and reaction to allergen test	3 [403-405]	1 [406]	4



Nervous System Disorders	Hemorrhage, Infarct, Hippocampal sclerosis (suspected), Encephalopathy, Leukoencephalopathy Amnestic syndrome	15 [407-418]	0	15
Gastrointestinal Disorders	Xerostomia, Bruxism, Dental erosion	15 [419-421]	0	15
Psychiatric Disorders	Psychotic episode, Depressive episode, Obsessive-compulsive disorder, Auto-enucleation	4 [422-424]	0	4
Respiratory, Thoracic, and Mediastinal Disorders	Subcutaneous Pneumomediastinum, Epidural pneumatosis, Diffuse alveolar hemorrhage, Asthma Airway necrosis	9 [367, 425-432]	1 [433]	10
Eye Disorders	Lagophthalmos, Keratopathy, Bilateral sixth nerve palsy	4 [434, 435]	0	4
General Disorders and Administration Site Conditions	Unknown cause of death Heat stroke <sup>A</sup>	0	207 [367, 436] [437]	207
Skin and Subcutaneous Tissue Disorders	Angioedema	1 [438]	0	1
Vascular disorders	Ischemia in person with myocardial bridging	0	1 [439]	1
Total Reports		231	282	513

<sup>A</sup> MDMA detected in blood of three fatalities but authors viewed as heat stroke resulting from combination of environmental condition (outdoor music festival in tropical climate) combined with drug use.

There were 513 case reports, with 231 case reports of morbidity and 282 case reports of mortality, associated with Ecstasy use from 1986 through 2021 are summarized in [Table 3](#). Of these 282 case reports of mortality, 32 were described in a cumulative 2002 literature review with incomplete citations of sources, and are conservatively reported in addition to individual case reports of morbidities in the literature [334]. Detectable levels of MDMA in blood or urine are reported in less than half of these case reports, and range from 50 ng/mL (reported as less than 0.05 mg/L) in the case of anaphylactic shock [406] to 1500 ng/mL (reported as 1.5 mg/L) in a fatal case of hyperthermia and rhabdomyolysis [353].

Assessment of brain and blood MDMA in 11 fatalities under forensic autopsy detected lower doses in deaths where MDMA was determined to be incidental (accident, homicide) or detected in combination with other drugs versus blood and brain levels in a pair of deaths where cause of death was MDMA and no other drugs [440]. It is more difficult to associate events with MDMA when the compound is not detected or when detection is for amphetamines in general. Some events, such as valvular heart disease (VHD), acute hepatitis with gallbladder inflammation, liver disease, or urinary retention occurred in individuals who self-reported daily use for months to years prior to the event. In the majority of the 202 poisoning cases with unknown cause of death

in the UK and Wales between 1996 and 2002, Ecstasy was used in combination with opiates [436]. Polysubstance use is common in the majority of serious reports presented.

Researchers sought to calculate the rate of fatalities associated with Ecstasy use within a nation or across nations in a given time period in studies that reported Ecstasy ingestion in at least some fatalities [441]. An examination of reports made to the FDA Adverse Event Reporting System (FAERS) database found that fatalities associated with Ecstasy use were incredibly rare (946 of 13,773,614 cases), and only two of these cases (0.2%) were associated with Ecstasy and no other substance. More typically, these fatalities were associated with coadministration of opiates, benzodiazepines, and stimulants. An examination of Ecstasy-related fatalities in Portugal, Turkey, Finland and Australia from 2001 to 2019 was conducted [442]. Standardized fatalities per 100,000 ranged from lower than 0.05 per 100,000 in Portugal to 0.35 per 100,000 in Turkey. These analyses of large national datasets are in agreement with low estimated fatality rates due to Ecstasy use.

### 5.1.1 Thermoregulatory Disorders

Thermoregulatory disorders play a part in the development of a constellation of disorders across body systems. Primary symptoms are hyperthermia resulting in rhabdomyolysis described in 138 reports of morbidity and 46 reports of mortality, constituting the most common acute and serious adverse effect associated with Ecstasy [77, 443]. Thermoregulatory effects of Ecstasy taken in epidemiological settings are highly dependent on dose [443, 444] and permissive factors, including high ambient temperature [445, 446], crowded conditions involving overwhelming social interaction, physical exertion, reduced fluid intake [445], and thyroid dysregulation [447, 448]. Sympathomimetic effects of MDMA, at unknown doses and purity, in combination with permissive factors in uncontrolled settings, can lead to serious reports of acute and persisting adverse effects on multiple organs. In research settings, the risk of hyperthermia is limited by controlling ambient temperature, conducting treatment sessions in relaxed, private environments, and generally limiting permissive factors. In addition to a case of hyperthermia and delayed rhabdomyolysis in a 20-year old man listing detectable MDMA [351], recent reports describe hyperthermia and rhabdomyolysis wherein Ecstasy use is based upon self-report or the report of friends [364, 449-451].

### 5.1.2 Cardiac Disorders

Cardiac disorders associated with Ecstasy in the context of hyperthermia resulted in 16 reports of morbidity and 13 reports of mortality. Several fatal cases of cardiac arrest were reported. The elevation of blood pressure and increased heart rate produced by MDMA, similar to that produced by other sympathomimetic drugs, can lead to additional risks and complications [408, 409, 452], such as stroke, cardiac events, or other cerebrovascular events, including cerebral venous sinus thrombosis [453] and cerebral or subarachnoid hemorrhage [66, 454-458]. In two such cases, a previously existing underlying arteriovenous malformation appeared to play a role in the event [454, 456]. High plasma MDMA concentrations occurred in another case of cardiac arrest that also included extreme hyperthermia [371]. Intra-cardiac pressures, intra-arterial pressures, angiotensin II, pain, and adrenergic ( $\alpha$ 2) central nervous stimuli can also influence AVP secretion [459]. Increased AVP concentration, which is also caused by MDMA as described in [Section 6.2.3.2 Cardiovascular System](#), is described in several studies as a strong predictor of mortality in patients with chronic heart failure and acute heart failure, and contributes to increases in blood pressure [460]. As with any amphetamine, increased heart rate (tachycardia) and elevated blood pressure can also lead to cardiac events, such as arrhythmias or myocardial infarction [355, 367]. Fatal dysrhythmias have been reported following heavy Ecstasy use, resulting in ventricular fibrillation and asystole. Individuals with underlying cardiac and/or

pulmonary disease and preexisting conditions such as Wolff-Parkinson-White syndrome are especially at risk for heart failure and fatal arrhythmias. Although the presence of MDMA was rarely confirmed in reported cases, these types of events are all well-established complications of hypertension and can occur after use of amphetamines.

Some researchers have expressed concern that MDMA activity at 5HT<sub>2B</sub> receptors might be indicative of increasing risk of valvular heart disease (VHD) with repeated use [24]. Studies in Ecstasy users indicated that only people reporting average lifetime exposure of 900 tablets had cardiac abnormalities indicative of potential VHD [461], and a case of VHD has occurred in a man reporting approximately 16 years of heavy Ecstasy use, from age 17 to 33 years old. [362]. No abnormalities were found in people reporting lifetime exposure of approximately 200 tablets in the same study. VHD only occurred after extremely heavy Ecstasy use. Ecstasy can alter cardiac function leading to rhythm disturbances and sudden death, as seen in a case report of a 16 year old woman who ingested 1 g of Ecstasy [462]. However, echocardiographic readings in a prospective study testing 1.5 mg/kg MDMA HCl conducted in Ecstasy users (N=8, reported use mean 49 +/- 65 times, range 5-200) failed to find any structural cardiac abnormalities [37].

A non-fatal cardiac arrest occurred in the context of a genetic arrhythmia disorder, catecholaminergic polymorphic ventricular tachycardia [357]. A non-fatal cardiac arrest occurred in a 19-year old man with a history of previous substance use who collapsed at work, apparently after ingesting MDMA and amphetamine, with detectable levels of both drugs found in blood [364]. Apparent use of Ecstasy, with concurrent use of other amphetamines during pregnancy, was associated with seizures and myocardial infarction [360, 361]. As evidenced by these reports, individuals consuming Ecstasy with pre-existing conditions that can influence cardiovascular and cardiac function are at increased risk when consuming drugs of unknown purity, identity, and dose in uncontrolled settings.

### 5.1.3 Metabolism and Nutrition Disorders

Disorders classified as 'Metabolism and nutrition disorders' associated with Ecstasy in the context of hyperthermia resulted in 19 reports of morbidity and seven reports of mortality, with acute renal failure (ARF) as the most common cause of death. Ecstasy use has been associated with acute symptomatic hyponatremia with the syndrome of inappropriate antidiuretic-hormone secretion (SIADH) involving raised antidiuretic-hormone, also known as AVP [233]. AVP plays a key role in osmoregulation, and is released upon a change in plasma osmolality [235]. AVP is also involved in the response and adaptation to stress, through its effects on the HPA axis [235]. The rise in AVP results from a pharmacological effect of MDMA compounded by excessive fluid ingestion [236]. SIADH refers to disorders related to water and sodium balance characterized by the impairment of urinary dilution and hypotonic hyponatremia in the absence of renal disease or other identifiable non-osmotic stimuli known to activate the release of AVP [234].

In Ecstasy users with confirmed urinary MDMA, a significant association was found between plasma osmolality, plasma sodium, and CYP2D6 extensive metabolizer/ intermediate metabolizer genotypes and COMT low-activity genotypes [463]. Effects of Ecstasy, combined with increased consumption of water and permissive factors, such as strenuous exercise in warm ambient temperatures, can be further exacerbated in the context of poor metabolism. Gauging appropriate water intake may be difficult for users to estimate because MDMA reduces perception of thirst and impairs judgment [464].

A number of case reports describe hyponatremia after uncontrolled, non-medical Ecstasy use [326, 327, 465, 466]. A recent meta-analysis showed that a moderate reduction of serum sodium concentration is associated with an increased risk of death in different pathologic conditions

[467]. Relationships have been found between reduced plasma sodium, a measure of hyponatremia, and variations in COMT and CYP2D6 genotypes, possibly related to increased AVP and oxytocin release associated with MDMA [463]. Active doses of MDMA likely inhibit CYP2D6 in most individuals, as described in [Section 6.2.1 Pharmacokinetics and Product Metabolism in Humans](#). Behavioral factors, including vigorous exercise and excessive consumption of water without an attempt to replace electrolytes, and an increase in the anti-diuretic hormones AVP and oxytocin, likely all contribute to this very rare but serious condition in Ecstasy users [468]. Women are generally more likely to exhibit hyponatremia than men [469, 470], including Ecstasy or MDMA related hyponatremia [326]. Heart failure is commonly associated with hyponatremia, and is also characterized by increased concentrations of AVP [471-473].

Increased AVP secretion caused by MDMA in combination with permissive factors in uncontrolled settings can lead to serious reports of acute and persisting adverse effects on multiple organs, including the liver. Individuals consuming Ecstasy with pre-existing conditions that can influence renal function are at increased risk. In response to this risk, many users tend to overcompensate with excessive consumption of water, leading to dilutional hyponatremia. Prevention of hyponatremia with limited consumption of electrolyte containing fluids and controlled ambient temperatures are required to preserve the body's homeostatic maintenance of fluid balance.

A patient with Insulin-dependent diabetes mellitus consumed alcohol and Ecstasy which caused diabetic ketoacidosis [391]. An autopsy revealed microhemorrhages in the brain with subnuclear vacuolization and Armanni-Ebstein changes in renal tubes. A low level of MDMA was found in the blood (<0.01 mg/L).

#### **5.1.4 Hepatobiliary Disorders**

Hepatobiliary disorders associated with Ecstasy use resulted in four reports of morbidity and five reports of mortality. One of the mortality reports happened 1 week after Ecstasy use and was consistent with acute fulminant hepatitis in the absence of viral infection. This patient died despite liver transplantation efforts [395]. Mortality resulted from disseminated intravascular coagulation caused by platelet dysfunction associated with liver failure. Non-fatal morbidity reports range from acute hepatitis associated with daily usage of five to eight tablets of Ecstasy for 3 months in combination with alcohol [392] to liver damage in combination with congestive cardiomyopathy [363]. Acute, but non-fatal, liver failure occurred in a 17-year old man, also exhibiting tachycardia and hyperthermia, who had ingested cocaine, ethanol, and Ecstasy and was treated with a molecular adsorbent; drug quantification or detection is not listed in the report [451]. Given that polysubstance use and prior insult to liver function cannot be ruled out, the frequency of isolated serious hepatotoxicity cases in the absence of hyperthermia are rare among serious reports associated with Ecstasy use. Hepatotoxicity is more common among serious reports in combination with hyperthermia and acute renal failure.

#### **5.1.5 Blood and Lymphatic System Disorders**

Blood and lymphatic system disorders associated with Ecstasy use resulted in three morbidity reports and one mortality report of aplastic anemia. The death after aplastic anemia occurred from complications of immunosuppressant therapy followed by an allogeneic stem cell transplant, 17 months after the first admission [402]. The patient had initially presented with progressive weakness and epistaxis, resulting from daily Ecstasy use for 7 months, combined with heavy alcohol intake. Further examination revealed the replacement of bone marrow tissue with fatty deposits, likely due to alcohol consumption and exacerbated by chronic Ecstasy use. Three

reports of morbidity ranged in prior Ecstasy use levels from one to four times in the prior year, with two cases spontaneously resolving within 2 months and the treated case failing immunosuppressive therapy and recovering 4 months after subsequent bone marrow transplant [402].

### **5.1.6 Injuries, Poisonings, and Procedural Complications**

MDMA may provoke allergic or immune responses in some people. Though rarely reported in the literature, there are several such cases on record. One of the clearest cases is that of a uvular edema that occurred in a 31-year old male after ingesting Ecstasy later determined to be 71% MDMA [405]. A prick test confirmed a positive immune reaction to the material, and there is a report of a previous occurrence of this response in the same individual [438]. A report of possible anaphylactic shock and subsequent death occurred in a 13-year old girl who had at least one previous exposure to Ecstasy [406]. Her friends reported that she experienced swelling lips after her first exposure. After approximately 1.5 tablets, the girl experienced nausea and vomited, and later had difficulty breathing. On admission she was hypothermic and hypotensive. A low level of MDMA (<0.5 mg/dL) was detected in blood. None of the other individuals consuming tablets from the same batch underwent similar experiences. Autopsy found a massive brain edema as well as laryngeal oedema and lung congestion. Chemical analyses ruled out hyponatremia. The reaction may have been to MDMA or to an adulterant in the tablet. The authors of the report do not report whether tablets were assessed for contents. A report of swollen lips in a woman with detectable levels of MDMA in blood (1.466 mg/L) is ambiguous as to cause of swelling, since the patient may have experienced a sexual assault and injuries in transit to ER, and cannot clearly be established as an allergic reaction [404].

### **5.1.7 Gastrointestinal Disorders**

Gastrointestinal disorders resulted in 15 reports of morbidity including xerostomia, bruxism, and dental erosion in the context of Ecstasy use. Between 93 to 99% of Ecstasy users experience dry mouth or xerostomia at higher doses for up to 48 hours after consumption of Ecstasy, which can lead to enamel erosion [419]. Jaw clenching and grinding of teeth is frequently reported during Ecstasy use as well as in clinical trials. Tooth wear through the enamel into the underlying bone occurred in 60% of Ecstasy users versus 11% of non-users in one study, which was attributed to jaw clenching rather than tooth grinding [419]. Necrotizing gingivitis and tenderness in the temporomandibular joint were also reported.

### **5.1.8 Respiratory, Thoracic, and Mediastinal Disorders**

Respiratory, thoracic, and mediastinal disorders resulted in 9 reports of morbidity and one report of mortality in the context of Ecstasy use. A single mortality report of airway necrosis occurred in a 25-year-old male who had a history of occasional Ecstasy use by inhalation. The patient was initially found unresponsive and was resuscitated, but airway necrosis due to vasoconstriction of airway walls led to hypoxic cardiac arrest [433]. This report is not consistent with the usual respiratory, thoracic, and mediastinal adverse outcomes reported from oral administration of Ecstasy. The mortality report is likely due to the patient's chosen route of administration.

### **5.1.9 Psychiatric Disorders**

Psychiatric disorders associated with Ecstasy use resulted in 4 morbidity reports and no mortality reports. Psychiatric problems after uncontrolled, non-medical Ecstasy use were reported in 22.1% of 199 case reports from the early 1990s to 2001 and are a common reason for appearance at an emergency department [465]. Psychiatric symptoms included affective responses, such as



dysphoria, anxiety, panic, and psychotic response, as well as cases with mixed psychotic and affective features. The most common problem reported included panic, restlessness and psychotic response, as seen in a systematic review and several epidemiological case series [77, 474]. The mechanisms behind Ecstasy-associated psychiatric problems remain unclear but are likely the result of an interaction between pharmacology and individual susceptibility. The difficulty of assessing the frequency of these events is increased given that pre-existing psychiatric problems occur in people who choose to use Ecstasy [475] and findings of an association between use of Ecstasy and other drugs and self-reported symptoms of anxiety and depression. As described earlier, most cases of psychological distress after Ecstasy use resolved after supportive care [325, 330]. Anxiety responses associated with MDMA administration reported in controlled trials have resolved over time, usually either during the period of acute drug effect or with the waning of drug effects.

Previous reports have found an association between Ecstasy use and symptoms of depression or anxiety [476, 477]. A meta-analysis of self-reported depressive symptoms detected an association between Ecstasy use and self-reported depression symptoms [478]. However, the association was strongest in studies with small samples, and drug use variables were often incompletely reported and not verified. Many studies found that increases in self-reported anxiety or depression were more strongly related to polydrug use rather than to use of any one substance [479-482]. Two studies found an equal or stronger association between regular use of cannabis, and not Ecstasy, with anxiety, depression or other psychological problems [483, 484]. An assessment of men reporting substance use in a large cohort found that the highest degree of mental health problems in respondents reporting Ecstasy use in the last 12 months, followed by those reporting stimulant use [485]; stressful life events and perceived stress also differed across groups. Anxiety regarding loss of control under the influence of Ecstasy could develop to a degree where it could lead to panic attacks. Case reports have been published describing panic attacks in individuals under the acute influence of Ecstasy [486]. Enduring panic attacks have been reported in individuals after repeated Ecstasy use [487, 488] and in one case, even after a single dose [489].

When compared with polydrug using controls, people who use Ecstasy report being more empathetic and exhibit greater cognitive empathy when viewing photographs of expressive emotions [490], and did not differ in degree of reaction to social exclusion. These findings may be affected by the same problems as other retrospective studies, such as the presence of another factor or factors influencing empathy and drug use patterns.

Neuroendocrine response to oral citalopram did not differ between Ecstasy users, cannabis users and controls [491]. People reporting regular drug use and Ecstasy use had higher levels of salivary cortisol in the evening, and higher salivary cortisol on the day of a multitasking activity [492], and higher salivary cortisol on waking that was unrelated to prefrontal SERT binding or self-reported depression symptoms [493]. A 4-year longitudinal study reported that factors other than Ecstasy use, including female sex and presence of financial and relationship difficulties, were more closely related to self-reported symptoms of depression [494]. Comparison of self-reported psychological symptoms in samples of people grouped by self-reported drug use found current Ecstasy users had lower global symptom severity scores than polydrug users [495]. In conclusion, it appears that the relationship between Ecstasy use on self-reported mood or psychiatric problems is not strong, with equal or stronger involvement of other factors.

### **5.1.10 Nervous System Disorders**

Nervous System disorders associated with Ecstasy use resulted in 15 morbidity reports and no mortality reports. Memory difficulties arising immediately after Ecstasy use have been reported in a sporadic user [413]. The memory difficulties arose in a man reporting use of Ecstasy five or



six times, with confusion and cognitive impairment reportedly occurring after taking a single tablet at a party. Cognitive function was assessed 7 years later. Imaging showed signs of hippocampal sclerosis. It is not clear from the report whether the individual used Ecstasy prior to or after this event. The individual had hypertension, raising questions concerning possibility of a cerebrovascular event. In a report of a serious neurological event with 0.83 ng/mL MDMA detected in the hair of a girl who developed encephalopathy [412] during chronic low or moderate Ecstasy use, cognitive function and memory problems associated with neurological damage was reported. Upon cessation of use 16 months later, extensive hippocampal remodeling was reported assessed through positron emission tomography (PET) scans. This finding is consistent with hippocampal dendritic spine remodeling observed in rats receiving 20 mg/kg MDMA HCl for 4 days intended to simulate chronic usage in humans [496], however, the clinical presentation was also similar to CNS herpes infection, so it is difficult to attribute this isolated case report to only Ecstasy use. Two reports have identified bilateral lesions in the globus pallidus of Ecstasy users during magnetic resonance imaging (MRI) or autopsy, with a third report finding hippocampal changes in imaging associated with amnesic syndrome [414-416]. Due to the retrospective and infrequent nature of these reports, it is difficult to determine causality.

Many researchers have studied the effects of repeated non-medical or recreational use of Ecstasy in humans [69-71, 497]. Early investigations had several methodological flaws, including retrospective design and poor matching of Ecstasy users with appropriate controls [76, 498]. Later studies sought to remedy some of these problems by using carefully matched polydrug user or cannabis user controls, or by relying on a sample with relatively low exposure to psychoactive substances, including alcohol [499-502]. Researchers comparing the average reported Ecstasy/MDMA use of samples in imaging studies with average use in a large, global internet survey found participants in imaging studies were in the top 5 to 10% in terms of size of usual dose and amount taken per occurrence [503]. Imaging studies may not represent effects in people reporting average use, or in people enrolled in clinical trials. Some of these investigators also conducted longitudinal studies, comparing Ecstasy users, sometimes alongside controls, at two separate time points [504-506]. Retrospective studies comparing Ecstasy users with various control groups have investigated brain serotonin, sleep architecture and quality, verbal memory and executive function. Most, but not all, detect at long-term deleterious effects in samples of people who use Ecstasy. Retrospective designs, compounded with lack of information concerning exposure and insufficiently matched controls, limits their interpretability.

Most studies have suggested that heavy, but not moderate, Ecstasy users had impaired verbal memory and lower numbers of estimated SERT sites, assessed via imaging with radioactively labeled ligands in PET or single photon emission tomography (SPECT), with heavy use often defined as 50 or more times or tablets. Taken together, findings from these studies suggest there is some risk of long-term effects in heavy Ecstasy users with respect to number of estimated SERT sites in specific brain areas and performance on measures of memory. However, interpreting findings of changes in serotonin receptors or cognitive function after repeated Ecstasy use are complicated by the possible impact of polydrug use and other potential pre-existing factors in retrospective reports, and the findings are not readily transferrable to use of MDMA in a therapeutic or research context.

## 5.2 Cognitive Function and Performance

Many investigations have examined cognitive function in Ecstasy users with the goal of demonstrating long-term effects of purported neurotoxicity of Ecstasy. Rogers and colleagues performed a meta-analysis on a large number of retrospective studies of Ecstasy users and various cognitive functions. Given methodological flaws in this type of analysis, the investigators

cautiously concluded that there might be a significant effect of Ecstasy use on verbal memory, and a lesser effect on visual memory [77].

Retrospective designs and inappropriately matched samples continue to appear in the literature [507-509], even when using multiple control groups. Two meta-analyses of memory in Ecstasy users arrived at somewhat contradictory conclusions [510, 511]. Both detected an association between Ecstasy use and impaired performance on at least some measures of memory. However, one reported that this association had a medium to large effect size with no effect of Ecstasy dose [510], while the other reported that the association had a small to medium effect size with an Ecstasy dose effect, and that polydrug use itself contributed to impaired cognitive function [511].

In a prospective study comparing cognitive function in people before and up to 18 months after reported initiation of Ecstasy use, Schilt and colleagues found an association between Ecstasy use and performance on measures of verbal memory, but not attention or working memory [512]. All scores were within normal range; people who did not use Ecstasy showed greater improvement in performance at the second time of assessment than people reporting some use. A second prospective study examined working memory in people reporting Ecstasy use similar to participants in Schilt's study with controls and failed to find any significant differences in working memory and selective attention [513]. An analysis of findings from largely retrospective studies of Ecstasy users reported a small deficit in verbal or working memory [77]. Retrospective studies of polydrug users who use Ecstasy and controls reported impaired global motion processing without changes to local processing [514].

Not all studies report that Ecstasy users fare worse on measures of cognitive function than controls, and methodological critiques and at least one commentary and review discuss the contribution of research and publication bias in driving findings [515]. Several reports detected little or no significant differences between Ecstasy users and polydrug user controls in performance on tasks of cognitive function [320, 513, 516-521], though other studies continue to find consistent differences, particularly in verbal memory [522-526]. Regular use of many substances, including alcohol, may affect cognitive function, with Ecstasy being only one of those substances [527]. Several reports have found relationships between cognitive function and use of other drugs as well as or instead of Ecstasy [516, 518, 522, 528-530]. The only study attempting to address effects of Ecstasy use on cognitive function in middle aged versus younger users did not find a greater degree of impairment [531].

A meta-analysis comparing current Ecstasy users and drug-using controls on visuospatial skills reported that current users performed less well on measures of visual recall, recognition and item production than controls [532], but found no significant relationship between lifetime Ecstasy use and visuospatial task performance. A longitudinal study comparing people who continued to use Ecstasy with those who did not do so detected lower performance on immediate and delayed visual memory [533]. In a second follow-up in the same sample reported lower scores in visual memory, at marginal significance and no further impairment [534]. An examination of the relationship between elements of Ecstasy use history and verbal memory reported that use in the past year, especially in men, was associated with impaired verbal memory [535]. The authors suggest that sex differences in polydrug use may be involved. A study comparing performance on a test of verbal memory in 65 Ecstasy users enrolled in clinical trials of MDMA and an equal number of age and sex matched non-drug using controls from other trials failed to detect significant differences between the two groups [536].

The nature and strength of the association between regular Ecstasy use and any impairments in executive function remains inconclusive, with studies reporting conflicting results [315, 501, 502, 537, 538]. Findings from a study published in 2014 did not find differences in multitasking [492].

A meta-analysis comparing executive function in Ecstasy users and non-Ecstasy using controls found a significant effect of Ecstasy use on one component of executive function (updating), no effect on another (shifting), and mixed results when looking at other components (response inhibition and access to long-term memory) [539]. Polydrug use likely contributes to findings of impaired executive function seen in Ecstasy users [481, 540]. Current research has not settled the question.

The relationship between Ecstasy use and impulsivity has also been extensively examined, with some researchers reporting greater impulsivity in Ecstasy users and others failing to find any differences [70, 541]. Studies using both behavioral and self-report measures of impulsivity reached contradictory conclusions [520, 542, 543]. Two studies using the same measure of behavioral impulsivity in samples of heavy Ecstasy users obtained different findings [520, 542]. It is notable that Quednow and colleagues compared Ecstasy users with abstinent cannabis users and drug-naïve controls while Roiser and colleagues compared Ecstasy users with former Ecstasy users, polydrug users and drug-naïve controls, raising the possibility that results might have differed in part due to control group selection. It is possible that people who self-administer Ecstasy may already possess above-average levels of sensation-seeking and impulsiveness. To date, all such studies have used retrospective study designs and cannot rule out this possibility, and some studies suggest that polydrug use may be equally or more strongly related to impulsivity in Ecstasy users [544-546]. A systematic review of decision-making that addressed many of these studies concluded that the current research does not permit drawing conclusions concerning effects of long-term Ecstasy use on decision-making [547]. Adolescents “at risk” for stimulant use, including MDMA, reported greater rates of gambling than at-risk adolescents not reporting stimulant use, with gambling considered a possible marker of impulsivity [548]. The relationship between drug use, including Ecstasy use, and impulsivity, is complex, including likely contributions of impulsivity and risk-assessment decisions on the decision to initiate and continue Ecstasy use that make it difficult to assess causality.

## **6.0 Effects in Humans in Clinical Settings**

### **6.1 History of Use in Clinical Settings**

Shulgin and Nichols were the first to report on the effects of MDMA in humans [48]. In the 1970s, psychotherapists used MDMA-assisted therapy to treat psychological disorders including anxiety [55]. Legal therapeutic use of MDMA continued until its placement on the U.S. list of Schedule I drugs in 1985 [54, 58, 312]. An estimated 500,000 doses of MDMA were administered during therapy sessions in North America prior to its scheduling [46, 312]. A few uncontrolled human studies of MDMA occurred in the 1980s [36, 51] including Greer and Tolbert's study of MDMA in a psychotherapeutic context.

Controlled human studies of MDMA commenced in the mid-1990s with a MAPS funded investigator-initiated Phase 1 dose-response safety study [40, 549]. As of October 01, 2021, approximately 78 human trials with MDMA have been conducted globally over the past four decades outside the development program (N=1,441) (see [Appendix Table 1: Summary of Investigator-Initiated Trials with MDMA](#)). MAPS also funded a Phase 2 investigator-initiated dose-response safety and efficacy pilot study in Spain that was terminated early due to political concerns. This study enrolled six participants, with four receiving a single session of MDMA-assisted therapy without any safety concerns and some PTSD symptom reduction [78].

Based on past reports of MDMA use, nonclinical studies, and the results from these investigator-initiated trials with MDMA, the sponsor launched a Phase 2 Clinical Development Program in 2001 to develop MDMA-assisted therapy for the treatment of chronic PTSD under a U.S. IND.

Eleven sponsor-supported studies of MDMA-assisted therapy for PTSD have been completed. The sponsor has initiated or plans to initiate several Phase 1 studies, at least one Phase 2 study including a study in Europe and at least one Phase 3 study. These studies will include studies of MDMA pharmacokinetics, additional studies of MDMA-assisted therapy in people with PTSD and a Phase 2 study of MDMA-assisted therapy in people with eating disorders (see [Table 5: Summary of Ongoing and Planned Sponsor-Supported Trials with MDMA](#)). As of October 01, 2021, 358 individuals were exposed to MDMA in the sponsor's clinical development program across various indications.

**Table 4: Summary of Completed Sponsor Supported Trials with MDMA <sup>A</sup>**

Study	NCT #	Location	Population	Therapy Teams (n)	MDMA HCl Initial Dose <sup>B</sup>	MDMA HCl Supplementary Dose <sup>B,C</sup>	Design	Exposed to MDMA at Any Dose <sup>D</sup>	Publications
<i>PTSD</i>									
MP-1	NCT00090064	Charleston, South Carolina	Crime, veterans	1	Placebo (n=8), 125 mg (n=15)	Placebo, 62.5 mg	Blinded RCT, open-label Stage 2	22	[41, 79]
MP-2	NCT00353938	Biberist, Switzerland	Various	1	25 mg (n=5), 125 mg (n=9)	12.5 mg, 62.5 mg	Blinded RCT, open-label Stage 2 Open label Stage 3	14	[42]
MP-3	NCT00402298	Beer Yaakov, Israel	Various	1	25 mg (n=2), 125 mg (n=3)	12.5 mg, 62.5 mg	Blinded RCT, planned Stage 2	5	Terminated early
MP-4	NCT01958593	Vancouver, Canada	Various	2	Placebo (n=2), 125 mg (n=4)	Placebo, 62.5 mg	Blinded RCT, open-label Stage 2	6	Terminated early
MP-8	NCT01211405	Charleston, South Carolina	Veterans, firefighters, police officers	1	30 mg (n=7), 75 mg (n=7), 125 mg (n=12)	15 mg, 37.5 mg, 62.5 mg	Blinded RCT, open-label Stage 2	26	[550]
MP-9	NCT01689740	Be'er Ya'aqov, Israel	Various	5	25 mg (n=3), 125 mg (n=7) <sup>E</sup>	12.5 mg, 62.5 mg	Blinded RCT, open-label Stage 2	10	
MP-12	NCT01793610	Boulder, Colorado	Various	9	40 mg (n=6), 100 mg (n=9), 125 mg (n=13)	20 mg, 50 mg, 62.5 mg	Blinded RCT, Open label Stage 2	28	[551]
MPVA-1	NCT02876172	Charleston, SC	Dyads w/one person w/ PTSD diag., one no PTSD	4	75 mg (1 <sup>st</sup> session), 100 mg (2 <sup>nd</sup> session)	37.5 mg, 50 mg	Open label Phase 1/Phase 2	12	[552]
MP16	NCT03282123	Multi-site; US, Israel	Various	33	80 mg, 100 mg	40 mg, 50 mg	Open label	33	[86]
MP17	NCT03485287	Multi-site, Canada	Various	4	100 mg, 125 mg	50 mg, 62.5 mg	Open label	4	[86]
MAPP1	NCT03537014	Multi-site; US, Canada, Israel	Various	40	Placebo 80 mg (1 <sup>st</sup> sessions), 80 or 120 mg (2 <sup>nd</sup> , 3 <sup>rd</sup> sessions)	Placebo, 40 mg, 40 mg or 60 mg	Blinded RCT	46	[30]

<i>Social anxiety</i>									
MAA-1	NCT02008396	Los Angeles, CA	Adults on autism spectrum with social anxiety	1	Placebo (n=4), 75-125 mg (8)	Placebo, 32 mg to 53 mg	Blinded RCT, open-label arm	12	[89]
<i>Illness/ Anxiety</i>									
MDA-1	NCT02427568	San Anselmo, CA	Anxiety related to life-threatening illness	3	Placebo (n=5), 125 mg (n=13)	Placebo, 62.5 mg	Blinded RCT, Open Label Stage 2	18	[553]
<i>Healthy Controls</i>									
MPVA-4	NCT03181763	Atlanta, GA	Healthy, aged 21-55, prev. experience w/MDMA	N/A	Placebo, 100 mg	Placebo, 50 mg	Between-subjects RCT	17	[88]

Abbreviations: NCT=clinicaltrials.gov identifier; n=number of participants; m=months; w=weeks; TBD=To be determined

<sup>A</sup> Completed Studies indicates that all subjects have completed the study. Clinical Study Reports are in progress.

<sup>B</sup> Values reflect the active MDMA free-base weight, not the total MDMA HCl weight. See [Appendix Table 23: MDMA Salt to Active Moiety Conversion](#) Chart.

<sup>C</sup> Study protocols include a divided-dosing regimen with an initial dose followed by a supplemental dose administered 1.5-2 hours later, unless tolerability issues emerge with the initial dose or the participant declined.

<sup>D</sup> At treatment exit.

<sup>E</sup> The first two participants were open-label (125 mg MDMA) and were included in the efficacy analyses.



**Table 5: Summary of Ongoing and Planned Sponsor Supported Trials with MDMA**

Study	NCT #	Location	Population	MDMA HCl Initial Doses <sup>A</sup>	MDMA HCl Supplementary Dose <sup>A,B</sup>	Design	Status/Publications
<i>PTSD</i>							
MP18	NCT04030169	Multi-site; Czechia, Netherlands, Norway, Portugal, UK, Germany	Various	80 mg (1 <sup>st</sup> sessions), 80 or 120 mg (2 <sup>nd</sup> , 3 <sup>rd</sup> sessions)	40 mg, 40 mg or 60 mg	Open label	Ongoing, open-label
MAPP2	NCT04077437	Multi-site; US, Canada, Israel	Various	Placebo, 80 mg (1 <sup>st</sup> sessions), 80 or 120 mg (2 <sup>nd</sup> , 3 <sup>rd</sup> sessions)	Placebo, 40 mg, 40 mg or 60 mg	Blinded RCT	Ongoing, blinded
MAPPUSX	NCT04714359	Multi-site; US, Canada, Israel	Various	80 mg (1 <sup>st</sup> session), 80 or 120 mg (2 <sup>nd</sup> , 3 <sup>rd</sup> sessions)	40 mg, 40 mg or 60 mg	Open label	Ongoing, open-label
MPVA6	NCT04784143	Bronx, NY	Various	120 mg	40 mg	Open label RCT	Ongoing, open-label
MPLONG	NCT05066282	Multi-site; US, Canada, Israel	Various	N/A	N/A	Long-term follow-up; observational	Ongoing
MAPP3	TBD	Multi-site; Czechia, Netherlands, Norway, Portugal, UK, Germany, and Spain	Various	Placebo, 80 mg (1 <sup>st</sup> session), 80 or 120 mg (2 <sup>nd</sup> , 3 <sup>rd</sup> sessions)	Placebo, 40 mg, 40 mg or 60 mg	Blinded RCT	Planned
MPG1	TBD	TBD	Various	100 mg	40 mg or 60 mg	Open label, group study	Planned
EAMP1	TBD	Multi-site	Various	80 mg (1 <sup>st</sup> session), 80 or 120 mg (2 <sup>nd</sup> , 3 <sup>rd</sup> sessions)	40 mg, 40 mg or 60 mg	Expanded Access; Open label	Planned
MPELON G	TBD	Multi-site; Czechia, Netherlands, Norway, Portugal, UK, Germany, and Spain	Various	N/A	N/A	Long-term follow-up; observational	Planned
<i>Eating Disorders</i>							

MED1	NCT04454684	Multi-site; Montreal, PQ; Vancouver, BC; (Canada); Denver, CO (US)	Anorexia nervosa; binge eating disorder	80 mg (1 <sup>st</sup> session), 80 or 120 mg (2 <sup>nd</sup> , 3 <sup>rd</sup> sessions)	40 mg, 40 mg or 60 mg	Open label, not randomized	Planned
<i>Healthy Controls</i>							
MT-1	NCT01404754	Charleston, SC; Boulder, CO; Santa Fe, NM	Candidate trainees in MDMA-assisted Therapy	Placebo, 120 mg	Placebo, 60 mg	WS, full crossover RCT	Ongoing, blinded
MT2	NCT04073433	Multi-site	Trainees in MDMA-assisted therapy	120 mg	40 mg or 60 mg	Open label	Planned
MPKF	TBD	Knoxville, TN	Healthy controls	120 mg	N/A	Open label crossover (with/without fasting)	Planned
MPKH	NCT03606538	San Francisco, CA	Healthy controls and participants with moderately impaired liver function	80 mg	N/A	Open label	Planned, post-marketing study for possible label expansion

Abbreviations: NCT=clinicaltrials.gov identifier, N/A=non-applicable

<sup>A</sup> Values reflect the active MDMA free-base weight, not the total MDMA HCl weight. See [Appendix Table 23: MDMA Salt to Active Moiety Conversion Chart](#).

<sup>B</sup> Study protocols include a divided-dosing regimen with an initial dose followed by a supplemental dose administered 1.5-2 hours later, unless tolerability issues emerge with the initial dose or the participant declined.

### 6.1.1 Phase 1 Studies

The sponsor has one completed (MPVA-4) and one ongoing (MT-1) Phase 1 studies. MPVA-4 is a Phase 1, randomized, placebo-controlled, double-blinded between-groups study in 34 healthy participants examining the effects of MDMA on presence and intensity of startle response after receiving cues that were previously paired with a startling stimulus. Participants received 100 mg MDMA HCl or placebo and repeated the startle-related task with the same cues in the absence of the startling stimuli to assess the effect of MDMA or placebo on the startle response. This study concluded in October 2020; the findings have been submitted for publication and the Clinical Study Report (CSR) is in preparation.

In ongoing study MT-1, healthy volunteers who have had completed training in MDMA-assisted therapy undergo two sessions in a within-subject, double-blind crossover study, receiving placebo during one session and 125 mg MDMA HCl during the other. Subjective effects, mood, and reactions are also being assessed in the ongoing Phase 1 placebo-controlled study of MDMA-assisted therapy, in healthy volunteers who have completed training in MDMA-assisted therapy (MT-1).

### 6.1.2 Phase 2 Studies

Most data reported are from Phase 2 studies of MDMA-assisted therapy for PTSD. Data from a pair of investigations of MDMA-assisted therapy for other indications are also presented. These studies have administered MDMA in divided doses, with an initial dose administered at the start of the session and a supplemental dose following 1.5 to 2 hours later. The supplemental dose given at approximately peak exposure from the initial dose does not significantly impact intensity of pharmacodynamic effects but does enable a longer period to process trauma in the context of dosing sessions. Studies have employed a range of comparator and active doses from an initial dose of 25 mg to 150 mg MDMA HCl. The lowest dose in use has been 25 mg MDMA HCl, used as a placebo or low dose comparator in studies MP-2 and MP-9. Typically, Stage 1 was blinded and Stage 2 was open-label in which participants who received placebo or comparator doses in Stage 1 received active MDMA. The highest initial dose (150 mg MDMA HCl) was offered to a limited number of participants in MP-2 as part of "Stage 3," an open-label arm for non-responders in Stage 1 and/or Stage 2. The most common dosing regimen employed was 125 mg MDMA HCl followed by a supplemental dose of 62.5 mg as the primary active treatment. The supplemental dose given at approximately peak exposure from the initial dose does not significantly impact intensity of pharmacodynamic effects but does enable a longer period to process trauma in the context of dosing sessions. In sponsor-supported studies, MDMA or placebo/comparator is administered after preparatory therapy during two or three 8-hour dosing sessions scheduled 2 to 5 weeks apart, each followed by at least three sessions of integrative therapy. This treatment model is based on historical experience with MDMA use as an adjunct to therapy. See [Table 4](#) for more details on completed studies and [Table 5](#) on planned and ongoing studies.

MAPS has completed eight blinded randomized, controlled and four open-label Phase 2 and Phase 3 investigations of MDMA-assisted therapy for PTSD including one extension study for treatment of relapse [31]. These studies explored the reproducibility and persistence of treatment outcomes of MDMA-assisted therapy in people with chronic PTSD, and in some protocols PTSD that failed to respond to at least one course of therapy or at least one course of pharmacotherapy. Phase 2 studies MP-1, MP-8 and MP-12, along with the Phase 2 lead-in study MP16 are highlighted below. The three smaller Phase 2 studies (MP-4, MP-9, and MP17) are summarized below, but due to their size and design differences from the Phase 3 studies, they are not expanded on here.

### 6.1.2.1 Study MP-1

Study MP-1 (N=23) compared two blinded dosing sessions of MDMA (125 mg initial dose with 62.5 mg supplemental dose) or placebo in participants with chronic, treatment-resistant PTSD from any cause, with an average age of 40.4 (SD:7.2) years. MDMA participants were subsequently offered a third dosing session with the same dose of MDMA. Placebo participants were subsequently offered participation in an open-label crossover segment wherein they underwent up to three open-label sessions with MDMA. An ITT analysis of this study found that the decrease in CAPS-IV PTSD symptom severity was significantly greater for the MDMA group compared to the placebo group at the primary endpoint ( $p=0.002$ ) with a large effect size (placebo-corrected Cohen's  $d=1.9$ ) with early onset of treatment efficacy after the first dosing session [41]. The seven placebo participants who completed the open-label cross-over also experienced comparable reduction in CAPS-IV PTSD symptom severity. At the Primary Endpoint, 73% of active dose subjects no longer met PTSD Diagnostic Criteria, compared to 25% of subjects receiving placebo. There were no significant differences on any of the three cognitive measures (RBANS total score, PASAT Trial 1, PASAT Trial 2, Rey-Osterrieth 30-minute delay score) or pre/post clinical laboratory assessments for safety. At Long-term follow-up, assessed 17 to 74 (mean = 45.4) months after the control study's final MDMA session, there were no statistically significant differences between mean CAPS-IV score 23.7 (SD:22.8) compared to mean CAPS-IV score obtained at study exit 24.6 (SD:18.6) [79]. No SARs were reported in this study. Detailed safety information from this study is included in [Section 6.4 Safety of MDMA in Humans](#).

### 6.1.2.2 Study MP-8

Study MP-8 (N=26) compared 3 doses of MDMA (30 mg, 75 mg, or 125 mg MDMA HCl) initial dose, with a supplemental dose equivalent to half the initial dose) in military veterans, firefighters, and police officers ("first responders") with service-related PTSD, with an average age of 37.2 (SD:10.3) years. Each dosing arm participated in two blinded dosing sessions with the assigned dose, followed by open-label crossover (three open-label sessions consisting of a full active dose of 100 mg or 125 mg) initial dose, with a supplemental dose equivalent to half the initial dose). These study results were published in 2018 [550]. This study found that the decreases in CAPS-IV PTSD symptom severity, expressed as mean (SD) at the Primary Endpoint, in the 75 mg (-58.3 (SD:9.8)) and 125 mg groups (-44.3 (SD:28.7)), had significantly decreased ( $p<0.001$ ) compared to the 30 mg group (-11.4 (SD:12.7)) [550].

There was one SAR that occurred in this study: one participant experienced an increase in frequency of ventricular extrasystoles, a form of cardiac arrhythmia, on the day of his third and final dosing session with open-label 125 mg MDMA HCl. For further detail see [Section 6.4.1.5 Serious Adverse Reactions](#). Detailed safety information from this study is included in [Section 6.4 Safety of MDMA in Humans](#).

### 6.1.2.3 Study MP-12

Study MP-12 (N=28) compared 3 doses of MDMA (40 mg, 100 mg, or 125 mg MDMA HCl initial dose, with a supplemental dose equivalent to half the initial dose) in participants with PTSD from any cause, with an average age of 42.0 (SD:12.9) years. Each dosing arm participated in two blinded dosing sessions with the assigned dose, followed by open-label crossover (three open-label sessions in the low dose arm or one open-label session in the other two active dose arms consisting of a full active dose of 100 mg or 125 mg MDMA HCl initial dose, with a supplemental dose equivalent to half the initial dose). These study results were published in 2018

[551]. This study found that in the intent-to-treat set, the CAPS-IV PTSD symptom severity score reduction, expressed as mean (SD), at the Primary Endpoint were -26.3 (29.5) for 125 mg, -24.4 (24.2) for 100 mg, and -11.5 (21.2) for 40 mg, though a statistically significant reduction ( $p=0.03$ ) was only demonstrated in the per protocol set for the 125 mg dose compared to the 40 mg dose [551]. Detailed safety information from this study is included in [Section 6.4 Safety of MDMA in Humans](#).

#### 6.1.2.4 Study MP16

Study MP16 (N=33) was conducted as a multi-site Phase 2 open-label study of MDMA-assisted therapy for PTSD. MDMA (80 mg or 120 mg MDMA HCl) with an optional supplemental dose equal to half of the initial dose) was administered in three therapy sessions with non-drug preparatory and Integrative Sessions. An aim of this was to provide supervision to newly trained therapy teams prior to participating in the Phase 3 trials. Thirty-three participants completed these studies. The findings from MP16 and another multi-site clinical trial (MP17) demonstrated that the observed treatment response to MDMA-assisted therapy can be scaled and replicated by newly trained therapy teams across multiple sites. These study results were published in 2021 [86]. MP16 also included a sub-study to pilot participants returning home following dosing sessions with MDMA-assisted therapy without having a post-visit overnight stay. At the Primary Endpoint, the mean change in CAPS-5 total severity score from Baseline was a reduction of 30.5 (SD: 14.1), with 90.6% of subjects reporting a clinically significant reduction in CAPS-5 total severity and 75% of subjects no longer meeting PTSD diagnostic criteria. Onset of treatment effectiveness was measured three to five weeks after the first dosing session, 21 (63.6%) subjects had a clinically significant reduction in CAPS-5 Total Severity Score, eleven (33.3%) subjects did not meet diagnostic criteria for PTSD, and two (6.1%) subjects were considered in remission, with a CAPS-5 Total Severity Score less than 11 and Loss of PTSD Diagnosis. The no overnight stay pilot sub-study group consisted of four participants and these participants showed similar improvement in both the primary and secondary outcomes. Comparing adverse events between the overnight stay and no overnight stay groups, there appeared to a greater percentage of fatigue, muscle tightness, and insomnia in the overnight stay group. However, it is difficult to compare across groups due to the small sample size (N=4) in the no overnight stay group. Overall, the no overnight stay group did not have a greater percentage of AEs compared to the overnight stay group and there were no meaningful differences between study groups. Detailed safety information from this study is included in [Section 6.4 Safety of MDMA in Humans](#).

#### 6.1.2.5 Other Phase 2 Studies

The sponsor has also completed three international Phase 2 studies. Study MP-4 (N=6), conducted in Canada, compared placebo to an initial dose of 125 mg MDMA HCl, with an optional supplemental dose equivalent to half the initial dose, in participants with an average age of  $47.7\pm 6.0$  years. Study MP-9 (N=10), conducted in Israel, compared an initial dose of 25 mg to 125 mg MDMA HCl, with an optional supplemental dose equivalent to half the initial dose, in participants with an average age of  $36.7\pm 8.0$  years. Study MP17 (N=4), a parallel Canadian study to the U.S. MP16 study described above, was conducted as a two-site Phase 2 open-label study of MDMA-assisted therapy for PTSD. An initial dose 100 mg or 125 mg MDMA HCl), with an optional supplemental dose equal to half of the initial dose was administered in three therapy sessions with non-drug preparatory and Integrative Sessions. Similar to MP16, one aim of this study was to provide supervision to newly trained therapy teams prior to participating in the Phase 3 trials.

The sponsor has additionally completed an open-label study of a combination of MDMA-assisted therapy and cognitive behavioral conjoint therapy in six dyads that include a participant with PTSD and a participant without PTSD, and relationship distress (MPVA-1, N=12).

### 6.1.3 Phase 3 Studies

#### 6.1.3.1 Study MAPP1

Study MAPP1 is a pivotal Phase 3 trial conducted to support planned marketing authorization applications for approval of MDMA-assisted therapy to treat PTSD. This multi-site trial enrolled 131, randomized 91, and treated 90 participants who received receive MDMA (N=46) or placebo (N=44) with identical therapy. The dosing regimen is a divided single-dose of 120 mg MDMA HCl (80 mg initial + 40 mg supplemental) for the first session and a dose escalation to 180 mg MDMA HCl (120 mg initial + 60 mg supplemental) during the second and third sessions. The supplemental dose and dose escalation could be withheld if the initial dose was not tolerated or the participant declined. MAPP1 began enrollment in November 2018 and the study was completed in October 2020. This study included a similar sub-study to pilot participants returning home following dosing sessions with MDMA-assisted therapy (and not having a post-visit overnight stay).

Demographics and baseline characteristics of study participants in MAPP1 were not significantly different in terms of race, ethnicity, sex, age, dissociative subtype of PTSD, disability, and CAPS-5 score across study arms. The average age was 41 (SD: 11.9). The majority of participants were assigned female at birth (65.6%) and were White (76.7%), see [Table 6: Demographics of Participants in MAPP1 Study of MDMA-Assisted Therapy](#). The average duration of PTSD was 14.1 (SD: 11.5) years and 21.1% of participants had the dissociative subtype of PTSD. On average, participants had severe PTSD with functional impairment, as evidenced by the Baseline CAPS-5 total severity mean score of 44.1 (SD: 6.04) and the mean SDS score of 7.1 (SD: 1.9). History of suicidal ideation was highly prevalent among participants in this trial (92.2%). The majority of participants (97.8%) had tried previous therapy options, the most common of which were cognitive behavioral therapy (CBT), eye movement desensitization and reprocessing (EMDR), and group therapy. Pre-study use of PTSD medications included 17.8% who used sertraline and 6.7% who used paroxetine.



**Table 6: Demographics of Participants in MAPP1 Study of MDMA-Assisted Therapy**

Demographics	Placebo 0 mg	Blinded 80-180 mg MDMA HCl	Total
Participants per Dose Group	44	46	90
	<b>Mean (SD)</b>	<b>Mean (SD)</b>	<b>Mean (SD)</b>
Age (years)	38.2 (10.4)	43.5 (12.9)	41.0 (11.9)
	<b>N (%)</b>	<b>N (%)</b>	<b>N (%)</b>
<b>Sex assigned at birth</b>			
Male	12 (27.3)	19 (41.3)	31 (34.4)
Female <sup>A</sup>	32 (72.7)	27 (58.7)	59 (65.6)
<b>Ethnicity</b>			
Hispanic or Latino	3 (6.8)	5 (10.9)	8 (8.9)
Not Hispanic or Latino	40 (90.9)	41 (89.1)	81 (90.0)
<b>Race</b>			
American Indian or Alaska Native	0 (0.0)	3 (6.5)	3 (3.3)
Asian	5 (11.4)	2 (4.3)	7 (7.8)
Black or African American	2 (4.5)	0 (0.0)	2 (2.2)
Native Hawaiian or Other Pacific Islander	0 (0.0)	0 (0.0)	0 (0.0)
White	30 (68.2)	39 (84.8)	69 (76.7)
Multiple	6 (13.6)	2 (4.3)	8 (8.9)

<sup>A</sup> Two participants included in the assigned female at birth MDMA group identified their gender as non-binary.

A total of 90 participants were randomized and completed dosing session 1 and received an initial dose of 80 mg MDMA HCl. Of these participants, 97.8 % (88 of 90) took the supplemental dose of 40 mg. At dosing session 2, 98.8% (83 of 84) participants escalated their dose to 120 mg MDMA HCl, and 97.6% (82 of 84) of these received the supplemental dose of 60 mg. At dosing session 3, 96.2% (76 of 79) participants received the escalation dose of 120 mg and the supplemental dose of 60 mg. One participant from the placebo with therapy group received an initial dose of 80 mg and a supplemental dose of 100 mg at the third dosing session due to a dosing administration error at the site.

At the Primary Endpoint, from Baseline to two months after three blinded dosing sessions, there was a significantly greater mean change in CAPS-5 total severity score in the MDMA-assisted therapy group, with a reduction of 24.4 (SD: 11.6), compared to the therapy paired with an inactive placebo group in which CAPS-5 score were reduced by 13.9 (SD: 11.5),  $p < 0.0001$ ,  $d = 0.91$ . In the MDMA group, 88% of participants reporting a clinically significant reduction in CAPS-5 total severity and 67% of participants no longer meeting PTSD diagnostic criteria, compared to the placebo group, 62% reporting a clinically significant reduction in CAPS-5 total severity and 32% no longer meeting PTSD diagnostic criteria. This finding was supported by a positive secondary efficacy result in reducing clinician-rated functional impairment. At the Primary Endpoint, there was a significantly greater mean change in SDS scores in the MDMA group, reduction of 3.1 (SD: 2.6), compared to the placebo group, reduction of 2.0 (SD: 2.4),  $p = 0.0116$ ,  $d = 0.43$ . There were no new safety signals found in MAPP1, including no increase in reported adverse events of special interest in the categories of suicidal ideation or behavior, cardiovascular, or abuse potential in the MDMA group as compared to the therapy with placebo control group.

**Table 7: MAPP1 Exposure Table**

MDMA HCl dose <sup>A</sup>	MDMA-assisted therapy (N=46)	Placebo with therapy (N=44)	Total (N=90)
Dosing Session 1	46	44	90
N Initial Dose (80 mg) Taken	46 (100)	44 (100.0)	90 (100)
N Supplemental Dose (40 mg) Taken	45 (97.8)	43 (97.7)	88 (97.8)
Dosing Session 2	43	41	84
N Initial Dose (80 mg) Taken	1 (2.3)	0 (0.0)	1 (1.1)
N Initial Dose (120 mg) Taken	42 (97.7)	41 (100.0)	83 (98.8)
N Supplemental Dose (40 mg) Taken	1 (2.3)	0 (0.0)	1 (1.2)
N Supplemental Dose (60 mg) Taken	42 (97.7)	40 (97.6)	82 (97.6)
Dosing Session 3	42	37	79
N Initial Dose (80 mg) Taken	1 (2.4)	2 (5.4)	3 (3.8)
N Initial Dose (120 mg) Taken	41 (97.6)	35 (94.6)	76 (96.2)
N Supplemental Dose (40 mg) Taken	1 (2.4)	1 (2.7)	2 (2.5)
N Supplemental Dose (60 mg) Taken	41 (97.6)	35 (94.6)	76 (96.2)
N Supplemental Dose (100 mg) Taken	0	1 (2.7)	1 (1.3)

<sup>A</sup> See [Appendix Table 23: MDMA Salt to Active Moiety Conversion Chart](#).

Detailed safety information from this study is included in [Section 6.4 Safety of MDMA in Humans](#).

#### 6.1.4 Non-PTSD Indication Phase 2 Studies

The sponsor has completed one Phase 2, placebo-controlled, double-blind study of MDMA-assisted therapy in autistic adults with social anxiety (MAA-1, N=12), which demonstrated improvement in social anxiety symptoms in autistic adults following MDMA-assisted therapy [89]. The sponsor has also completed one study of MDMA-assisted therapy in people experiencing anxiety in the face of a life-threatening illness (MDA-1, N=18), which demonstrated that MDMA was well tolerated in the population but differences in the state-trait anxiety scale did not reach statistical significance despite a large effect size [90].

The sponsor is planning to initiate a study of MDMA-assisted therapy in people with eating disorders (MED-1). It will take place at two sites in Canada, and one in the US, and will enroll 12 people with anorexia nervosa and six with binge eating disorder.

#### 6.2 Pharmacology in Humans

The effects in humans presented in the sections below will include findings from both sponsor-supported clinical trials in patient populations as well as studies conducted in controlled laboratory settings in healthy volunteers without sponsor support. Findings from extensive human research being conducted on the pharmacology and mechanism of action will be presented in addition to the information required by FDA in order to support the safety profile of MDMA.

Common AEs of MDMA reported in non-sponsor supported Phase 1 studies in healthy volunteers include elevation in blood pressure and heart rate, increased anxiety or dysphoria, and dilated pupils [12-15]. Some reports indicated decreased rather than increased alertness [12]. Other common AEs reported in controlled studies of MDMA include reduced appetite, dizziness, tight jaw, bruxism (tooth-grinding), disturbance in attention, impaired gait or balance, dry mouth, and thirst. Participants in some studies also reported or exhibited changes in cognition, such as increases in speed of thought or thought blocking, facilitated imagination or recall [17], and

unusual thoughts or ideas [14]. Other less commonly reported events include paraesthesia (unusual body sensations) such as tingling or feeling hot or cold. MDMA can produce anxiety in healthy volunteers [14, 15, 17]. These effects are transient and dissipate as drug effects wane. One study found that women were more likely to report these events than men [15], while another study failed to support sex differences in reporting AEs [554].

The sponsor will conduct pharmacokinetic studies in humans to assess the effects of moderate hepatic impairment and effects of food or diet on MDMA metabolism concurrent with Phase 3 trials for treatment of PTSD. The following description of pharmacodynamics or pharmacokinetics of MDMA are from available published literature. Beginning in the early to mid-1990s, several research teams conducted studies of the pharmacodynamics and pharmacokinetics of MDMA [15, 18, 22, 81, 253, 264, 555-557] without receiving sponsor support.

### 6.2.1 Pharmacokinetics and Product Metabolism in Humans

The maximum proposed clinical dosing regimen consists of three divided single-dose exposures to racemic MDMA spaced approximately a month apart with an 80 mg or 120 mg initial dose followed by a 40 mg or 60 mg supplemental dose, administered 1.5 to 2 hours after initial dose at  $C_{max}$ . Mean (%CV)  $C_{max}$  and AUC at 125 mg MDMA HCl [232] is  $223.5 \pm 38.5$  ng/mL (N=136) and mean AUC:  $948 \pm 172.9$  ng\*h/mL (N=136). The clinical dosing regimen does not reach steady state, as the intended usage is up to 3 exposures to single-dose with at least 2 weeks washout between doses.

Onset of MDMA effects occurs 30 to 60 minutes after oral administration of 75 to 125 mg [12, 13], peak effects appear 75 to 120 minutes post-drug [11, 14-16], and duration of effects lasts from 3 to 6 hours with most effects returning to baseline or near-baseline levels 6 hours after final drug administration [14, 15, 17]. Self-reported duration of effects may increase as the dose of MDMA increases [11]. In a repeated dose study, an initial dose of 50 mg MDMA HCl, followed two hours later by a second dose of 100 mg MDMA HCl, does not significantly extend the duration of measurable physiological or subjective effects in comparison to a single dose of 100 mg MDMA HCl [265]. Orally administered MDMA has a half-life of 7 to 9 hours in humans and half-life is non-significantly extended from 10.41 hours to 10.48 hours if an additional dose is administered 2 hours after an initial dose [265]. MDMA and its metabolites have been found in oral fluid samples at much higher concentrations than in plasma, for 24 to 48 hours for the former and 12 to 47 hours for the latter after oral administration of 1 to 1.6 mg/kg MDMA HCl [558].

The potential for MDMA to be an inhibitor or substrate of human transporters was evaluated in a validated *in vitro* system. This *in vitro* interaction study demonstrated that MDMA: is not a substrate for BCRP, MDR1, OATP1B1, and OATP1B3; is not an inhibitor of BCRP, BSEP, MDR1, OATP1B1, and OATP1B3 at up to 500  $\mu$ M concentrations; and is not an inhibitor of MATE2-K, OAT1, and OAT3 at up to 50  $\mu$ M concentrations.

*In vitro* MDMA is an inhibitor of MATE1 ( $IC_{50}$  of 6.90  $\mu$ M), hOCT1 ( $IC_{50}$  of 2.15  $\mu$ M), and hOCT2 ( $IC_{50}$  of 1.91  $\mu$ M). In order to predict whether a drug has the potential to inhibit these transporters, the unbound  $C_{max}/IC_{50}$  value must be greater than 0.1 [559]. Previous data demonstrates that the unbound fraction of MDMA in human plasma to be 49% at therapeutically active concentration (200 ng/mL) [560] and the  $C_{max}$  mean to be  $223.5 \pm 38.5$  ng/mL, using 125 mg MDMA HCl [232]. Based on these findings, unbound  $C_{max}$  was estimated to be 0.48  $\mu$ M.

- For MATE1, at this concentration, the unbound  $IC_{max}/IC_{50}$  value for MATE1 is  $<0.1$  and the  $IC_{50}$  is no greater than 50-fold over unbound  $C_{max}$ , indicating that MDMA is unlikely to inhibit MATE1, *in vivo*.
- For both hOCT1 and hOCT2 the unbound  $C_{max}/IC_{50}$  value was  $\geq 0.1$  (hOCT1=0.22 and hOCT2=0.25), suggesting inhibition potential. Hepatic inlet  $C_{max}$  for MDMA was not evaluated *in vivo*. However, because 1) the relative inhibitions of hOCT1 and OCT2 are less than 25%; 2) hOCT2 are less than 25%, based on unbound  $C_{max}/IC_{50}$  values, MDMA is metabolized through multiple metabolic pathways; and 3) MDMA is given as a single divided dose regimen spaced 3-5 weeks apart, transporter-based interactions are unlikely to be clinically significant.

### 6.2.1.1 Absorption

MDMA has not been studied in humans with i.v. administration. As such, absolute or relative bioavailability is unknown. At a dose of 75 mg, MDMA is rapidly absorbed in humans, with an observed  $T_{max}$  of  $1.8\pm 0.4$  hours by the oral route. At higher oral doses of 125 mg a slightly longer  $T_{max}$   $2.4\pm 1.0$  hours was observed [18].


### 6.2.1.2 Distribution

MDMA has been shown to be partially bound to plasma proteins in humans. The unbound fraction of MDMA in human plasma was measured to be 49% at therapeutically active concentration (200 ng/mL) [560]. The volume of distribution of MDMA at 1 mg/kg was observed to be  $5.5\pm 1.1$  L/kg (dose range based on weight 43 mg-106 mg) in humans [253]. The volume of distribution of MDMA at 1.6 mg/kg was observed to be  $5.5\pm 1.3$  L/kg (dose range based on weight 69 mg-150 mg) in humans [253].

### 6.2.1.3 Metabolism

MDMA metabolism in the liver is saturable in a dose-dependent manner and follows non-linear pharmacokinetics. MDMA is metabolized by N-demethylation to the only active metabolite MDA by several enzymes, including CYP2D6 ( $>30\%$ ), CYP1A2, CYP3A4, CYP2C19, and CYP2B6, followed by COMT. The parent compound and MDA are further O-demethylated to HHMA and HHA, respectively. Both HHMA and HHA are subsequently O-methylated mainly to HMMA and HMA. These four metabolites, particularly HMMA and HMA, are excreted in the urine as conjugated glucuronide or sulfate metabolites. Metabolites of MDMA are summarized in [Figure 2](#) [561-566].

**Figure 2: Metabolism of MDMA in Humans**



Metabolism of MDMA in humans (in red) compared to metabolism in rats (in blue). Reproduced with permission of R. de la Torre [252].

It is likely that active doses of MDMA inhibit CYP2D6 function, as measured by examining the effects of MDMA on dextromethorphan metabolism. Inhibition of CYP2D6 by MDMA was demonstrated first in a physiological model derived from data collected after oral administration in humans [567]. O'Mathuna and colleagues present evidence that CYP2D6 activity may not fully recover until 10 days after MDMA [568, 569]. After reviewing their data and the literature on MDMA pharmacokinetics, de la Torre and colleagues concluded variation in CYP2D6 genotype is not clinically significant, due in part to the fact that the enzyme is inhibited in most people after administration of an active dose [264]. However, a pooled analysis of 10 clinical studies in healthy volunteers (n=194) examining predictor variables of physiological and psychological response to MDMA found a higher activity of the enzyme CYP2D6 predicted lower MDMA plasma concentrations, after adjusting for dose per body weight [570]. MDMA may produce increased activity of the enzyme CYP1A2, as evidenced by comparing caffeine metabolism before and after MDMA [571]. Findings support the enantioselective nonlinear metabolism of MDMA and its metabolites measured in blood and urine [572-574]. CYP2D6 may be involved in stereoselective metabolism of MDMA, but to a clinically insignificant degree [574].

Comparison of pharmacokinetic-pharmacodynamic relationships for MDMA reveals acute pharmacodynamic tolerance. Despite 7 to 9 hours of half-life of MDMA, and persistent high drug levels in the blood, most pharmacodynamic effects of the initial dose rapidly return to baseline within 4 to 6 hours [557]. A study comparing the effects of a single 100 mg dose with an initial administration of 50 mg followed 2 hours later by 100 mg, a dose regimen similar but not identical to timing between the initial and supplemental dose of MDMA in sponsor-supported trials, reported higher peak plasma MDMA than might be expected and lower levels of the MDMA metabolites HMMA and HMA, but other pharmacodynamic effects were not altered [265]. The initial dose appears to saturate or inhibit the metabolic pathway mediated by CYP2D6, leading a supplemental dose to form metabolites at a lower rate than expected and increasing exposure to the parent drug (see Figure 2). A study comparing the effects of a single 100 mg dose

with an initial administration of 50 mg followed two hours later by 100 mg reported plasma MDMA concentrations increased by more than expected based on dose proportionality,  $C_{max}$  +12.8% and AUC +16.2%. inactive metabolite HMMA concentration decreasing in plasma by  $C_{max}$  -38.2% and AUC -29.8%, which was more than what would be expected based on dose proportionality. These findings are further supported by examining plasma MDMA after two doses of 100 mg given four hours apart [575], plasma MDMA concentrations increased  $C_{max}$  +23.1% and AUC +17.1%, and active metabolite MDA concentration increased in plasma by  $C_{max}$  +14.2% and AUC +10.3%, which was also more than would be expected based on dose proportionality, likely due to metabolic autoinhibition of CYP2D6. These findings suggest that intensity of most subjective and physiological effects of MDMA would not be significantly impacted by the supplemental doses in sponsor-supported studies due to acute tolerance to its prototypical effects [575].

This acute tolerance could be caused by functional depletion of stored serotonin that prevent further release despite MDMA still being present [557], or are a result of MDMA transport into intracellular spaces is saturable due to limited transport capacity [106]. Additionally, reversible inhibition of tryptophan hydroxylase as observed in rodents [262], or internalization of serotonin reuptake transporters from the plasma membrane leading to less serotonin release [74], would support self-limiting effects of MDMA. On the other hand, although SERT can be internalized, the evidence suggests that accumulation of extracellular serotonin stimulated by MDMA affects SERT trafficking by perpetuating cell-surface SERT expression, but in contrast promotes internalization of DAT and NET [106, 576].

#### 6.2.1.4 Elimination

Although the hepatic route is thought to be the major route of metabolism in humans with 50% to 75% of the parent compound being metabolized, renal clearance accounts for 8% to 11% of elimination of MDMA and its metabolites. After 1.0 mg/kg MDMA HCl, the majority was excreted in urine as the inactive metabolites HMMA sulfate (13%), followed by DHMA 3-sulfate (9%), and HMMA glucuronide (5%), and only 8% as the parent compound MDMA [253]. After 1.6 mg/kg MDMA HCl, the majority was excreted in urine as the inactive metabolites HMMA sulfate (10%), followed by DHMA 3-sulfate (9%), and HMMA glucuronide (4%), and only 11% as the parent compound MDMA. Studies examining metabolism of 100 mg MDMA HCl reported similar excretion values [253, 577-581].

Metabolites are primarily excreted as glucuronide and sulfate conjugates [563, 582, 583] with some evidence for stereoselective metabolism of the glucuronide and sulfate metabolites [582]. Urinary excretion of the metabolite HHMA after 100 mg MDMA HCl in four men was  $91.8 \pm 23.8$  mol and 17.7% recovery [581]. By contrast, urinary recovery of the major metabolite HMMA after 100 mg was 40% [584]. Urinary recovery for MDMA and MDA were higher when a second dose of 100 mg MDMA HCl was administered 24 hours after an initial dose of 100 mg MDMA HCl when compared with a single dose [577]. In one study, urinary excretion of the metabolite HMMA exceeded that of MDMA by 33 hours after a dose of 1.6 mg/kg MDMA HCl [585].

Renal clearance (CL) by dose of MDMA HCl administered were  $12.8 \pm 5.6$  L/h at 75 mg,  $20.4 - 12.3$  L/h at 100 mg,  $13.0 \pm 5.4$  L/h at 125 mg, and  $5.2 - 11.3$  L/h at 150 mg [18]. Oral clearance (CL/F) by dose of MDMA administered was  $0.62 \pm 0.19$  L/h/kg at 1.0 mg/kg (dose range by weight 43 mg-106 mg) and  $0.48 \pm 0.11$  L/h/kg at 1.6 mg/kg (dose range by weight 69 mg-150 mg) [253].

To date, there are no known clinical trials quantifying excretion of MDMA into breastmilk in humans.



### 6.2.1.5 Pharmacogenomics

The effects of variation in genotypes for the enzymes CYP2C19, CYP2B6, and CYP1A2 on metabolism of 75 and 125 mg MDMA HCl in a pooled sample of 139 participants found that variants with less functional versions of CYP2C19 and CYP2B6 exhibited +15%  $C_{max}$  for MDMA, +50%  $C_{max}$  of MDA, and -50 to 70%  $C_{max}$  of HMMA. Two participants with the poor metabolizer variants of CYP2C19 had greater cardiovascular response to MDMA, and tobacco smokers with inducible CYP1A2 exhibited higher conversion of MDMA to MDA [586]. These results demonstrate compensatory mechanisms that involve contributions from multiple enzymes when CYP2D6 is inhibited through a metabolic complex with MDMA. A pooled analysis of 10 clinical studies (n=194) examining predictor variables of physiological and psychological response to MDMA in healthy volunteers found a higher activity of the enzyme CYP2D6 predicted lower MDMA plasma concentrations, after adjusting for dose per body weight [570]. A pair of *in vitro* studies modeling metabolism in human liver cells and insect cells reported that CYP2D6 may have functional heterogeneity, or variation in response to substrates, and that less than 50% of CYP2D6 may be inhibited by MDMA, and concluded that the ability of MDMA to inhibit CYP2D6 may be overestimated [587]. The *in vitro* models seem at odds with lingering reduction in activity detected in humans.

The enzyme COMT and monoamine oxidase may also be involved in the metabolism of MDMA [584]. At least one variation in COMT genotype may affect MDMA elimination rate ( $K_e$ ) and systolic blood pressure (SBP) after MDMA [588]. As a monoamine reuptake inhibitor that leads to monoamine release and inhibits monoamine oxidase-A [111], combining MDMA with a MAOI medication presents a risk for provoking serotonin syndrome and increases in sympathetic activity. Fatalities have occurred apparently as a result of combining MAOI medications with MDMA [112, 113]. For this reason, MAOI medications are tapered for at least five half-lives of the medication and active metabolites, plus 1 week for symptom stabilization in sponsor-supported studies.

An examination of subjective, physiological, and pharmacokinetic effects of variations in genes tied to the serotonin system in a sample of 124 participants sought to investigate differences in plasma levels after 125 mg MDMA HCl [589]. While they detected a slight increase in cumulative MDMA levels (AUC) in one variant of the 5-HT<sub>1A</sub> receptor and very slight decrease in  $C_{max}$  MDMA levels in variant of the 5HT<sub>1B</sub> receptor, neither effect was found to be significant after correcting for number of tests.

Variations in genes related to serotonin synthesis and three serotonin receptors (5HT<sub>1A</sub>, 5HT<sub>1B</sub>, and 5HT<sub>2A</sub>), and SERT made very little difference in vital signs or subjective effects of 125 mg MDMA HCl in a study in 124 healthy controls [589]. Gene variants in the 5HT<sub>2A</sub> receptor, SERT, and tryptophan hydroxylase-1 influenced subjective effects, but these effects were no longer significant after correcting for number of tests. Pooled analyses of a sample of 132 healthy participants who received 125 mg MDMA HCl in placebo-controlled studies reported that variation in an oxytocin receptor gene (rs1042778TT) reported greater feelings of trust after MDMA, but that variations in oxytocin receptor genes did not affect cognitive or emotional empathy [590].

### 6.2.1.6 Pharmacokinetic Drug Interactions

Co-administration studies with MDMA after pre-treatment with CYP2D6 inhibiting prescription drugs paroxetine [591] and bupropion [592] have been completed. In addition, drug interaction studies with methylphenidate [557] and dextromethorphan [569] have been completed. MDMA

reversibly inhibits CYP2D6 and decreases CYP3A4 activity, with CYP2D6 function normalizing after 10 days. MDMA increases CYP1A2 activity, as measured by caffeine challenge, by 20% to 40% when CYP2D6 is saturated or inhibited [569]. Due to known MDMA effects of CYP2D6 inhibition, drug interaction studies with CYP2D6 inhibitors are presented in detail below. For additional pharmacokinetic parameters from drug interaction studies, please refer to [Appendix Table 22: Highlights of MDMA Clinical Pharmacology and Cardiac Safety](#).

Paroxetine is an SSRI approved for PTSD and patients interested in MDMA-assisted therapy are likely to be on maintenance treatment with this drug. In a randomized, double-blind, crossover, placebo-controlled trial in healthy male volunteers who were CYP2D6 extensive metabolizers (N=7), paroxetine given for 3 days before MDMA resulted in significant increases of MDMA area under the plasma concentration-time curve from 0 to 27 hours ( $AUC_{27}$ ) by +23%,  $AUC$  from zero to infinity ( $AUC_{\infty}$ ) by +27% and maximum plasma concentration ( $C_{max}$ ) by +17%, without significant differences in MDMA  $T_{max}$  [591]. MDMA elimination-related pharmacokinetic parameters showed a significant reduction of plasma clearance by -29%, renal clearance by -19%, and hepatic clearance by -32%. Elimination half-life extended from 8.3 to 9.9 hours. A 21% decrease in  $C_{max}$  of HHMA which is an MDMA metabolite, with no significant differences in  $AUC_{27}$ ,  $AUC_{\infty}$ ,  $K_e$  and elimination half-life were found. HMMA showed a decrease in plasma concentrations with a reduction in  $AUC_{27}$  of -28%,  $AUC_{\infty}$  of -20% and  $C_{max}$  of -46%. The active metabolite MDA, which is produced in the minor metabolic pathway, was shown to have an increase in  $C_{max}$  of +17% and  $AUC_{27}$  +16%. Following paroxetine pretreatment, the urinary recovery (0-45 hours) of the parent compound MDMA increased by 11%; HHMA and HMMA urinary recoveries were 27% and 16% lower, respectively, compared to placebo. The ratio of  $C_{max}$  values of paroxetine and its metabolite on Days 1 and 3 showed a threefold reduction, with no differences in  $T_{max}$ . As these elevations were not clinically meaningful, the sponsor concludes that drug interactions with previously approved PTSD medications that are also CYP2D6 inhibitors, such as paroxetine, would be suitable from a safety standpoint for co-administration with MDMA, although some subjective MDMA-induced effects may be reverted or attenuated [591].

As MDMA is a monoamine reuptake inhibitor that leads to monoamine release and inhibits monoamine oxidase-A [111], combining MDMA with a MAOI medication may present a risk for provoking serotonin syndrome and increases in sympathetic activity, as reported in four deaths associated with concomitant use of MDMA and the MAOI moclobemide [112]. However, a recent *in vitro* study examining the  $IC_{50}$  of MDMA and MDA against serotonin (24.7 micrometer ( $\mu M$ ) and  $>8.5 \mu M$ , respectively) and dopamine (19.2  $\mu M$  and  $>8.4 \mu M$ , respectively) concluded that inhibitory potential ( $<20\%$ ) was unlikely to be relevant at plasma values observed in humans, which are estimated to be in the range of  $1 \mu M$  [593].

Bupropion is a norepinephrine dopamine reuptake inhibitor approved for treatment of major depression and smoking cessation, and patients interested in MDMA-assisted therapy may be on maintenance treatment with this drug. Bupropion inhibits CYP2D6 and also competitively inhibits CYP2B6, which metabolizes bupropion to hydroxybupropion. 125 mg MDMA HCl was administered after 1 week of bupropion pre-treatment in a double-blind, placebo-controlled, crossover study in 16 healthy volunteers, in CYP2D6 extensive metabolizers (N=13) and intermediate metabolizers (N=3). Bupropion pretreatment increased the  $C_{max}$  of MDMA by +14% ( $p<0.01$ ),  $AUC_{24}$  by +33% ( $p<0.001$ ), and prolonged its  $t_{1/2}$  by +24% ( $p<0.01$ ). In contrast, bupropion pretreatment decreased the  $C_{max}$  of MDA by -15% ( $p<0.01$ ), and decreased  $AUC_{24}$  by -12% but this failed to reach significance [592]. When results were re-analyzed with stereoselective methods [574], bupropion pre-treatment increased the  $C_{max}$  of R-MDMA by +9% and the  $AUC$  from 0 to 24 hours ( $AUC_{24}$ ) by +25%. Bupropion pre-treatment increased the  $C_{max}$  of S-MDMA by +16% and the  $AUC_{24}$  by +38%. In contrast, bupropion pre-treatment decreased the  $C_{max}$  of R-MDA by -27% and the  $AUC_{24}$  by -26%, and the  $C_{max}$  of S-MDA by -24% and the

AUC<sub>24</sub> by -20%. Bupropion pre-treatment decreased the C<sub>max</sub> and the AUC<sub>24</sub> of CYP2D6-dependent inactive metabolite stereoisomers by approximately -40%. The changes that were observed in the intermediate metabolizers were comparable to the extensive metabolizers, although the intermediate metabolizer sample was small (N=3). Although changes in stereoselectivity based on CYP2D6 activity were observed, these are unlikely to have clinical relevance. Bupropion and hydroxybupropion stereoisomer kinetics were unaltered by MDMA co-administration. As these elevations were not clinically concerning, the sponsor concludes that drug interactions with non-serotonergic medications that are also CYP2D6 inhibitors, such as bupropion, would be suitable from a safety standpoint for co-administration with MDMA.

## 6.2.2 Pharmacodynamics

### 6.2.2.1 Primary Pharmacodynamics

MDMA promotes release and inhibits reuptake of monoamine neurotransmitters, and directly binds or indirectly activates downstream receptors, with actions on the serotonin system likely responsible for most of its subjective and physiological effects in humans. MDMA is associated with changes in several neurohormones as well with some of these actions likely responsible for some changes in subjective and physiological effects.

Typically, human trials have used doses between 1 and 2 mg/kg, with therapeutic studies using fixed dosing rather than adjusting dosing on a mg/kg basis, in order to achieve a more consistent subjective response between individuals. The pharmacokinetics of MDMA in humans have been characterized in blood and urine samples using oral doses of up to 150 mg MDMA HCl [18]. MDMA is a triple monoamine reuptake inhibitor and similar drugs in this class have been found to exert potent anti-depressant activity with a potentially favorable safety profile [19, 20]. MDMA concomitantly promotes release, inhibits reuptake, and extends duration of serotonin, norepinephrine, and dopamine in the synaptic cleft to increase serotonergic, noradrenergic, and dopaminergic neurotransmission. MDMA has self-limiting subjective and physiological effects as previously described.

In addition to neuroendocrine and norepinephrine-mediated effects, MDMA may target similar binding sites on the SERT, as do already approved PTSD medications Paxil and Zoloft, which are both SSRIs. Like the SSRI Prozac, MDMA also inhibits MAO-A to extend presence of serotonin in the synaptic cleft [111]. Pre-treatment or co-administration studies of SSRIs with MDMA suggest that this combination is safe within controlled settings and that it attenuates most effects of MDMA. SSRIs appear to attenuate or eliminate most subjective, physiological and immunological effects of MDMA likely due to competition for binding sites on the SERT, which may prevent transporter-mediated serotonin release [82, 594-597] (see [Appendix Table 1: Summary of Investigator-Initiated Trials with MDMA](#)). Additional effects of each SSRI beyond reuptake inhibition on production, release, and degradation of serotonin are likely responsible for variations between SSRI co-administration findings.

The role of serotonin release on the potentially therapeutic effects of MDMA-assisted therapy has yet to be investigated, however reduced feelings of sociability and closeness to others after paroxetine pre-administration suggests that serotonin release is at least partially involved in prosocial effects that are thought to be therapeutically relevant [82]. These subjective effects are predominately mediated by direct or indirect action on 5HT<sub>2A</sub> receptors [84, 190, 598] with at least one study concluding that the effects of MDMA upon positive mood are at least due in part to 5HT<sub>2A</sub> receptor activation [84]. Findings suggest that the 5HT<sub>1A</sub> receptor was partially involved in producing the subjective effects of MDMA [84, 188-190]. A study using receptor-enriched brain mapping of functional connectivity (described in more detail below) reported that changes

in functional connectivity in 5HT<sub>2A</sub>-receptor enriched maps were associated with increased reports of having a spiritual experience [599].

Human MDMA studies suggest that norepinephrine release also contributes to the pharmacodynamic, physiological, and psychological effects of MDMA [225, 226, 228, 600, 601], with noradrenergic antagonists attenuating MDMA effects on blood pressure and mood (see [Appendix Table 1: Summary of Investigator-Initiated Trials with MDMA](#)).

Most of the psychostimulant-like and prosocial or 'entactogenic' subjective effects of MDMA are blocked after administration of the dual SNRI duloxetine [228, 601], and that these effects may relate to changes in neurohormones such as oxytocin and copeptin. [601, 602]. As the NET unexpectedly has a greater affinity than the DAT for dopamine, it preferentially clears dopamine in brain areas where there is a greater concentration of NET, such as the frontal cortex [603].

Some MDMA effects on human mood and anxiety may be attributed to dopamine release based on the finding that pretreatment with haloperidol, a dopamine receptor antagonist with partial selectivity for the D2 receptor subtype, diminished MDMA-induced positive mood and increased anxiety, though haloperidol alone was associated with dysphoria [604]. Studies comparing MDMA with the dopaminergic and adrenergic drug methylphenidate and bupropion suggest that dopamine release and inhibition of uptake play a minor role, if any, in producing the effects of MDMA [605]. MDMA, but not methylphenidate, increased trust, openness, and closeness to others, and bupropion prolonged the course of subjective effects without reducing or enhancing them [592].

#### 6.2.2.2 Secondary Pharmacodynamics

MDMA produces a robust increase in the neurohormone oxytocin, a neurohormone associated with trust and affiliation, [81, 606-608], a finding first seen in a naturalistic study that reported elevated levels of oxytocin in clubgoers with detectable blood MDMA levels when compared to clubgoers without detectable levels of MDMA [468], and confirmed in blinded placebo-controlled experiments [81]. However, studies comparing increases in empathy or prosocial effects of MDMA with intranasal oxytocin have failed to find indications that the two substances produce similar effects with MDMA producing greater feelings of sociability and emotional empathy than oxytocin [53, 609]. Using pindolol to block 5-HT<sub>1A</sub> receptor mediation of oxytocin's effects, Kuypers and colleagues determined that MDMA increased emotional empathy while oxytocin did not produce similar effects on measures of empathy and social interaction [609]. Pooled data across six placebo-controlled within-subjects' studies in 118 participants confirmed an increase in emotional empathy without an increase in cognitive empathy [608]. However, interpretation of these results were limited because Kuypers and colleagues [608, 609] did not measure within-subject correlation of subjective effects with multiple post-MDMA oxytocin levels, as was done by Dumont and colleagues in their clinical trial showing a positive within-subject correlation after MDMA for oxytocin and prosocial effects [81].

MDMA acutely increases cortisol, prolactin, and adrenocorticotrophic hormone concentrations in a dose dependent manner [13, 14, 52, 83, 227, 549, 577, 610-613], whereas growth hormone levels are unchanged by up to 125 mg MDMA HCl [13]. A crossover study comparing the effects of MDMA and methylphenidate found that MDMA increased serum cortisol while methylphenidate did not [613]. Increases in cortisol and prolactin peak at about 2 hours after MDMA administration [13, 549]. A second dose of 100 mg MDMA HCl, given 4 hours after an initial 100 mg, produces a second increase in cortisol during an interval when cortisol levels are declining [614], and a dose of 100 mg MDMA HCl, given 24 hours after an initial dose,

stimulates a greater release of cortisol but not prolactin [577]. Doses of 0.5 and 1.5 mg/kg MDMA HCl elevated cortisol, and under stressful versus less stressful conditions [615].

MDMA may affect levels of other hormones. In a study of the effects of 0.5 and 1.5 mg/kg MDMA HCl in eight people, there was a trend for increased levels of the hormone dehydroepiandrosterone (DHEA) after 0.5 mg/kg MDMA HCl, and a significant increase after 1.5 mg/kg MDMA HCl, with peak levels appearing 2 to 3 hours post-drug [14]. These findings suggest a relationship between serotonin release and increased serum cortisol. Two studies have found that MDMA increased AVP [236, 601]. Neither study reported analysis or findings concerning any relationship between AVP levels and the subjective, emotional or social effects of MDMA.

A study applying a high-throughput detection method using liquid chromatography/mass spectrometry to assess changes in chemical markers (the “metabolome”), after 100 mg MDMA HCl in 16 healthy volunteers, and detected elevation in cortisol, pregnenolone, and calcitriol, a metabolite of vitamin D 4 hours after MDMA [610]. Boxler and colleagues detected a comparable increase of several factors (hydroxyeicosatetraenoic acid, dihydroxyeicosatetraenoic acid, and octadecadienoic acid) associated with mediating inflammation, and that the authors interpreted as signs of an inflammatory process.

A study applying receptor-enriched mapping and functional connectivity in a sample of 20 men reported that 100 mg MDMA HCl activated brain areas assumed to have high 5HT<sub>1A</sub> density or high levels of SERT density. Despite failing to find a significant change in functional connectivity after MDMA in brain regions high in 5HT<sub>2A</sub> receptors, Dipasquale and colleagues reported that activity seen in these areas after MDMA were associated with reporting a spiritual experience [599]. This investigation also found a relationship between time course of MDMA effects and changes in functional connectivity in brain areas associated with 5HT<sub>1A</sub> receptor density, and reported decreased functional connectivity in several cortical areas, including specific areas of the temporal and frontal cortex, and insula, acutely after MDMA. Another investigation of functional connectivity after administering 100 mg to healthy volunteers reported decreased network connectivity in the right insula/salience network [616] with decreased connectivity associated with changes in subjective ratings of trait anxiety and bodily sensations.

### 6.2.3 Physiological Effects

Physiological effects from published literature are reported in the sub-sections below; data derived from MAPS sponsored Phase 2 and Phase 3 studies are included in [Section 6.4 Safety of MDMA in Humans](#).

#### 6.2.3.1 Central Nervous System

Early investigations of MDMA in healthy volunteers with PET detected decreased left amygdalar activity and increased frontal activity [617]. Subsequent studies in healthy volunteers have found signs of reduced activity in R amygdala and hippocampus, a decrease in medial prefrontal cortex coupling with the hippocampus, and reduced right insular/salience network connectivity [616] (see [Appendix Table 1: Summary of Investigator-Initiated Trials with MDMA](#)). Decreased activity in the amygdala may be indicative of reduced reactions to potential threats [618]. MDMA (100 mg MDMA HCl) increased subjective ratings of positive mood in response to positive memories and decreased negative response to negative memories. Attenuated activity in the left anterior temporal area was detected after MDMA during worst memory recall [26].



During a task that required keeping a visual target cue in mind, visual attention, and response inhibition, brain imaging detected changes in parietal activity after 75 mg MDMA HCl but not with placebo [619]. MDMA increased activity in frontal areas and decreased activity in occipital sites as measured via functional MRI (fMRI) [620]. Reduced resting-state cerebral blood flow (CBF) in right amygdala and hippocampus after MDMA was associated with greater intensity of self-reported subjective effects [621]. Participants given MDMA exhibited similar brain activity when reading or encoding a word list, which suggests that they were investing similar effort into both tasks.

### **Behavioral Effects**

MDMA increases positive mood and anxiety [12, 14-16] on measures of alteration in consciousness and subjective effects. People receiving active doses of MDMA defined as 75 to 125 mg MDMA HCl, experience euphoria, positive mood, vigor, and positively experienced derealization, consonant with early retrospective reports, but also report experiencing anxiety, tension, and dysphoria, as well as concern over losing control over the self [12, 14-16, 554] (see [Table 32](#) and [Table 33](#) for more details). There is evidence that increases in positive mood and anxiety increased with dose [12, 14, 80, 622]. Healthy controls reported greater interpersonal closeness to others [17, 80-83, 597]. It is uncertain whether the increases in positive and negative mood occurred simultaneously or at different times throughout the duration of MDMA effects; evidence from two different teams suggests that peaks in negative mood may precede peaks in positive mood [16, 604].

People have reported feeling anxious or experiencing negative derealization while under the influence of MDMA, including increased anxiety related to loss of control and experiences of racing or blocked thoughts [12, 15, 17]. More information on the effects of MDMA on affect may be found in [Section 6.4.5 Abuse Potential](#).

An examination of personality assessed prior to and after receiving MDMA-assisted therapy from a sponsor-supported study (MP-1) reported increased openness to the experience attributable to MDMA when compared with placebo [623], a finding similar to those reported in studies of people given the classic psychedelic psilocybin [624, 625]. Neuroticism was reduced in both MDMA and placebo groups likely as a function of the accompanying psychotherapy. Wagner and colleagues also found that changes in openness, but not neuroticism, were associated with reductions in PTSD symptoms [623].

MDMA may alter detection and receptivity to expressions of emotion. Findings suggest that MDMA might change the way emotional facial expressions might be processed or the response to them. MDMA improved accuracy of recognizing expressions of positive mood and were less accurate in recognizing expressions of negative mood [83], and reduced amygdalar response to angry faces to suggest possibly an altered response to expressions of anger [38]. Despite contradictory findings from a naturalistic study, a controlled trial reported that MDMA impaired detection of expressions of fear [626]. An fMRI study found that 0.75 and 1.5 mg/kg MDMA HCl reduced signaling in the amygdala in response to angry faces when compared with placebo without changing the response to faces showing fear [38]. MDMA reduced the aversiveness of hearing sounds associated with negative emotions [627]. In addition, and contrary to the finding in the early naturalistic study described above, there is some evidence that MDMA might produce selective difficulty in recognizing faces expressing fear [53, 557].

At least four research teams published relevant findings in studies of healthy volunteers that examine the effects of MDMA on social cognition with several experimental paradigms assessing brain activity during episodic memory recall and contributions of oxytocin and cortisol to the



acute effects of MDMA [38, 616, 620, 628, 629]. Findings include reduced reactivity to simulated social exclusion, reduced negative emotional response to self-selected “worst” memories, increased use of language related to interpersonal closeness, increased emotional empathy, and increased perceived partner empathy (see [Appendix Table 1: Summary of Investigator-Initiated Trials with MDMA](#)). Taken together, this research lends greater support that MDMA possesses unique psychological effects, distinct from psychostimulants that can be beneficial when combined with therapy.

MDMA in healthy participants makes social activities more attractive [630], people more generous toward a friend [631], and more willing to trust a stranger in a “trust game.” Rather than increasing trust indiscriminately, trust was given only to trustworthy actors [628]. Studies in healthy controls, comparing doses between 0.75 and 1 mg/kg and 1.5 to 2 mg/kg, suggest that the higher dose produced greater prosocial effects than the lower dose, while the lower dose may have increased self-reported loneliness and use of empathy-related language [28, 29, 632, 633].

In a study by Bedi and colleagues, MDMA induced changes in semantic speech content measured with natural language learning software [27]. Proximity of speech to the concepts of friend, support, intimacy, rapport, and empathy was increased over placebo in the MDMA group, which may bear some significance for the use of MDMA in therapy. MDMA did not affect the overall structure of participants’ speech, and these findings were confirmed in an additional sample using a different method of analysis. The study by Bedi and colleagues reported a greater use of social words and words describing emotions [634]. A systematic examination of statements (discourse) from participants enrolled in MAPS’ study MP-1 conducted by an independent researcher found greater attention to and concern for the therapists and others in participants receiving MDMA versus inactive placebo [635].

### **Sensorimotor Reflex Responses**

MDMA does not acutely affect responses on tasks requiring attention and response to visual stimuli or visually presented words [17, 617], but has been shown to interfere with performance on digit-symbol substitution - a measure of attention, psychomotor speed and visual memory [12]. A dose of 75 mg improved visual tracking speed, but impaired estimating the position of a blocked (occluded) object in a study of acute effects on skills used for driving cars [636], though without effects on performance monitoring [637]. Subsequently, a series of studies have thoroughly examined the effects of MDMA on road-tracking and car-following performance in both stimulated and on-the-road driving in normal traffic as part of the Driving Under the Influence of Drugs, alcohol and medicines (DRUID) research consortium funded by a European Union grant. A single-dose of 25 mg, 50 mg, 75 mg, or 100 mg MDMA HCl did not produce any dose- or concentration-related effects on driving performance and was found to be generally safe for driving at therapeutic doses in the absence of sleep loss or alcohol intoxication [638-642]. In one of these studies, driving tests were conducted between 3 and 5 hours after a dose of 75 mg MDMA HCl. Subjects returned the following day for a repetition of the driving tests between 27 and 29 hours post-MDMA. Although changes in cognitive function and psychomotor skills occurred during peak drug effects, these were not detectable on the following day. Acute effects such as excessive caution and impaired positional memory support refraining from driving or using heavy machinery [643] during dosing sessions.

MDMA causes slight changes in visual or auditory perception, including changes in the brightness or colors, sounds seeming closer or farther away, simple visual distortions [11, 12, 14, 15], and altered time perception [14, 16, 17] Participants also experienced altered time perception and changes in meaning or significance of perceptions after MDMA. There is little indication that MDMA produces any strong alterations to the sense of self or control over the experience [14].

Women reported experiencing all subjective effects of MDMA more intensely compared to men, but especially those related to perceptual changes [15, 188, 598]. The effects of MDMA on perception have not been studied in sponsor-supported studies.

### Body Temperature

Grob and colleagues noted that in a Phase 1 safety study MDMA was found to cause a significant increase in body temperature in some healthy volunteers [549]. However, these increases were transient and tolerable in a controlled clinical setting. Studies conducted by other researchers reported that doses between 1.5 and 2 mg/kg MDMA HCl produced a slight elevation in body temperature that was not clinically significant [15, 232, 595, 598] and this elevation was unaffected by ambient temperature [215]. Further, 2 mg/kg produced a slight but statistically significant increases in core body temperature with a mean elevation of 0.6°C, at cool (18°C) and warm (30°C) ambient temperatures [215]. A supplemental dose twice as large as the initial dose of MDMA elevated body temperature, but not beyond what was expected after the cumulative dose [265].

Thermogenic effects of MDMA are distinct from malignant hyperthermia and mediated by noradrenergic signaling, which contributes to peripheral effects of MDMA by affecting cutaneous vasoconstriction of blood flow and stimulation of heat production and attenuated by norepinephrine blocking drugs. Research participants in clinical trials do not engage in vigorous exercise and either sit or lie down throughout duration of drug effects. It may be the case that heat dissipation impaired by a hot environment, heat generation increased by exertion, interactions of serotonergic drugs, and potential disturbance of central heat regulation mechanisms contribute to the occurrence of hyperpyrexia (body temperatures >41°C) in people ingesting Ecstasy in uncontrolled settings.

When compared with placebo, findings from 74 people that were given MDMA in oral doses ranging from 70-150 mg MDMA HCl (1.35-1.8 mg/kg) found that men exhibited a greater elevation in body temperature than women when given the dose of MDMA in mg/kg [15]. Subsequent studies have not confirmed this sex difference [38, 570]. A report in a sample of 17 men and women reported higher oral temperatures in women [588]. Prior to correction for number of tests, a study on the effects of serotonin-related genotypes on MDMA reported higher body temperature in people with a variant of the TPH-2 gene, but these findings were no longer significant after applying corrections [589]. A review of clinical placebo-controlled laboratory studies conducted without sponsor support found that route of measurement influences variability in body temperature findings, with oral and tympanic, but not axillary, temperatures frequently rising above 38°C into moderate hyperthermia ranges at 125 mg MDMA HCl.

#### 6.2.3.2 Cardiovascular System

MDMA produces sympathomimetic effects that include elevation in blood pressure and heart rate, first recorded by Downing [36] and replicated by other research teams in the U.S. and Europe [11, 13-15, 37-39, 232]. MDMA has also been found to decrease respiratory sinus arrhythmia, the natural variation in heart rate over the course of each respiratory cycle [644]. Cardiovascular effects of MDMA typically first appear 30 to 45 minutes after administration [36], peak between 1- and 2-hours post-drug [16, 37], and wane 3 to 5 hours after drug administration. Men given the same mg/kg dose of MDMA as women exhibited a significantly greater elevation in blood pressure and heart rate in a study summarizing and pooling data from a series of human MDMA studies [15]. These studies did not report any discomfort or increased distress accompanying cardiovascular effects.

Elevation in blood pressure above 140/90 mmHg occurred in approximately 5% of research participants receiving a single dose of at least 100 mg MDMA HCl in Phase 1 research studies [13, 17]. Peiro and colleagues observed elevation in blood pressure above 150/90 mmHg as well as in all 10 participants given 50 mg followed by 100 mg MDMA HCl 2 hours later [265](see [Appendix Table 1: Summary of Investigator-Initiated Trials with MDMA](#)). When compared with 100 mg MDMA HCl and placebo given 4 hours apart, two doses of 100 mg 4 hours apart significantly elevated SBP, while other physiological effects were not significantly elevated beyond values seen after a single dose. None of these individuals needed clinical intervention and blood pressure returned to normal as drug effects waned [13, 17, 265].

Of relevance, in an investigator-initiated safety and tolerability proof-of-concept study of MDMA-assisted therapy for treatment of alcohol use disorder (AUD) post-detoxification [645], the investigators report that one participant with controlled hypertension experienced a transient abnormal rise in blood pressure (SBP/DBP of 183/118 mmHG) two hours after initial dose of 125 mg MDMA HCl, attributed to the participant forgetting to take their hypertensive medication. The supplemental dose was withheld and the participant was asymptomatic with no medical intervention needed. The participant took their hypertensive medication prior to the subsequent second dosing session and did not experience abnormal changes in blood pressure. This independent report supports the sponsor’s mitigation strategy of maintaining participants on hypertensive medication during MDMA-assisted therapy treatment.

The  $\alpha$ 1- and beta-adrenergic receptor antagonist carvedilol is capable of reducing MDMA-induced elevations in blood pressure, heart rate, and body temperature when administered 1 hour before MDMA without affecting the subjective effects of MDMA, indicating the norepinephrine release is primarily responsible for cardiovascular effects of MDMA [227]. Other concomitant antihypertensive medications either alter some of the effects of MDMA [626] or do not significantly reduce MDMA-induced blood pressure elevation [225].

### 6.2.3.3 Hepatic System and Other Laboratory Values

An examination of liver function as assessed approximately 1 month after MDMA administration in 166 participants, most of them MDMA-naïve, failed to detect any post-drug changes [232]. The first two sponsor-supported Phase 2 studies (MP-1, MP-2) assessed liver function after completion of two or three blinded dosing sessions. Values that differ from established age-appropriate norms were evaluated for clinical significance. Laboratory assessments of liver function were not conducted after dosing sessions in subsequent sponsor-supported studies and no AEs related to liver function have been reported in these studies.

**Table 8: List of All Abnormal Clinically Significant Changes in Laboratory Values in Two Participants from MP-2**

Laboratory Value	Abnormal Test Value	Value at Baseline	Normal Value/Range	MDMA HCl Dose
Bilirubin	2.8	2.2	<2.5 mg/dL	125 mg
ESR	32	2.4	<10 mm	125 mg

Two participants in the MP-2 study reported two clinically significant abnormal laboratory values. One was an elevation in bilirubin in a subject with a family history of elevated bilirubin (probably Gilbert’s syndrome), a benign liver condition in which the liver does not properly process bilirubin, with the elevation occurring after open-label treatment with an initial dose of 125 mg to 150 mg MDMA HCl. Family history of mildly elevated bilirubin is considered an indicator of Gilbert’s syndrome. Bilirubin levels can be indicative of decreased liver function, but the liver enzymes were normal at that time, supporting the interpretation that the bilirubin levels

were slightly elevated compared to baseline due to hereditary factors. The other abnormal laboratory value, an elevation in erythrocyte sedimentation rate (ESR), a marker of inflammation and not a specific liver function marker, occurred in a subject with a medical history of breast cancer. This value was recorded 3 months after the last administration of MDMA as an unrelated AE.

**Table 9: Average ALT Values at Baseline and 2-Month Follow-up After Two Dosing Sessions in Participants from MP-1**

Timepoint	Placebo	MDMA HCl (125 mg)
Baseline	25.6 (13.4) N=8	22.75 (12.89) N=12 <sup>a</sup>
Primary Endpoint After Two Dosing Sessions	26.4 (13.5) N=8	19.7 (12.7) N=13

<sup>a</sup> Post-drug liver panels or other laboratory tests were not conducted in studies subsequent to studies MP-1 and MP-2.

No clinically significant changes in liver function occurred in MP-1. Values for laboratory tests were within the normal range in MP-1. Phase 1 studies conducted outside of sponsor support involving administration of MDMA to healthy volunteers have not published any results of liver function after MDMA administration. There have been no reported adverse effects on the liver from these studies.

#### 6.2.3.4 Renal System

Cardiovascular Effects as correlating with AVP in blood, was detected in women acutely after 125 mg MDMA HCl administration [601], and this finding was reproduced in another study reporting that 47.5 mg MDMA HCl caused an acute rise in AVP and a small decrease in plasma sodium, at a time of day when it would not be expected to change, in an all-male sample. [236].

Norepinephrine release induced by MDMA leads to indirect activation of the AVP system, likely stimulating secretion of copeptin (CTproAVP), a 39-aminoacid glycopeptide that is a C-terminal part of the precursor to pre-proAVP that directly affects AVP. Heart failure is commonly associated with hyponatremia and is also characterized by increased concentrations of basal AVP and CTproAVP in humans [471]. Intra-cardiac pressures, intra-arterial pressures, angiotensin II, pain, and adrenergic ( $\alpha$ 2) central nervous stimuli can also influence AVP secretion [459]. Increased CTproAVP concentration was described in several studies as a strong predictor of mortality in patients with chronic heart failure and acute heart failure. [460].

#### 6.2.3.5 Immune System

Various groups have studied immunological effects of MDMA in laboratory settings and studies in men conducted by researchers in Spain have found 100 mg MDMA HCl to have immunosuppressive and anti-inflammatory effects [596, 614, 646-648]. Findings included a decline in CD4 cells, smaller CD4/CD8 ratio, attenuated lymphocyte proliferation in response to mitogen, and an increase in natural killer (NK) cells, with effects diminishing but still detectable 24 hours after drug administration. These researchers also found that MDMA decreased production of pro-inflammatory cytokines (see [Appendix Table 1: Summary of Investigator-Initiated Trials with MDMA](#)). Generally, MDMA appeared to decrease the concentration of Th1 cytokines, including IL-2, and increase the amount of Th2 cytokines, including IL-4, measured in blood. Changes of similar magnitude and duration have been previously noted after ingestion of other psychoactive agents such as alcohol or cocaine [647, 648]. Interestingly, meta-analysis and meta-regression of 20 studies investigating inflammatory markers in PTSD found an association

with increased IL-6, IL-1 $\alpha$ , TNF- $\alpha$ , and INF- $\gamma$ , consistent with chronic low-grade inflammation [276]. Any effects of MDMA on these immune markers remain to be tested.

Immunological changes seen after an initial dose of MDMA were enhanced by a second dose of identical size given 4 or 24 hours after the initial dose [614, 649]. Given these data, it is possible that administering a smaller supplemental dose 1.5 to 2.5 hours after the first dose could slightly enhance the immunological effects set in motion by the initial dose of MDMA.

To date, the clinical significance of these immunological findings have not been established and no reports of an increase in infections related to MDMA administration have been found in PTSD studies.

### 6.2.3.6 Reproductive System

Human data on effects of MDMA during pregnancy is limited. Several epidemiological survey studies have attempted to study this issue and found mixed results [650-652]. A 2012 survey of 96 women in the UK interviewed about their drug use during pregnancy found a link between self-reported extent of prenatal Ecstasy exposure and delays in infant development at 12 months, with heavily exposed infants delayed in mental and motor development, but not language or emotional development [653]. These results were repeated in a 2016 survey of 96 mothers who reported heavier Ecstasy use ( $1.3 \pm 1.4$  tablets per week) during pregnancy. Infants had motor delays from 4 months to 2 years of age that were not attributable to other drug or lifestyle factors [654]. There is no suspicion of human teratogenicity or data that supports genotoxic potential, and non-clinical reproductive toxicity studies of relevance for early human pregnancy have been completed and demonstrated results that do not generate strong suspicion of human teratogenicity/fetotoxicity.

### 6.2.3.7 Cognition and Performance

Research has assessed acute effects of MDMA on perception and cognition acutely after MDMA, commonly at doses between 75 and 125 mg MDMA HCl (or 0.5 to 1.5 mg/kg). In these studies, acute subjective effects peaked 90 to 120 minutes after oral administration and returned to pre-drug levels 3 to 6 hours later [17, 633, 636]. Sub-acute effects assessed in controlled and naturalistic studies occurred 1 to 3 days after drug administration but were no longer apparent 7 to 14 days later [14, 545, 655]. A study of variations in serotonin-related genes across a pooled sample reported that people with a variant of the 5HT<sub>2A</sub> gene reported experiencing more “good drug effect,” “trust,” “high mood,” and “dreaminess,” and people with a variant in the 5HT<sub>1A</sub> gene reported a higher “good drug effect,” “closeness to others”, and lower ratings of a “bad drug effect” [589]. People with a variant of the SERT gene reported greater “fear” and “depression” after MDMA.

A second dose of MDMA 2 hours after the first did not increase subjective effects beyond that of an initial dose, which was interpreted by Peiro and colleagues as an indication of tolerance to these effects [265]. When two 100 mg doses were given 4 hours apart, most subjective effects were comparable to those after a single dose, despite double the amount of plasma MDMA [575]. It is notable that the second dose in this study was identical to the first dose, in contrast to sponsor-supported studies, wherein the second dose was half the size of the initial dose. See [Section 6.2.3 Physiological Effects](#) for further details on subjective effects.

Earlier findings from a pooled set of drug-naïve participants reported differences in intensity of subjective effects with women reporting greater intensity of all subjective effects, and especially perceptual effects [15]. However, the same researchers performed a larger pooled analysis 10



clinical studies (n=194) examining predictor variables of physiological and psychological response to MDMA in healthy volunteers, reporting that after adjusting for body weight, sex was no longer predictive for plasma concentration or subjective effects [570]. Using univariable analysis, after adjusting for dose per body weight, the study reported participants with higher scores on the personality trait “openness to experience,” predicted more perceived “closeness,” a stronger decrease in “general inactivation,” and higher scores in feelings of “oceanic boundlessness” and “visionary restructuralization”, while participants with higher scores on the personality trait “neuroticism” or “trait anxiety” were more likely to have unpleasant or anxious reactions. Separate analyses of pooled samples also failed to support these sex effects [554].

An analysis of changes in PTSD symptom severity and changes in personality traits “openness” and “neuroticism” following MDMA-assisted therapy, found a significant increase in openness in the MDMA-assisted therapy group compared to the placebo with therapy group [656]. Openness, but not neuroticism, moderated the relationship between MDMA treatment and reduction in PTSD symptoms indicating openness may be a potential mechanism of therapeutic change. As the personality trait “openness to experience” was reported as a predictor variable of a positive MDMA experience [570], the authors suggest that these findings support a multi-dosing session treatment model. As participants are more likely to become more open to the experience following each session, participants with PTSD may be more likely to derive greater benefit from subsequent dosing sessions, which justifies a 3-session MDMA treatment package.

The effects of MDMA on perception have not been studied within sponsor-supported studies. The perceptual effects of MDMA appear to be the result of direct or indirect action on 5HT<sub>2A</sub> receptors; co-administration of the 5HT<sub>2A</sub> antagonist ketanserin reduced reported perceptual alterations, as well as eliminated slight elevations in body temperature after 1.5 mg/kg MDMA HCl [598], while co-administration with the 5HT<sub>1A</sub> antagonist pindolol did not affect perceptual alteration [188].

## 6.3 Efficacy of MDMA Across Populations

### 6.3.1 PTSD

When combined with therapy, MDMA permits people to confront and consider emotionally intense memories, thoughts, or feelings, and perhaps through changes in mood and perception, increase empathy and compassion for others and oneself [41, 51, 78]. In a sub-study of MP-8, the Self Compassion Scale [657] was administered before and 2 months after MDMA-assisted therapy. Preliminary results in this small sub-study (N=7) were promising; participants were low in self-compassion with a mean total score of 2.4±0.63 prior to the study and experienced an increase to moderate self-compassion with a mean total score of 2.8±0.84. In this assessment, self-kindness and a sense of common humanity increased, while self-judgment and feelings of isolation decreased on average within-subjects.

### Phase 2 Efficacy Data


Completed sponsor-supported Phase 2 studies of MDMA-assisted therapies employed recognized clinician-administered gold-standard measures of the condition or symptoms. The primary outcome measure of efficacy in the first six Phase 2 studies of MDMA-assisted therapy was the Clinician Administered PTSD Scale (CAPS-IV) following DSM-IV, an established semi-structured interview conducted by a trained clinician [658-660]. The Total Severity CAPS-IV score encompasses frequency and intensity scores for three symptom domains: re-experiencing, avoidance, and hyperarousal. An Independent Rater that does not see the participants during any of the therapy sessions administers the CAPS-IV at the Baseline Visit and at the Primary



Endpoint (1 or 2 months after blinded MDMA-assisted therapy sessions). Secondary endpoints include an assessment 1 to 2 months after a third dosing session and 12 months after the last treatment.

[Figure 3](#) below shows pooled mean Total Severity CAPS-IV scores for sponsor-supported studies (MP-1, MP-2, MP-4, MP-8, MP-9, MP-12), as reported in a comparison of active dose (75 mg to 125 mg MDMA HCl) versus placebo dose (40 mg MDMA HCl) at Primary Endpoint, 1 to 2 months after a second dosing session and 1 to 2 months after the third dosing session (End of Stage 1) [31]. Despite slight differences in study designs, including length of time post second dosing session to outcome assessment (3 to 8 weeks), and language of the CAPS (English or translated), these results demonstrate reproducibility and generalizability across multiple international studies of MDMA-assisted therapy in the treatment of chronic PTSD. Placebo and comparator groups cross over to Stage 2 after the Primary Endpoint; therefore, CAPS was not administered at the End of Stage 1 for these groups. Active dose groups (100 mg and 125 mg MDMA HCl) do not crossover, hence no data for Stage 2 endpoints.

**Figure 3: Least Squares Mean Estimates of Change in CAPS-IV from Baseline to Post 3<sup>rd</sup> Dosing Session**




Across studies, CAPS-IV scores are downward trending at the Primary Endpoint, after two dosing sessions of MDMA-assisted therapy. Primary endpoint results after active initial doses of 75 mg to 125 mg MDMA HCl, with an optional supplemental half-dose administered 1.5 to 2.5 hours later, appear lower than placebo or comparator dose results after two dosing sessions. Two-month follow-up results at the End of Stage 1 after a blinded or open-label third dosing session demonstrate further mean decreases in CAPS score.

Across studies, CAPS-IV scores trended downward at the Secondary Endpoint after two open-label dosing sessions of MDMA-assisted therapy, consistent with Stage 1 results. Secondary endpoint results in the crossover set receiving an active dose of 100 mg to 125 mg MDMA HCl)

after receiving comparator dose or placebo in Stage 1 are in range with participants receiving active doses in Stage 1. At treatment exit (the end of Stage 1 or 2, final assessment), CAPS-IV severity scores dropped 44.8 points (SD 2.82), Cohen’s d effect size of 1.58 [33]. Symptom severity remained essentially the same as treatment exit when assessed at least 12 months later, with scores dropping 5.2 more points, indicating an enduring reduction in symptoms after MDMA-assisted therapy (Figure 4). The number of participants who no longer met PTSD criteria increased from treatment exit (56.0%) to long-term follow-up (67.0%) [33]. However, the lack of a control group at 12-month follow-up limited the interpretation of these results and warrants further investigation.

**Figure 4: Least Squares Mean Change in CAPS-IV from Baseline to Long-Term Follow-Up**




Subsequent to completing these studies, the sponsor assessed PTSD symptoms with the CAPS-5, designed to capture the diagnostic criteria for PTSD found in the DSM-5. Like the CAPS-IV, the updated CAPS-5 is a structured interview, administered by a central blinded Independent Rater who has not been present during any therapy sessions. CAPS-5 total severity scores range from 0 to 80 [661]. CAPS-5 was employed in completed Phase 2 studies MPVA-1, MP16 and MP17, for the completed Phase 3 study MAPP1, and for future planned studies of MDMA-assisted therapy in people with PTSD.

### Phase 3 Efficacy Data

Efficacy data from the pivotal Phase 3 study, MAPP1, were positive and support the conclusions of the Phase 2 studies. MDMA as an adjunct to supportive therapy was statistically superior for PTSD treatment in CAPS-5 severity scores from Baseline to Primary Endpoint, 8 weeks after three blinded dosing sessions, in comparison to therapy paired with an inactive placebo ( $p < 0.0001$ ,  $d = 0.91$ ) [30]. The pooled mean Total Severity CAPS-5 scores for MAPP1 are shown in Figure 5, as reported in a comparison of MDMA-assisted therapy versus placebo with therapy groups at Baseline (T1); three weeks after dosing session 1 (T2); three weeks after dosing session 1 (T3); and Primary Endpoint, eight weeks after dosing session 3 (T4).


**Figure 5: Change in Mean CAPS-5 Score from Baseline to Primary Outcome**



Reproduced from *Nature Medicine* [30].

Responder analysis indicated that at the primary endpoint, 88% of participants in the MDMA-AT group had a clinically significant improvement, defined as a  $\geq 10$ -point decrease on CAPS-5, compared to 62% of the placebo group. Additionally, 67% of participants in the MDMA-AT group no longer met diagnostic criteria for PTSD, compared to 32% of the placebo group, and 33% of participants in the MDMA-AT group were considered in remission, with a CAPS-5 Total Severity Score less than 11 and Loss of PTSD Diagnosis, compared to 5% of the placebo group, see [Figure 6](#).

**Figure 6: Treatment Response and Remission for Treatment Groups**



Withdrawal is defined as a post-randomization early termination; Non-responders did not show clinically significant improvement, defined as a  $< 10$ -point decrease on CAPS-5; Responders showed clinically significant improvement, defined as a  $\geq 10$ -point decrease on CAPS-5; Loss of diagnosis is defined by specific diagnostic measure on CAPS-5; and Remission is defined as a loss of diagnosis and a total CAPS-5 score of  $\leq 11$ . Reproduced from *Nature Medicine* [30].

A long-term follow-up study among Phase 3 participants who were randomized to receive MDMA or placebo with therapy in the parent study is ongoing in order to assess the durability of these results. These findings will be reported when completed.

### 6.3.2 Social Anxiety in Autistic Adults

The primary outcome measure for the study of social anxiety in people on the autism spectrum is the Liebowitz Social Anxiety Scale (LSAS). This observer-blind measure is an established clinician-administered measure of social anxiety, assessing fear and avoidance in different situations. The LSAS consists of 24 items, with each item rated on a four-point scale (from 0 to 3), with subscales for performance fear, performance avoidance, social fear, and social avoidance.

Data was analyzed and findings appear in the following publication [89]. Improvement in LSAS scores from the Baseline Visit to the Primary Endpoint was significantly greater for MDMA group compared to the placebo group ( $P=0.037$ ), and placebo-subtracted Cohen's  $d$  effect size was very large ( $d=1.4$ , CI: -0.074, 2.874). Change in LSAS scores from the Baseline Visit to 6-month follow-up showed similar positive results ( $P=0.036$ ), with a Cohen's  $d$  effect size of 1.1 (CI: -0.307, 2.527). The study safety and efficacy data were published [89].

### 6.3.3 Anxiety Associated with Life-Threatening Illness

MAPS is studying the effects of MDMA-assisted therapy on people experiencing anxiety as they face a potentially life-threatening illness. A manuscript containing results was published in *Scientific Reports* in November 2020. Participants with anxiety from life-threatening illnesses were randomized to receive MDMA (125 mg MDMA HCl) or placebo in combination with two eight-hour therapy sessions. At the primary endpoint, the MDMA group had a greater mean (SD) reduction in State-Trait Anxiety Inventory (STAI) Trait scores, -23.5 (SD:12.3), indicating less anxiety, compared to the placebo group, -8.8 (SD:14.7); however, the group difference was not statistically significant [90].

### 6.3.4 Alcohol Use Disorder

An investigator-initiated trial investigated the safety and tolerability proof-of-concept of MDMA-assisted therapy for treatment of alcohol use disorder (AUD) post-detoxification in an open-label study [645]. Participants with AUD ( $N=14$ ), post-detoxification, completed a ten-session course of recovery-based therapy over eight weeks that included two sessions where participants received an initial dose of 125 mg MDMA HCl followed by a supplementary dose of 62.5 mg MDMA HCl in combination with eight-hour therapy sessions. There were no new safety signals reported or unexpected AEs observed. The mean units of alcohol consumption decreased from 130.6 units per week prior to detoxification to 18.7 units per week nine months post-detoxification, indicating a change in drinking behavior. These findings provide initial support for the safety and tolerability of MDMA-assisted therapy for treatment of AUD post-detoxification.

## 6.4 Safety of MDMA in Humans

All sponsor-supported safety data (adverse events, spontaneously reported reactions, vitals during dosing sessions, and suicidal ideation and behavior) are presented in this IB through a cutoff date of October 01, 2021 unless indicated otherwise. For more information on completed, ongoing and planned sponsored studies, please see [Table 4](#) and [Table 5](#).

Safety was addressed and closely monitored through several measures in these studies. Vital signs, concomitant medications, unexpected, and expected AEs were collected in all studies. Suicidal ideation and behavior were formally measured with the Columbia Suicide Severity Rating Scale (C-SSRS) in all but the MP-1 and MP-2 studies. Three completed studies (MP-1, MP-12, MP-4) measured cognitive function before and after treatment. Psychological distress during therapy sessions was assessed in most Phase 2 studies with the single-item Subjective Units of Distress (SUD) scale.

Partial safety data from the Phase 1 study MT-1 in healthy volunteers are not presented in the current report since the data remain blinded. No medical intervention has been required for AEs during this study to date.

The most common reactions pooled across Phase 2 studies in which these reactions were collected were transient and decreased over time, as the drug was metabolized during treatment sessions and excreted over the next 24 hours with the majority of reactions resolving within several days and up to 1 week after dosing. Overall, across treatment groups, the most frequently reported spontaneous reactions or adverse events were anxiety, headache, and fatigue. In the active MDMA dose groups, participants reported spontaneously reported reactions including dry mouth, diarrhea, heavy legs, impaired judgment, and nystagmus; none were reported as severe and all had resolved by day 7 following the dosing session. The most frequently reported severe reactions in these Phase 2 studies were anxiety, nausea, insomnia, and tight jaw (see [Table 10-13](#) and [Appendix Tables 17-21](#)). In the active MDMA dose groups, □10% of participants reported the following reactions had not resolved 7 days following the dosing session: anxiety, fatigue, difficulty concentrating, increased irritability, insomnia, and low mood.

In the Phase 3 study MAPP1, the most common adverse events occurring 2x more frequently in the MDMA-assisted therapy versus the placebo with therapy arm were muscle tightness (63.0% MDMA, vs 11.4% placebo), decreased appetite (52.2% MDMA, vs 11.4% placebo), nausea (30.4% MDMA, vs 11.4% placebo), hyperhidrosis (19.6% MDMA, vs 2.3% placebo), feeling cold (19.6% MDMA, vs 6.8% placebo), restlessness (15.2% MDMA, vs 0% placebo), mydriasis (15.2% MDMA, vs 0% placebo), dizziness postural (13.0% MDMA, vs 4.5% placebo), bruxism (13.0% MDMA, vs 2.3% placebo), nystagmus (13.0% MDMA, vs 0% placebo), blood pressure increased (10.9% MDMA, vs 0% placebo), feeling jittery (10.9% MDMA, vs 0% placebo), non-cardiac chest pain (10.9% MDMA, vs 2.3% placebo), dry mouth (10.9% MDMA, vs 4.5% placebo), vision blurred (8.7% MDMA, vs 2.3% placebo), pollakiuria (8.7% MDMA, vs 2.3% placebo), intrusive thoughts (8.7% MDMA, vs 0% placebo), vomiting (8.7% MDMA, vs 0% placebo), stress (8.7% MDMA, vs 0% placebo), musculoskeletal pain (8.7% MDMA, vs 0% placebo), pyrexia (6.5% MDMA, vs 2.3% placebo), chills (6.5% MDMA, vs 0% placebo), substance use (6.5% MDMA, vs 0% placebo), micturition urgency (6.5% MDMA, vs 0% placebo), muscle twitching (6.5% MDMA, vs 0% placebo), somnolence (6.5% MDMA, vs 0% placebo), and nervousness (6.5% MDMA, vs 0% placebo).

The half-life of MDMA doses used in these studies was 7 to 9 hours and the majority of AEs have been transient, resolving within 2 to 3 days after MDMA had been metabolized and excreted. The observed reactions in the Phase 2 and Phase 3 studies also overlapped with symptoms of pre-existing conditions in medical history associated with PTSD (depression, somatic symptoms, insomnia, anxiety), which might have influenced the frequency of events observed during clinical trials of MDMA-assisted therapy.

## 6.4.1 Adverse Events

### 6.4.1.1 Commonly Reported Reactions from Early Phase Studies

Common AEs of MDMA reported in non-sponsor supported Phase 1 studies in healthy volunteers include elevation in blood pressure and heart rate, increased anxiety or dysphoria, and dilated pupils [12-15]. Some reports indicated decreased rather than increased alertness [12]. Other common AEs reported in controlled studies of MDMA include reduced appetite, dizziness, tight jaw, bruxism (tooth-grinding), disturbance in attention, impaired gait or balance, dry mouth, and thirst. Participants in some studies also reported or exhibited changes in cognition, such as increases in speed of thought or thought blocking, facilitated imagination or recall [17], and unusual thoughts or ideas [14]. Other less commonly reported events include paraesthesia (unusual body sensations) such as tingling or feeling hot or cold. MDMA can produce anxiety in healthy volunteers [14, 15, 17]. These effects are transient and recede as drug effects wane. One



study found that women were more likely to report these events than men [15], while another study failed to support sex differences in reporting AEs [554].

#### 6.4.1.2 Spontaneously Reported Reactions from Early Phase Studies

The most commonly reported AEs from Phase 1 studies published between 1986 and 2012 were used to develop a list of common adverse reactions to MDMA, or Spontaneously Reported Reactions, to record daily occurrence, duration and severity [14, 17, 36, 51, 78, 225, 228, 594, 598, 600, 604, 617]. Based on the reports, 24 reactions were identified to be tracked during sponsor-supported studies MP-1 and MP-2, and three were added after examining data from the first sponsor-supported study in a PTSD sample (MP-1). The investigators noted that participants in MP-1 reported greater incidence of diarrhea and muscle tightness, which were added to the list, and further observation led to the addition of impaired judgment. Based on the half-life of active MDMA doses being 7 to 9 hours, it was most important to collect reactions on the day of drug administration and the following 7 days after each dosing session. The subset of AEs referred to as spontaneously reported reactions included: anxiety, depressed mood, insomnia, obsessive rumination, restlessness, irritability, headache, disturbance in attention, dizziness, paresthesia, judgment impaired, hypersomnia, nausea, diarrhea, fatigue, asthenia, feeling cold, muscle tension, decreased appetite, hyperhidrosis, disturbed gait, dry mouth, thirst, sensation of heaviness, somnolence, and nystagmus.

In sponsor-supported Phase 2 studies, researchers recorded any spontaneous (unsolicited) reports of common reactions on the day of each dosing session and 7 days after. The same severity coding system for AEs was employed throughout all studies, based on limitation in daily function. Table 10 and Table 11 below display data from studies investigating MDMA-assisted therapy for PTSD (MP-1, MP-2, MP-4, MP-8, MP-9 and MP-12), social anxiety in autistic adults (MAA-1) (see Appendix Tables 17), and anxiety associated with life-threatening illness (MDA-1) (see Appendix Table 18 and Appendix Table 19). For all clinical studies conducted after MP-12, adverse events were collected following enrollment and spontaneously reported reactions were not collected.

#### Spontaneous Reactions in Phase 2 PTSD Studies

In Table 10, the relative incidence of spontaneously reported reactions (SRR), which occurred during dosing sessions, are summarized for studies MP-1, MP-2, MP-4, MP-8, MP-9, and MP-12 (N=105). SRR's were collected with AEs in MP16, MP17, and Phase 3 trials. In the placebo group (N=10), participants most frequently reported anxiety (n=9), insomnia (n=9), headache (n=8), and fatigue; severe SRRs included anxiety. (n=7). In subjects who received blinded 25 mg to 40 mg MDMA HCl (N=21), most frequently reported SRRs included headache (n=14), fatigue (n=11), anxiety (n=8), and muscle tension (n=7); severe SRRs included anxiety (n=1), insomnia (n=1), lack of appetite (n=1), and needing more sleep (n=1). In subjects who received blinded 75 mg to 125 mg MDMA HCl (N=74), frequently reported SRRs included anxiety (n=52), tight jaw (n=46), headache (n=38), fatigue (n=36), and lack of appetite (n=35); severe SRRs included anxiety (n=5), nausea (n=4), tight jaw (n=4), dizziness (n=2), fatigue (n=2), increased irritability (n=1), insomnia (n=1), lack of appetite (n=1), low mood (n=1), and restlessness (n=1). Similarly, in participants who received open-label 100 mg to 150 mg MDMA HCl (N=78), the most frequently reported SRRs were tight jaw (n=47), anxiety (n=38), lack of appetite (n=38), headache (n=35), and fatigue (n=33); and severe SRRs included anxiety (n=8), insomnia (n=5), tight jaw (n=3), headache (n=2), nausea (n=2), increased irritability (n=1), lack of appetite (n=1), and sensitivity to cold (n=1).

Overall, across placebo and active dose treatment groups, the most frequently reported SRRs were anxiety, headache, and fatigue. There were several SRRs that were not reported in the placebo group but were reported in either the active blinded 75 mg to 125 mg MDMA HCl or open-label 100 mg to 150 mg MDMA HCl groups: dry mouth, diarrhea, heavy legs, impaired judgement, and nystagmus; none of which were reported as severe. All of these SRRs were resolved by 7-day follow-up after the dosing sessions (Table 10). For other SRRs, in the active MDMA dose groups, those that were not resolved by 7-day follow-up after dosing sessions in □10% of participants included anxiety (25.7% blinded, 17.9% open-label), fatigue (12.2% blinded, 10.3% open-label), difficulty concentrating (9.5% blinded only), increased irritability (10.8% blinded only), insomnia (10.8% blinded only), and low mood (17.6% blinded only). The placebo group had significantly fewer participants which limits direct comparison against the active MDMA dose groups. Nonetheless, in a total of 10 participants, a large proportion of the placebo sample also reported anxiety, fatigue, and insomnia at 7-day follow-up. The remaining SRRs that were unresolved at 7-day follow-up that could have been linked to active MDMA were difficulty concentrating, increased irritability, and low mood. Studies with larger and more balanced sample sizes are needed to make direct comparisons against placebo vs. active dose MDMA groups to elucidate whether SRRs had occurred during and/ or after dosing sessions. In the meantime, clinical actions are taken to closely monitor all unresolved SRRs throughout the treatment period and later assessed at long-term follow-up.

**Table 10: Relative Incidence of Spontaneously Reported Reactions at Any Severity During Dosing Sessions in Sponsor-Supported Phase 2 PTSD Studies of MDMA-Assisted Therapy MP-1, MP-2, MP-4, MP-9, MP-8, MP-12 (N=105)**

Dose	Blinded Placebo (N=10) N (%)	Blinded 25-40 mg MDMA HCl (N=21) N (%)	Blinded 75-125 mg MDMA HCl (N=74) N (%)	Open-label 100-150 mg MDMA HCL (N=78) N (%)
Anxiety	9 (90.0)	8 (38.1)	52 (70.3)	38 (48.7)
Severe	4 (40.0)	1 (4.8)	5 (6.8)	8 (10.3)
Diarrhea <sup>a</sup>	---	---	---	3 (3.8)
Severe	---	---	---	---
Difficulty Concentrating	1 (10.0)	3 (14.3)	16 (21.6)	14 (17.9)
Severe	---	---	---	---
Dizziness	2 (20.0)	4 (19.0)	29 (39.2)	23 (29.5)
Severe	---	---	2 (2.7)	---
Drowsiness	2 (20.0)	2 (9.5)	10 (13.5)	8 (10.3)
Severe	---	---	---	---
Dry Mouth	---	5 (23.8)	15 (20.3)	20 (25.6)
Severe	---	---	---	---
Fatigue	7 (70.0)	11 (52.4)	36 (48.6)	33 (42.3)
Severe	---	---	2 (2.7)	---
Headache	8 (80.0)	14 (66.7)	38 (51.4)	35 (44.9)
Severe	---	---	---	2 (2.6)
Heavy Legs	---	---	9 (12.2)	5 (6.4)
Severe	---	---	---	---
Impaired Gait/Balance	1 (10.0)	3 (14.3)	18 (24.3)	17 (21.8)
Severe	---	---	---	---
Impaired Judgment <sup>a</sup>	---	---	---	1 (1.3)
Severe	---	---	---	---
Increased Irritability	3 (30.0)	1 (4.8)	7 (9.5)	5 (6.4)
Severe	---	---	1 (1.4)	1 (1.3)

Insomnia	9 (90.0)	3 (14.3)	21 (28.4)	22 (28.2)
Severe	---	1 (4.8)	1 (1.4)	5 (6.4)
Tight Jaw	3 (30.0)	3 (14.3)	46 (62.2)	47 (60.3)
Severe	---	---	4 (5.4)	3 (3.8)
Lack of Appetite	2 (20.0)	5 (23.8)	35 (47.3)	38 (48.7)
Severe	---	1 (4.8)	1 (1.4)	1 (1.3)
Low Mood	2 (20.0)	2 (9.5)	18 (24.3)	7 (9.0)
Severe	---	---	1 (1.4)	---
Muscle Tension <sup>a</sup>	2 (20.0)	7 (33.3)	27 (36.5)	29 (37.2)
Severe	---	---	---	---
Nausea	3 (30.0)	4 (19.0)	29 (39.2)	29 (37.2)
Severe	---	---	4 (5.4)	2 (2.6)
Need More Sleep	3 (30.0)	4 (19.0)	7 (9.5)	2 (2.6)
Severe	---	1 (4.8)	---	---
Nystagmus	---	---	10 (13.5)	10 (12.8)
Severe	---	---	---	---
Paresthesia	---	1 (4.8)	9 (12.2)	7 (9.0)
Severe	---	---	---	---
Perspiration	1 (10.0)	2 (9.5)	24 (32.4)	26 (33.3)
Severe	---	---	---	---
Restlessness	2 (20.0)	5 (23.8)	26 (35.1)	26 (33.3)
Severe	---	---	1 (1.4)	---
Ruminations	1 (10.0)	3 (14.3)	11 (14.9)	5 (6.4)
Severe	---	---	---	---
Sensitivity to Cold	2 (20.0)	5 (23.8)	28 (37.8)	22 (28.2)
Severe	---	---	---	1 (1.3)
Thirst	1 (10.0)	2 (9.5)	18 (24.3)	16 (20.5)
Severe	---	---	---	---
Weakness	1 (10.0)	---	7 (9.5)	7 (9.0)
Severe	---	---	---	---

<sup>a</sup> Diarrhea, impaired judgment, and muscle tension were added based on observations from early studies to reactions list.

**Table 11: Relative Incidence of Spontaneously Reported Reactions During Telephone Contact on Day 1-7 After Dosing Sessions in Sponsor-Supported Phase 2 PTSD Studies of MDMA-Assisted Therapy MP-1, MP-2, MP-4, MP-8, MP-9, MP-12**

Post-drug MDMA HCl mg	Day 1 N (%)	Day 2 N (%)	Day 3 N (%)	Day 4 N (%)	Day 5 N (%)	Day 6 N (%)	Day 7 <sup>A</sup> N (%)
<b>Anxiety</b>							
Blinded Placebo (N=10)	7 (70.0)	6 (60.0)	5 (50.0)	6 (60.0)	6 (60.0)	6 (60.0)	5 (50.0)
25-40 mg Blinded (N=21)	2 (9.5)	7 (33.3)	7 (33.3)	7 (33.3)	7 (33.3)	5 (23.8)	2 (9.5)
75-125 mg Blinded (N=74)	23 (31.1)	33 (44.6)	36 (48.6)	25 (33.8)	28 (37.8)	32 (43.2)	19 (25.7)
Open-label 100-150 mg (N=78)	19 (24.4)	25 (32.1)	31 (39.7)	28 (35.9)	31 (39.7)	22 (28.2)	14 (17.9)
<b>Diarrhea <sup>B</sup></b>							
Blinded Placebo (N=2)	---	---	---	---	---	---	---
25-40 mg Blinded (N=16)	---	---	---	1 (6.3)	1 (6.3)	1 (6.3)	1 (6.3)
75-125 mg Blinded (N=50)	1 (2.0)	1 (2.0)	1 (2.0)	1 (2.0)	---	1 (2.0)	---
Open-label 100-150 mg (N=62)	---	---	---	---	---	---	---
<b>Difficulty Concentrating</b>							
Blinded Placebo (N=10)	3 (30.0)	3 (30.0)	3 (30.0)	3 (30.0)	3 (30.0)	4 (40.0)	1 (10.0)
25-40 mg Blinded (N=21)	2 (9.5)	3 (14.3)	2 (9.5)	---	1 (4.8)	---	---
75-125 mg Blinded (N=74)	8 (10.8)	7 (9.5)	11 (14.9)	8 (10.8)	10 (13.5)	9 (12.2)	7 (9.5)
Open-label 100-150 mg (N=78)	6 (7.7)	6 (7.7)	4 (5.1)	4 (5.1)	3 (3.8)	3 (3.8)	---
<b>Dizziness</b>							
Blinded Placebo (N=10)	1 (10.0)	1 (10.0)	1 (10.0)	---	1 (10.0)	---	---
25-40 mg Blinded (N=21)	2 (9.5)	1 (4.8)	1 (4.8)	1 (4.8)	---	---	---
75-125 mg Blinded (N=74)	6 (8.1)	8 (10.8)	7 (9.5)	6 (8.1)	5 (6.8)	6 (8.1)	3 (4.1)
Open-label 100-150 mg (N=78)	4 (5.1)	---	2 (2.6)	2 (2.6)	2 (2.6)	2 (2.6)	1 (1.3)
<b>Drowsiness</b>							
Blinded Placebo (N=10)	1 (10.0)	1 (10.0)	1 (10.0)	---	1 (10.0)	---	---
25-40 mg Blinded (N=21)	2 (9.5)	1 (4.8)	---	---	---	---	---
75-125 mg Blinded (N=74)	1 (1.4)	---	2 (2.7)	1 (1.4)	---	1 (1.4)	1 (1.4)
Open-label 100-150 mg (N=78)	4 (5.1)	4 (5.1)	2 (2.6)	1 (1.3)	---	---	---
<b>Dry Mouth</b>							
Blinded Placebo (N=10)	---	---	---	---	---	---	---
25-40 mg Blinded (N=21)	---	1 (4.8)	---	---	---	---	---
75-125 mg Blinded (N=74)	7 (9.5)	1 (1.4)	4 (5.4)	1 (1.4)	---	1 (1.4)	---
Open-label 100-150 mg (N=78)	4 (5.1)	3 (3.8)	---	---	---	1 (1.3)	---

<b>Fatigue</b>							
Blinded Placebo (N=10)	6 (60.0)	4 (40.0)	4 (40.0)	6 (60.0)	7 (70.0)	5 (50.0)	4 (40.0)
25-40 mg Blinded (N=21)	12 (57.1)	8 (38.1)	6 (28.6)	5 (23.8)	5 (23.8)	5 (23.8)	5 (23.8)
75-125 mg Blinded (N=74)	46 (62.2)	34 (45.9)	29 (39.2)	24 (32.4)	23 (31.1)	23 (31.1)	9 (12.2)
Open-label 100-150 mg (N=78)	36 (46.2)	38 (48.7)	34 (43.6)	22 (28.2)	20 (25.6)	13 (16.7)	8 (10.3)
<b>Headache</b>							
Blinded Placebo (N=10)	5 (50.0)	2 (20.0)	1 (10.0)	1 (10.0)	---	---	---
25-40 mg Blinded (N=21)	8 (38.1)	3 (14.3)	2 (9.5)	2 (9.5)	2 (9.5)	2 (9.5)	2 (9.5)
75-125 mg Blinded (N=74)	19 (25.7)	10 (13.5)	7 (9.5)	9 (12.2)	7 (9.5)	8 (10.8)	3 (4.1)
Open-label 100-150 mg (N=78)	23 (29.5)	9 (11.5)	3 (3.8)	4 (5.1)	5 (6.4)	5 (6.4)	---
<b>Heavy Legs</b>							
Blinded Placebo (N=10)	---	---	---	---	---	---	---
25-40 mg Blinded (N=21)	---	---	---	---	---	1 (4.8)	---
75-125 mg Blinded (N=74)	3 (4.1)	1 (1.4)	---	---	---	1 (1.4)	---
Open-label 100-150 mg (N=78)	---	1 (1.3)	2 (2.6)	---	---	---	---
<b>Impaired Gait/Balance</b>							
Blinded Placebo (N=10)	---	---	1 (10.0)	---	---	---	---
25-40 mg Blinded (N=21)	---	---	---	---	---	---	---
75-125 mg Blinded (N=74)	4 (5.4)	---	1 (1.4)	1 (1.4)	1 (1.4)	2 (2.7)	---
Open-label 100-150 mg (N=78)	2 (2.6)	---	---	---	---	---	---
<b>Impaired Judgment<sup>B</sup></b>							
Blinded Placebo (N=2)	---	---	---	---	---	---	---
25-40 mg Blinded (N=16)	1 (6.3)	1 (6.3)	1 (6.3)	---	---	---	---
75-125 mg Blinded (N=50)	---	---	---	---	---	---	---
Open-label 100-150 mg (N=62)	---	---	---	---	---	---	---
<b>Increased Irritability</b>							
Blinded Placebo (N=10)	2 (20.0)	2 (20.0)	3 (30.0)	2 (20.0)	3 (30.0)	3 (30.0)	---
25-40 mg Blinded (N=21)	3 (14.3)	3 (14.3)	3 (14.3)	2 (9.5)	2 (9.5)	1 (4.8)	---
75-125 mg Blinded (N=74)	12 (16.2)	13 (17.6)	14 (18.9)	11 (14.9)	11 (14.9)	15 (20.3)	8 (10.8)
Open-label 100-150 mg (N=78)	3 (3.8)	4 (5.1)	5 (6.4)	12 (15.4)	6 (7.7)	7 (9.0)	1 (1.3)
<b>Insomnia</b>							
Blinded Placebo (N=10)	5 (50.0)	3 (30.0)	5 (50.0)	4 (40.0)	5 (50.0)	7 (70.0)	4 (40.0)
25-40 mg Blinded (N=21)	8 (38.1)	8 (38.1)	6 (28.6)	5 (23.8)	4 (19.0)	7 (33.3)	2 (9.5)
75-125 mg Blinded (N=74)	37 (50.0)	20 (27.0)	21 (28.4)	16 (21.6)	19 (25.7)	13 (17.6)	8 (10.8)
Open-label 100-150 (N=78)	19 (24.4)	16 (20.5)	17 (21.8)	15 (19.2)	11 (14.1)	10 (12.8)	6 (7.7)
<b>Tight Jaw</b>							
Blinded Placebo (N=10)	2 (20.0)	---	---	---	---	---	---

25-40 mg Blinded (N=21)	---	2 (9.5)	1 (4.8)	2 (9.5)	2 (9.5)	1 (4.8)	1 (4.8)
75-125 mg Blinded (N=74)	19 (25.7)	11 (14.9)	2 (2.7)	6 (8.1)	5 (6.8)	3 (4.1)	5 (6.8)
Open-label 100-150 mg (N=78)	14 (17.9)	6 (7.7)	3 (3.8)	5 (6.4)	3 (3.8)	2 (2.6)	3 (3.8)
<b>Lack of Appetite</b>							
Blinded Placebo (N=10)	---	---	---	---	---	---	---
25-40 mg Blinded (N=21)	5 (23.8)	3 (14.3)	3 (14.3)	1 (4.8)	1 (4.8)	1 (4.8)	---
75-125 mg Blinded (N=74)	21 (28.4)	17 (23.0)	11 (14.9)	10 (13.5)	7 (9.5)	9 (12.2)	6 (8.1)
Open-label 100-150 mg (N=78)	20 (25.6)	10 (12.8)	8 (10.3)	5 (6.4)	6 (7.7)	3 (3.8)	2 (2.6)
<b>Low Mood</b>							
Blinded Placebo (N=10)	2 (20.0)	1 (10.0)	1 (10.0)	4 (40.0)	3 (30.0)	3 (30.0)	1 (10.0)
25-40 mg Blinded (N=21)	4 (19.0)	5 (23.8)	5 (23.8)	4 (19.0)	5 (23.8)	4 (19.0)	4 (19.0)
75-125 mg Blinded (N=74)	20 (27.0)	25 (33.8)	22 (29.7)	24 (32.4)	20 (27.0)	14 (18.9)	13 (17.6)
Open-label 100-150 mg (N=78)	13 (16.7)	17 (21.8)	12 (15.4)	12 (15.4)	13 (16.7)	4 (5.1)	3 (3.8)
<b>Muscle Tension<sup>B</sup></b>							
Blinded Placebo (N=2)	---	---	---	---	---	---	---
25-40 mg (N=16)	4 (25.0)	2 (12.5)	2 (12.5)	2 (12.5)	2 (12.5)	2 (12.5)	2 (12.5)
75-125 mg (N=50)	4 (8.0)	3 (6.0)	---	---	1 (2.0)	2 (4.0)	---
Open-label 100-150 mg (N=62)	---	---	---	---	---	---	---
<b>Nausea</b>							
Blinded Placebo (N=10)	4 (40.0)	1 (10.0)	1 (10.0)	---	1 (10.0)	---	---
25-40 mg Blinded (N=21)	2 (9.5)	3 (14.3)	3 (14.3)	1 (4.8)	1 (4.8)	---	---
75-125 mg Blinded (N=74)	16 (21.6)	13 (17.6)	10 (13.5)	6 (8.1)	7 (9.5)	5 (6.8)	4 (5.4)
Open-label 100-150 mg (N=78)	12 (15.4)	4 (5.1)	10 (12.8)	6 (7.7)	6 (7.7)	1 (1.3)	1 (1.3)
<b>Need More Sleep</b>							
Blinded Placebo (N=10)	3 (30.0)	2 (20.0)	1 (10.0)	2 (20.0)	2 (20.0)	2 (20.0)	2 (20.0)
25-40 mg Blinded (N=21)	4 (19.0)	5 (23.8)	3 (14.3)	5 (23.8)	4 (19.0)	5 (23.8)	4 (19.0)
75-125 mg Blinded (N=74)	18 (24.3)	25 (33.8)	13 (17.6)	15 (20.3)	9 (12.2)	8 (10.8)	4 (5.4)
Open-label 100-150 mg (N=78)	22 (28.2)	20 (25.6)	19 (24.4)	15 (19.2)	15 (19.2)	12 (15.4)	7 (9.0)
<b>Nystagmus</b>							
Blinded Placebo (N=10)	---	---	---	---	---	---	---
25-40 mg Blinded (N=21)	---	---	---	---	---	---	---
75-125 mg Blinded (N=74)	---	---	---	---	---	---	---
Open-label 100-150 mg (N=78)	---	---	---	---	---	---	---
<b>Parasthesia</b>							
Blinded Placebo (N=10)	---	---	---	---	---	---	---
25-40 mg Blinded (N=21)	---	---	---	---	---	---	---
75-125 mg Blinded (N=74)	1 (1.4)	1 (1.4)	---	1 (1.4)	---	1 (1.4)	1 (1.4)



Open-label 100-150 mg (N=78)	---	1 (1.3)	2 (2.6)	1 (1.3)	1 (1.3)	---	---
<b>Perspiration</b>							
Blinded Placebo (N=10)	2 (20.0)	---	---	---	---	---	---
25-40 mg Blinded (N=21)	1 (4.8)	---	1 (4.8)	---	---	---	---
75-125 mg Blinded (N=74)	3 (4.1)	---	1 (1.4)	---	---	---	---
Open-label 100-150 mg (N=78)	3 (3.8)	4 (5.1)	1 (1.3)	---	1 (1.3)	1 (1.3)	---
<b>Restlessness</b>							
Blinded Placebo (N=10)	---	---	---	---	---	---	---
25-40 mg Blinded (N=21)	3 (14.3)	1 (4.8)	1 (4.8)	---	2 (9.5)	1 (4.8)	---
75-125 mg Blinded (N=74)	8 (10.8)	6 (8.1)	4 (5.4)	6 (8.1)	5 (6.8)	7 (9.5)	3 (4.1)
Open-label 100-150 mg (N=78)	1 (1.3)	2 (2.6)	2 (2.6)	3 (3.8)	2 (2.6)	---	---
<b>Ruminations</b>							
Blinded Placebo (N=10)	3 (30.0)	1 (10.0)	1 (10.0)	---	---	1 (10.0)	1 (10.0)
25-40 mg Blinded (N=21)	2 (9.5)	1 (4.8)	3 (14.3)	3 (14.3)	2 (9.5)	1 (4.8)	1 (4.8)
75-125 mg Blinded (N=74)	7 (9.5)	11 (14.9)	12 (16.2)	5 (6.8)	8 (10.8)	10 (13.5)	6 (8.1)
Open-label 100-150 mg (N=78)	6 (7.7)	6 (7.7)	7 (9.0)	2 (2.6)	3 (3.8)	2 (2.6)	1 (1.3)
<b>Sensitivity to Cold</b>							
Blinded Placebo (N=10)	---	---	---	---	---	---	---
25-40 mg Blinded (N=21)	2 (9.5)	---	---	---	1 (4.8)	1 (4.8)	---
75-125 mg Blinded (N=74)	3 (4.1)	3 (4.1)	3 (4.1)	3 (4.1)	1 (1.4)	1 (1.4)	---
Open-label 100-150 mg (N=78)	4 (5.1)	1 (1.3)	1 (1.3)	2 (2.6)	1 (1.3)	1 (1.3)	1 (1.3)
<b>Thirst</b>							
Blinded Placebo (N=10)	---	---	---	---	---	---	---
25-40 mg Blinded (N=21)	1 (4.8)	---	---	---	---	---	---
75-125 mg Blinded (N=74)	5 (6.8)	1 (1.4)	1 (1.4)	1 (1.4)	---	---	---
Open-label 100-150 mg (N=78)	---	1 (1.3)	---	---	---	---	---
<b>Weakness</b>							
Blinded Placebo (N=10)	---	---	---	---	---	---	---
25-40 mg Blinded (N=21)	1 (4.8)	2 (9.5)	---	---	---	---	---
75-125 mg Blinded (N=74)	3 (4.1)	7 (9.5)	4 (5.4)	2 (2.7)	4 (5.4)	2 (2.7)	2 (2.7)
Open-label 100-150 mg (N=78)	9 (11.5)	1 (1.3)	4 (5.1)	1 (1.3)	---	1 (1.3)	---

<sup>A</sup> Severe reactions on Day 7=25-40 mg MDMA HCl: fatigue (n=2, 9.5%), insomnia (n=2, 9.5%); 75-125 mg MDMA HCl: anxiety (n=1, 1.4%), low mood (n=2, 2.7%), muscle tension (n=1, 1.4%), nausea (n=1, 1.4%). Listing on day 7 does not necessary mean listed as present or severe on previous days.

<sup>B</sup> Diarrhea, impaired judgment, and muscle tension were added based on observations from early studies to reactions list.

In the Phase 1/Phase 2 study MPVA-1, among six dyads consisting of one participant diagnosed with PTSD, along with their concerned significant others (CSO), the most common spontaneously reported reactions during open-label dosing sessions were lack of appetite (83.3% PTSD and 83.3% CSO participants), anxiety (83.3% PTSD and 66.7% CSO participants), headache (83.3% PTSD and 50.0% CSO participants), and tight jaw (50.0% PTSD and 66.7% CSO participants). During the 7 days following open-label dosing sessions, at least half of either PTSD or CSO participants reported fatigue (up to 100.0%), headache (up to 83.3%), lack of appetite (up to 83.3%), anxiety (up to 66.7%), insomnia (up to 66.7%), and nausea (up to 50.0%). Fatigue (50.0%) was the most commonly reported reaction that lasted to Day 7 but only among participants with PTSD. Anxiety (33.3%), lack of appetite (33.3%), and nausea (33.3%) were also reported on Day 7, and again, only among participants with PTSD. Overall, few participants reported any reactions later in the week, which suggests most reactions were short-term and self-limiting.

In summary, in Phase 2 trials most reactions were not long-lasting in PTSD studies, nor did they warrant cause for clinical concern. Elevations in anxiety and poor sleep were managed across dose groups with short-acting low dose benzodiazepine, or sleep aids as needed, per clinical judgment of the study physician. SRRs were typically observed during drug administration and most were transient and diminished as the drug was metabolized and excreted over a period of 24 hours with the majority of reactions resolving within several days and up to 1 week after dosing. Given the benign safety profile and positive efficacy signal, the sponsor concluded that the risk-benefit analysis of MDMA-assisted therapy for treatment of PTSD weighs in favor of continuation of the Clinical Development Program for this treatment.

### **Spontaneous Reactions in Anxiety Associated with Life-threatening Illness**

Spontaneously reported reactions were collected in a sample of 18 participants in MAPS' Phase 2 study MDA-1 during blinded and open-label sessions with inactive placebo or an active dose of 125 mg MDMA HCl and a supplemental half-dose. Prevalence of reactions is displayed based on number of participants reporting the reaction at least once ([Appendix Table 18](#)).

The most commonly reported reactions for the active dose groups were tight jaw /jaw clenching (84.6% in 125 mg blinded sessions versus 20.0% in inactive placebo sessions), thirst (84.6% in 125 mg blinded sessions versus 40.0% in inactive placebo sessions), perspiration (69.2% in 125 mg sessions versus none in placebo sessions), dry mouth (69.2% in 125 mg blinded sessions versus 20.0% in inactive placebo sessions), and headache (61.5% in 125 mg MDMA versus 20.0% placebo). The only severely rated reaction for participants in MDA-1 was a single report of diarrhea recorded during the second day of contact (Day 2) in the 125 mg open-label Stage 2, which was assumed to be related. Due to temporal proximity to dosing, relationship to drug cannot be ruled out. Owing to the very small sample size, it is difficult to draw firm conclusions concerning frequency of spontaneously reported reactions in this sample.

Comparing blinded session active dose with placebo controls during the 7-day safety window ([Appendix Table 19](#)), the most commonly reported reactions were fatigue (up to 92.3% in active dose versus 40.0% for inactive placebo), insomnia (up to 46.2% in active dose versus 40.0% in inactive placebo), need more sleep (up to 46.2% in active dose versus 20.0% of inactive placebo), and drowsiness (up to 30.8% in active dose versus 20.0% in inactive placebo). During the 7-day follow-up period after dosing sessions, participants most commonly reported headache (up to 46.2% in active dose versus 40.0% in inactive placebo) and anxiety (up to 30.8% of active dose participants versus 40.0% of inactive placebo). In most cases, number of spontaneously reported reactions declined across days of contact.

In summary, spontaneously reported reactions reported in this small sample of participants with anxiety associated with a life-threatening illness receiving 125 mg MDMA HCl were similar to those reported in participants with PTSD. Most of these reactions were resolved by day 7 after drug administration, and were almost entirely of mild to moderate intensity, with only a single report of a severe reaction (diarrhea).

### **Spontaneous Reactions in Social Anxiety in Autistic Adults**

Spontaneously reported reactions were collected in a sample of 12 individuals within MAPS' study MAA-1 ([Appendix Table 17](#)). Participants in this study received inactive placebo or ascending active doses, with the first session being either 75 mg or 100 mg MDMA HCl and the second session being 100 mg or 125 mg MDMA HCl; participants in Stage 2 all received 75 mg in Session 1 and 125 mg in Session 2. No supplemental dose was administered in this study. Prevalence of reactions is displayed based on number of participants reporting the reaction at least once.

The most commonly reported SRRs were anxiety (75.0% of those receiving active dose in blinded sessions and 25.0% of those receiving active dose in open-label sessions versus 25.0% in inactive placebo sessions), lack of appetite (37.5% of those receiving active dose in blinded sessions and 75.0% of those receiving active dose in open-label sessions versus 25% in inactive placebo sessions), and difficulty concentrating (62.5% in active dose blinded sessions, 50% in active dose open-label sessions versus 25% inactive placebo). Additionally, at least 50% of participants in either the active dose blinded sessions or active dose open-label sessions reported fatigue (vs. 25.0% inactive placebo), headache (vs. 25.0% inactive placebo), muscle tension (vs. 25.0% inactive placebo), perspiration (vs. 25.0% inactive placebo), rumination (vs. 0% in inactive placebo), and sensitivity to cold (0% inactive placebo). The only severe spontaneously reported reaction in this sample was a single report of headache in a participant in the active dose group on the first day of contact.

Most commonly reported SRRs among participants on the autism spectrum with social anxiety during the 7 days after dosing sessions was fatigue (up to 75.0% in the active dose groups versus 50.0% in the inactive placebo group) ([Appendix Table 17](#)). Low mood (up to 50.0% in the active dose groups vs. 50.0% in the inactive placebo group), headache (up to 37.5% in the active dose groups vs. 25.0% in the inactive placebo group), difficulty concentrating (up to 37.5% in the active dose blinded group vs. 0% in the inactive placebo group), and lack of appetite (up to 37.5% in the active dose blinded group vs. 0% in the inactive placebo group) were also reported. This sample reported experiencing fewer reactions during the 7-day period than participants with PTSD; there were no reports of diarrhea, impaired gait, or nausea. However, the sample consisted of 12 participants, and a slightly lower dose of 75 mg MDMA HCl was used in blinded and open-label sessions. Spontaneously reported reactions after 75 mg to 125 mg MDMA HCl in autistic adult participants with social anxiety were also mild to moderate and transient, which was similar to other studies conducted for treatment of different indications.

## Summary of Spontaneous Reactions Across Indications

In summary, commonly reported acute and sub-acute reactions to MDMA are generally well-tolerated and are rarely reported after the 24-hour period beyond drug administration. Reports of reactions grow increasingly rare after the third day of contact.

### 6.4.1.3 Adverse Events Summary

#### Adverse Events in Phase 2 PTSD Studies

Frequency of AEs among participants with PTSD treated with MDMA at any dose across MAPS-sponsored Phase 2 studies conducted under U.S. IND are summarized in [Table 12](#). These studies included MP-4, MP-8, MP-9, MP-12, MP16, MP17, and MPVA-1. Adverse events were collected throughout the treatment period and post-treatment (up to 12-month long-term follow-up). See [Table 12](#) for prevalence of all adverse events regardless of investigator judgement of relationship.

In this sample, participants most frequently reported anxiety and fatigue across treatment groups. Anxiety was reported among 20.0% (n=2) of the placebo group participants, 14.3% (n=2) of the blinded 25-40 mg MDMA HCl group participants, 17.6% (n=13) of the blinded 75-125 mg MDMA HCl group participants, and 19.7% (n=23) of the open-label 80-150 mg MDMA HCl group participants; fatigue was reported among 20.0% (n=2), 19.0% (n=4), 8.1% (n=6), and 13.7% (n=16) of participants, respectively. There were 3 reports of anxiety (3.1%) and no reports of fatigue at long-term follow-up to indicate that fatigue and most reports of anxiety occurred during the treatment period. In the comparator and active dose MDMA groups, >5% of all participants reported having a headache: 9.5% (2 of 21 participants) in the blinded 25-40 mg MDMA HCl, 6.8% in the blinded 75-125 mg MDMA HCl (5 of 74 participants), and 23.1% (27 of 117 participants) in the open-label 80-150 mg MDMA HCl group; and there were no reports of headache in the placebo group. Sample sizes in both the placebo and comparator- blinded 25-40 mg MDMA HCl groups however were relatively low to adequately compare against the active MDMA groups. Therefore, it is unclear whether occurrence of headache might be linked to MDMA treatment. However, there were no reports of headache across all treatment groups at long-term follow-up.

Greater than 5% of both blinded and open-label active MDMA dose group participants reported muscle tightness (9.5% vs. 17.1%, respectively) and nausea (5.4% vs. 12.8%, respectively). There was only one other report of muscle tightness in the placebo group and no other reports of nausea in any other treatment groups. No participant reported headache or nausea at the long-term follow-up. An AE that was most prevalent in the blinded 75-125 mg MDMA HCl group was irritability (5.4%). In comparison, there was only one other report of irritability, which occurred in the open-label 80-150 mg MDMA HCl group (0.9%). There were no reports of irritability at long-term follow-up. In contrast, there were a few AE's that were more prevalent in the open-label 80-150 mg MDMA HCl dose group vs. the 75-125 mg MDMA HCl group; these AEs included upper respiratory infection (7.7% vs. 1.4%, respectively), decreased appetite (6.8% vs. 1.4%, respectively), and insomnia (14.5% vs. 2.7%, respectively). AEs that were completely unique to the open-label 80-150 mg MDMA HCl dose group included palpitations (5.1%), myalgia (6.8%), nystagmus (6.8%), and suicidal ideation (10.3%). None of these AEs were reported at long-term follow-up.

The main differences between the active blinded and open-label sessions was unblinding of drug and the duration of time in treatment. Specifically, by the time participants were in open-label

dosing sessions, they would have already had several therapy sessions prior to active treatment. It is possible that having both the inactive and open-label active MDMA-assisted therapy sessions, compared to only 2-3 dosing sessions in the blinded active MDMA treatment group, generated more AEs. For example, therapy involves reexamining traumatic experiences, and over the course of several months, this could have triggered mood-related symptoms such as decreased appetite, insomnia, and/ or suicidal ideation. The stress and endurance from prolonged treatment could have compromised participants’ immune systems that placed them at higher risk for illness such as an upper respiratory infection. In summary, the AEs that were characteristic of the open-label 80-150 mg MDMA HCl group were likely a consequence of prolonged treatment rather than having an active dose of MDMA.

**Table 12: Adverse Events by Body System Organ Class (MedDRA 17.1) At Any Severity among Participants with PTSD in Sponsor-Supported Phase 2 Studies of MDMA-Assisted Therapy**

SOC	Adverse Event Preferred Term	Placebo 0 mg	Blinded 25-40 mg MDMA HCl	Blinded 75-125 mg MDMA HCl	Open-label 80-150 mg MDMA HCl	Long-Term Follow-up <sup>A</sup>
	Subjects per Dose Group	10	21	74	117 <sup>B</sup>	97
	Participants who reported at least 1 AE	9	11	55	96	10
		N (%)	N (%)	N (%)	N (%)	N (%)
Cardiac disorders						
	Palpitations	---	---	---	6 (5.1)	---
	Sinus tachycardia	---	---	1 (1.4)	---	---
	Ventricular extrasystoles	---	---	---	1 (0.9)	---
Ear and labyrinth disorders						
	Ear discomfort	---	---	---	1 (0.9)	---
	Tinnitus	---	1 (4.8)	1 (1.4)	1 (0.9)	---
Endocrine disorders						
	Hypothyroidism	---	1 (4.8)	1 (1.4)	---	1 (1.0)
Eye disorders						
	Altered visual depth perception	---	---	---	1 (0.9)	---
	Dry Eye	---	---	---	1 (0.9)	---
	Ocular discomfort	---	---	---	1 (0.9)	---
	Photophobia	---	---	---	1 (0.9)	---
	Vision blurred	---	---	1 (1.4)	3 (2.6)	---
	Visual impairment	---	---	5 (6.8)	4 (3.4)	---
	Vitreous floaters	---	---	1 (1.4)	---	---
Gastrointestinal disorders						
	Abdominal discomfort	---	---	---	5 (4.3)	---
	Abdominal pain	---	---	2 (2.7)	2 (1.7)	---
	Abdominal pain, upper	1 (10.0)	---	---	---	---
	Anal fissure	---	---	---	1 (0.9)	---
	Aphthous ulcer	---	---	---	1 (0.9)	---
	Constipation	---	---	1 (1.4)	---	---
	Diarrhea	---	1 (4.8)	4 (5.4)	4 (3.4)	---
	Dyspepsia	---	---	1 (1.4)	1 (0.9)	---
	Dry Mouth	---	---	---	2 (1.7)	---
	Eructation	---	---	---	1 (0.9)	---
	Food poisoning	---	---	---	1 (0.9)	---

Gastric Ulcer	---	---	---	1 (0.9)	---
Intestinal obstruction	---	---	1 (1.4)	---	---
Irritable Bowel Syndrome	---	---	---	1 (0.9)	---
Nausea	---	---	4 (5.4)	15 (12.8)	---
Oropharyngeal blistering	---	---	1 (1.4)	---	---
Tongue discomfort				1 (0.9)	
Vomiting	---	---	5 (6.8)	3 (2.6)	---
<b>General disorders and administrative site conditions</b>					
Asthenia	---	---	1 (1.4)	1 (0.9)	---
Chest discomfort				2 (1.7)	---
Chills	---	---	---	2 (1.7)	---
Cyst	---	---	---	1 (0.9)	---
Fatigue	2 (20.0)	4 (19.0)	6 (8.1)	16 (13.7)	---
Facial pain	1 (10.0)	---	---	---	---
Feeling abnormal	---	---	1 (1.4)	---	---
Feeling hot	---	---	2 (2.7)	1 (0.9)	---
Feeling cold	---	---	---	1 (0.9)	---
Feeling of body temperature change	---	---	---	1 (0.9)	---
Gait disturbance	---	---	---	1 (0.9)	---
Hangover	---	---	---	1 (0.9)	---
Influenza-like illness	---	---	1 (1.4)	---	---
Malaise	---	---	1 (1.4)	---	---
Oedema peripheral	---	---	---	1 (0.9)	---
Pain	1 (10.0)	2 (9.5)	2 (2.7)	4 (3.4)	---
Pyrexia	---	1 (4.8)	2 (2.7)	4 (3.6)	---
Temperature intolerance	---	---	---	2 (1.7)	---
<b>Infections and infestations</b>					
Acute sinusitis	---	---	---	1 (0.9)	---
Angina tonsils	---	---	---	1 (0.9)	---
Appendicitis	---	---	---	---	1 (1.0)
Conjunctivitis	---	---	---	1 (0.9)	---
Hordeolum	---	1 (4.8)	---	---	---
Infected cyst	---	---	---	1 (0.9)	---
Influenza	---	2 (9.5)	2 (2.7)	---	---
Laryngitis	---	---	1 (1.4)	---	---
Nasopharyngitis	---	---	---	1 (0.9)	---
Otitis Media	1 (10.0)	1 (4.8)	---	---	---
Pharyngitis	1 (10.0)	---	---	---	---
Pharyngitis, streptococcal	---	---	1 (1.4)	---	---
Pneumonia	---	---	1 (1.4)	2 (1.7)	---
Pneumonia, chlamydia	---	---	1 (1.4)	---	---
Sinusitis	---	1 (4.8)	2 (2.7)	1 (0.9)	---
Tinea pedis	---	---	---	1 (0.9)	---
Tooth abscess	---	1 (4.8)	---	---	---
Tooth infection					1 (1.0)
Upper respiratory tract infection	1 (10.0)	---	1 (1.4)	9 (7.7)	---
Urethritis	---	---	---	---	1 (1.0)



	Urinary tract infection	---	---	1 (1.4)	2 (1.7)	---
	Vaginal infection	---	---	1 (1.4)	---	---
	Viral upper respiratory infection	---	---	---	3 (2.6)	---
<b>Immune system disorders</b>						
	Hypersensitivity	---	---	---	1 (0.9)	---
<b>Injury, poisoning, procedural complications</b>						
	Arthropod bite	---	---	---	1 (0.9)	---
	Concussion	---	---	---	1 (0.9)	1 (1.0)
	Contusion	---	---	2 (2.7)	2 (1.7)	---
	Corneal abrasion	---	---	---	1 (0.9)	---
	Fracture	---	---	---	1 (0.9)	---
	Exposure to violent event	---	---	---	1 (0.9)	---
	Head injury	---	---	---	1 (0.9)	---
	Incision site pain	---	---	---	1 (0.9)	---
	Incorrect dose administered	---	---	1 (1.4)	---	---
	Intentional product misuse [of a concomitant medication]	---	---	---	1 (0.9)	---
	Joint dislocation	---	---	---	1 (0.9)	---
	Laceration	---	---	---	2 (1.7)	---
	Ligament sprain	---	1 (4.8)	---	2 (1.7)	---
	Limb injury	---	---	1 (1.4)	---	---
	Lower limb fracture	---	---	1 (1.4)	---	---
	Post-concussion syndrome	---	---	---	---	1 (1.0)
	Procedural nausea	---	---	---	1 (0.9)	---
	Road traffic accident	1 (10.0) <sup>C</sup>	---	---	---	1 (1.0)
	Skeletal injury	---	---	1 (1.4)	---	---
	Skin abrasion	---	---	1 (1.4)	---	---
	Sunburn	---	---	---	1 (0.9)	---
	Thermal burn	---	---	---	1 (0.9)	---
	Wound	---	---	---	1 (0.9)	---
<b>Investigations</b>						
	Body temperature fluctuations	---	---	---	1 (0.9)	---
	Red blood cell sedimentation rate increased	---	---	---	---	1 (1.0)
	Weight decreased	---	---	---	1 (0.9)	---
<b>Metabolism and nutrition disorders</b>						
	Anorexia	---	---	1 (1.4)	---	---
	Decreased appetite	---	---	1 (1.4)	8 (6.8)	---
	Dehydration	---	---	---	1 (0.9)	---
	Iron deficiency anemia	---	---	---	1 (0.9)	---
	Vitamin D deficiency	---	1 (4.8)	---	---	---
<b>Musculoskeletal and connective tissue disorders</b>						
	Arthralgia	1 (10.0)	---	---	2 (1.7)	---
	Back pain	1 (10.0)	---	2 (2.7)	4 (3.4)	---
	Clavicle fracture	---	---	1 (1.4)	---	---

Joint stiffness	---	---	---	2 (1.7)	---
Muscle spasms	1 (10.0)	---	2 (2.7)	1 (0.9)	---
Muscle strain	---	---	---	1 (0.9)	---
Muscle tightness	1 (10.0)	---	7 (9.5)	20 (17.1)	---
Muscle twitching	---	---	1 (1.4)	---	---
Muscular weakness	---	---	---	1 (0.9)	---
Musculoskeletal chest pain	1 (10.0)	---	---	---	---
Musculoskeletal pain	---	---	2 (2.7)	2 (1.7)	---
Musculoskeletal stiffness	---	---	---	3 (2.6)	---
Myalgia	---	---	---	8 (6.8)	---
Neck pain	1 (10.0)	---	---	5 (4.3)	---
Pain in extremity	---	---	---	3 (2.6)	---
Pain in jaw	---	---	---	4 (3.4)	---
Plantar fasciitis	---	---	---	1 (0.9)	---
Synovitis	---	---	---	1 (0.9)	---
Trismus	---	---	---	1 (0.9)	---
<b>Neoplasms benign, malignant and unspecified</b>					
Breast cancer stage 1	---	---	---	1 (0.9)	---
Metastases to central nervous system	---	---	---	---	1 (1.0)
Neuroma	---	---	---	1 (0.9)	---
<b>Nervous system disorders</b>					
Burning sensation	1 (10.0)	---	1 (1.4)	1 (0.9)	---
Disturbance in attention	---	---	---	2 (1.7)	---
Dizziness	---	---	3 (4.1)	9 (7.7)	---
Dysgeusia	---	---	---	2 (1.7)	---
Exaggerated startle response	---	---	---	1 (0.9)	---
Headache	---	2 (9.5)	5 (6.8)	27 (23.1)	---
Hypoaesthesia	---	---	---	1 (0.9)	---
Hypoaesthesia facial	---	---	1 (1.4)	---	---
Hypersomnia	---	1 (4.8)	---	3 (2.6)	---
Migraine	---	1 (4.8)	---	1 (0.9)	---
Muscular contractions involuntary	---	---	---	1 (0.9)	---
Myoclonus	---	---	1 (1.4)	---	---
Neuritis	---	---	---	1 (0.9)	---
Nystagmus	---	---	---	8 (6.8)	---
Paresthesia	---	---	1 (1.4)	4 (3.4)	---
Restless legs syndrome	---	---	---	1 (0.9)	---
Sciatica	1 (10.0)	---	---	---	---
Syncope (postural)	---	---	1 (1.4)	3 (2.6)	---
Tension headache	---	---	1 (1.4)	1 (0.9)	---
Tremor	---	---	---	3 (2.6)	---
<b>Psychiatric disorders</b>					
Aggression	---	---	---	1 (0.9)	---
Agitation	---	---	---	1 (0.9)	---
Anger	---	---	---	1 (0.9)	---
Anxiety	2 (20.0)	2 (9.5)	13 (17.6)	23 (19.7)	3 (3.1)
Bruxism	---	---	2 (2.7)	4 (3.4)	---
Confusional state	---	---	---	1 (0.9)	---

Conversion disorder	---	---	---	1 (0.9)	---
Depressed mood	1 (10.0)	2 (9.5)	8 (10.8)	4 (3.4)	---
Depression	---	---	1 (1.4)	1 (0.9)	2 (2.1)
Derealization	---	---	1 (1.4)	1 (0.9)	---
Dermatillomania	---	---	---	1 (0.9)	---
Dissociation	1 (10.0)	1 (4.8)	1 (1.4)	---	---
Disturbance in attention	---	---	3 (4.1)	---	---
Emotional disorder	---	---	---	1 (0.9)	---
Emotional distress	1 (10.0)	1 (4.8)	1 (1.4)	---	---
Fear of eating	---	---	---	1 (0.9)	---
Feelings of worthlessness	---	---	---	1 (0.9)	---
Flashback	1 (10.0)	---	1 (1.4)	3 (2.6)	---
Grief reaction	---	---	---	1 (0.9)	---
Hypnagogic hallucination	---	---	---	1 (0.9)	---
Hypnopompic hallucination	---	---	---	1 (0.9)	---
Initial insomnia	---	---	---	1 (0.9)	---
Insomnia	1 (10.0)	1 (4.8)	2 (2.7)	17 (14.5)	---
Intentional self-injury	1 (10.0)	1 (4.8)	---	1 (0.9)	1 (1.0)
Intrusive thoughts	---	---	---	1 (0.9)	---
Irritability	---	---	4 (5.4)	1 (0.9)	---
Major depression	---	---	1 (1.4)	---	1 (1.0)
Memory impairment	1 (10.0)	---	---	---	---
Negative thoughts	---	1 (4.8)	---	---	---
Nightmare	---	---	---	3 (2.6)	---
Obsessive rumination	---	---	2 (2.7)	1 (0.9)	---
Obsessive thoughts	---	---	---	1 (0.9)	---
Panic attack	---	---	3 (4.1)	1 (0.9)	1 (1.0)
Panic reaction	---	---	---	2 (1.7)	---
PTSD	---	---	---	1 (0.9)	---
Restlessness	---	---	2 (2.7)	2 (1.7)	---
Somatoform disorder	---	---	1 (1.4)	---	---
Somnolence	---	---	1 (1.4)	---	---
Suicidal ideation	---	1 (4.8)	1 (1.4)	12 (10.3)	2 (2.1)
Suicide attempt	---	---	---	1 (0.9)	---
Tension	---	---	1 (1.4)	---	---
Tic	---	---	1 (1.4)	1 (0.9)	---
Time perception altered	---	1 (4.8)	---	---	---
Trichotillomania	---	1 (4.8)	---	---	---
<b>Renal and urinary disorders</b>					
Dysuria	---	---	1 (1.4)	1 (0.9)	---
Micturition urgency	---	---	---	2 (1.7)	---
Nocturia	---	---	1 (1.4)	---	---
Urinary retention	---	---	---	2 (1.7)	---
<b>Reproductive disorders</b>					
Dysmenorrhoea	---	---	---	1 (0.9)	---
Menorrhagia	---	---	---	1 (0.9)	---
Menstruation irregular	---	---	---	1 (0.9)	---
Ovarian Cyst	---	---	1 (1.4)	---	1 (1.0)
Ovarian cyst ruptured	---	---	---	---	1 (1.0)
<b>Respiratory, thoracic and mediastinal disorders</b>					

Asthma	---	---	---	1 (0.9)	---
Cough	---	1 (4.8)	---	1 (0.9)	---
Dyspnea	---	---	2 (2.7)	2 (1.7)	---
Nasal congestion	---	1 (4.8)	---	1 (0.9)	---
Oropharyngeal pain	---	---	1 (1.4)	4 (3.4)	---
Sinus headache	---	---	1 (1.4)	---	---
Throat tightness	1 (10.0)	---	---	---	---
<b>Skin and subcutaneous tissue disorders</b>					
Acne	---	---	---	1 (0.9)	---
Dermatitis	1 (10.0)	---	---	---	---
Erythema	---	---	---	1 (0.9)	---
Hyperhidrosis	---	---	---	4 (3.4)	---
Night sweats	---	---	---	1 (0.9)	---
Petechiae	---	---	1 (1.4)	---	---
Photosensitivity reaction	---	---	---	1 (0.9)	---
Pruritis	1 (10.0)	---	---	2 (1.7)	---
Pseudofolliculitis barbae	---	---	1 (1.4)	---	---
Psoriasis	---	---	1 (1.4)	---	---
Urticaria	---	1 (4.8)	---	---	---
<b>Social circumstances</b>					
Substance Use	---	---	---	1 (0.9)	---
<b>Surgical and medical procedures</b>					
Foot operation	---	---	1 (1.4)	---	---
<b>Vascular disorders</b>					
Hypertension	---	---	1 (1.4)	---	---
Deep vein thrombosis	---	---	1 (1.4)	---	---
Orthostatic hypotension	---	---	---	1 (0.9)	---
Peripheral coldness	---	---	---	2 (1.7)	---

<sup>A</sup> Participants in MPVA1 (N=6) had a 6-month follow-up. All other participants had a 12-month or more follow-up.

<sup>B</sup> The 24-27 events collected separately as “spontaneously reported reactions in studies MP-1 through MP-12 were collected as adverse events in this manner for studies MP16 and MP17. Absence of these events blinded studies / times may occur because these events were reported as spontaneously reported reactions. See [Table 10](#) and [Table 11](#).

<sup>C</sup> A previously uncoded event in a previous study (“passenger in traffic accident, no injury”) has been upversioned to “road traffic accident”.

The number of severe adverse events across all treatment groups was relatively low ([Table 13](#)). The only severe AEs that were reported by more than one participant receiving active drug were depressed mood and panic attack, which occurred in the blinded 75 mg to 125 mg MDMA HCl group. Neither were reported in the open-label 80 mg to 150 mg MDMA HCl group or in the long-term follow-up study. At long-term follow-up, there was one report each of severe depression, anxiety, and severe suicidal ideation. The placebo group sample was too small for adequate comparison across groups. Nonetheless, these data suggest the need for careful monitoring of PTSD participants for such psychiatric disorders throughout the study period irrespective of MDMA dose.

**Table 13: Severe Adverse Events by Body System Organ Class (MedDRA 17.1) among Participants with PTSD in Sponsor-Supported Phase 2 Studies of MDMA-Assisted Therapy**

SOC	Adverse Event Preferred Term	Placebo 0 mg	Blinded 25-40 mg MDMA HCl	Blinded 75-125 mg MDMA HCl	Open-label 80-150 mg MDMA HCl	Long-Term Follow-up <sup>A</sup>
Subjects per Dose Group		10	21	74	117 <sup>B</sup>	97
		N (%)	N (%)	N (%)	N (%)	N (%)
Gastrointestinal disorders						
	Abdominal pain	---	---	---	1 (0.9)	---
	Anal fissure	---	---	---	1 (0.9)	---
	Intestinal obstruction	---	---	1 (1.4)	---	---
General disorders and administrative site conditions						
	Pain	---	1 (4.8)	---	---	---
Infections and infestations						
	Appendicitis	---	---	---	---	1 (1.0)
	Sinusitis	---	---	1 (1.4)	---	---
Injury, poisoning, procedural complications						
	Concussion	---	---	---	1 (0.9)	---
	Exposure to violent event	---	---	---	1 (0.9)	---
	Lower limb fracture	---	---	1 (1.4)	---	---
Musculoskeletal and connective tissue disorders						
	Musculoskeletal chest pain	1 (10.0)	---	---	---	---
Neoplasms benign, malignant and unspecified						
	Breast cancer stage 1	---	---	---	1 (0.9)	---
Nervous system disorders						
	Headache	---	1 (4.8)	---	1 (0.9)	---
	Migraine	---	1 (4.8)	---	---	---
	Sciatica	1 (10.0)	---	---	---	---
	Syncope (postural)	---	---	---	1 (0.9)	---
Psychiatric disorders						
	Anger	---	---	---	1 (0.9)	---
	Anxiety	---	---	1 (1.4)	---	1 (1.0)
	Depressed mood	---	---	2 (2.7)	---	---
	Depression	---	---	---	---	1 (1.0)
	Flashback	1 (10.0)	---	---	---	---
	Insomnia	---	1 (4.8)	---	---	---
	Major depression	---	---	1 (1.4)	---	---
	Obsessive rumination	---	---	1 (1.4)	---	---
	Panic attack	---	---	2 (2.7)	---	---
	Suicidal ideation	---	1 (4.8)	1 (1.4)	1 (0.9)	1 (1.0)
	Suicide attempt	---	---	---	1 (0.9)	---
Reproductive disorders						
	Ovarian cyst ruptured	---	---	---	---	1 (1.0)

<sup>A</sup> Participants in MPVA1 (N=6) had a 6-month follow-up. All other participants had a 12-month or more follow-up.

<sup>B</sup> The 24-27 events collected separately as “spontaneously reported reactions in studies MP-1 through MP-12 were collected as adverse events in this manner for studies MP16 and MP17. Absence of these events blinded studies / times may occur because these events were reported as spontaneously reported reactions. See [Table 10](#) and [Table 11](#).

Since MDMA is administered as an adjunct to therapy, judging relationship to MDMA is a known challenge for this combined therapy and highlights the necessity of placebo-controlled trials. In the context of complex medical histories and high rates of background events associated with the PTSD diagnosis, somatic symptoms may wax and wane independent of treatment. In addition, it is known that processing trauma during therapy for PTSD, with or without concomitant pharmacological treatment, can temporarily increase symptoms as an expected aspect of the therapeutic process. This was demonstrated by the high incidence of spontaneously reported reactions and AEs in the placebo group.

Among related AEs reported during and after drug administration, somatic symptoms were more frequently experienced in active dose participants, such as pain associated with body tension, muscle tightness, musculoskeletal pain in the shoulder, back pain, and myalgia. As previously discussed in [Section 6.4.1 Adverse Events](#), it is difficult to judge relationship between Investigational Product and conditions associated with medical history diagnoses. Pain and somatic symptoms can be directly related to traumatic events, such as physical or sexual assault, a motor vehicle accident, or combat [662]. A meta-analytic review and several large studies have found a robust association between PTSD and somatic symptoms, suggesting that PTSD itself may be a contributing factor beyond combat exposure, sexual, or physical abuse that led to the PTSD [663-666].

Although MDMA is not a classic hallucinogen, as classified by chemical structure and mechanism of action, data from sponsor-supported studies suggest MDMA was associated with mild psychedelic effects, such as hypnagogic and hypnopompic hallucinations in one participant and visual distortions in some individuals. Hallucinogenic subjective effects were not actively assessed during therapy sessions, as was done in Phase 1 studies of healthy volunteers [12, 15, 16, 667]. Any unsolicited reports of hallucinogenic effects were collected as AEs in sponsor-supported studies.

### **Adverse Events in Phase 3 PTSD Studies**

With the placebo-controlled Phase 3 trials of MDMA-assisted therapy for treatment of PTSD, it became possible to separate background events from AEs attributable to MDMA in the Clinical Development Program. AEs were collected from participants treated with blinded MDMA (n=46) or placebo (n=44) in the MAPS-sponsored Phase 3 study MAPP1 from enrollment to study termination. Treatment-emergent Adverse Events (TEAEs) were defined as AEs that occur during the Treatment Period from the first dosing session through the last Integrative Session (3-4 weeks post last dose). Relationship to MDMA was determined based on relative incidence of TEAEs across the study with at least two-fold difference between MDMA vs. placebo. [Table 14](#) below reports on the most common (>6.5%) TEAEs related to MDMA in this study.

In MAPP1, the most common related TEAEs reported more frequently in the MDMA group were muscle tightness (63.0% MDMA vs 11.4% placebo), decreased appetite (52.2% MDMA vs 11.4% placebo), nausea (30.4% MDMA vs 11.4% placebo), hyperhidrosis (19.6% MDMA vs 2.3% placebo), and feeling cold (19.6% MDMA vs 6.8% placebo). The full list of related TEAEs is reported below.



**Table 14: MAPP1 Treatment-emergent Adverse Events Related to MDMA <sup>A</sup>**

Adverse Event Preferred Term	Blinded 80-180 mg MDMA HCl	Placebo 0 mg
Subjects per Dose Group	46	44
	N (%)	N (%)
Muscle Tightness	29 (63.0%)	5 (11.4%)
Decreased Appetite	24 (52.2%)	5 (11.4%)
Nausea	14 (30.4%)	5 (11.4%)
Hyperhidrosis	9 (19.6%)	1 (2.3%)
Feeling Cold	9 (19.6%)	3 (6.8%)
Restlessness	7 (15.2%)	0
Mydriasis	7 (15.2%)	0
Dizziness Postural	6 (13.0%)	2 (4.5%)
Bruxism	6 (13.0%)	1 (2.3%)
Nystagmus	6 (13.0%)	0
Blood Pressure Increased	5 (10.9%)	0
Feeling Jittery	5 (10.9%)	0
Non-Cardiac Chest Pain	5 (10.9%)	1 (2.3%)
Dry Mouth	5 (10.9%)	2 (4.5%)
Vision Blurred	4 (8.7%)	1 (2.3%)
Pollakiuria	4 (8.7%)	1 (2.3%)
Intrusive Thoughts	4 (8.7%)	0
Vomiting	4 (8.7%)	0
Stress	4 (8.7%)	0
Musculoskeletal Pain	4 (8.7%)	0
Pyrexia	3 (6.5%)	1 (2.3%)
Chills	3 (6.5%)	0
Substance Use ( <i>cannabis use</i> )	3 (6.5%)	0
Micturition urgency	3 (6.5%)	0
Muscle Twitching	3 (6.5%)	0
Somnolence	3 (6.5%)	0
Nervousness	3 (6.5%)	0

<sup>A</sup> Relationship was derived in analysis based on 2-fold difference over placebo as specified in the Statistical Analysis Plan (SAP). Investigator judgement on AE relationship was not collected per protocol, except for SAEs to facilitate regulatory reporting.

Common TEAEs reported across both groups of blinded participants were fatigue (30.4% MDMA vs 34.1% placebo), headache (71.7% MDMA vs 54.5% placebo), dizziness (19.6% MDMA vs 11.4% placebo), anxiety (32.6% MDMA, vs 40.9% placebo), insomnia (43.5% MDMA vs 29.5% placebo), depressed mood (10.9% MDMA vs 9.1% placebo), nightmare (15.2% MDMA vs 15.9% placebo), and suicidal ideation (45.7% MDMA vs 47.7% placebo).

These commonly reported AEs were observed in both treatment arms and also overlap with symptoms of pre-existing conditions in medical history associated with PTSD (depression, somatic symptoms, insomnia, anxiety), which might have influenced the frequency of events observed during clinical trials of MDMA-assisted therapy. See [Table 15](#) for a listing of TEAEs with a prevalence greater than 5% across both groups in MAPP1.

**Table 15: Treatment-emergent Adverse Events with a Prevalence of 5% or Greater by Body System Organ Class (MedDRA 17.1) among Participants with PTSD in MAPP1 Study of MDMA-Assisted Therapy**

SOC	Adverse Event Preferred Term	Placebo 0 mg	Blinded 80-180 mg MDMA HCl
Participants per Dose Group		44	46
		N (%)	N (%)
<b>Cardiac disorders</b>			
	Palpitations	6 (13.6)	4 (8.7)
<b>Eye disorders</b>			
	Mydriasis	---	7 (15.2)
	Vision blurred	1 (2.3)	4 (8.7)
<b>Gastrointestinal disorders</b>			
	Abdominal discomfort	3 (6.8)	6 (13.0)
	Abdominal pain upper	4 (9.1)	5 (10.9)
	Diarrhea	5 (11.4)	2 (4.3)
	Dry Mouth	2 (4.5)	5 (10.9)
	Nausea	5 (11.4)	14 (30.4)
<b>General disorders and administrative site conditions</b>			
	Asthenia	3 (6.8)	6 (13.0)
	Fatigue	14 (31.8)	14 (30.4)
	Feeling cold	3 (6.8)	9 (19.6)
	Feeling hot	4 (9.1)	4 (8.7)
	Feeling jittery	---	5 (10.9)
	Influenza-like illness	3 (6.8)	2 (4.3)
	Non-cardiac chest pain	1 (2.3)	5 (10.9)
	Pain	2 (4.5)	4 (8.7)
	Temperature Intolerance	2 (4.5)	4 (8.7)
<b>Infections and Infestations</b>			
	Upper respiratory tract infection	4 (9.1)	6 (13.0)
	Viral upper respiratory tract infection	6 (13.6)	8 (17.4)
<b>Investigations</b>			
	Blood pressure increased	---	5 (10.9)
<b>Metabolism and nutrition disorders</b>			
	Decreased appetite	5 (11.4)	24 (52.2)
<b>Musculoskeletal and connective tissue disorders</b>			
	Arthralgia	3 (6.8)	4 (8.7)
	Back pain	4 (9.1)	5 (10.9)
	Muscle tightness	5 (11.4)	29 (63.0)
	Neck pain	3 (6.8)	2 (4.3)
	Pain in jaw	3 (6.8)	3 (6.5)
<b>Nervous system disorders</b>			
	Disturbance in attention	3 (6.8)	4 (8.7)
	Dizziness	5 (11.4)	9 (19.6)
	Dizziness postural	2 (4.5)	6 (13.0)
	Headache	24 (54.5)	33 (71.7)

Hypoaesthesia	2 (4.5)	3 (6.5)
Nystagmus	---	6 (13.0)
Paraesthesia	3 (6.8)	5 (10.9)
Tremor	3 (6.8)	5 (10.9)
<b>Psychiatric disorders</b>		
Agitation	3 (6.8)	2 (4.3)
Anger	5 (11.4)	3 (6.5)
Anxiety	18 (40.9)	15 (32.6)
Bruxism	1 (2.3)	6 (13.0)
Depressed Mood	4 (9.1)	5 (10.9)
Depression	4 (9.1)	4 (8.7)
Emotional disorder	4 (9.1)	2 (4.3)
Flashback	2 (4.5)	3 (6.5)
Insomnia	13 (29.5)	20 (43.5)
Intentional self-injury	4 (9.1)	1 (2.2)
Irritability	5 (11.4)	2 (4.3)
Nightmare	7 (15.9)	7 (15.2)
Panic reaction	5 (11.4)	---
Restlessness	---	7 (15.2)
Suicidal ideation	21 (47.7)	21 (45.7)
<b>Renal and urinary disorders</b>		
Pollakiuria	1 (2.3)	4 (8.7)
<b>Respiratory, Thoracic, and Mediastinal Disorders</b>		
Oropharyngeal pain	3 (6.8)	2 (4.3)
<b>Skin and subcutaneous tissue disorders</b>		
Hyperhidrosis	1 (2.3)	9 (19.6)

### Special Report on MDMA-assisted Therapy and Covid-19

The advent of the COVID-19 pandemic has necessitated a closer examination of any potential links between MDMA-assisted therapy and increased risk of contracting the virus. In Phase 2 studies, among PTSD participants, a total of 9.4% (10 of 106) participants reported an upper respiratory tract infection (URTI) that had occurred within 30 days after an active MDMA-assisted session. [Note: In [Section 6.4.1.3 Adverse Events Summary](#), URTI was reported by blinded 75 mg to 125 mg MDMA HCl vs. open-label treatment groups.] Two participants reported an URTI that occurred more than 30 days after an active MDMA-assisted session. One placebo participant, who did not receive any active MDMA, also reported an URTI 3 days following placebo. The Phase 2 sample consisted of participants from both blinded and open-label active MDMA groups without adequate controls for comparisons.

In the Phase 3 placebo-controlled study MAPP1, a total of 26% of participants (12 of 46) reported an upper respiratory tract infection (URTI) that had occurred within 30 days after an active MDMA-assisted session and 22% of participants (10 of 44) after an experiment session with placebo. These data suggest that URTIs were not more common in the MDMA arm than the placebo arm. Of note, while a subset of MAPP1 participants completed study visits following the declaration of the COVID-19 pandemic by the WHO in March 2020, there were no additional URTIs reported in the study after this time.

While it remains unclear whether reports of URTI are specifically linked to MDMA, the relative incidence in the placebo-controlled Phase 3 trial indicates relationship to MDMA is unlikely. There is additionally evidence from multiple epidemiologic studies to suggest that having a stress-related disorder, including PTSD, was associated with higher risk of infections, with hazard

ratios ranging from 1.47 (95% CI: 1.37, 1.58) [668] to 1.8 (95% CI: 1.6, 2.0) [669]. Therefore, even without any treatment, PTSD participants might be at increased risk of infections that could include COVID-19. At present, there is no evidence to suggest MDMA-assisted therapy would increase these risks.

#### 6.4.1.4 Serious Adverse Events of Suicidality

Overall, the incidence of serious suicidal ideation or behavior in sponsor-supported studies was low, occurring in only a few participants post-MDMA treatment and an equivalent number of participants either prior to dosing or after therapy with placebo, and returning to lower scores while participants were closely monitored. As of March 01, 2022, three participants reported SAEs of suicidality (suicidal ideation and/or behavior) after receiving MDMA in MAPS-supported Phase 1, Phase 2, and Phase 3 studies. All were deemed unrelated to MDMA in the opinion of the investigator and sponsor. Of interest, three participants reported SAEs of suicidality either prior to receiving study drug (n=1, Study MP-2), or after receiving placebo (n=2, Study MAPP1). These events are likely related to background events representing the underlying illness being treated, or the expected result of therapy addressing traumatic experiences.

In study MP-8, suicidal ideation was reported in a participant in study MP-8, reported 6 days after treatment with 30 mg MDMA HCl and lasted 6 days, concurrent with increased depressive symptoms triggered by external trauma cues, and was treated with prescription medication and hospitalization. The participant who experienced suicidal ideation later experienced depression that was rated serious and unrelated to the Investigational Product, with the event occurring approximately 9 months after a final dosing session. The episode resolved approximately 3 weeks after it developed. Depression in this subject was rated severe. The depression led to hospitalization, and the participant reported full recovery after the episode.

In Study MP-1-E2, an extension to study MP-1 involving a single additional administration of 125 mg MDMA HCl for participants exhibiting relapse after completing the study, a participant was hospitalized with major depressive episode and suicidal ideation 9 months after the additional dosing session, and fully recovered after this episode.

In Study MP16, a Phase 2 open-label study, there was one SAE of suicide attempt. Twenty-eight days after the 3<sup>rd</sup> dosing session with a divided dose of 180 mg MDMA HCl (120 mg + 60 mg MDMA HCl), the participant initiated a suicide attempt by taking diazepam, drinking alcohol, and taking a bath with the intent to drown herself. The event was aborted with no bodily harm. The participant was evaluated at the ER without being admitted and discharged 3 hours later.

#### Adverse Events in Social Anxiety in Autistic Adults

In autistic adult participants with social anxiety (MAA-1), the frequency of any given AE in each study group was less than 25% (or 1 to 2 participants). The majority of AEs were psychiatric disorders (ten in active dose groups and two in the inactive placebo group), followed by infections and infestations (three in active dose groups and two in the inactive placebo group) (see [Appendix Table 20](#) for more details). Participants in the blinded 75 mg to 125 mg MDMA HCl group reported the highest proportion of depressed mood (25%) and suicidal ideation (25%). There was no report of depressed mood in the placebo group, although there was one report of depression. There was also one count of suicidal ideation in the placebo group. The occurrence of depressed mood/ depression and suicidal ideation in both blinded placebo and 75 mg to 125 mg MDMA HCl groups suggest these AEs likely occurred independent of drug administration. There

were three counts of panic attack/panic reaction in only active dose groups, which might be attributed to drug administration. There were no severe adverse events reported in the study. However, small sample size warrants further investigation to elucidate relationships between AEs and MDMA-assisted therapy in autistic adults with social anxiety.

### **Adverse Events in Anxiety Associated with Life-threatening Illness**

Adverse events reported during the study of MDMA-assisted therapy in participants with anxiety in response to facing life-threatening disorders (MDA-1) included psychiatric disorders, nervous system disorders, gastrointestinal symptoms, and infections ([Appendix Table 21](#)). Of the seven AEs rated as severe, six AEs occurred in a single individual after cancer recurrence: meningitis, sepsis, aphasia, cerebrovascular accident, and spinal cord paralysis. The participant's last visit was the Primary Endpoint. The subject died prior to Long-term Follow-up. The other severe AE (invasive ductal breast carcinoma) occurred in a different participant during the long-term follow-up.

Overall, 40.0% of blinded placebo participants, 84.6% of blinded 125 mg MDMA HCl participants, and 41.2% of open-label 125 mg MDMA HCl participants reported any AE's during dosing sessions. The most commonly reported AE was insomnia, which was reported among 20.0% of blinded placebo participants, 15.4% of blinded 125 mg MDMA HCl participants, and 23.5% of open-label 125 mg MDMA HCl participants. Three counts of fatigue (23.1%) were reported only among blinded 125 mg MDMA HCl participants. It may be possible drug administration was linked to insomnia and fatigue, which were also commonly reported AEs in other sponsor-supported study samples. In this sample, apart from insomnia, all other psychiatric AEs were reported by participants in active dose groups. Anxiety was reported in one blinded 125 mg MDMA HCl participant and two open-label 125 mg MDMA HCl participants, which was expected given the indication under study. There were single reports of bruxism, depressed mood, depression, dissociation, and hypomania in either the blinded 125 mg MDMA HCl or open-label 125 mg MDMA HCl groups.

Non-psychiatric AEs with more than one count included influenza (15.4%), contusion (15.4%), and back pain (15.4%), which occurred only among blinded 125 mg MDMA HCl participants, although these events were likely unrelated to drug administration. Similarly, there were a total of nine participants, and a total of 16 AEs, that were reported at 12-month follow-up across all study participants. But, given the small sample sizes, it is unlikely that any occurrence of AEs 1 year or more following dosing sessions were associated with the study treatment.

One subject in this study experienced a cascade of adverse events, including several SAEs, after completing the course of the main study and prior to or at long-term follow-up that all followed from recurrence of chordoma. This event was expected given the participant's medical history of chordoma. After the recurrence was noted, the subject received one additional dosing session. She then underwent debulking surgery, radiation, immunotherapy, and chemotherapy for treatment before significant deterioration (including spinal cord paralysis, spinal meningitis, septicemia, and cerebrovascular accident followed by aphasia and inability to speak) and subsequent death.

It is challenging to make comparisons or draw conclusions about nature or frequency of adverse events in this sample owing to small sample size. Psychiatric AEs in general, and anxiety in particular, are expected in this patient population and with MDMA combined with therapy that encourages confronting emotionally distressing material. It is also expected that participants diagnosed with a life-threatening illness may experience more severe AEs related to their medical history.

### 6.4.1.5 Serious Adverse Reactions

SARs are serious adverse events possibly or probably related to MDMA administration. As of March 01, 2022, there has been one SAR reported in the clinical development program following MDMA administration across indications. See [Table 16](#) below for a summary of SARs.

**Table 16: Serious Adverse Reactions in Sponsor-Supported Studies of MDMA-Assisted Therapy Across Indications**

Dose	Comparator Dose 0-40 mg MDMA HCl	Active Dose 75-125 mg MDMA HCl	Open-label 100-150mg MDMA HCl
	N	N	N
<b>Cardiovascular</b>			
Ventricular Extrasystoles (exacerbation)	---	---	1

One cardiac SAR has occurred within all sponsor-supported studies to date. In a PTSD study (MP-8), subject 0811 experienced an increase in frequency of ventricular extrasystoles, a form of cardiac arrhythmia, on the day of his third and final dosing session with open-label 125 mg MDMA HCl. The subject had no other signs and no symptoms of cardiac distress. In the absence of any symptoms of coronary insufficiency, the investigator judged the only medical measure necessary to be withholding the supplemental dose of MDMA. This was the final drug administration in the open-label crossover period of the study known as Stage 2. No similar events were detected during the first two 125 mg MDMA HCl dosing sessions, nor the two blinded dosing sessions with 30 mg MDMA HCl in the blinded period of the study known as Stage 1. There was no evidence of acute cardiac damage or ischemia or underlying heart disease. At baseline during screening, the subject had one ventricular extrasystole on the electrocardiogram (EKG), but the EKG was otherwise normal. The subject had a positive family history: his father had a coronary artery bypass graft, which had prompted the subject to consult a cardiologist several years before study enrollment, and the cardiologist’s note indicated that he did not suspect cardiovascular disease or see the need for further workup. Based on the medical history and clinical presentation of this subject, the investigator judged the SAR to be a moderate exacerbation probably related to drug administration, although since the subject was under observation when the event was noted, it cannot be determined if the same event occurred undetected prior to MDMA administration while the subject was not being monitored. The event required overnight monitoring in the hospital but did not lead to any adverse sequelae. He was given one dose of 25 mg metoprolol by the hospital physician but did not require any ongoing treatment. Serial cardiac isoenzymes, an echocardiogram and a nuclear stress test performed during the overnight hospital admission failed to show evidence of cardiovascular or other cardiac disease. Full recovery occurred 1 day after MDMA administration. Arrhythmia is described in Section [5.1.2 Cardiac Disorders](#) and Section [6.2.3.2 Cardiovascular System](#) as an expected adverse effect of MDMA based on scientific literature and does not rise to the level of inclusion in the Reference Safety Information since the 13<sup>th</sup> Edition of the IB issued in March 2021 as it has been observed once in the Clinical Development Program.

### Adverse Events Summary

Most AEs reported in MAPS supported studies were rated mild or moderate and transient in nature. The most common treatment-emergent adverse events more prevalent in the MDMA group from blinded, placebo-controlled Phase 3 study data were (>20%) muscle tightness,



decreased appetite, nausea, (>10%) hyperhidrosis, feeling cold, restlessness, mydriasis, postural dizziness, bruxism, nystagmus, increased blood pressure, feeling jittery, non-cardiac chest pain, and dry mouth. Common anxiety-related psychiatric symptoms were reported equally in both the MDMA and placebo arms in the Phase 3 trial. As of March 01, 2022, there have been 19 event-level SAEs in 14 participants in the clinical development program following MDMA administration across indications. Of these, 18 were unrelated and one was determined to be a SAR. This cardiac event (increase in frequency of ventricular extrasystoles), that occurred in Study MP-8 was reported as a SAR and is described above. Suspected Unexpected Serious Adverse Events (SUSARs) were infrequent in the program and the sponsor closely monitors any SUSARs to determine if any should be upgraded to SARs. To date, there has been one SUSAR of preparatory suicidal behavior that was subsequently downgraded to an SAE when it was determined that the participant was randomized to placebo. If any new risks are identified, the IB will be updated with this information accordingly.

#### **6.4.2 Suicidal Ideation and Behavior**

Suicidal ideation and behavior are disease related events in populations of people with PTSD, occurring at high frequencies, especially those suffering from chronic, treatment-resistant PTSD [670, 671]. The FDA has responded to concerns over the occurrence of treatment-emergent suicidal ideation or behavior by requiring clinical trials of psychiatric drugs to measure suicidality via the C-SSRS, a clinician-administered guided interview [672]. Individuals with serious ideation or behavior are to be closely monitored until levels return to normal or additional interventions are recommended by the therapist.

Data on suicidal ideation or behavior was not formally measured in the first two sponsor-supported studies (MP-1 and MP-2). The C-SSRS was added to subsequent studies in order to monitor suicidal ideation and behavior. The C-SSRS was assessed throughout each study, including lifetime incidence, baseline, before/during/after drug administration, endpoints when other measures were administered, and follow-up visits. In MDMA-assisted therapy, thoughts of suicide may surface due to the nature of the therapeutic method, wherein a person may re-experience emotions associated with the traumatic event and reprocess the memory. However, evidence from clinical studies indicates that these thoughts were more often transient, returned to normal, or even improved following MDMA treatment.

##### **6.4.2.1 C-SSRS in PTSD Studies**

Suicidal ideation and behavior were collected using the C-SSRS and data are reported according to the C-SSRS Scoring and Data Analysis Guide [673]. The presence of suicidal ideation was reported when a subject responded “yes” to any one of the five suicidal ideation questions (Categories 1 to 5) on the C-SSRS (i.e., a score >0 for suicidal ideation score). Serious suicidal ideation was a suicidal ideation category score of 4 or 5. The presence of suicidal behavior was reported when a subject responded “yes” to any one of the five suicidal behavior questions (Categories 6 to 10) on the C-SSRS (i.e., a score >0 for suicidal behavior score). Lifetime scores accounted for all suicidal ideation and behavior prior to enrollment according to subject recall and medical records. Pre-drug exposure represents measures collected on the Since Last Visit C-SSRS after enrollment during Preparatory Sessions and before first drug administration in dosing session 1 upon completion of tapering off psychiatric medications. Frequencies were presented as subject counts at each time point. When time points covered multiple visits, percentages were based on the number of observations in which participants would have had the opportunity to report.

## Phase 2 C-SSRS Data

In studies MP-4, MP-8, MP-9, MP-12, MPVA-1, MP16, and MP17, the majority of participants reported lifetime prevalence of suicidal ideation and there were some reports of serious ideation and suicidal behavior, which was expected among study samples diagnosed with PTSD (see [Table 17](#)). At baseline, or Pre-drug Exposure (i.e., in the Preparatory Session prior to dosing session 1), compared to lifetime prevalence, there were far fewer reports of the presence of suicidal ideation, no reports of serious ideation, and one report of the presence of suicidal behavior. Overall, participants in the blinded active dose (75 mg to 125 mg MDMA HCl) and open-label Stage 2 active dose (100 mg to 125 mg MDMA HCl) groups reported the presence of suicidal ideation throughout the dosing sessions at pre-drug, during-drug, and integration days 1, 2, and 7. The prevalence of reported ideations, particularly in the earlier dosing session, might have been due to withdrawal symptoms after prescription medications tapering of SSRIs and/ and benzodiazepines [[674-676](#)], which was a study eligibility criterion. Additionally, in both the non-drug and active MDMA-assisted therapy sessions, participants were asked to recall and discuss experiences related to their PTSD diagnosis, which could have triggered thoughts of suicidality throughout the dosing sessions. Therefore, it is not surprising participants in the blinded active dose (75 mg to 125 mg MDMA HCl) and open-label Stage 2 active dose (100 mg to 125 mg MDMA HCl) groups had reported ideation throughout the dosing sessions.

At post-treatment, following all dosing sessions, blinded active dose (75 mg to 125 mg MDMA HCl) group participants continued to report ideation at the Primary or Secondary Endpoint, End of Stage 1 or 2, and Long-term Follow-up: 34.9% (15 of 43 participants), 28.9% (11 of 38 participants), and 27.7% (13 of 47 participants), respectively; and, there were a few reports of serious ideation: 4.7% (2 of 43 participants), 0 (0 of 38 participants), and 2.1% (1 of 47 participants), respectively. In the open-label Stage 2 active dose (100 mg to 125 mg MDMA HCl) group, 5 participants reported ideation at Primary or Secondary Endpoint, 3 participants at End of Stage 1 or 2, and 0 at Long-term Follow-up. Among the placebo group and blinded 25 mg to 40 mg MDMA HCl group, at any given post-treatment assessment of CSSRS, there were only up to one participant who reported having ideation: 1 of 2 participants in the placebo and 1 of 12 to 13 participants in the blinded comparator group; and no reports of serious ideation or suicidal behavior. In the context of MDMA-assisted therapy, MDMA can modulate consolidation or reconsolidation of fear-related memories [[282](#), [284](#), [677](#), [678](#)].

**Table 17: C-SSRS Suicidal Ideation and Serious Ideation Reported During Screening, Dosing Sessions Including Integrative Sessions, and Post-treatment for PTSD Studies MP-4, MP-8, MP-9, MP-12, MP16, MP17 and MPVA-1<sup>A</sup>**

MDMA HCl Dose		Screening N (%)	Session 1 N (%)	Session 2 N (%)	Session 3 N (%)	Post-treatment N (%)
		Lifetime <sup>B</sup> / Pre-drug Exposure <sup>C</sup>	Pre-drug <sup>D</sup> / During-drug <sup>E</sup> / D1/ D2/ D7	Pre-drug <sup>D</sup> / During-drug <sup>E</sup> / D1/ D2/ D7	Pre-drug <sup>D</sup> / During-drug <sup>C</sup> / D1/ D2/ D7	1□ or 2□ Endpoint/ End of Stage 1 or 2/ Long-term Follow-up <sup>F</sup>
Blinded Placebo (0 mg)	PI	2 (100.0)/ 1 (25.0)	0/ 0/ 0/ 0/ 0	0/ 0/ 1 (50.0)/ 0/ 0	-	0/ -/ 1 (50.0)
	SI	1 (50.0)/ 0	0/ 0/ 0/ 0/ 0	0/ 0/ 0/ 0/ 0	-	0/ -/ 0
	PB	1 (50.0)/ 0	0/ 0/ 0/ 0/ 0	0/ 0/ 0/ 0/ 0	-	0/ -/ 0
	N	2/ 2	2/ 2/ 2/ 2/ 2	2/ 2/ 2/ 2/ 2	-	2/ -/ 2
Blinded Comparator (25-40 mg)	PI	12 (75.0)/ 5 (14.3)	1 (6.3)/ 1 (6.3)/ 0/ 0/ 0	0/ 0/ 0/ 0/ 0	1 (50.0)/ 0/ 0/ 0/ 0	1 (8.3)/ 0/ 1 (7.7)
	SI	3 (18.8)/ 0	0/ 0/ 0/ 0/ 0	0/ 0/ 0/ 0/ 0	0/ 0/ 0/ 0/ 0	0/ 0/ 0
	PB	5 (31.3)/ 0	0/ 0/ 0/ 0/ 0	0/ 0/ 0/ 0/ 0	0/ 0/ 0/ 0/ 0	0/ 0/ 0
	N	16/ 16	16/ 16/ 15/ 16/ 16	14/ 14/ 14/ 14/ 14	2/ 2/ 2/ 4/ 4	12/ 2/ 13
Blinded Active Doses (75-125 mg)	PI	45 (90.0)/ 35 (31.8)	11 (22.0)/ 4 (8.0)/ 6 (12.0)/ 7 (14.3)/ 10 (20.4)	9 (18.8)/ 9 (18.8)/ 5 (10.4)/ 12 (25.5)/ 8 (17.0)	4 (8.0)/ 6 (12.0)/ 3 (8.0)/ 5 (13.5)/ 5 (13.5)	15 (34.9)/ 11 (28.9)/ 13 (27.7)
	SI	21 (42.0)/ 0	0/ 0/ 0/ 0/ 0	0/ 0/ 0/ 0/ 1 (2.1)	0/ 0/ 0/ 0/ 1 (2.7)	2 (4.7)/ 0/ 1 (2.1)
	PB	15 (30.0)/ 1 (0.9)	0/ 0/ 0/ 0/ 0	0/ 0/ 0/ 0/ 0	0/ 0/ 0/ 0/ 0	0/ 0/ 0
	N	50/ 50	50/ 50/ 50/ 49/ 49	48/ 50/ 48/ 47/ 47	38/ 38/ 38/ 37/ 37	43/ 38/ 47
Open-label Stage 2 Active Dose (100-125 mg)	PI	39 (90.7)/ 22 (51.2)	9 (14.1)/ 3 (4.7)/ 5 (8.8)/ 7 (12.7)/ 6 (10.9)	5 (7.8)/ 2 (3.1)/ 3 (4.9)/ 4 (6.6)/ 4 (6.8)	3 (7.3)/ 1(2.4)/ 1 (1.9)/ 2 (3.8)/ 2 (3.7)	5 (10.9)/ 3 (12.5) <sup>G</sup> / 0
	SI	21 (48.8)/ 0	0/1 (1.6)/1 (1.6)/2 (3.1)/ 0	0/ 0/ 0/ 0/ 1(1.7)	0/0/0/0/0	0/ 0/ 0
	PB	20 (46.5)/ 0	0/ 0/ 0/ 0/ 0	0/ 0/ 0/ 0/ 0	0/0/0/0/0	0/ 0/ 0
	N	43/ 43	64/ 64/ 57/ 55/ 55	64/ 64/ 61/ 61/ 59	41/ 41/ 54/ 53/ 54	46/ 24/ 6

Abbreviations: PI=Positive Ideation, SI=Serious Ideation, PB=Positive Behavior, O=Observations, N=Number of Participants, D1=Day 1, D2=Day 2, D7=Day 7

<sup>A</sup> MPVA-1 data included PTSD participants only, excluded CSOs (concerned significant others) and offered only two dosing sessions.

<sup>B</sup> Lifetime accounts for suicidality prior to study enrollment.

<sup>C</sup> Pre-drug Exposure represents measures taken during the Preparatory Session prior to the first dosing session.

<sup>D</sup> Pre-drug measurement taken on the day of the dosing session prior to drug administration.

<sup>E</sup> During-drug observation measured, on the day of the dosing session, approximately 6 hours after drug administration.

<sup>F</sup> Post-treatment: 1□ or 2□ Endpoint excluded MPVA-1; End of Stage 1/ Stage 2 excluded MP16 and MP17; Long-term Follow-up excluded MP16 and MP17.

<sup>G</sup> End of Stag 1/End of Stage 2: For MPVA1, 3-month follow-up used for End of Stage 1/End of Stage 2.

### Phase 3 C-SSRS Data

In the Phase 3 study MAPP1, a majority of the participants (92.2%) reported lifetime suicidal ideation with 41.1% reporting serious lifetime ideation and 32.2%, reporting lifetime suicidal behavior. [Table 18](#) and [Figure 7](#) below present the prevalence of participants reporting suicidal ideation and behavior measured by C-SSRS in MAPP1. At baseline, 37% of participants in the MDMA group reported the presence of suicidal ideation, compared to 31.8% in the placebo group. After the first dosing session, 4.3% of participants reported suicidal ideation in the MDMA group, and 13.6% in the placebo group. Presence of suicidal ideation increased in both groups after the first dosing session during follow-up assessments at the three integrative sessions. After the second dosing session, 2.3% of participants in the MDMA group reported the presence of suicidal ideation, compared to 7.3% of placebo participants. Prevalence of suicidal ideation increased in the follow-up integrative sessions. After the third dosing session, no participants in the MDMA group reported the presence of suicidal ideation, serious ideation, or positive behavior, while one participant in the placebo group reported the presence of suicidal ideation. At the integrative session that occurred the next morning, 19% of participants in the MDMA group and 30.8% of participants in the placebo group reported the presence of suicidal ideation. At study termination, 18.2% of subjects reported the presence of suicidal ideation, compared to 20.0% of participants in the placebo group.


**Table 18: MAPP1 Suicidal Ideation and Behavior Measured by C-SSRS**

Assessment Timepoint	MDMA-assisted therapy (N=46)			Placebo with therapy (N=44)		
	Suicidal Ideation n/N (%)	Serious Ideation n/N (%)	Positive Behavior n/N (%)	Suicidal Ideation n/N (%)	Serious Ideation n/N (%)	Positive Behavior n/N (%)
Lifetime <sup>A</sup>	42/46 (91.3)	20/46 (43.5)	16/46 (34.8)	41/44 (93.2)	17/44 (38.6)	13/44 (29.5)
Baseline (Visit 4)	17/46 (37.0)	0/46 (---)	0/46 (---)	14/44 (31.8)	1/44 (2.3)	1/44 (2.3)
Pre-Dose Dosing Session 1 (Visit 5)	9/46 (19.6)	0/46 (---)	0/4 (0.0)	5/44 (11.4)	1/44 (2.3)	1/44 (2.3)
Post-Dosing Session 1 (Visit 5)	2/46 (4.3)	0/46 (---)	0/46 (---)	6/44 (13.6)	1/44 (2.3)	0/44 (---)
Integrative Session 1.1 (Visit 6)	7/46 (15.2)	0/46 (---)	0/46 (---)	15/44 (34.1)	3/44 (6.8)	3/44 (6.8)
Integrative Session 1.2 (Visit 7)	9/46 (19.6)	0/46 (---)	0/46 (---)	11/43 (25.6)	1/43 (2.3)	1/43 (2.3)
Integrative Session 1.3 (Visit 9)	13/45 (28.9)	0/45 (---)	0/45 (---)	11/42 (26.2)	1/42 (2.4)	1/42 (2.4)
Pre-Dose Dosing Session 2 (Visit 10)	7/43 (16.3)	0/43 (---)	0/43 (---)	7/41 (17.1)	1/41 (2.4)	0/41 (---)
Post-Dosing Session 2 (Visit 10)	1/43 (2.3)	0/43 (---)	0/43 (---)	3/41 (7.3)	0/41 (---)	0/41 (---)
Integrative Session 2.1 (Visit 11)	13/44 (29.5)	0/44 (---)	0/44 (---)	11/41 (27.5)	3/41 (7.3)	0/41 (---)
Integrative Session 2.2 (Visit 12)	5/44 (11.4)	0/44 (---)	0/44 (---)	8/40 (20)	2/40 (5.0)	0/40 (---)
Integrative Session 2.3 (Visit 14)	11/42 (26.2)	0/42 (---)	0/42 (---)	13/40 (32.5)	2/40 (.0)	1/40 (2.5)
Pre-Dose Dosing Session 3 (Visit 15)	3/42 (7.1)	0/42 (---)	0/42 (---)	2/37 (5.4)	0/37 (---)	0/37 (---)

Post-Dosing Session 3 (Visit 15)	0/42 (---)	0/42 (---)	0/42 (---)	1/37 (2.7)	0/37 (---)	0/37 (---)
Integrative Session 3.1 (Visit 16)	8/42 (19.0)	0/42 (---)	0/42 (---)	12/39 (30.8)	1/39 (2.6)	1/39 (2.6)
Integrative Session 3.2 (Visit 17)	6/42 (14.3)	1/42 (2.4)	0/42 (---)	8/39 (20.5)	2/39 (5.1)	1/39 (2.6)
Integrative Session 3.3 (Visit 18)	8/42 (19.0)	0/42 (---)	0/42 (---)	9/40 (22.5)	2/40 (5.0)	2/40 (5.0)
Study Termination (Visit 20)	8/44 (18.2)	1/44 (2.3)	0/44 (---)	8/40 (20)	1/40 (2.5)	0/40 (---)

<sup>A</sup> Lifetime represents reporting at screening for lifetime C-SSRS score

**Figure 7: MAPP1 Participants Reporting Suicidal Ideation on C-SSRS by Visit**



Reproduced from *Nature Medicine* [30].

Overall, the number of subjects reporting the presence of suicidal ideation varied throughout the study visits, but never exceeded the prevalence at baseline levels and was not increased in the MDMA group. Serious ideation (defined as a score of 4 or 5 on the C-SSRS) was minimal during the study and almost entirely present in subjects in the placebo group. Throughout the study, there were two reports of serious ideation in the MDMA group and 22 reports of serious ideation in the placebo group. Importantly, no increase in adverse events related to suicidality were observed in the MDMA group.

**C-SSRS in Social Anxiety in Autistic Adults**

In MAA-1, the MDMA study in autistic adults, 0 to 12.5% of participants had a history of serious suicidal ideation and 12.5 to 25.0% reported suicidal behavior. During the preparatory phase prior to blinded drug administration, there were no reports of suicidal ideation or behavior. There was one report of positive ideation on the day of an MDMA-assisted session, and one on the day following. At endpoints, 25.0 to 50.0% had positive ideation. Two participants reported positive ideation, although not serious, during follow-up which may have resulted from ending the therapeutic relationship. These participants were transitioned to non-study therapists and went back on psychiatric medications under the care of their prescribing physician. No serious ideation or behavior occurred during the study. Generally, rates of suicidal thoughts were lower in this population than the PTSD sample (see [Appendix Tables 10-12](#)).



### **C-SSRS in Anxiety Associated with a Life-threatening Illness**

In MDA-1, in participants with a life-threatening illness, 0 to 20.0% of participants had a history of serious ideation and 0 to 23.1% reported positive behavior. During the preparatory phase prior to blinded drug administration, one participant experienced positive behavior, and 25.0% had positive ideation. There were no reports of suicidal ideation or behavior during the Preparatory Sessions or during the treatment period. One occurrence of positive ideation was recorded at the Primary Endpoint and long-term follow-up (see [Appendix Tables: 13-16](#)).

### **Summary of Suicidal Ideation and Behavior Across Populations and Indications**

Overall, the incidence of serious suicidal ideation or behavior in sponsor-supported studies was low, fluctuating in some participants post-treatment with MDMA-assisted therapy and placebo with therapy, and returning to category 1 to 3 suicidal ideation scores while participants were closely monitored. Given that severe PTSD sufferers are known to experience suicidal ideation and behavior, it is difficult to identify a single cause of the increase in suicidal thinking or behavior (i.e., exacerbation of PTSD symptoms, MDMA-stimulated effects, or processing of traumatic memories during therapy). A large percentage of people enrolled in the studies reported suicidal ideation and behavior during sometime in their lives prior to study enrollment, which may reflect a manifestation of PTSD or co-morbid affective disorders. When positive serious ideation or behavior occurred after enrollment, the investigators made follow-up observations of C-SSRS to ensure subject safety and tracked scores until they returned to non-serious levels. Frequency of ideation and behavior was greater in the PTSD population compared to healthy individuals, autistic adults, and people with life-threatening illnesses. In the placebo-controlled Phase 3 trial MAPP1, the prevalence of suicidal ideation, serious ideation, and suicidal behavior was not greater in the MDMA arm of the study. Throughout the study, there were two instances of serious ideation reported via the C-SSRS in the MDMA group and 22 instances of serious ideation in the placebo group.

#### **6.4.3 Vital Signs**

In all sponsor-supported studies to date, vital signs readings (temperature, blood pressure, and heart rate) were taken at baseline, with study-specific differences in data collection times post-drug. The data presented in the below sections is final for completed studies and preliminary for studies ongoing at the time of the data cutoff.

##### **6.4.3.1 Body Temperature**

In most sponsor-supported studies to date, tympanic body temperature readings were taken at baseline, then every 60 to 90 minutes after drug administration during each blinded or open-label dosing session, with some differences in collection methods across studies. Peak values during each dosing session were ascertained for all studies. Across studies, the final value was either at a relatively set time (MP-8, MP-12, MP1-E2, MP16, MP17, MPVA-1) or as the final reading with varying time points (MP-1). In the MP-1 and MP-2 studies two pre-drug values were reported (15 minutes and 5 minutes before dosing) and the results of these measurements were averaged. Average post-drug values served as the final value for MP-2. If body temperature rose  $>1^{\circ}\text{C}$  above the pre-drug (baseline) reading, each duration above specific values required more frequent monitoring as listed in the study protocols. Clinical signs and symptoms were monitored and more frequent readings of body temperature were collected in cases where readings were above these values.

**Table 19: Pre-Drug, Peak, and Final Body Temperature (°C) During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored Studies of PTSD (MP-1, MP-2, MP-4, MP-8, MP-12)**

MDMA HCl Dose	N	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with BT 1 ° C above Baseline
Placebo	10	36.4 (0.51) 35.1/37.2	36.9 (0.36) 36.4/37.6	36.6 (0.36) 35.9/37.5	2 (20.0)
25 mg	8	36.4 (0.39) 35.5/37.1	37.2 (0.78) 36.0/38.5	36.8 (0.65) 35.4/38.0	4 (50.0)
30 mg	7	36.2 (0.47) 35.3/36.9	37.0 (0.42) 36.4/37.9	36.6 (0.47) 35.7/37.3	4 (57.1)
40 mg	6	36.4 (0.50) 35.8/37.2	37.1 (0.33) 36.6/37.6	37.0 (0.38) 36.5/37.6	2 (33.3)
75 mg	7	36.6 (0.46) 35.9/37.8	37.1 (0.52) 36.3/37.8	36.7 (0.42) 36.1/37.3	2 (28.6)
100 mg	9	35.9 (1.00) 33.9/37.9	37.0 (0.64) 35.5/38.7	36.5 (0.74) 34.8/38.1	4 (44.4)
125 mg	58	36.5 (0.47) 35.4/37.6	37.3 (0.49) 36.1/38.6	36.9 (0.54) 34.5/38.2	26 (44.8)
Open-label (100-150 mg)	78	36.4 (0.54) 34.3/37.7	37.3 (0.57) 36.0/38.7	36.8 (0.58) 35.2/38.4	39 (50.0)

In MAPS-sponsored PTSD studies MP-1 to MP-12, body temperature above (1°C above pre-drug reading) was detected in 44% (42 of 95) participants who received any dose of MDMA during blinded sessions and 50% (39 of 78) participants receiving 100 mg to 150 mg MDMA HCl during open-label sessions. Note that body temperature above 1°C above pre-drug reading was observed in 20% (2 of 10) of participants who received placebo. End of session temperature readings were lower than peak drug readings, though they remained above pre-drug measurements. Body temperature increases that were 1°C or more above initial temperature occurred in all dose groups, suggesting a minimal role for dose. The maximum body temperature observed for any subject receiving MDMA was 38.7°C, observed after a 100 mg MDMA HCl blinded session, and during open-label sessions. No participants required medical intervention to decrease body temperature and values returned to baseline as drug effects waned. Body temperature measured during dosing sessions in sponsor-supported studies of PTSD was commensurate with values seen in Phase 1 clinical trials described above.

In the MAPS study MAA-1, body temperature 1°C above pre-drug reading was detected in 28.6% (2 of 7) participants who received 100 mg MDMA HCl during a blinded session. Body temperature above the 1°C increase predetermined as cause for increased assessment did not occur during open-label sessions with 75 mg or 125 mg MDMA HCl. The maximum body temperature observed for any subject receiving MDMA in MAA-1 was 37.7°C. No participants required medical intervention to decrease body temperature and values dropped below peak values or returned to baseline as drug effects waned. Body temperature measurements in this sample were similar to those reported in Phase 1 studies and the sample of people with PTSD (see [Appendix Tables 2, 4, 6, and 8](#) for data).

In the MAPS study-Phase 2 clinical trial of MDMA-assisted therapy for anxiety in relation to a life-threatening illness (MDA-1), body temperature rose 1°C above pre-drug reading in 53.8% (7 of 13) of participants receiving MDMA during blinded dosing sessions and in none of the participants given placebo during blinded sessions. Body temperature rose 1°C above pre-drug reading in 52.9% (9 of 17) participants during open-label sessions. Body temperature recorded at end of session was lower than peak body temperature. The maximum body temperature observed

for any subject receiving 125 mg MDMA HCl was 39.9°C. No participants required medical intervention to decrease body temperature and values returned to baseline as drug effects waned (see [Appendix Tables 3, 5, 7, and 9](#) for data).

In MPVA-1, vital signs were assessed on the day of MDMA-assisted sessions prior to drug dosing, just before the optional supplemental dose (midpoint), and at the end of the session. The maximum body temperature observed for any subject receiving 75 mg or 100 mg MDMA HCl was 38.4°C and the mean (SD) temperature prior to the supplemental dose was 37.1°C (SD:0.53) in the CSO participant and 37.2°C (SD:0.48) in the PTSD+ participant.

In the MAPS sponsored Phase 3 PTSD study MAPP1, participants in both groups had minor increases (on average <1°C) in body temperature during dosing sessions. The maximum body temperature observed for any subject receiving 80 mg or 120 mg MDMA HCl) was 38.1°C and the mean temperature prior to the supplemental dose was 36.9°C.

**Table 20: Predose, Interim, and Endpoint Body Temperature (°C) Across Dosing Sessions in MAPP1**

	MDMA-assisted therapy (N=46)	Placebo with therapy (N=44)	Total (N=90)
<b>Dosing Session 1</b>			
Predose (n)	46	44	90
Mean (SD)	36.6 (0.49)	36.6 (0.39)	36.6 (0.44)
Min/Max	35.1/37.6	35.3/37.3	35.1/37.6
Interim (n)	46	44	90
Mean (SD)	36.9 (0.42)	36.7 (0.36)	36.8 (0.40)
Min/Max	36.0/37.8	35.5/37.5	35.5/37.8
Endpoint (n)	46	44	90
Mean (SD)	36.8 (0.51)	36.9 (0.30)	36.8 (0.42)
Min/Max	35.5/37.7	36.0/37.4	35.5/37.7
<b>Dosing Session 2</b>			
Predose (n)	43	41	84
Mean (SD)	36.6 (0.44)	36.5 (0.41)	36.6 (0.42)
Min/Max	35.6/37.3	35.4/37.6	35.4/37.6
Interim (n)	43	41	84
Mean (SD)	36.9 (0.46)	36.7 (0.30)	36.8 (0.40)
Min/Max	36.0/38.1	36.0/37.5	36.0/38.1
Endpoint (n)	43	41	84
Mean (SD)	36.9 (0.48)	36.7 (0.29)	36.8 (0.41)
Min/Max	36.0/38.1	36.1/37.4	36.0/38.1
<b>Dosing Session 3</b>			
Predose (n)	42	37	79
Mean (SD)	36.6 (0.46)	36.6 (0.50)	36.6 (0.47)
Min/Max	35.4/37.7	35.0/37.4	35.0/37.7
Interim (n)	41	37	78
Mean (SD)	37.0 (0.47)	36.7 (0.325)	36.8 (0.44)
Min/Max	36.0/38.1	35.9/37.2	35.9/38.1
Endpoint (n)	42	37	79
Mean (SD)	36.9 (0.50)	36.8 (0.40)	36.8 (0.45)
Min/Max	35.5/37.8	36.0/37.5	35.5/37.8

Based on the published literature, MDMA is expected to produce elevations in body temperature. Humans are not susceptible to changes in ambient temperature when given MDMA, exhibiting slight to moderate increases in body temperature regardless of the temperature of the

environment. Findings from previous Phase 1 trials indicate that MDMA administered in a controlled setting produces a statistically but not clinically significant increase in body temperature (mean elevation of 0.6°C). Controlled clinical settings have been sufficient to manage body temperature in humans. In the above MAPS-sponsored studies, adjustments were made to the ambient temperature and to air circulation in the room in response to observed elevation in body temperatures, but no participants required medical intervention to decrease body temperature, and values returned to baseline as drug effects waned. Body temperature greater than 1°C above baseline was detected after any dose of MDMA, in 44% of participants with PTSD, with most of these cases observed in sessions with 125 mg MDMA HCl. In individuals with autism or a life-threatening illness, 29% and 50% of subject respectively exhibited elevated body temperature after 100 mg to 125 mg MDMA HCl. In contrast, in 20% of participants that were administered therapy with placebo had an elevation of body temperature above cut-off in PTSD studies. Both peak and longest duration of body temperature elevation were observed in the 125 mg MDMA HCl group. Across all indications, the maximum peak reading was 38.7°C. Findings from the MAPP1 Phase 3 trial showed a similar pattern for transient increases in body temperature in the MDMA group. In conclusion, controlled settings for treatments with MDMA-assisted therapy were sufficiently optimized with the capacity to control the ambient temperature for subject comfort, though there is no evidence that these measures significantly influenced or were needed for control of core body temperature.

#### 6.4.3.2 Cardiovascular System

In all sponsor-supported studies to date, blood pressure readings were taken at baseline, with study-specific differences in data collection times after drug administration. Peak values during each dosing session were ascertained for studies MP-1 through MP-12. In MP16, MP17, and MPVA-1, peak values were collected just prior to the optional supplemental dose (midpoint). The final or endpoint was recorded as the final value at a relatively set time (MP-8, MP-12, MP16, MP17, MPVA-1), as the final value available, or with varying timepoints (MP-1). MP-1 and MP-2 reported two pre-drug values (15 minutes and 5 minutes before dosing) and the results of these measurements were averaged, whereas all other studies reported a single time point pre-drug. Average post-drug values served as the final value for MP-2. If systolic blood pressure (SBP) rose above 160 mmHg or if diastolic blood pressure (DBP) rose above 110 mmHg, additional measurements were collected in studies MP-8, MP-12, MP-9, and MP-4. In MAA-1, if SBP rose above 180 mmHg or if DBP rose above 110 mmHg, each duration above the pre-determined cut-off was collected. If SBP rose above 180 mmHg and DBP rose above 120 mmHg, each timepoint above the pre-determined cut-off was collected in MDA-1. The cut-off for blood pressure (as SBP/DBP) in MP-2 was >160/110 mmHg. Clinical signs and symptoms were monitored and more frequent readings were collected in cases where readings were above the cut-off. Systolic and diastolic pressure data are presented separately. SBP results are summarized in [Tables 21-23](#) and DBP results summarized in [Tables 24-26](#), and in [Appendix Tables 4-7](#). Values recorded during blinded sessions and those from open-label sessions are reported separately (see [Appendix Tables 4-7](#)).

Candidates with hypertension were excluded from participation in early sponsor-supported studies, but more recent studies have allowed enrollment of participants with well-controlled hypertension. For example, in MP-8, four participants with hypertension controlled by medications were permitted to enroll after completion of carotid ultrasound and nuclear stress test (per protocol) in addition to usual medical screening for the study (see [Table 22](#) and [Table 25](#), below, for data from these participants).

### Systolic Blood Pressure

In MAPS-sponsored Phase 2 studies, the observed increase in SBP was greater when doses of 75 mg MDMA HCl or more of MDMA were administered. In MAPS-sponsored PTSD studies MP-1 through MP-12, systolic blood pressure above 160 mmHg was detected in 32% (30 of 95) participants who received MDMA at any dose during blinded sessions. It is notable that the majority of these cases occurred after 125 mg of MDMA HCl, but failed to occur after inactive placebo or doses lower than 30 mg MDMA HCl. SBP rose above 160 mm Hg in 36% (28 of 78) participants after 100 mg to 150 mg of MDMA HCl in open-label sessions. Similar to blinded sessions, SBP returned to baseline levels at the end of the session. The maximum systolic blood pressure for any subject receiving MDMA was 200 mmHg. Final (end of session) values returned to pre-drug levels with no clinical intervention required. No clinically significant AEs were reported based on elevations in blood pressure and no treatment was required for these transient elevations of blood pressure.

In, the MPVA-1 study, after two open-label sessions with 75 mg to 100 mg MDMA HCl, both members of dyads consisting of people with PTSD and concerned significant others exhibited a rise in systolic blood pressure in a study of MDMA-assisted therapy and cognitive-behavioral conjoint therapy (CBCT). SBP returned to near baseline levels at the closing of a dosing session, with final readings 0.5 to 2.6 units higher than baseline. Additional or high SBP values were not recorded for any of the participants. Peak SBP was not recorded per protocol. Observed SBP did not appear to differ on the basis of PTSD diagnosis. Maximum recorded SBP during this study was 180 mmHg in a concerned significant other at dosing session midpoint.

**Table 21: Pre-drug, Peak, and Final Systolic Blood Pressure During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored Studies of PTSD (MP-1, MP-2, MP-4, MP-8, MP-12)**

MDMA HCl Dose	N	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with SBP Above 160 mm Hg
Placebo	10	114.9 (11.61) 90.5/136.5	129.7 (15.27) 102.0/157.0	111.4 (12.88) 83.0/133.0	0
25 mg	8	119.3 (7.13) 107.0/141.0	132.5 (9.09) 114.0/147.0	119.3 (11.23) 107.0/146.0	0
30 mg	7	114.0 (11.91) 94.0/134.0	132.3 (14.02) 110.0/155.0	118.5 (11.63) 98.0/140.0	0
40 mg	6	124.7 (14.14) 100.0/154.0	134.3 (15.47) 112.0/163.0	123.6 (12.52) 107.0/148.0	1 (16.7)
75 mg	7	125.4 (9.99) 109.0/145.0	147.0 (14.43) 123.0/179.0	127.4 (11.85) 107.0/147.0	1 (14.3)
100 mg	9	121.4 (20.16) 96.0/161.0	138.6 (23.55) 100.0/180.0	116.7 (13.50) 92.0/140.0	2 (22.2)
125 mg	58	126.2 (16.03) 98.0/177.0	153.7 (18.49) 114.0/200.0	127.3 (16.25) 86.0/168.0	26 (44.8)
Open-label 100-150 mg	78	124.1 (14.37) 95.0/171.0	151.1 (17.10) 105.0/193.0	124.7 (14.88) 77.0/161.0	28 (35.9)

In MP-8, systolic blood pressure above 160 mmHg was detected in 75% (3 of 4) of participants with hypertension kept controlled by medication during blinded sessions with 30 mg to 125 mg MDMA HCl and in 67% (2 of 3) participants receiving 100 mg to 125 mg MDMA HCl during open-label sessions. No increase in SBP >160 mmHg occurred after administration of 30 mg MDMA HCl. The maximum systolic blood pressure for these participants with controlled hypertension was 193 mmHg, which occurred during an open-label session. The baseline values

and elevations after MDMA appear higher in this sub-group than the overall sample but any meaningful comparison is limited by the sample size. Pre-drug SBP was typically higher in this sub-group, and peak SBP of these participants was typically at the upper end of the range of the overall sample. Final SBP readings remained 11 to 14 mmHg higher on average than pre-drug SBP readings in the subject who received 75 mg MDMA HCl in two blinded dosing sessions and 100 mg MDMA HCl in three open-label crossover dosing sessions. However, two participants who received 125 mg MDMA HCl had final readings that returned to pre-drug values, which might suggest these could have been due to these individual’s medical history of both hypertension and hyperlipidemia. One subject with controlled hypertension dropped out (not due to blood pressure concerns) after receiving a single dosing session with 30 mg MDMA HCl but did not experience SBP above 160 mmHg. None of the participants with controlled hypertension experienced AEs of the cardiovascular system and SBP returned to baseline or near-baseline levels at final session reading without any additional medication.

**Table 22: Pre-drug, Peak, and Final Systolic Blood Pressure During Dosing Sessions in Controlled Hypertension Participants in MAPS-Sponsored PTSD Study MP-8**

MDMA HCl Dose	N	Pre-drug	Peak	Final	SBP Above 160 mm HG N
		Mean (SD) Min/Max	Mean (SD) Min/Max	Mean (SD) Min/Max	
30 mg	1	125 125/125	131 131/131	124 124/124	0
75 mg	1	139 (8.49) 133/145	174.5 (6.36) 170/179	147 147/147	1
125 mg	2	130.8 (11.53) 124/148	160.5 (13.30) 147/177	128.5 (9.54) 118/141	2
Open-label 100-125 mg	3	139.2 (18.97) 122/171	174.6 (18.47) 144/193	142.8 (10.28) 133/158	2

In the MAA-1 study, systolic blood pressure did not rise above 180 mmHg during blinded sessions with inactive placebo or 75 mg to 125 mg MDMA HCl, nor during open-label sessions with 75 mg to 125 mg MDMA HCl [89]. The maximum systolic blood pressure for any subject receiving MDMA was 174 mmHg, which occurred after 75 mg MDMA HCl). Peak SBP values in this sample suggests slightly lower values than in studies in people with PTSD, but the sample was much smaller, and this may reflect a chance fluctuation. It is also notable that, in general, this study employed lower active doses of MDMA than the PTSD studies. Final values returned to pre-drug levels with no clinical intervention required. No clinically significant AEs were reported based on elevations in blood pressure (see [Appendix Table 4](#)).

In the MDA-1 study, systolic blood pressure rose above threshold (180 mmHg) in 54% (7 of 13) of participants who received 125 mg MDMA HCl during blinded sessions and in 29% (5 of 17) after open-label 125 mg MDMA HCl sessions. In comparison, SBP above 180 mm Hg was detected in 40% (2 of 5) of participants who received placebo. The maximum systolic blood pressure for any subject receiving MDMA was 196 mmHg, observed after 125 mg MDMA HCl in an open-label session. Final values returned to pre-drug levels with no clinical intervention required. No clinically significant AEs were reported based on elevations in blood pressure. SBP values in this sample appear to be similar to values reported in sample with PTSD (see [Appendix Table 5](#)).

In the MAPS sponsored Phase 3 PTSD study MAPP1, participants in the MDMA group had transient increases (on average +16 mmHg) in systolic blood pressure (SBP) during dosing sessions that returned to pre-drug levels at the end of the sessions. Participants in the placebo group had relatively stable SBP across sessions.



**Table 23: Predose, Interim, and Endpoint Systolic Blood Pressure Across Dosing Sessions in MAPP1**

	MDMA-assisted therapy (N=46)	Placebo with therapy (N=44)	Total (N=90)
<b>Dosing Session 1</b>			
Predose (n)	46	44	90
Mean (SD)	126.4 (18.55)	120.2 (13.92)	123.4 (16.65)
Min/Max	90/180	96/151	90/180
Interim (n)	46	44	90
Mean (SD)	139.1 (19.70)	122.3 (14.95)	130.9 (19.37)
Min/Max	104/191	94/168	94/191
Endpoint (n)	46	44	90
Mean (SD)	130.8 (16.63)	119.2 (14.77)	125.1 (16.71)
Min/Max	89/168	96/164	89/168
<b>Dosing Session 2</b>			
Predose (n)	43	41	84
Mean (SD)	127.2 (14.46)	117.0 (15.33)	122.2 (15.67)
Min/Max	94/158	83/156	83/158
Interim (n)	43	41	84
Mean (SD)	146.5 (15.09)	118.1 (18.14)	132.7 (21.85)
Min/Max	116/183	85/166	85/183
Endpoint (n)	43	41	84
Mean (SD)	128.8 (17.66)	118.9 (15.12)	123.9 (17.11)
Min/Max	94/162	98/167	94/167
<b>Dosing Session 3</b>			
Predose (n)	42	37	79
Mean (SD)	128.5 (15.30)	118.0 (15.79)	123.6 (16.31)
Min/Max	95/153	87/154	87/154
Interim (n)	41	37	78
Mean (SD)	145.9 (19.23)	117.9 (15.74)	132.6 (22.51)
Min/Max	110/201	94/154	94/201
Endpoint (n)	42	37	79
Mean (SD)	127.6 (16.62)	117.5 (13.74)	122.9 (16.06)
Min/Max	99/162	92/146	92/162

In all cases across studies, final values returned to pre-drug levels with no clinical intervention required. No clinically significant AEs were reported based on elevations in blood pressure.

**Diastolic Blood Pressure**

In MAPS-sponsored Phase 2 PTSD studies, doses of 75mg and 125 mg MDMA HCl produced greater elevation in DBP than lower doses of 25 mg to 40 mg MDMA HCl. The lower increase in DBP after 100 mg MDMA HCl may reflect random variation in a small sample. At the end of session or final reading, DBP had returned to baseline levels across all doses of MDMA. DBP above 110 mmHg was detected in 7% (7 of 95) of participants who received any dose of MDMA during blinded study sessions, and 6.4% (5 of 78) participants who received 100 mg to 150 mg MDMA HCl during open-label sessions. The maximum diastolic blood pressure for any subject receiving MDMA was 135 mmHg, and no clinical intervention was required. No clinically significant AEs were reported based on elevations in blood pressure. These observations suggest that people with PTSD experience similar elevations in SBP and DBP as those seen in healthy controls.

MPVA-1 was the open-label study of MDMA-assisted psychotherapy and CBCT in dyads made up of one person with PTSD and a significant other without PTSD. DBP was elevated at midpoint compared with baseline in both groups (3.6 to 11.3 mmHg) and returned to near-baseline levels after 75 mg to 100 mg MDMA HCl. DBP returned to baseline or near-baseline levels at session end (dropping 4.5 to 7.5 mmHg). The highest value was recorded at midpoint (106 mm Hg). No additional readings were required during either dosing session.

**Table 24: Pre-drug, Peak, and Final Diastolic Blood Pressure During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored Studies of PTSD (MP-1, MP-2, MP-4, MP-8, MP-9, MP-12)**

MDMA HCl Dose	N	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with DBP Above 110 mm Hg
Placebo	10	72.7 (7.88) 56.5/87.5	83.4 (9.73) 65.0/102.0	68.5 (9.71) 48.0/89.0	0
25 mg	8	73.4 (6.44) 59.0/84.0	82.7 (5.30) 74.0/92.0	71.9 (5.43) 63.0/81.0	0
30 mg	7	73.5 (8.03) 60.0/87.0	85.5 (7.52) 75.0/99.0	76.7 (6.23) 68.0/91.0	0
40 mg	6	80.0 (9.96) 62.0/95.0	86.1 (9.28) 72.0/96.0	79.9 (9.74) 68.0/96.0	0
75 mg	7	77.9 (9.73) 56.0/95.0	91.4 (12.06) 78.0/118.0	78.4 (11.19) 59.0/100.0	1 (14.3)
100 mg	9	79.0 (13.45) 58.0/102.0	84.4 (11.38) 65.0/101.0	74.4 (7.72) 61.0/88.0	0
125 mg	58	79.5 (10.03) 52.0/102.0	92.5 (10.88) 70.0/135.0	78.6 (10.27) 53.0/104.0	6 (10.3)
Open-label 100-150 mg	78	78.1 (9.31) 56.0/103.0	92.8 (10.8) 64.0/126.0	77.5 (9.79) 54.0/100.0	5 (6.4)

In MP-8, participants with controlled hypertension responded similarly to MDMA as normotensive people, with final values returning to at- or near-baseline levels, and peak levels higher after 75 mg to 125 mg MDMA HCl compared with 30 mg MDMA HCl. Diastolic blood pressure above 110 mmHg was detected in 25% (1 of 4) participants with controlled hypertension in blinded sessions and in one of three participants who received 100 mg to 125 mg MDMA HCl during open-label sessions. The maximum DBP for these participants with controlled hypertension was 125 mmHg. Final values returned to pre-drug levels at end of session with no clinical intervention required. No clinically significant AEs were reported based on elevations in blood pressure.

**Table 25: Pre-drug, Peak, and Final Diastolic Blood Pressure During Dosing Sessions in Controlled Hypertension Participants in MAPS-Sponsored PTSD Study MP-8**

MDMA HCl Dose	N (Observations)	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	DBP Above 110 mm Hg N (Observations)
30 mg	1	85 85/85	86 86/86	77 77/77	0
75 mg	1 (2)	92 (4.24) 89/95	115.5 (3.54) 113/118	95.5 (6.36) 91/100	1 (2)
125 mg	2 (4)	86.0 (6.68) 79/95	97.0 (6.06) 91/105	83.0 (7.62) 72/89	0

Open-label 100-125 mg	3 (5)	86.8 (9.39) 77/101	114.4 (13.3) 93/125	91.2 (6.10) 82/99	1 (3)
--------------------------	-------	-----------------------	------------------------	----------------------	-------

In the MAPS sponsored Phase 3 PTSD study MAPP1, participants in the MDMA group had transient increases (on average 6 mmHg) in diastolic blood pressure (DBP) during dosing sessions that returned to pre-drug levels at the end of the sessions. Participants in the placebo group had relatively stable DBP across sessions.

**Table 26: Predose, Interim, and Endpoint Diastolic Blood Pressure Across Dosing Sessions in MAPP1**

	MDMA-assisted therapy (N=46)	Placebo with therapy (N=44)	Total (N=90)
<b>Dosing Session 1</b>			
Predose (n)	46	44	90
Mean (SD)	79.4 (11.23)	79.6 (8.76)	79.5 (10.04)
Min/Max	51/103	62/103	51/103
Interim (n)	46	44	90
Mean (SD)	85.3 (10.41)	79.1 (11.38)	82.3 (11.28)
Min/Max	65/108	58/109	58/109
Endpoint (n)	46	44	90
Mean (SD)	81.7 (9.63)	77.2 (11.17)	79.5 (10.60)
Min/Max	55/102	52/103	52/103
<b>Dosing Session 2</b>			
Predose (n)	43	41	84
Mean (SD)	81.1 (10.35)	76.8 (9.52)	79.0 (10.13)
Min/Max	56/100	51/96	51/100
Interim (n)	43	41	84
Mean (SD)	89.1 (10.39)	76.4 (12.45)	82.9 (13.02)
Min/Max	67/110	48/115	48/115
Endpoint (n)	43	41	84
Mean (SD)	81.5 (12.36)	75.2 (9.02)	78.4 (11.25)
Min/Max	57/107	56/92	56/107
<b>Dosing Session 3</b>			
Predose (n)	42	37	79
Mean (SD)	82.4 (8.00)	76.1 (10.98)	79.4 (9.96)
Min/Max	64/97	56/102	56/102
Interim (n)	41	37	78
Mean (SD)	86.8 (10.32)	76.2 (10.07)	81.7 (11.45)
Min/Max	69/108	52/95	52/108
Endpoint (n)	42	37	79
Mean (SD)	78.4 (11.15)	74.0 (9.39)	76.3 (10.53)
Min/Max	51/97	59/94	51/97

Comparison of the changes in blood pressure during MDMA sessions by participants less than 65 years old and elderly participants 65 years or older in the MAPP1 study is depicted below. Post-dosing systolic blood pressure (SBP) of 180 mmHg or greater was detected in 6.52% (3 of 46) participants who received MDMA during blinded sessions. The maximum systolic blood pressure for any subject after receiving MDMA was 201 mmHg. Of note, a repeat measurement two minutes later in the participant where this occurred showed a SBP of 162 mmHg. Post-dosing diastolic blood pressure (DBP) of 110 mmHg or greater was detected in one participant who received MDMA during blinded sessions. Final (end of session) values returned to pre-drug levels in the majority of these occurrences with no clinical intervention required. No clinically

significant cardiovascular AEs were reported based on elevations in blood pressure and no treatment was required for these transient elevations of blood pressure.

**Table 27: Pre-Initial Dose, Post-Initial Dose / Pre-Supplemental Dose, and Final Blood Pressure in MDMA Sessions by Dose and Age Bracket in MAPP1**

Age	MDMA HCl Dose at Dosing Session	Vitals	Pre-Initial Dose Mean (SD) Min, Max	Post-Initial Dose, Pre-Supplemental Dose Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with SBP ≥ 180 mmHg Post-Dosing	N (%) with SBP Increase ≥ 40 mmHg Post-Dosing	N (%) with DBP ≥ 110 mmHg Post-Dosing	N (%) with DBP Increase ≥ 25 mmHg Post-Dosing
Patients < 65 years old	Session 1 80 mg + 40 mg (N=40 participants, N=40 measures) <sup>A</sup>	SBP <sup>B</sup> (mmHg)	125.03 (17.51) 90.0, 180.0	138.48 (19.01) 105.0, 191.0	129.18 (15.36) 89.0, 168.0	2 (5.0)	2 (5.0)	---	---
		DBP <sup>C</sup> (mmHg)	78.78 (10.92) 51.0, 94.0	84.90 (9.82) 65.0, 108.0	81.23 (9.50) 55.0, 102.0	---	---	0 (0.0)	1 (2.5)
	Sessions 2 and 3 120 mg + 60 mg (N=37 participants, N=74 measures) <sup>A</sup>	SBP (mmHg)	126.4 (14.51) 94, 153	145.2 (16.19) 110, 183	127.4 (16.80) 94, 162	1 (2.6)	6 (15.8)	---	---
		DBP (mmHg)	81.6 (9.50) 56, 100	87.7 (10.00) 69, 110	79.9 (11.83) 51, 107	---	---	1 (2.6)	2 (5.3)
Patients ≥ 65 years old	Session 1 80 mg + 40 mg (N=5 participants, N=5 measures) <sup>A</sup>	SBP (mmHg)	135.40 (27.27) 110.0, 165.0	146.20 (27.17) 104.0, 172.0	146.60 (20.78) 112.0, 165.0	0 (0.0)	1 (20.0)	---	---
		DBP (mmHg)	83.00 (15.05) 70.0, 103.0	90.60 (15.01) 69.0, 104.0	87.60 (9.15) 75.0, 97.0	---	---	0 (0.0)	1 (20.0)
	Sessions 2 and 3 120 mg + 60 mg (N=5 participants, N= 9 measures) <sup>A</sup>	SBP (mmHg)	139.4 (13.43) 111, 158	155.7 (23.20) 116, 201	133.1 (18.18) 103, 162	1 (20.0)	1 (20.0)	---	---
		DBP (mmHg)	83.2 (8.04) 72, 100	90.8 (13.69) 67, 105	80.9 (11.85) 57, 94			0 (0.0)	0 (0.0)

<sup>A</sup> Excluded participants who did not escalate in dose or take the supplemental dose.

<sup>B</sup> SPB, systolic blood pressure

<sup>C</sup> DBP, diastolic blood pressure

In the MAA-1 study, MDMA produced greater elevation in DBP than inactive placebo: an increase of 5.4 mmHg after placebo versus an increase of 11.8 mmHg after 75 mg MDMA HCl, 15.4 mmHg after 100 mg MDMA HCl, and 10.5 mmHg after 125 mg MDMA HCl, respectively. At the end of the session, DBP returned to baseline levels in all blinded and open-label dosing sessions. DBP above 110 mmHg was not detected during any session, regardless of dose. The maximum DBP for any subject receiving MDMA was 106 mmHg, which occurred after inactive placebo administration. Final (end of session) values returned to pre-drug levels with no clinical intervention required. No clinically significant AEs were reported based on elevations in blood pressure (see [Appendix Table 6](#)).

In the MDA-1 study, peak DBP was higher after 125 mg MDMA HCl than after inactive placebo as expected, and final values returned to pre-drug levels with no clinical intervention required. Diastolic blood pressure above 120 mmHg was detected in 31% (4 of 13) participants who received 125 mg MDMA HCl during blinded sessions and 11.8% (2 of 17) participants receiving MDMA during open-label sessions. In comparison, diastolic blood pressure above threshold was detected in 20% (1 of 5) of participants who received placebo. The maximum DBP for any

subject receiving MDMA was 154 mmHg, which was observed in a subject who received 125 mg MDMA HCl. No clinically significant AEs were reported based on elevations in blood pressure and DBP returned back to pre-drug levels with no treatment required (see [Appendix Table 7](#)).

### **Summary of Blood Pressure Effects**

The supplemental dose, when administered 1.5 to 2.5 hours after the initial dose, may cause further SBP increases above that of the initial dose of MDMA. In one study (MP-1), 9 of 23 participants received the supplemental dose, with four in the 125 mg MDMA HCl group. In all subsequent studies, most of the participants received the optional supplemental dose. A comparison of participants receiving the supplemental dose to those who only received the initial dose in MP-1 indicated that the supplemental dose did not cause further elevation in blood pressure or heart rate beyond the initial dose, although the sample was underpowered to detect a significant effect. Maximum SBP observed to date was 201 mmHg in a single MAPP1 participant 2 hours after administration of 120 mg MDMA HCl as the initial dose. A repeat measurement two minutes following this reading showed a SBP of 162 mmHg. This participant had a medical history of prediabetes and hypercholesterolemia/hyperlipidemia. The next closest observation to this maximum was 200 mmHg in a single MP-2 participant who was administered 125 mg MDMA HCl as the initial dose which lasted 5 hours. This participant had a medical history of mild systolic hypertension, and the traumatic event that caused PTSD for this participant was medical malpractice. This participant was only enrolled after 24-hour monitoring of blood pressure at baseline to confirm this diagnosis. None of the participants with controlled hypertension whose BP was kept normal with medications experienced AEs of the cardiovascular system and no lasting effects on the transient increases in BP measurements have been observed in any of the clinical trials. Despite elevations in SBP and to a lesser extent DBP, no clinical signs or symptoms of hypertension were observed, and no additional treatment was required. In all cases across the Clinical Development Program, including in participants with PTSD, autistic adults with social anxiety, and people with anxiety arising from facing a life-threatening illness, blood pressure returned to pre-drug levels at end of session with no clinical intervention required. No clinically significant AEs were reported based on elevations in blood pressure.

### **Heart Rate**

In all sponsor-supported studies to date, heart rate readings were taken at baseline, with study-specific differences in data collection times after drug administration. Peak values during each dosing session were ascertained for all studies. The final or endpoint value was recorded as the final value, either at a relatively set time (MP-4, MP-8, MP-9, MP-12, MP16, MP17, MPVA-1) or as the final value available, with varying time points (MP-1). MP-1 and MP-2 reported two pre-drug values (15 minutes and 5 minutes before dosing) and these measurements were averaged, whereas all other studies reported single time point pre-drug value. Average post-drug values serve as the final value for MP-2. If heart rate rose above 110 beats per minute (bpm), each duration above the pre-determined cut-off was collected in MP-8, MP-12, MP-9, and MP-4. Duration of pulse above cut-off was not collected in MP-2. Clinical signs and symptoms were monitored, and more frequent readings were collected in cases where readings were above the pre-determined cut-off.

**Table 28: Pre-drug, Peak, and Final Heart Rate During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored Studies of PTSD (MP-1, MP-2, MP-4, MP-8, MP-9, MP-12)**

MDMA HCl Dose	N	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with HR Above 110 BPM
Placebo	10	64.9 (11.53) 45.0/91.0	77.8 (13.02) 54.0/107.0	67.6 (11.14) 45.0/89.0	0
25 mg	8	69.6 (13.14) 47.0/94.0	84.2 (19.27) 50.0/124.0	72.4 (12.37) 51.0/90.0	2 (25.0)
30 mg	7	67.7 (13.89) 45.0/91.0	81.1 (15.98) 54.0/102.0	72.7 (13.01) 50.0/89.0	0
40 mg	6	79.1 (11.00) 66.0/103.0	87.5 (11.51) 69.0/103.0	80.1 (15.50) 56.0/103.0	0
75 mg	7	73.7 (8.31) 61.0/85.0	96.2 (16.12) 75.0/123.0	82.9 (13.34) 63.0/102.0	2 (28.6)
100 mg	9	70.8 (17.40) 46.0/118.0	97.0 (21.50) 65.0/140.0	81.4 (13.21) 63.0/114.0	3 (33.3)
125 mg	58	74.8 (13.89) 45.0/122.0	103.2 (16.75) 67.0/160.0	85.6 (15.56) 47.0/135.0	29 (50.0)
Open-label 100-150 mg	78	74.0 (14.98) 36.0/116.0	106.0 (20.28) 63.0/156.0	83.7 (14.72) 52.0/120.0	36 (46.2)

In MAPS-sponsored Phase 2 PTSD studies, MDMA appears to increase peak heart rate compared with placebo, with a greater difference between pre-drug and peak values observed with active doses, and greater differences between peak and pre-drug for every dose except for 40 mg MDMA HCl during blinded sessions. In PTSD studies, heart rate was temporarily elevated above 110 bpm was detected in 38% (36 of 95) of participants receiving MDMA in blinded dosing sessions, and heart rate never arose above threshold in placebo subjects. Heart rate was elevated above 110 BPM in 46% (36 of 78) of participants given 100 mg to 150 mg MDMA HCl in open-label sessions. The maximum heart rate for any subject receiving MDMA was 160 bpm. Values at end of session returned to pre-drug levels with no clinical intervention required. No clinically significant AEs were reported based on elevations in heart rate.

In the MPVA-1 open-label study of CBCT combined with MDMA-assisted therapy in dyads, which comprised of a person diagnosed with PTSD and a significant other without PTSD, heart rate was recorded at baseline, midpoint, and at dosing session end. Heart rate was elevated by 15.8 to 19.6 BPM at session midpoint, prior to administering supplemental dose of MDMA, compared with baseline in participants with and without PTSD respectively. Mid-session HR was elevated compared with baseline in participants with and without PTSD. Heart rate remained above baseline at the end of the session. The highest value was 137 BPM, recorded at session midpoint in a PTSD participant. No extra readings were taken for any participant. No cardiac disorder AE was reported.

In the MAPS sponsored Phase 3 PTSD study MAPP1, participants in the MDMA group had transient increases (on average 15 beats per minute) in heart rate during dosing sessions that decreased at the end of dosing sessions but were still slightly elevated above pre-dose levels. Participants in the placebo group showed a trend toward slightly decreased heart rate during dosing sessions that returned to pre-drug levels at the end of sessions.



**Table 29: Predose, Interim, and Endpoint Heart Rate (Beats Per Minute) Across Dosing Sessions in MAPP1**

	MDMA-assisted therapy (N=46)	Placebo with therapy (N=44)	Total (N=90)
<b>Dosing Session 1</b>			
Predose (n)	46	44	90
Mean (SD)	71.0 (11.16)	73.2 (11.20)	72.0 (11.17)
Min/Max	49/93	50/110	49/110
Interim (n)	46	44	90
Mean (SD)	82.3 (14.49)	69.6 (11.57)	76.1 (14.56)
Min/Max	56/109	50/101	50/109
Endpoint (n)	46	44	90
Mean (SD)	79.4 (12.51)	73.7 (10.13)	76.6 (11.70)
Min/Max	60/108	54/96	54/108
<b>Dosing Session 2</b>			
Predose (n)	43	41	84
Mean (SD)	71.7 (10.44)	67.1 (10.28)	69.5 (10.55)
Min/Max	54/96	50/90	50/96
Interim (n)	43	41	84
Mean (SD)	87.3 (12.80)	66.1 (10.61)	77.0 (15.84)
Min/Max	64/122	49/90	49/122
Endpoint (n)	43	41	84
Mean (SD)	85.3 (14.66)	69.8 (8.75)	77.7 (14.35)
Min/Max	62/115	51/88	51/115
<b>Dosing Session 3</b>			
Predose (n)	42	37	79
Mean (SD)	72.7 (11.80)	69.4 (11.49)	71.2 (11.70)
Min/Max	50/104	52/98	50/104
Interim (n)	41	37	78
Mean (SD)	91.6 (16.95)	66.4 (12.99)	79.8 (19.75)
Min/Max	59/132	48/108	48/132
Endpoint (n)	42	37	79
Mean (SD)	82.1 (14.95)	71.6 (11.84)	77.2 (14.49)
Min/Max	56/116	53/101	53/116

In the MAA-1 study, peak heart rate increased ranging from 15 bpm after inactive placebo to 16.5 bpm after 125 mg MDMA HCl in blinded sessions, and from 13 to 23 bpm after open-label sessions. In most cases, heart rate had returned to baseline levels or near baseline levels, except after blinded 125 mg MDMA HCl, where average final reading remained 15.7 bpm greater than baseline. However, this dose group consisted of only three individuals. Heart rate above 110 bpm was detected in 25% (1 of 4) of participants given 125 mg MDMA HCl during blinded dosing sessions and in none of the participants receiving placebo during blinded dosing sessions or after open-label sessions with 75 mg to 125 mg MDMA HCl. The maximum heart rate for any subject receiving MDMA was 114 bpm. No clinical intervention was required during the study. No clinically significant AEs were reported based on elevations in heart rate (see [Appendix Table 8](#)).

In MAPS-sponsored MDA-1, MDMA produced a greater increase in heart rate than inactive placebo during blinded and open-label sessions. End of session heart rate was lower than peak value for all dose groups, with end of session heart rate at pre-drug levels after placebo and lower than peak value but at least 15.5 bpm higher than pre-drug levels after 125 mg MDMA HCl in blinded or open-label sessions. Elevation in heart rate above threshold (20 bpm) was detected in 46.2% (6 of 13) of participants given 125 mg MDMA HCl during blinded dosing sessions and in none of the participants who received inactive placebo. Heart rate elevation above cut off was

seen in 35.3% (6 of 17) of participants given 125 mg MDMA HCl during open-label dosing sessions. This study was comprised of a small sample, making comparisons with other samples or with healthy controls difficult. The maximum heart rate for any subject receiving MDMA was 140 bpm, observed after 125 mg MDMA HCl during an open-label session. No clinical interventions were required, and no clinically significant AEs were reported based on elevations in heart rate (see [Appendix Table 9](#)).

### **Summary of Cardiovascular Effects**

The values presented above suggest a dose-dependent transient increase in SBP, heart rate and to a lesser extent DBP in participants in clinical trials that received MDMA, a finding that is supported in the literature in studies with healthy volunteers [[11](#), [13](#), [14](#), [554](#)]. Both highest peak and maximum duration above clinically important thresholds in cardiovascular parameters were observed in 125 mg MDMA HCl sessions. A comparison of participants receiving the supplemental dose to those who only received the initial dose in MP-1 indicate that the supplemental dose did not cause further elevation in BP and heart rate beyond the initial dose. On average, cardiovascular vital signs returned to baseline or near-baseline values by final reading, which is the case across all doses of MDMA. Blood pressure and pulse readings permitted the detection of the SAR of increased ventricular extrasystoles described in Section [6.4.1.5 Serious Adverse Reactions](#), but elevated blood pressure or pulse were not the cause of the event. There were far fewer observations of above threshold values of DBP than SBP. None of the participants have required treatment for sympathomimetic effects, and they were self-limiting.

### **6.4.4 Cognition and Performance**

Acute effects on cognitive function were not assessed in sponsor-supported studies. In three MAPS-sponsored studies, MP-1, MP-4, and MP-12, long-term effects on cognitive function was assessed by administering the Repeatable Battery for Assessment of Neuropsychological Status (RBANS), a relatively brief measure that assesses memory, attention and processing speed, visual-spatial and constructional abilities, and expressive language [[679](#)]; and the Paced Auditory Serial Addition Task (PASAT), a measure of auditory processing speed and mental flexibility [[680](#), [681](#)]. These instruments were given prior to and 1 to 2 months after therapy assisted with either full dose MDMA or a comparator/placebo dose.

In MP-1, no significant differences in cognitive function were detected at the 2-month Follow-up between subjects who received two sessions with 125 mg of MDMA HCl compared to participants who received placebo, as measured by RBANS and PASAT [[41](#)]. These findings suggest that MDMA did not impair cognitive function in this sample or that the effect was too small to attain statistical significance in this small pilot study. Two completed studies (MP-12 and MP-4) included these measures to assess reproducibility of this finding. Available data pooled across studies are presented by dose in [Table 30](#) and [Table 31](#).

**Table 30: Neurocognitive Function – RBANS Mean Total Scores at Baseline, Primary Endpoint, End of Stage 1, and End of Stage 2 for MP-1, MP-4, and MP-12**

MDMA HCl Dose	Baseline Mean (SD) N	Primary Endpoint Mean (SD) N	End of Stage 1 Mean (SD) N	End of Stage 2 Mean (SD) N
Placebo	100.9 (15.38) N=10	106.9 (15.15) N=10	---	117.0 (2.83) N=2
40 mg	94.7 (5.20) N=6	104.0 (9.52) N=4	---	103.3 (5.91) N=4
100 mg	95.9 (15.47) N=8	103.4 (13.98) N=9	99.9 (16.50) N=9	---
125 mg	103.2 (15.11) N=30	103.4 (13.21) N=27	99.9 (12.86) N=14	---

On average, RBANS scores trended towards improvement after treatment with placebo and initial dose of 40 mg to 100 mg MDMA HCl, whereas scores stayed the same after treatment with initial dose of 125 mg MDMA HCl. The trend towards improvement could be a practice effect from repeated assessments, although stimuli were varied across these assessments, or could possibly be correlated with PTSD symptom reduction. One to three additional treatments with open-label active dose MDMA do not appear to worsen cognitive function based on preliminary End of Stage 1 and End of Stage 2 results. The statistical significance of these pooled findings is yet to be determined.

**Table 31: Neurocognitive Function – PASAT Trial 1 and Trial 2 Mean Raw Total Scores at Baseline, Primary Endpoint, End of Stage 1, and End of Stage 2 for MP-1, MP-4, and MP-12**

PASAT Trial 1				
MDMA HCl Dose	Baseline Mean (SD) N	Primary Endpoint Mean (SD) N	End of Stage 1 Mean (SD) N	End of Stage 2 Mean (SD) N
Placebo	42.1 (12.59) N=10	43.7 (12.03) N=10	---	40.0 (4.24) N=2
40 mg	44.3 (9.44) N=6	54.3 (3.86) N=4	---	54.5 (5.51) N=4
100 mg	46.5 (11.56) N=8	48.6 (9.32) N=9	50.2 (9.02) N=9	---
125 mg	45.0 (10.92) N=30	49.4 (8.02) N=27	48.9 (9.21) N=14	---
PASAT Trial 2				
Placebo	34.2 (11.21) N=10	38.6 (11.66) N=10	---	42.5 (3.54) N=2
40 mg	34.8 (12.12) N=6	44.8 (9.18) N=4	---	45.3 (6.70) N=4
100 mg	33.9 (12.25) N=8	33.1 (14.16) N=9	37.8 (12.33) N=9	---
125 mg	33.3 (9.55) N=30	35.8 (8.33) N=26	36.9 (11.12) N=14	---

On average, PASAT scores stayed about the same after treatment with placebo and 100 mg MDMA HCl and trended towards improvement after treatment with 40 mg and 125 mg MDMA HCl. The trend towards improvement could be a practice effect from repeated assessments or could be correlated with PTSD symptom reduction. One to three additional treatments with open-label active dose MDMA do not appear to have worsened cognitive function and continued to trend towards improvement on average based on preliminary End of Stage 1 and End of Stage 2 results. Cognitive function tests such as the PASAT are also known to be subject to individual

variability, as they require basic proficiency with mathematical skills that are influenced by education level. The significance of these pooled findings has yet to be determined, but it does not appear that MDMA-assisted therapy negatively impacted cognitive function.

#### 6.4.5 Abuse Potential

##### Subjective Effects

MDMA produces anxiolytic and prosocial effects, which could counteract avoidance and hyperarousal. These subjective effects of MDMA are hypothesized to create a desirable psychological state that enhances the therapeutic process in treating PTSD and other anxiety disorders. Findings using both subjective and objective indices of mood alterations suggest that MDMA generates prosocial feelings and mental states in humans in controlled laboratory settings. These effects may also be associated with determining the abuse liability of MDMA. Subjective effects of moderate doses of MDMA in controlled laboratory settings to healthy non-dependent volunteers, with a range of Ecstasy use history, have been reported in 28 publications summarized in a NIDA-funded review (N=657) [682]. These self-reported ratings include a broad range of mood states with relevance to social behavior.

As presented in [Table 32](#), participants endorsed the following verbatim terms as VAS items: feeling loving, talkative, extroverted, sociable, self-confident, friendly, playful, open, trusting, close to other people, and emotionally concerned. MDMA's subjective prosocial effects may be enhanced in group settings when other individuals have also been administered MDMA in laboratory studies. Increased feelings of loneliness may have resulted from testing conditions where participants receive MDMA in comparative isolation; however, these effects are not dependent on a permissive environment. From latent speech analysis and self-report data, "want more drug" ratings were predictive of prosocial effects, supporting this as the basis for moderate abuse liability of MDMA in healthy volunteers [682, 683].

A prospective pooled analysis of eight controlled non-sponsor supported clinical studies was conducted in an overall sample of 139 healthy nondependent individuals (mean age 24.9, SD:4.1). In participants receiving 75 mg (N=29) or 125 mg MDMA HCl (N=110), subjective "any drug effect" ratings were significantly higher than regular metabolizers ( $p < 0.05$ ) at 0.6 hours post-drug in poor metabolizers with CYP2D6 polymorphisms, which leads to 15% elevated  $C_{max}$  of MDMA and 50% elevated  $C_{max}$  of MDA. However, these effects were no longer significant at 1.5 hours post-drug.

**Table 32: Summary of Ecstasy Use History and Subjective Effects of MDMA Among Healthy Volunteers in Controlled Studies Conducted Without Sponsor Support**

Sample Size (N)	Mean # of Times Used Ecstasy (SD)	MDMA Doses	Mean Age (SD)	Finding by Dose <sup>A</sup>	Study
9	63.9 (94.9)	0.75 mg/kg, 1.5 mg/kg	24.0 (3.2)	1.5 mg/kg ↑ VAS Sociable, Friendly	Bedi et al. 2009 [38]
21	15 (23.1)	0.75 mg/kg, 1.5 mg/kg	24.4 (4.9)	1.5 mg/kg ↑ VAS Loving, Playful, POMS Friendly, ↓ fear recognition 0.75 mg/kg ↑ VAS Lonely	Bedi et al. 2010 [80]
8	23.0 <sup>B</sup>	75 mg, 125 mg	26.5 <sup>B</sup>	125 mg: ↑ ARCI sedation, dysphoria, amphetamine-like ↑ VAS High, body perception changes, confusion, difficulty concentrating ↑ POMS Elation, positive mood 75 mg: ↑ ARCI dysphoria, VAS euphoria, drunken	Cami et al. 2000 [12]
15	110.5 (175.3)	100 mg	21.1 (1.7)	↑ BLMRS Gregarious, Amicable, positive correlation with plasma oxytocin level	Dumont et al. 2009 [684]
36	4-40 <sup>C</sup>	0.75 mg/kg, 1.5 mg/kg	24.6 (4.7)	0.75 mg/kg, 1.5 mg/kg ↑ VAS Loving ↓ Cyberball mood & self-esteem effect of social rejection; 1.5 mg/kg ↑ estimate of rejection	Frye et al. 2014 [632]
16	0 (-)	1.7 mg/kg	26.0 (2.5)	↑ EWL Self-confidence, Extroversion	Gamma et al. 2000 [617]
8	5-200 <sup>C</sup>	0.5 mg/kg, 1.5 mg/kg	24-39 <sup>C</sup>	1.5 mg/kg ↑ VAS Confident	Harris et al. 2002 [14]
16	≤5	125 mg	25.7 (5.5)	↑ VAS Closeness to Others, AMRS Extroversion	Hysek et al. 2011 [600]
48	≤5	125 mg	26.0 (5.0)	↑ VAS Open, Closeness to Others, Talkative	Hysek et al. 2012a [83]

16	≤5	125 mg	25.4 (4.9)	↑ VAS Open, Closeness to Others	Hysek et al. 2012b [225]
16	0	125 mg	26.1 (6.0)	↑ VAS Open, Closeness to Others, Talkative, AMRS Extroversion	Hysek et al. 2012c [228]
16	≤5	125 mg	25.8 (3.3)	↑ AMRS Extroversion, Self-confidence	Hysek et al. 2013 [685]
32	≤5	125 mg	25.0 (3.0)	↑ VAS Open, Closeness to Others, AMRS Extroversion ↑ MET Emotional empathy	Hysek et al. 2014a [52]
16	≤5	125 mg	24.8 (2.6)	↑ VAS Closeness to Others, AMRS Extroversion	Hysek et al. 2014b [557]
8	20.0 <sup>B</sup>	1.0 mg/kg, 1.5 mg/kg	25.0 <sup>B</sup>	↑ VAS Friendly	Johanson et al. 2006 [686]
14	13.5 (12.0)	0.75 mg/kg, 1.5 mg/kg	25.4 (3.7)	1.5 mg/kg ↑ VAS Friendly, Loving, Sociable	Kirkpatrick et al. 2014a [607]
65	G1: 13.5 (10.6) G2: 18.1 (12.0)	0.75 mg/kg, 1.5 mg/kg	G1: 24.1 (4.1) G2: 23.1 (3.5)	0.75, 1.5 mg/kg ↑ VAS Friendly, Loving, Playful, Sociable 1.5 mg/kg ↑ VAS Lonely	Kirkpatrick et al. 2014b [53]
32	SOL: 14.5 (22.2) RAP: 18.4 (13.1) OPP: 20.9 (21.5)	0.5 mg/kg, 1.5 mg/kg	SOL: 24.7 (2.7) RAP: 25.7 (4.8) OPP: 24.5 (3.3)	SOL: 1.0 mg/kg ↑ VAS Insightful RAP: 1.0 mg/kg ↑ VAS Insightful, Loving OPP: 0.5, 1.0 mg/kg ↑ VAS Insightful, 1.0 mg/kg ↑ VAS Loving	Kirkpatrick & de Wit 2015 [630]
8	≥5	1.0 mg/kg, 1.6 mg/kg	21.1 (0.8)	1.6 mg/kg ↑ VAS Closeness to Others	Kolbrich et al. 2008 [11]
14	65.8 (134.5)	75 mg	23.4 (3.0)	↑ POMS Friendliness	Kuypers et al. 2011 [620]
17	18.0 (33.0)	75 mg	21.0 (1.2)	↑ POMS Friendliness	Kuypers et al. 2013 [612]
16	N=13 naïve; N=3 unknown	1.5 mg/kg	27.4 (4.4)	↑ AMRS Extroversion, Self-confidence	Liechti et al. 2000a [594]
14	N=12 naïve; N=2 unknown	1.5 mg/kg	26.0 <sup>B</sup>	↑ AMRS Extroversion, Self-confidence	Liechti et al. 2000b [598]
30	≤5	75 mg	24.0 (4.2)	↑ VAS Openness, Trust, Close to Others	Schmid et al. 2014 [605]



12	14.5 <sup>B</sup>	1.0 mg/kg, 2.0 mg/kg	22.3 <sup>B</sup>	2.0mg/kg ↑ VAS Friendly, Social, Talkative	Tancer and Johanson 2003 [ <a href="#">16</a> ]
8	28.6 <sup>B</sup>	1.5 mg/kg	23.9 <sup>B</sup>	↑ VAS Talkative, Friendly, not effected by fluoxetine co-admin	Tancer and Johanson 2007 [ <a href="#">597</a> ]
17	72.4 <sup>B</sup>	75 mg	22.8 (2.8)	↑ POMS Friendliness	van Wel et al. 2012 [ <a href="#">84</a> ]
101	13.3 (10.5)	0.75 mg/kg, 1.5 mg/kg	24.1 (4.2)	↑ VAS Playful, Loving	Wardle et al. 2014 [ <a href="#">28</a> ]
36	10.2 (8.2)	0.75 mg/kg, 1.5 mg/kg	24.6 (4.7)	↑ VAS Loving	Wardle and de Wit 2014 [ <a href="#">29</a> ]

Source: [[682](#), [683](#)]

Abbreviations: ARCI=Addiction Research Center Inventory, AMRS=Adjective Mood Rating Scale, FERT=Facial Emotion Recognition Task, BOLD=Blood Oxygen Level Dependent, MET=Multifaceted Empathy Test, SVO=Social Value Orientation Test, mFER=morphed Facial Emotion Recognition Task, RMET=Reading the Mind in the Eyes Test, MASC=Movie for the Assessment of Social Cognition, MJT=Moral Judgment Task, DANVA=Diagnostic Analysis of Nonverbal Accuracy, DEIT=Dynamic Emotional Identification Task, IPT=Interpersonal Perception Task (Modified), POMS=Profile of Mood States, VAS=Visual Analog Scale, G1= Group 1, G2=Group 2

<sup>A</sup> ↑ =Drug increased function relative to placebo, ↓ =Drug decreased function relative to placebo

<sup>B</sup> SD not presented in original publication

<sup>C</sup> These studies reported range (min-max) in lieu of mean (SD)

In a study conducted without sponsor support of 22 individuals (mean age 23.6) with a history of stimulant drug use (more than six times) and previous Ecstasy use (more than 3 times) in a double-blind randomized study, participants were asked to identify 2.0 mg/kg MDMA HCl and serotonergic drug meta-chlorophenylpiperazine (mCPP), which has both serotonin releasing and post-synaptic effects. At 1 to 2.1 mg/kg MDMA HCl, 80% of participants identified MDMA as an empathogen or hallucinogen and only 20% identified MDMA as a stimulant [633]. In contrast, results were mixed with 0.25 to 0.75 mg/kg mCPP, with results varying from hallucinogen to stimulant to sedative depending on the dose. On the “drug liking” VAS, 1.6 mg/kg ( $p < 0.004$ ) and 2.1 mg/kg MDMA HCl ( $p < 0.008$ ) were significantly higher than placebo, whereas mCPP ratings were not significantly higher than placebo at any dose [633]. In another study in a sample of 74 largely drug-naïve participants receiving MDMA in a controlled laboratory setting, Liechti and colleagues stated that “none of the participants expressed any interest in taking MDMA as a recreational drug” after receiving MDMA [15]. Collectively, these findings support the interpretation that MDMA received in controlled settings is inherently different than MDMA taken in recreational settings, and abuse liability of MDMA-assisted therapy should be evaluated in its intended setting and population for clinical use.

### **Drug Discrimination and Stimulant Comparison**

The abuse liability of MDMA has been investigated in healthy volunteers utilizing a drug discrimination paradigm in two studies. The first study was in healthy nondependent volunteers with moderate MDMA experience (mean age 22.3) with a history of stimulant drug use (more than 6 times) and previous Ecstasy use (mean 14.5 times) comparing placebo, 10 mg and 20 mg d-amphetamine, 0.5 mg/kg and 0.75 mg/kg mCPP and 1.0 mg/kg and 2.0 mg/kg MDMA HCl in a within-subject design (N=12). In this study, MDMA and d-amphetamine had similar reinforcing effects, and both were more than the effects of mCPP [16]. In humans trained to discriminate in a three-way procedure among 20 mg d-amphetamine, 0.75 mg/kg mCPP, and placebo, both 1.0 mg/kg and 1.5 mg/kg MDMA HCl was reported by half the participants to be like amphetamine and half like mCPP (N=22). Individuals who identified MDMA to be more like amphetamine were more sensitive to the subjective effects of all drugs, and they were more experienced with using Ecstasy and stimulants prior to the study [686]. [Table 33](#) below presents a summary of studies with direct comparisons of MDMA vs. stimulants. Seven of ten studies found differences between MDMA vs. stimulants, with doses of 2.0 mg/kg MDMA HCl and higher having more similar effects to stimulants.

**Table 33: Summary of Selected Effects in Controlled Clinical Studies Comparing MDMA and Stimulants Among Healthy Volunteers Conducted Without Sponsor Support**

Pre-study Ecstasy Use History		During Controlled MDMA Administration			During Controlled Stimulant Administration	
Sample Size (N)/ Study	Mean # of Times Used Ecstasy (SD)	Mean Age (SD)	MDMA HCl Doses Tested	Finding by Dose <sup>A</sup>	Stimulant Doses Tested	Finding by Dose <sup>A</sup>
28/ Holze et al. 2020 [602]	≤ 5	28 (4)	125 mg	↑ VAS: any drug effect, good drug effect, drug liking, drug high, stimulated, ego dissolution, open, talkative, concentration; ↓ VAS: concentration, sense of time, speed of thinking; ↑ AMRS: extroversion, introversion, well-being	<i>d</i> -Amph 40 mg	↑ VAS: any drug effect, good drug effect, drug liking, drug high, stimulated, open, talkative, concentration; ↑ AMRS: activity, extroversion, well-being, emotional excitement
8/ Cami et al. 2000 [12]	23.0 <sup>B</sup>	26.5 <sup>B</sup>	75 mg, 125 mg	125 mg: ↑ ARCI sedation, dysphoria, amphetamine-like ↑ VAS High, body perception changes, confusion, difficulty concentrating ↑ POMS elation, positive mood 75 mg: ↑ ARCI dysphoria ↑ VAS euphoria, drunken	<i>d</i> -Amph 40 mg	↑ ARCI amphetamine-like, energy, intellectual efficiency ↓ ARCI sedation
21/ Bedi et al. 2010 [80]	15 (23.1)	24.4 (4.9)	0.75 mg/kg, 1.5 mg/kg	1.5 mg/kg ↑ POMS Friendly, ↓ fear recognition No effect on VAS Social	Meth 20 mg	No effect on fear recognition or POMS Friendly ↑ VAS Social
13/ Bedi et al. 2014 [27]	2 (-)	18-38 <sup>C</sup>	0.75 mg/kg, 1.5 mg/kg	1.5 mg/kg ↑ social words	Meth 20 mg	No effect on social words
16/ Hysek et al. 2014b [557]	≤ 5	24.8 (2.6)	125 mg	↑ VAS Closeness to Others, AMRS Extroversion ↓ recognition: negative emotions	Methylph 60 mg	↑ recognition: negative emotions

8/ Johanson et al. 2006[686]	20.0 <sup>B</sup>	25.0 <sup>B</sup>	1.0 mg/kg, 1.5 mg/kg	↑ VAS Friendly	<i>d</i> -Amph 20 mg	↑ VAS Friendly
11/ Kirkpatrick et al. 2012[39]	2.1 (1.8) per month	29.3 (50)	100 mg	↑ VAS Social, Talkative	Meth 20 mg 40 mg	20 mg ↑ VAS Social 40 mg ↑ VAS Social, Talkative
30/ Schmid et al. 2014 [605]	≤ 5	24.0 (4.2)	75 mg	↑ MET Emotional empathy for positive situations ↓ recognition: sadness	Methylph 40 mg	No effect on emotional empathy for positive situations or recognition of sadness
12/ Tancer, Johanson 2003 [16]	14.5 <sup>B</sup>	22.3 <sup>B</sup>	1.0 mg/kg, 2.0 mg/kg	2.0 mg/kg ↑ VAS Friendly, Social, Talkative	<i>d</i> -amph 10 mg, 20 mg	20 mg ↑ VAS Friendly
30/ Schmid et al. 2015 [687]	≤ 5	24.0 (4.2)	75 mg	No effect on ratings of erotic images	Meth 40 mg	↑ ratings of erotic images
11/Marrone et al. 2010 [688]			100 mg	No effect on speech quantity ↓ fluency	Meth 20 mg 40 mg	↑ speech quantity, fluency

Abbreviations: ARCI= Addiction Research Center Inventory, FERT= Facial Emotion Recognition Task, BOLD=Blood Oxygen Level Dependent, MET=Multifaceted Empathy Test, SVO=Social Value Orientation Test, mFER=morphed Facial Emotion Recognition Task, RMET=Reading the Mind in the Eyes Test, MASC=Movie for the Assessment of Social Cognition, MJT=Moral Judgment Task, DANVA=Diagnostic Analysis of Nonverbal Accuracy, DEIT=Dynamic Emotional Identification Task, IPT=Interpersonal Perception Task (Modified), POMS=Profile of Mood States, *d*-Amph=*d*-Amphetamine, Meth=Methamphetamine, Methylph=Methylphenidate

<sup>A</sup>↑ = Drug increased function relative to placebo, ↓ = Drug decreased function relative to placebo

<sup>B</sup> SD not presented in original publication

<sup>C</sup> These studies reported range (min-max) in lieu of mean (SD)

A dose of 100 mg MDMA HCl was directly compared to 20 mg and 40 mg methamphetamine in a placebo-controlled blinded in-patient study measuring pharmacokinetics, physiological effects, and subjective effects (N=11) [39]. The study was in healthy non-dependent volunteers (mean age 29.3, SD:50) with current stimulant (4.2 days/month) and Ecstasy use (2.1 days/month). Both drugs had a similar time course of effects with oral administration. Plasma levels peaked at 3 hours and declined over the 24-hour period post-administration, with minor levels of drug remaining above baseline in plasma at the end of this period. Both drugs enhanced cardiovascular parameters, ratings of stimulation, euphoria, and mood, and decreased food intake. Methamphetamine, but not MDMA, caused significant residual pulse and DBP elevation at the end of the 24-hour period (p<0.01). MDMA did not enhance performance, indicating the absence of this contributor to reinforcing effects, in contrast to methamphetamine. Methamphetamine produced primarily positive effects (Good Drug Effect, Stimulated, Desire to Take Again, Drug Liking), whereas MDMA had some positive (Good Drug Effect, Stimulated) and some negative effects (Bad Drug Effect, Can't Concentrate, Tired, Sleepy). Only methamphetamine disrupted sleep, objectively measured via Actigraphy, and increased tiredness. MDMA did not disturb sleep, and instead facilitated ability to more readily fall asleep. As most participants were unable to correctly identify the drug received, and important confound is that experienced Ecstasy users may have based their opinions about MDMA on material of low purity and unknown dose. The sponsor has been given permission to access primary data for this study under IND #074039. Taken together, these observations and other studies support distinct differences in subjective and reinforcing effects, supporting a lower abuse liability for MDMA than stimulants.

## Prevalence of Dependence

There have been no reports of MDMA dependence developing after participation in controlled MDMA studies. In the absence of drug dependence studies on MDMA, a summary of Ecstasy dependence studies is presented. Ecstasy is purported to contain MDMA, but in the majority of pills submitted for anonymous testing, no MDMA is found and/or impurities abound. Some adulterants, such as amphetamines, that are commonly found in Ecstasy tablets may be responsible for the dependence and cravings associated with Ecstasy [689]. Research of Ecstasy dependence comes from a combination of published studies with assessment of symptoms based on the Composite International Diagnostic Interview, the DSM-4, and/or the Severity of Dependence Scale [690]. One study with a non-representative sample (N=173) including participants recruited from substance abuse programs reported 30% had used Ecstasy and of these, 43% met Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria for dependence (N=52) [691]. In a large Australian sample (N=329), approximately 25% of polydrug users wanted to reduce their Ecstasy use and 20% had received treatment for an Ecstasy-related problem, although this sample likely had “an over-representation of chaotic intravenous polydrug users [692].

In a study of self-reported cravings in Ecstasy users utilizing an 8-item questionnaire (N=169), a negative mean score for participants exposed to Ecstasy-related cues was obtained, indicating that participants disagreed with statements reflecting craving on average. In a subscale analysis, about 50% of survey participants agreed on some level with two of eight statements that supported the craving to use Ecstasy after exposure to Ecstasy-related cues, suggesting that some respondents may experience a low level of craving for Ecstasy [689]. It also appears that Ecstasy has fewer or less intensely rewarding effects than stimulants, and even heavy Ecstasy users fail to report the intensive patterns of use seen with other stimulants [193, 314, 693]. Based on two structural analyses, Ecstasy dependence is bifactorial [694]. Although Ecstasy dependence does have a compulsive use factor as well as an escalating use factor, withdrawal symptoms do not include significant physical symptoms such as those occurring with alcohol, cocaine, methamphetamine, opioids, and tobacco [695, 696]. In a prospective longitudinal study conducted over an average of 42 months in a representative sample of Munich residents aged 14 to 24 (N=2446), only 1.0% were diagnosed with Ecstasy abuse and 0.6% with dependence. A substantial decline in use factors was noted 12+ months later, suggesting that Ecstasy use is a self-limiting transient phenomenon in many cases [697]. Features of Ecstasy abuse and dependence in healthy human volunteers are consistent with nonclinical findings in self-administration studies of moderate abuse liability that is greater than that for serotonergic hallucinogens, but less than that for stimulants (see [Section 4.3.6.3 Abuse Potential](#)).

When reviewing the effects of MDMA in a sample of 74 largely drug-naïve participants in a study conducted outside of sponsor support, Liechti and colleagues stated that “none of the participants expressed any interest in taking MDMA as a recreational drug” after receiving MDMA in a controlled research setting [15]. When assessed in terms of willingness to choose money over receiving the drug, participants previously experienced with Ecstasy provided similar responses to 2 mg/kg MDMA HCl and 20 mg d-amphetamine, a sign of having reinforcing effects [633]. A study that enrolled participants with a history of Ecstasy use (4 to 40 occasions) found that only self-reported feelings of playfulness were associated with participants’ desire to take MDMA in a controlled research setting [29].

In addition to the extensive published clinical and nonclinical literature on the abuse liability potential associated with MDMA, the sponsor has collected self-reported Ecstasy use data at long-term follow-up and assessed the AEs for signals of abuse. At screening participants who met

DSM-4 criteria for active substance abuse for 60 days prior to enrollment were excluded from participation in all but one study, where active substance abuse for 180 days prior to enrollment was excluded (MP-4). Participants who had used Ecstasy more than five times within the past 10 years prior to enrollment were also excluded. As a part of the Informed Consent process, study staff informed participants about the difference between Ecstasy and MDMA used in research studies. [Table 34](#) below summarizes self-reported Ecstasy use data (recreational drug purported to be MDMA, unknown purity and dose) pre-study at least 6 months prior to study entry vs. long-term follow-up at 12+ months in Phase 2 PTSD clinical trials. Participants were encouraged to report use honestly under coverage of a Certificate of Confidentiality from FDA.

**Table 34: Pre-Study Ecstasy Use Compared to Ecstasy Use Based on Long-term Follow-up Questionnaire After All Participants Received Two to Three Blinded or Open-label Active Dose MDMA-Assisted Therapy for Treatment of PTSD**

Pre-study Ecstasy Use			Long Term Follow-Up Post MDMA				
Enrolled N	People Reporting Pre-study Use Pre-study N (%)	Mean # of Times Used (SD)	LTFU N	People Reporting Post-Study Use N (%)	Mean # of Times Used (SD)	Context of Use	
MP-1	23	10 (43.5%)	2.0 (1.25)	19 <sup>A</sup>	1 (5.3%)	1 (-)	Attempted Therapeutic
MP-2	14	1 (7.1%)	3.0 (-)	11 <sup>B</sup>	0 (0.0%)	-	-
MP-4	6	0 (0.0%)	-	6	0 (0.0%)	-	-
MP-8	26	6 (23.1%)	2.7 (1.21)	24	2 (8.3%)	1 (-)	Attempted Therapeutic; Recreational
MP-9	10	2 (20.0%)	1.0 (0.00)	9	2 (22.2.0%)	1.5 (0.71)	Attempted Therapeutic; Recreational
MP-12	28	13 (46.4%)	2.6 (1.71)	24	3 (12.5%)	1.3 (0.58)	Attempted Therapeutic; Recreational
Phase 2 Studies Pooled							
	107	32 (29.9%)	2.3 (1.43)	93	8 (8.6%)	1.3 (0.49)	Attempted Therapeutic; Recreational

<sup>A</sup> CAPS data available from N=16 only, questionnaire available from N=19

<sup>B</sup> One subject died prior to completing long-term follow-up due to progression of cancer.

In sponsor-supported Phase 2 PTSD studies in 107 participants treated with MDMA-assisted therapy in a controlled clinical setting, 29.9% (32 of 107) of participants had tried Ecstasy at least 6 months prior to enrollment, with U.S. samples demonstrating a higher prevalence of use than international studies. Participants reported using Ecstasy an average (SD) of 2.3 (1.43) times pre-study at least 6 months prior the study. At long-term follow-up, 8.6% of participants (8 of 93) reported use across studies. Six of the eight participants had used Ecstasy prior to the study. Of these participants, most were attempting to recreate a therapeutic experience, and none indicated a desire to repeat this. In addition to self-report data, urine drug screens specific for MDMA were performed at random and two, six and 12 months after the final dosing session during one study (MP-2, N=12). All were negative, supporting the observation that study participants did not seek out MDMA or Ecstasy after taking part in the study [42]. In the sponsor-supported Phase 3 PTSD study MAPP1, 32.2% (29 of 90) reported prior Ecstasy use, mirroring the overall rate seen in the Phase 2 studies. Reported history of Ecstasy use within ten years prior to participation in MAPP1



was equal between MDMA and placebo groups. Additional data will be collected on post-study use in a long-term follow up study.

In addition to data on Ecstasy use at follow-up, AEs were reviewed for clinically significant AEs indicating abuse potential across all Phase 2 and Phase 3 studies. There were no AEs were reported supporting the terms “drug dependence”, “intentional drug misuse,” or “substance abuse.” In the context of therapy, MDMA does not exhibit signals that would suggest abuse potential. For example, there were no more than two 2 AEs reported in Phase 2 and Phase 3 studies (< 2%) which included AE terms reflecting acute intoxication (hypnapompic and hypnagogic hallucinations). These were both reported by the same PTSD participant the day after the final open label 125 mg MDMA HCl dosing session, were rated as mild and resolved within 24 hours with no treatment. There were 3 subjects in the Phase 3 study, MAPP1 who reported AEs of substance use (cannabis) in the MDMA group (see [Table 13](#)). Of note, the MAPP1 study included participants with mild or moderate in early remission cannabis and alcohol use disorder. One AE of drug abuse was reported in study MDA-1 in a population with anxiety associated with life-threatening illness. This AE referred to a single nondependent use of a hallucinogen, which MedDRA coding places under the preferred term drug abuse but does not indicate a substance use disorder. Data drawn from sponsor-supported studies suggests that MDMA has low abuse liability when given within a controlled, psychotherapeutic setting.

### **Conclusions on Safety of MDMA**

Safety data from studies in controlled research settings and clinical trials show that MDMA produces sympathomimetic effects that include statistically significant, self-limiting increases in body temperature, heart rate, and blood pressure that are likely to be transient and well tolerated by healthy individuals [[11](#), [13-15](#), [36-42](#), [78](#), [79](#), [232](#), [549](#)] and patients with PTSD and other indications in which MDMA-assisted therapy has been studied. Risks posed by elevated blood pressure are addressed in clinical trials by excluding candidates with a history of cardiovascular or cerebrovascular disease or with pre-existing uncontrolled hypertension and by monitoring blood pressure and pulse during MDMA-assisted dosing sessions. The most common treatment-emergent adverse events more prevalent in the MDMA group from blinded, placebo-controlled Phase 3 study data were muscle tightness, decreased appetite, nausea, hyperhidrosis, feeling cold, restlessness, mydriasis, dizziness postural, bruxism, nystagmus, blood pressure increased, feeling jittery, non-cardiac chest pain, dry mouth, vision blurred, pollakiuria, intrusive thoughts, vomiting, stress, musculoskeletal pain, pyrexia, chills, substance use, micturition urgency, muscle twitching, somnolence, and nervousness. Common anxiety-related psychiatric symptoms were reported equally in both the MDMA and placebo arms in the Phase 3 trial. Reactions were transient and diminished as drug effects waned during treatment sessions and over a next 24-hour period. No increase in suicidality, cardiovascular, or abuse potential AESIs were observed in MDMA participants in the placebo-controlled Phase 3 study MAPP1. In studies conducted with and without sponsor support in controlled clinical settings, with individuals exposed to MDMA, there have been no published or reported unexpected SARs to date and expected SARs have been rare and non-life threatening. To date, one subject experienced an expected SAR (increased ventricular extrasystoles, reported in Study MP-8) in MAPS-sponsored clinical trials. SUSARS occur infrequently in the program and the sponsor is monitoring any SUSARS and once definitive information is available to determine if any SUSARS should be upgrade to SARs, the IB will be updated with this information.



## 7.0 Summary of Data and Guidance for the Investigator

MDMA is a psychoactive compound that affects mood, perception, and increases prosocial feelings. The sponsor is investigating use of this compound as an adjunct to therapy for treating PTSD, anxiety, and eating disorders. Researchers with and without sponsor support have conducted non-clinical and clinical studies with MDMA, and is currently in late-stage clinical development for a PTSD indication with a pivotal Phase 3 trial completed and a confirmatory trial ongoing. Currently, MDMA is listed as a Schedule I controlled substance in the U.S. and is not permitted for medical use outside of approved research settings. Psychotherapists in the U.S. began to use MDMA as an adjunct to therapy in the mid to late 1970s, and narrative accounts describe therapeutic use with an estimated 500,000 doses of MDMA administered during therapy sessions in North America prior to its scheduling [46, 312]. As of October 01, 2021, MDMA has been administered to 358 participants in MAPS' Clinical Development Program and at least 1,441 individuals reported in the scientific literature, for a total of 1,799 research participants who have been exposed to MDMA in clinical research studies conducted with or without sponsor support. These studies have demonstrated that MDMA can be safely administered to people with PTSD and other indications in a controlled clinical setting.

MDMA is responsible for a series of dose dependent physiological effects due to enhanced neurochemical release of serotonin, norepinephrine, and dopamine, and for indirect effects on hormone secretion, including oxytocin and AVP, which act on different target organs to modulate physiological functions in the body. MDMA is contraindicated in patients with cardiovascular or cerebrovascular conditions where an acute increase in blood pressure may pose a significant clinical concern, such as aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels), arteriovenous malformation, or acute stroke or recent history of intracerebral hemorrhage and during or within 14 days following the administration of monoamine oxidase inhibitors (MAOI). The elevation of blood pressure and increased heart rate produced by MDMA, like that produced by other sympathomimetic drugs, can lead to increased risk in people with pre-existing medical conditions.

In comparison to anxiolytics, antidepressants, and atypical antipsychotics, MDMA does not require steady state levels in the blood to function as a catalyst to therapy with rapid onset in some participants. A limited number of single divided-dose exposures to MDMA, spaced approximately 1 month apart in the therapeutically active dose range, are sufficient to obtain therapeutic outcomes. This intermittent dosing mitigates AE frequency and improves the risk/benefit ratio of MDMA, which may provide a significant advantage over medications that require daily dosing. Based on the current state of scientific knowledge and the risk/benefit profile of therapeutic doses of MDMA, MAPS concludes that it appears favorable to continue the clinical development of MDMA as a medicine used as an adjunct to therapy.

### 7.1 Pharmacology

The pharmacology of MDMA is complex; it activates multiple signaling cascades in the body. The current formulation consists of fixed doses in HPMC capsules of 40 and 60 mg MDMA HCl (as the hydrochloride salt) with the excipients mannitol and magnesium stearate. There is a placebo to match. Due to a wide range of responses to identical mg/kg dosing between individuals, possibly as a result of inconsistent relationship between body weight and pharmacodynamic activity, the sponsor's human trials use initial doses between approximately 1 and 4 mg/kg MDMA (active doses range from 75 to 125 mg, with divided-dose 112.5mg to 187.5 mg, assuming a 70 kg individual,) to achieve a more consistent response between participants. The clinical dose tested in Phase 3 trials is a divided dose of 120 mg is administered in the first dosing session (initial dose of 80 mg + supplemental dose of 40 mg) and a divided dose of 180

mg (120 mg initial + 60 mg supplemental) is administered in the second and third dosing sessions. The supplemental dose and/or dose escalation can be withheld if the initial dose is not tolerated or the participant declines. In humans, onset of MDMA effects occurs approximately 30 to 60 minutes after initial administration, peak effects occur 75 to 120 minutes after administration and duration of effects lasts 3 to 6 hours [11, 12, 14, 15, 17]. In a repeated dose study, an initial dose of 50 mg MDMA HCl, followed two hours later by a second dose of 100 mg MDMA HCl, does not significantly extend the duration of measurable physiological or subjective effects in comparison to a single dose of 100 mg MDMA HCl [265].

The pharmacokinetic properties of MDMA in humans have been characterized using initial oral doses up to 150 mg MDMA HCl in humans. MDMA disposition in the body follows nonlinear pharmacokinetics. MDMA is metabolized in the liver by several enzymes. Active doses of MDMA may autoinhibit CYP2D6 function for an extended period, with function normalizing up to 10 days post-MDMA. The enzymes CYP1A2, COMT, and MAO-A are also involved in the metabolism of MDMA. MDMA is metabolized by N-demethylation to MDA. The parent compound and its active metabolite MDA are further O-demethylated to HHMA and HHA, respectively. Both HHMA and HHA are subsequently O-methylated mainly to HMMA and HMA. These four metabolites, particularly HMMA and HMA, are known to be excreted in the urine as conjugated glucuronide or sulfate metabolites. The elimination half-life of active MDMA doses is 7 to 9 hours. The end of systemic exposure is within 48 hours post-dose [253].

MDMA is a triple monoamine reuptake inhibitor, which concomitantly promotes carrier-mediated release, inhibits reuptake, and extends duration of serotonin, norepinephrine, and dopamine in the synaptic cleft to increase serotonergic, noradrenergic, and dopaminergic neurotransmission. Additionally, MDMA appears to alter the conformation of the transporters, enabling monoamines to diffuse out of the neuron rather than being actively transported into the presynaptic neuron. MDMA was found to compete with monoamines for sites on the VMAT2, suggesting MDMA also promotes active release of monoamines from vesicular stores, in addition to inhibiting reuptake. MDMA extends the presence of monoamines in the synaptic cleft by inhibiting MAO-A, an enzyme that breaks down monoamines in the synapse. MDMA has self-limiting subjective and physiological effects. Co-administration with an SSRI or SNRI may eliminate or attenuate the effects of MDMA, and these medications should be tapered in line with the investigator's clinical judgment and an approved study protocol.

Brain imaging studies report that MDMA has been shown to acutely decrease activity in the left amygdala and increase activity in the prefrontal cortex. The chief mechanism behind its therapeutic effects is likely to be serotonergic, along with some norepinephrine and to a minor extent dopamine-mediated effect. Indirect, but potentially significant effects of MDMA include association with release or elevated levels of the hormones cortisol, oxytocin, prolactin, and AVP. MDMA likely stimulates secretion of oxytocin into peripheral blood via indirect activation of 5HT<sub>1A</sub>, 5HT<sub>2C</sub>, and 5HT<sub>4</sub> receptor subtypes, as well as AVP secretion via activation of 5HT<sub>2C</sub>, 5HT<sub>4</sub>, and 5HT<sub>7</sub> receptor subtypes. Both oxytocin and AVP are implicated in the widespread regulation of behavioral aspects of mood and act on different target organs to modulate physiological functions in the body. Taken together, MDMA has a diverse array of pharmacodynamic effects in animals and humans.

## 7.2 Toxicology

The toxicity of MDMA has been investigated in numerous animal and *in vitro* studies published in peer-reviewed journals. Intravenous MDMA doses that cause lethality in 50% of the cases, known as the LD<sub>50</sub>, are 97 mg/kg in mice, 49 mg/kg in rats, 14 to 18 mg/kg in dogs, and 22 mg/kg in monkeys. LD<sub>50</sub> varies between different strains of the same animal species, across the sexes,

housing conditions, environmental conditions, social interactions with cohabiting animals, exercise levels, and water supply. Translation of these doses to human-equivalent doses should be undertaken with caution due to known non-linearity in pharmacokinetics that appear in a dose dependent manner. Exposure-based endpoints are more reliable than simple dose conversions based on body surface area.

MDMA appears to alter regulation of serotonergic signaling in the rat brain without producing damage to serotonin axons, based on transient reductions in forebrain (striatum, hippocampus, and cortex) serotonin and SERT protein levels, in the absence of indicators of CNS neuronal injury/degeneration [75]. MAPS-sponsored definitive GLP follow-up Extended Single-Dose Neurotoxicology studies in the rat and the dog were conducted to conclusively study neurotoxicity with modern experimental methods. Both studies did not find MDMA-related evidence of CNS neurotoxicity based on expanded neurohistopathology through the MTD. In the rat study, microscopic findings included degeneration of myofibers in skeletal muscle associated with infiltration of mononuclear leukocytes or neutrophils at 25 mg/kg/dose (MTD) one day post dosing. Within 7 days after the last repeated dose, these effects were associated with some level of repair or adaptation. On this basis, the risk of CNS neurotoxicity with the intended clinical dosing regimen appears to be minimal, with low risk of transient adverse effects in myofibers of skeletal muscle in the periphery.

MDMA has minimal risk of QTc interval prolongation based on a definitive hERG study which found an IC<sub>50</sub> of 206 μM with a 170-fold ratio over the expected unbound MDMA plasma concentration in the clinical exposure scenario. There was no effect of the oral administration of MDMA on qualitative or quantitative ECG parameters in an *in vivo* dog cardiovascular study. MDMA has no significant effects on respiratory rate or blood oxygen saturation by pulse oximetry.

MDMA has been demonstrated to be negative for genotoxicity. Consistent with this, despite very high doses of MDMA being tested in preclinical studies, none have reported carcinogenic effects. Rodent fertility, reproductive, and developmental toxicity studies with MDMA have generally found no abnormalities in gestational duration, neonatal birth weights, or physical appearance when exposure occurs during organogenesis through lactation. Repeated dose toxicity studies of adequate duration, fertility, early embryonic development, and embryofetal development studies of MDMA have been completed. Studies in rats and rabbits have not shown direct or indirect harmful effects with respect to reproductive toxicity. These studies established the NOAEL dose to be the highest dose level evaluated at ≤10 mg/kg/day (supratherapeutic dose) in both sexes of the rat for fertility, reproductive performance, and for maternal and developmental toxicity in the rabbit. The NOAEL dose was the highest dose level evaluated at ≤15 mg/kg/day (supratherapeutic dose) for maternal and developmental toxicity in the rat.

## 7.3 Safety in Humans

### 7.3.1 Adverse Events

Overall, adverse effects of MDMA were modest and generally have not been associated with serious discomfort in healthy volunteers or in subjects in MAPS-sponsored Phase 2 or Phase 3 studies with PTSD and other indications. Risks posed by sympathomimetic effects of MDMA treatments are addressed in MAPS' clinical trials by excluding people with pre-existing cardiovascular disease, cerebrovascular disease or uncontrolled hypertension, and by monitoring blood pressure, body temperature, and pulse. Common reactions reported in clinical trials were transient and diminished as drug effects waned during the MDMA-assisted session and over the

next 24 hours. Once the drug is fully cleared from the body within 48 hours post-dose, most reactions diminish within 3-4 days post-dose.

In Phase 1 and Phase 2 studies, a subset of AEs were collected as spontaneously reported reactions in participants receiving a therapeutically active dose of MDMA: dry mouth, diarrhea, heavy legs, impaired judgement, and nystagmus. AEs that did not resolve within 7 days post-dose and were reported in  $\square$ 10% of participants in the active MDMA dose groups included: anxiety, fatigue, difficulty concentrating, increased irritability, insomnia, and low mood. The amount of placebo data in these studies precludes thorough separation of background events from reactions to MDMA.

In the Phase 3 study MAPP1, the most common related treatment-emergent adverse events (TEAEs) reported more frequently in the MDMA group were muscle tightness (63.0% MDMA vs 11.4% placebo), decreased appetite (52.2% MDMA vs 11.4% placebo), nausea (30.4% MDMA vs 11.4% placebo), hyperhidrosis (19.6% MDMA vs 2.3% placebo), and feeling cold (19.6% MDMA vs 6.8% placebo). No SAEs, AESIs suggestive of abuse potential, or AESIs involving cardiac function that could be indicative of QT interval prolongation or cardiac arrhythmias were reported in subjects who were randomized to the MDMA group in the Phase 3 study MAPP1 (n=46 of 90 treated). Three participants randomized to MDMA vs. five participants randomized to placebo reported AESIs of self-injurious behavior or suicidality (See Section 7.3.2 Suicidal Ideation and Behavior).

Overall, the risks of SARs have been addressed and constrained by limited exposure and drug administration in controlled settings with adequate screening according to eligibility criteria defined in study protocols. To date, only one SAR (exacerbation of pre-existing ventricular extrasystoles) has been reported within the context of MAPS-sponsored clinical studies. The possibly drug-related expected of exacerbation of pre-existing ventricular extrasystoles occurred during open-label treatment with 125 mg MDMA HCl (supplemental dose was withheld), which resolved with full recovery to baseline after the effects of MDMA ceased. The subject was hospitalized for observation and recovered fully after the event, with no cardiac damage.

### **7.3.2 Suicidal Ideation and Behavior**

There is high incidence of suicidal ideation and behavior in populations of people with PTSD, especially those suffering from chronic PTSD. To determine if suicidal ideation and behavior worsens or improves after treatment in MAPS-sponsored trials, the C-SSRS is administered repeatedly throughout MAPS sponsored clinical trials. Due to the nature of the therapeutic method, wherein a person may re-experience emotions associated with the traumatic event in order to reprocess the memory in a new, therapeutic way, thoughts of ending one's life may surface during this process. In MAPS-sponsored clinical trials C-SSRS scores have escalated during the Preparatory Sessions (before any drug administration), which is thought to be a result of preparatory discussion of traumatic experiences, and/or of participants tapering off long-prescribed medications, such as SSRIs and benzodiazepines. Withdrawal of these medications is known to induce suicidal ideation or behavior in some people. During both non-drug and MDMA-assisted therapy sessions, participants are asked to think about and discuss their experiences, thoughts, and emotions related to their condition. They may experience intense emotional responses to recalling and speaking about this material. As MDMA is only administered in combination with therapy, the distress associated with therapy is unavoidable and is considered a necessary part of the therapeutic process that requires proper facilitation and support from therapists.

Overall, the incidence of serious suicidal ideation or behavior in sponsor-supported studies was low, occurring in only a few participants post-MDMA treatment and an equivalent number of participants either prior to dosing or after therapy with placebo, and returning to lower scores while participants were closely monitored. As of March 01, 2022, three participants reported SAEs of suicidality (suicidal ideation and/or behavior) after receiving MDMA in MAPS-supported Phase 2 and Phase 3 studies. All were deemed unrelated to MDMA in the opinion of the investigator and sponsor. Of interest, three participants reported SAEs of suicidality either prior to receiving study drug (n=1, Study MP-2), or after receiving placebo (n=2, Study MAPP1). In aggregate, the comparable incidence across groups demonstrates that these SAEs remain unexpected for MDMA and the underlying disease presents an alternative explanation for these SAEs.

In the placebo-controlled Phase 3 trial MAPP1, suicidality as measured by C-SSRS and reported as AE, occurred with equal prevalence in both study arms; the prevalence was not greater in the MDMA arm of the study. There were no reports of positive suicidal ideation or behavior after the first dosing session in participants with a life-threatening illness and only few incidences, none serious, of positive ideation in adults on the autism spectrum during the study.

Therapy teams minimize risks by carefully evaluating all participants to determine if there is a current risk of suicidal behavior. Participants with a history of suicide attempts are not excluded unless significant risk of suicidal behavior is present at the time of Screening. When positive serious ideation or behavior occurred after study enrollment, the investigators made follow-up observations of C-SSRS to ensure subject safety and tracked scores until they returned to non-serious levels. This risk is important to monitor due to the high prevalence of background events in the psychiatric population.

### **7.3.3 Immunological Effects**

Humans exhibit transient immunological changes after a dose of 100 mg, including reduced numbers of CD4 cells, increased numbers of NK cells, and an increase in levels of immunosuppressive and anti-inflammatory cytokines compared with levels of pro-inflammatory and immunostimulating cytokines. In several respects, these effects are similar to those that occur with other psychoactive substances, so are not unique to MDMA. Immunological effects last for approximately 24 hours after administration, and most arise indirectly from serotonin release. The significance of these immunological effects remains unclear. Based on results from trials conducted by the sponsor to date, the impact of these effects is expected to be modest. Further evaluation in the placebo-controlled Phase 3 study MAPP1 did not demonstrate an increase in upper respiratory tract infections in the MDMA group compared to the placebo group (see [Section 6.4.1.3 Adverse Events Summary](#)).

### **7.3.4 Hepatic Effects and Other Laboratory Values**

Phase 1 studies conducted outside of sponsor support involving administration of MDMA to healthy volunteers have not reported any results of liver function after MDMA administration, and a recent published examination of safety data in a pooled sample of healthy participants found no changes in hepatic function assessed via standard liver panel. There have been no reported adverse effects on the liver from these studies. The first two sponsor-supported Phase 2 studies (MP-1, MP-2) assessed clinical lab values for safety after completion of two or three dosing sessions. On average, no clinically or statistically significant changes in ALT, as a measure of liver function, occurred in MP-1. All post-treatment values for laboratory tests were within the normal range in MP-1. No MDMA-related AEs related to liver function have been reported in subsequent sponsor-supported studies. Only one participant in the MP-2 study

reported a clinically significant hepatic abnormalities, likely due to hereditary factors. The other observed laboratory value (increased ESR) indicated inflammation in a subject with a medical history of breast cancer 3 months after the last administration of MDMA as an unrelated AE. Hepatic function one month post-MDMA was assessed in nine independent published safety pharmacology clinical trials that were published in a pooled analysis (N=164) [232]. These studies found one significant change found in  $\gamma$ -glutamyl transpeptidase ( $p < 0.01$ ). There were no significant changes in creatinine, GFR, ALT or AST. These results support that on average, MDMA does not influence hepatobiliary function in most people, however there is evidence of a rare idiosyncratic hepatotoxicity.

#### **7.4 Risk Assessment and Mitigation**

Study procedures and eligibility criteria have been developed based on Phase 2 and Phase 3 PTSD trials which exclude potential participants with pre-existing exclusionary medical conditions that would exacerbate risk. The therapy teams and site physicians are available via telephone throughout the study if any problem occurs when a participant is not at the site. In the event of a medical emergency or any other medical problem during a dosing session, the site physician should be immediately available by telephone, and based on assessment of the situation, they should make the decision to either evaluate the participant themselves at the site or arrange for transfer of the participant to the Emergency Department.

Risk mitigation procedures are described by risk category below. Risk Categories were determined by review of possible risks within the Risk Assessment and Categorization Tool (RACT).

##### **7.4.1 High Level Risks**

High Risk does not indicate an event is more likely to happen but indicates per the RACT assessment that new and or more complex procedures are required in the study to ensure screening is adequate to eliminate or manage the risk in the patient population. No high-level risks of MDMA have been identified based on the RACT assessment.

##### **7.4.2 Medium Level Risks**

Medium Risk does not indicate the likelihood the event will occur but indicates per the RACT assessment that new or many procedures, which are not complex, are needed to ensure screening is adequate to eliminate or manage the risk in the patient population.

#### **Cardiovascular and Cerebrovascular Risks and Mitigation**

MDMA is known to transiently increase heart rate and blood pressure in a dose-dependent manner that is generally not problematic for physically healthy individuals. These changes typically last no more than 6 hours. Participants with PTSD in MAPS-sponsored Phase 2 and Phase 3 studies do not appear to differ from healthy individuals in this sympathomimetic, physiological response. Most people do not experience elevations in cardiovascular parameters that exceed those seen after moderate exercise. An examination of safety data drawn from Phase 2 and Phase 3 studies of MDMA-assisted therapy detected a dose-dependent increase in SBP and to a lesser extent DBP. Characterization of sympathomimetic effects among participants with controlled hypertension is ongoing. MDMA is unlikely to increase risk of QTc interval prolongation based on a definitive hERG study and had no effect on qualitative or quantitative ECG parameters in an *in vivo* dog cardiovascular study.



Risks posed by elevated blood pressure are addressed by excluding people with pre-existing uncontrolled hypertension and monitoring blood pressure and pulse, as described in study protocols. Before and after drug administration in dosing sessions, the therapy teams monitor vital signs. The therapy team should attend to clinical signs and symptoms of potential rare complications of the cardiovascular effects of MDMA, such as stroke or acute myocardial infarction (AMI) during dosing sessions. Any symptoms such as chest pain, shortness of breath, neurological deficit or confusion other potential indicators of end organ effects of hypertension should prompt additional vital sign measurements and intervene if appropriate. Therapy teams should notify the site physician if this occurs for evaluation. If any participant has neurological deficits, as assessed by the site physician, whether or not they are associated with hypertensive crisis, they should be monitored as described above and transported to the hospital if medically indicated. If evaluation at the hospital reveals an acute ischemic stroke, there should be sufficient time to administer recombinant tissue plasminogen within the 3-hour time frame recommended in the 2019 American Heart Association/American Stroke Association (AHA/ASA) guidelines [698].

If a participant experiences ischemic type chest pain, whether or not it is associated with hypertensive crisis, the study physician should be contacted immediately, and the participant should be taken to an emergency room by ambulance as expeditiously as possible to assess the patient and act in accordance with the assessment of the expert on site supported by national and local/AHA and European Society of Cardiology (ESC) Guidelines. Pending transport to the hospital the site team may take any measures ordered by the site physician including administering medication such as aspirin or nitroglycerin or providing supplemental oxygen per local standards. If further evaluation at the hospital reveals that the participant has had an AMI, they should be well within the time frame required for definitive therapy. Any participant who experiences such medical complications during a dosing session should not be given another dosing session.

QT interval may be evaluated in the event of hospitalization for management of cardiovascular or cerebrovascular event. If at any time a participant develops a QT/QTcF interval >450 ms or of >30 ms over baseline during ECG evaluation, the participant should be discontinued from treatment.

### **Psychological Risks and Mitigation**

A medium-level risk of exacerbation of psychological distress exists in participants with a psychiatric diagnosis. Data in PTSD patients from the sponsor's Phase 3 clinical trial (MAPP1) indicate TEAEs related to psychological distress were similarly reported across both groups of blinded participants: anxiety (32.6% MDMA, vs 40.9% placebo), depressed mood (10.9% MDMA vs 9.1% placebo), and suicidal ideation (45.7% MDMA vs 47.7% placebo). These commonly reported AEs were observed in both treatment arms, transient in duration, mild to moderate in severity, and also overlap with background events associated with PTSD, which might have influenced the frequency of events observed during clinical trials of MDMA-assisted therapy. While these data do not support that psychological distress is a specific risk of MDMA, psychological distress may be exacerbated in participants with moderate to severe PTSD following the onset of MDMA effects until the last effects have dissipated.

In clinical studies, these symptoms, which may occur in participants receiving MDMA or placebo, have been self-limiting and have responded well to reassurance from the therapy team, with occasional use of benzodiazepines for anxiety. During these studies, participants have the intention of confronting and working through traumatic experiences. Accordingly, signs of

psychological distress, panic, or other unpleasant psychological reactions are to be expected and may be considered an element of the psychotherapeutic process.

Proper preparation and follow-up support will reduce the difficulties participants might have with acute or sub-acute reactions. The potential for destabilizing psychological distress will be minimized by:

- Excluding people who might be more vulnerable to it (such as people diagnosed with bipolar affective disorder type 1 or with psychotic disorders).
- Preparatory Sessions of non-drug therapy before the dosing session.
- Creating an atmosphere of trust during the dosing session.
- Close monitoring.
- Phone contact with participants during the week after the dosing session.
- Integrative Sessions.
- If deemed necessary, overnight stay at the study site for the night of each dosing session for PTSD studies. If this occurs, qualified personnel will be available during the overnight stay to respond to the needs of the participant. Attendants will be instructed to contact the therapy team upon request or at the appearance of signs of a potential SAE.

During the Preparatory Sessions, participants should be made aware of the fact that difficult emotions, including grief, rage, fear, or panic, may arise during dosing sessions. Every effort should be made to help participants resolve difficult symptoms and to arrive at a more comfortable and relaxed state by the conclusion of the dosing session, including empathic listening on the part of the therapy team and performance of diaphragmatic breathing by participants.

Although unexpected, if the participant is severely agitated, anxious, in danger of self-harm or suicide, or is experiencing any other severe psychological distress, at the end of a therapy session, at least one member of the therapy team remains with the participant for at least 2 more hours. During this time, the therapy team employs affect management techniques, talks with the participant to help them gain cognitive perspective of their experiences, and helps the participant implement the self-soothing and stress inoculation techniques presented during the Preparatory Sessions. If the participant remains severely anxious, agitated, in danger of self-harm or suicide, or is otherwise psychologically unstable at the end of the 2-hour stabilization period, the site physician and therapy team decide between the following options:

1. If severe distress occurs at the end of a dosing session, a nurse, therapeutic assistant, physician, or therapy team member should stay with the participant until the severe distress resolves or until the time of their Integrative Session appointment the following morning. The therapy team should then meet with the participant daily until the period of destabilization has passed.
2. If the participant experiences severe, persisting emotional distress, such as panic attacks, severe generalized anxiety, or insomnia following a dosing session, the site physician may prescribe a benzodiazepine (specifically, lorazepam) and/or sleep aid (e.g., zolpidem). The site physician should not prescribe an SSRI, SNRI, or MAOI in this context, unless it has been determined that the participant will be withdrawn from the study. Residual symptoms would be addressed during the frequent follow-up therapy visits with the therapy team.
3. If a participant should become psychotic, arrangements should be made to stabilize them or transfer them to the Emergency Department (ED) if hospitalization is necessary. If any participant is hospitalized after a severe psychological reaction they would be suspended

from the protocol until after recovery or stabilization, at which time the investigator and/or site physician would carefully evaluate the participant's emotional status.

For those participants engaged in an ongoing therapeutic relationship with a psychotherapist or psychiatrist, the participant's outside therapist(s) should be involved in the management of any psychiatric complications. For those participants engaged in an ongoing psychotherapeutic relationship with the investigator or member of the therapy team, the management of any psychiatric complications should be undertaken by them in their capacity as the participant's therapist.

### **7.4.3 Low Level Risks**

Low Level Risk does not indicate the likelihood the event will occur but indicates per the RACT assessment that no new or complex procedures are needed to ensure screening is adequate to eliminate or manage the risk in the patient population.

#### **Thermoregulatory Risks and Mitigation**

MDMA administered in a controlled setting produces only a slight increase in body temperature [15]. Ambient temperature does not enhance or attenuate this slight elevation in humans. In data gathered from sponsor-supported Phase 2 and Phase 3 studies, it was found that compared to placebo, a higher percentage of participants receiving MDMA had peak body temperatures greater than 1°C above baseline. However, there was no strong relationship between dose of MDMA and peak body temperature or between MDMA dose and elevation above threshold of 1°C above baseline.

Ambient temperature should be kept at a comfortable level during dosing sessions. If temperature rises more than 1°C or the participant states that they feel hot, attempts should be made to decrease body temperature and increase comfort by removing blankets and layers of clothing, decreasing the ambient temperature, and, if necessary, directing a fan toward the participant. If at any time the temperature rises more than 1.5°C above baseline despite these efforts, the site physician should be consulted for further evaluation and treatment.

#### **Osmoregulatory Risk and Mitigation**

MDMA administered in a controlled setting is not expected to have any risks of osmoregulatory changes. Participants are not allowed to drink more than three liters of water over the course of the dosing session and fluid intake is spread out appropriately during the session. If a participant exhibits any signs of toxicity or clinically significant dilutional hyponatremia despite these precautions after a dosing session, they should not receive another dosing session unless it is approved by the investigator, site physician, and the Medical Monitor.

#### **Genotoxicity Risk and Mitigation**

The standard genotoxicity battery for MDMA has demonstrated that MDMA is negative for *in vitro* and *in vivo* genotoxicity, both with and without metabolic activation.

#### **Reproductive and Developmental Risks and Mitigation**

There are no data from the use of MDMA in pregnant people. In the absence of these data, epidemiological studies of Ecstasy are the only source of human data. One of two studies of Ecstasy users suggest that use of Ecstasy and polydrug use during pregnancy may be associated

with some abnormalities at birth while the other failed to find this association [650, 651]. Studies in rats and rabbits have not shown direct or indirect harmful effects with respect to reproductive toxicity. Repeated dose toxicity studies of adequate duration, fertility, early embryonic development, and embryofetal development studies of MDMA with toxicokinetics have been completed. These studies established the NOAEL dose to be the highest dose level evaluated at  $\leq 10$  mg/kg/day (supratherapeutic dose) in both sexes of the rat for fertility, reproductive performance, and for maternal and developmental toxicity in the rabbit. The NOAEL dose was the highest dose level evaluated at  $\leq 15$  mg/kg/day (supratherapeutic dose) for maternal and developmental toxicity in the rat. Due to the short half-life and single-dose dosing regimen of MDMA, pre- and post-natal development studies are not considered necessary for assessment of risk to the unborn. Assessment of embryofetal risk based on all available non-clinical (see [Section 4.3.5 Reproductive and Developmental Toxicity](#)) and clinical data (see [Section 6.2.3.6 Reproductive System](#)) supports unlikely human teratogenicity/fetotoxicity in early pregnancy. On the basis of male fertility studies, the embryofetal risk posed from treatment of male participants with MDMA is also unlikely.

People able to become pregnant are included in the studies in this program, defined as those who are fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. Postmenopausal state is defined as no menses for 12 months without an alternative medical cause. As a precautionary measure in clinical trials, participants who are able to become pregnant must have a negative pregnancy screen before undergoing each dosing session, which are conducted at approximately monthly intervals, and must agree to use adequate contraception at least during the Treatment Period, ending 10 days after the last dosing session. The end of relevant systemic exposure to MDMA is approximately 48 hours [255].

#### **7.4.4 Minimal Risks**

Minimum Level Risk does not indicate the likelihood the event will occur but indicates per the RACT assessment that no procedures are needed beyond basic monitoring to ensure screening is adequate to eliminate or manage the risk in the patient population.

#### **Common Expected AEs**

Common expected AEs were typically observed during dosing sessions but were transient and typically diminished as MDMA was metabolized and excreted over the next 48 hours after dosing. In the Phase 3 study MAPP1, the most common adverse events reported more frequently in the MDMA group were (>20%) muscle tightness, decreased appetite, nausea, hyperhidrosis, feeling cold, (>10%) restlessness, mydriasis, dizziness (postural), bruxism, nystagmus, increased blood pressure, feeling jittery, chest pain (non-cardiac), dry mouth, vision blurred, pollakiuria, intrusive thoughts, vomiting, stress, and musculoskeletal chest pain. AEs were typically self-limiting.

#### **Neurotoxicity Risk**

It does not appear that MDMA-assisted therapy negatively impacts cognitive function based on data from Phase 2 studies sponsored by MAPS. The sponsor has carefully considered the risks of neurotoxicity and concludes that they are minimal in the intended clinical dosing regimen. This conclusion is supported by empirical and toxicokinetic evidence and is consistent with the lack of CNS toxicity reported in nonclinical MDMA studies.

## Abuse Potential

Despite its classification as a Schedule I drug, an examination of findings in humans and animals suggests that MDMA possesses moderate abuse potential that is higher than that reported for “classic hallucinogens” like psilocybin, but lower than that reported for psychostimulants, such as cocaine or methamphetamine. There have been no AESIs reported in Phase 2 and Phase 3 studies that could be suggestive of abuse potential among research study participants treated with MDMA. Diversion is not an issue for sponsor-supported studies because MDMA is only administered under the supervision of the clinical investigator. MDMA administration and handling follows all regulations pertaining to the use of controlled substances within research studies.

Studies assessing prevalence of problematic Ecstasy use or dependence suggest that a small percentage of individuals, especially those with prior psychological difficulties, may develop problematic Ecstasy use or dependence. An observational long-term follow-up assessment conducted at least 12 months after participation in a MAPS-sponsored early Phase 2 PTSD study of MDMA-assisted therapy found that 8.7% (8 of 92) participants reported using Ecstasy subsequent to study participation, with 6 of these 8 participants having used Ecstasy prior to study enrollment. Several participants volunteered that they would not seek out MDMA outside of a psychotherapeutic setting.

## Epidemiological Studies

In epidemiological studies, there are reports of morbidity and mortality in individuals who use Ecstasy (material represented as containing MDMA, as defined above) around the world in unsupervised and uncontrolled settings, usually involving poly-drug use (see [Table 3](#) in [Section 5.1 Serious Reports of Incidents, Mortality, and Morbidity](#)). These events are relatively rare given the prevalence of Ecstasy use, estimated to be approximately 20 million worldwide. The most common adverse effects in Ecstasy and poly-drug use described in published case reports include hyperthermia, psychiatric problems, hepatotoxicity secondary to hyperthermia, and hyponatremia (see [Section 4.3 Toxicology](#) and [Section 5.1 Serious Reports, Morbidity, and Mortality](#)). Published reports examining emergency department admission after Ecstasy use cite anxiety and panic reactions as the most frequent reason for admission. Fatal dysrhythmias have been reported following heavy MDMA use, resulting in ventricular fibrillation and asystole. Individuals with underlying cardiac and/or pulmonary disease and preexisting conditions such as Wolff-Parkinson-White syndrome are especially at risk for heart failure and fatal arrhythmias when using MDMA. Set and setting likely play a role in the development of some Ecstasy-related adverse reports, such as vigorous exercise, lack of attention to somatic cues, and too little or too much hydration combined with pharmacological action on AVP, resulting in hyperthermia or hyponatremia. Even if ambient temperature does less to moderate the effects of MDMA on body temperature in humans than originally believed based on animal studies, other environmental and behavioral factors, as those related to vigorous exercise, may be involved.

## 7.5 Reference Safety Information for Regulatory Reporting

The Reference Safety Information (RSI) below outlines expected Serious Adverse Reactions (SARs) that have been observed at least twice in the Clinical Development Program for worldwide regulatory reporting purposes and the information within the RSI does not present a comprehensive overview of the safety profile of the IMP ([Table 35](#)).

**Table 35: Serious Adverse Reactions for the IMP Considered Expected for Safety Reporting Purposes**

System Organ Class	SARs	As of October 01, 2021:		
		Number of subjects exposed within the development program (N)=358		
		Number of subjects exposed outside the development program (N)=1,441		
		All SARs	Occurrence of fatal SARs	Occurrence of life-threatening SARs
		N <sup>A</sup> (%)	N (%)	N (%)
None	None	0 (0.0)	0 (0.0)	0 (0.0)

<sup>A</sup> N=number of subjects who have experienced the SAR

No SARs are considered expected by the sponsor for the purpose of expedited reporting of SUSARs. Although one SAR has been observed to date in MAPS-sponsored clinical trials (See [Table 16](#)), it has not been observed more than once and hence does not meet the definition of an SAR for the RSI.

### 8.0 Conclusions

Based on the current state of scientific knowledge, the risk for subjects meeting criteria for clinical studies who are exposed to MDMA at the single divided-dosing schedule, administered up to 3 times per treatment course, used in sponsor-supported studies appears to be low. Across Phase 2 and Phase 3 studies, the overall rates of AEs and reactions are acceptable and generally self-limiting. Safety data from the placebo-controlled Phase 3 trial indicates that common AEs reported at equivalent rates across groups are likely to represent the underlying illness being treated or the expected result of psychological therapy addressing traumatic experiences. The sponsor’s pivotal Phase 3 trial (MAPP1) demonstrated that PTSD symptoms were significantly attenuated by MDMA-assisted therapy and confirm findings seen in Phase 2 studies. MDMA as an adjunct to supportive therapy was statistically superior for PTSD treatment in CAPS-5 severity scores from Baseline to 2 months after three blinded dosing sessions in comparison to therapy paired with an inactive placebo

Future studies conducted by the sponsor are intended to further develop the safety profile of MDMA in the PTSD subject population, and subjects with other indications. The sponsor is exploring the use of MDMA-assisted therapy in the treatment of anxiety and eating disorders. MDMA-assisted therapy appears to be a promising treatment method for chronic PTSD. It is hoped that MDMA, with its unique pharmacological mechanisms combined with a novel mode of administration as an integrative multimodal therapy, can improve upon available PTSD and anxiety treatments in terms of safety profiles, efficacy, and persistence of effectiveness. Based on the previously reported data and the current state of scientific knowledge, MDMA-assisted therapy demonstrates significant benefit that outweighs the risks using a 3-session treatment model combined with non-drug therapy sessions for preparation and integration in the treatment of PTSD.



## Appendix

**Appendix Table 1: Summary of Investigator-Initiated Trials with MDMA**

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
ACTRN1261300068 5718 (Australia/New Zealand trial registry, 2013)	Two studies; Randomized, double- blind placebo controlled, within- subjects design	13	Study 1: 3/2 (M/F) Average age 60  Study 2: 6/2 (M/F) Average age 53.4	Study 1: 30 mg (~0.42 mg/kg) Study 2: 70 mg (~1 mg/kg)	Placebo	No AEs of concern reported, no interventions required. No SAEs reported [699]
NCT03019822	Randomized, double- blind, placebo- controlled, cross-over design. Four Dosing Sessions.	28	14/14 (M/F) Age range 25-45	125 mg (~1.8 mg/kg)	Placebo, 100 µg LSD, 40 mg d- amphetamine	No AEs of concern were reported, and no interventions required. No SAEs reported. [602]
NCT04158778	Open-label MDMA, two sessions	14	8/6 (M/F); Average age: 48; Age range 34-64; 14 White	125 mg (~1.8 mg/kg)	None	No AEs of concern, no interventions required. No SAEs reported. [645, 700]
DA02812; 2T32GM007281	Double-blind, randomized, placebo- controlled within- subjects crossover (4 sessions)	36	18/18 (M/F) Average age 24.8; 22 Caucasian, 5 African-American, 5 Asian, 4 Other	0.75 mg/kg 1.5 mg/kg	Placebo, 20 mg methamphetamine	No AEs of concern were reported, and no interventions required. No SAES were reported. [701, 702]
Excellence Aware, Medical Research Council Fellowship Grant MR/J008915/1	Double-blind, placebo-controlled crossover study	20	20/0 (M/F) Average age 24.8	100 mg (~1.4 mg/kg)	Placebo	No AEs of concern, no interventions required. No SAEs reported. [628, 703]
Research Council [IoPPN-MRC] Excellence award Beckley Foundation Channel 4	Double-blind, placebo- controlled	25	18/7 (M/F) Average age 34	100 mg (~1.4 mg/kg)	Placebo (Ascorbic acid)	No AEs of concern, no interventions required. No SAEs reported [26, 616, 621, 704, 705]

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
NCT01951508	crossover with repeated measures *Five participants recorded for documentary without any further analysis Randomized, double-blind, placebo-controlled crossover design, 5 conditions	24	12/12 (M/F) Age range 19-29	125 mg (~1.8 mg/kg)	Placebo,  60 mg methylphenidate,	No AEs of concern were reported, and no interventions required. No SAEs reported. [ <a href="#">629</a> , <a href="#">706</a> , <a href="#">707</a> ]
NCT01771874	Randomized, double-blind, placebo-controlled, crossover design. 4 conditions. Drug interaction study	16	8/8 (M/F) Average age 24.3	125 mg (~1.8 mg/kg)	600 mg modafinil Placebo, bupropion (300 mg 1 week prior) pretreatment	Bupropion did not alter adverse effects of MDMA  No AEs of concern were reported, no intervention required. No SAEs reported. [ <a href="#">574</a> , <a href="#">583</a> , <a href="#">592</a> , <a href="#">610</a> ]
NCT01465685	Randomized, double-blind, placebo-controlled, crossover design. 4 conditions. Drug interaction study	16	8/8 (M/F) Average age 24.8	125 mg (~1.8 mg/kg)	Placebo (mannitol), 60 mg methylphenidate pretreatment	Concomitant methylphenidate does not enhance the risk of MDMA-induced increase in body temperature. No AEs of concern reported, and no interventions needed. No SAEs reported. [ <a href="#">557</a> , <a href="#">613</a> , <a href="#">708</a> ]
NCT01386177	Randomized, placebo-controlled double-blind crossover design, four conditions	16	8/8 (M/F) Average age 25.8	125 mg (~1.8 mg/kg)	Placebo, doxazosin	No AEs of concern were reported, and no interventions required. No SAEs reported. [ <a href="#">685</a> ]
NCT01616407	Randomized, double-blind, placebo-controlled, crossover design. 3 conditions.	30	15/15 (M/F) Age range 18-32	75 mg (~1.1 mg/kg)	Placebo, methylphenidate pretreatment	No AEs of concern were reported, and no interventions required. No SAEs reported. [ <a href="#">605</a> ]

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
NCT00990067	Randomized, double-blind, placebo-controlled, crossover design. 4 conditions.	16	8/8 (M/F) Average age 26.1	125 mg (~1.8 mg/kg)	Placebo, duloxetine pretreatment	No AEs of concern were reported, and no interventions required. No SAEs reported. [228, 601]
NCT01270672	Randomized, placebo-controlled double-blind crossover design, four conditions	16	8/8 (M/F) Average age 24.2	125 mg (~1.8 mg/kg)	Placebo, 50 mg carvedilol pretreatment	No AEs of concern were reported, and no interventions required. No SAEs reported. [227]
NCT00886886	Randomized, double-blind, placebo-controlled, crossover design. 4 conditions.	16	8/8 (M/F) Average age 25.7	125 mg (~1.8 mg/kg)	Placebo, reboxetine pretreatment	No AEs of concern reported, no intervention required. No SAEs reported. [600]
European Union grant TREN-05-FP6TR-S07.61320-518404-DRU	Double-blind, placebo-controlled within-subjects (four conditions)	16	8/8 (M/F) Average age 22.0	25 mg (~0.36 mg/kg), 50 mg (~0.7 mg/kg) or 100 mg (~1.4 mg/kg)	Placebo	Sleep deprivation worsened driving skills (signs of weaving); no dose of MDMA mitigated, or worsened, performance. No AEs of concern were reported, and no interventions required. No SAEs reported. [622, 638, 709]
European Commission Grant GMAI-2000-27043	Double blind, placebo controlled, 3-way crossover (within-subjects), treatment-balanced	18	9/9 (M/F) Average age 26.22	75 mg (~1.1 mg/kg)	Placebo, 20 mg methylphenidate	No AEs of concern were reported, and no interventions were required. No SAEs were reported. [639, 642, 643]
IMMORTAL research consortium funded by EU grant GMA1-2000-27043.	double blind, placebo-controlled, 6-way crossover	18	9/9 (M/F) Average age 26.6	75 mg (~1.1 mg/kg),  100 mg (~1.4 mg/kg)	Placebo, ethanol	No AEs of concern were reported, and no interventions were required. No SAEs were reported. [640, 641]
No grants listed, internal funds	double-blind, placebo controlled, within subjects, two-way,	14	7/7 (M/F) Average age 22.9	50 mg (~0.7 mg/kg) followed 3 h later by 75 mg (~1.1 mg/kg)	Placebo	No AEs of concern reported, and no interventions required. No SAEs reported. [710, 711]

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
Financial support for this study was provided by the Dutch Ministry of Transport. NTR 1416	Double-blind, placebo-controlled three-way cross-over (within-subjects)	12	8/4 (M/F) Average age 23.5	75 mg (~1.1 mg/kg)	Placebo, crossed with placebo or ethanol	No AEs of concern reported, and no interventions required. No SAEs reported. [636]
	double-blind, randomized, placebo controlled, (within-subjects) crossover	14	11/3 (M/F) Average age 23.43		Placebo	No AEs of concern reported, and no interventions required. No SAEs reported. [619, 620]
NTR 2352; Netherlands Organization for Scientific Research (NWO) Grant number: 400-05-096; DIUE de la Generalitat de Catalunya (2009 SGR 718	double-blind, placebo controlled, within-subject	15	11/4 (M/F) Age range 20-28, Average age 22.2	75 mg (~1.1 mg/kg)	Placebo, 20 mg memantine	No AEs of concern reported, and no interventions required. No SAEs reported. [712]
NTR 3691; NWO Grant: 400-07-2013; DIUE Grant: 2014SGR 680	Double-blind, placebo-controlled within subjects 2x2 crossover	20	12/8 (M/F) Average age 21.2		Placebo, 40 mg ketanserin	No AEs of concern reported, and no interventions required. No SAEs reported. [713]
NTR 1421	Placebo controlled, within subject	17	11/6 (M/F) Average age 21.0	75 mg (~1.1 mg/kg)	Placebo, crossed with placebo or 750 mg metyrapone	No AEs of concern reported, and no interventions required. No SAEs reported. [612]
NTR 2636; NWO Grant 400-07-2013	2x2 double blind, placebo controlled, within-subject	20	12/8 (M/F) Age range 18-26	75 mg (~1.1 mg/kg)	Placebo, crossed with 20 mg pindolol, intranasal oxytocin (40 IU+16 IU)	No AEs of concern reported, and no interventions required. No SAEs reported. [609]

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
NTR 3691; NWO Grant: 400-07-2013; DIUE Grant: 2014SGR 680	2×2 double blind, placebo controlled, within-subject	20	12/8 (M/F) Average age 21.2	75 mg (~1.1 mg/kg)	Placebo, crossed with placebo or 40 mg ketanserin	No AEs of concern were reported, and no interventions required. No SAEs reported. [627]
NWO grant 400-05-096; NTR 2352	double blind, placebo controlled, within-subject, 6 conditions	17	9/8 (M/F) Average age 22.76	75 mg (~1.1 mg/kg)	Placebo, 20 mg pindolol, 50 mg ketanserin	No AEs of concern were reported, and no interventions required. No SAEs reported. [84, 190]
NTR 3691	Randomized, double-blind, placebo controlled	18	9/9 (M/F) Average age 21.4; 5-HTTLPR genotype: 5 (l/l), 13 (*s)	75 mg (~1.1 mg/kg)	Placebo	No AEs of concern, and no interventions needed. No SAEs reported. [298]
DA02812	4-session, within-subject, double-blind, placebo controlled, four conditions	21	10/9 (M/F), 2 not specified; Average age 24.4; 17 Caucasian, 2 Asian, 1 African-American, 1 of mixed race	0.75 mg/kg; 1.5 mg/kg	Placebo, 20 mg methamphetamine	No AEs of concern were reported, and no interventions required. No SAEs reported. [27, 80]
National Institutes of Health (NIH) (DA017716 and DA016776) and the NIH/National Center for Research Resources (UCSF-CTSI UL1 RR024131)	Within-subject double-blind, placebo controlled	12	6/6 (M/F) Average age 24	1.5 mg/kg	Placebo	No AEs of concern reported, no interventions required. No SAEs reported. [714]
DA02812	Double-blind, randomized 3-session; ascending dose, randomized placebo	9	7/2 (M/F): Average age 24.0; 6 Caucasian	0.75 mg/kg; 1.5 mg/kg	Placebo (lactose)	No AEs of concern were reported, and no interventions required. No SAEs reported. [38]

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
R01 DA002812; T32 DA007255	3-session, counter- balanced, double- blind design	36	18/18 (M/F): Average age 24.6; 23 Caucasian	0.75 mg/kg; 1.5 mg/kg	Placebo (D- glucose)	No AEs of concern were reported, and no interventions required. No SAEs reported. [632, 644] Sponsor conducted post-hoc analysis of 2-lead ECG and found low likelihood of QT prolongation
R01 DA02812 and R21 DA026579	4-session, mixed within-and-between- subject, double- dummy design	14	12/2 (M/F) Average age 25.4	0.75 mg/kg; 1.5 mg/kg	Placebo (lactose), 20 or 40 IU intranasal oxytocin	No AEs of concern were reported, and no interventions required. No SAEs reported. [607, 715]
DA02812; DA026570	4-session, mixed within-and-between- subject, double- dummy design	65	40/25 (M/F) Average age 23.8	0.75 mg/kg; 1.5 mg/kg	Placebo (lactose), 20 or 40 IU intranasal oxytocin	No AEs of concern were reported, and no interventions required. No SAEs reported. [53, 634, 716]
R21 DA026570 and R01 DA02812	3-session, mixed between- and within- subject; 3 conditions: solitary, in the presence of a research assistant, or in the presence of two other active participants receiving the same dose (MDMA or placebo)	33	24/9 (M/F) Average age 25; 22 Caucasian, 6 African, 4 Hispanic, 1 Asian	0.5 mg/kg; 1.0 mg/kg (max to 125 mg)	Placebo, between group compared environment (alone, with sober researcher vs. with participant on same drug)	No AEs of concern were reported, and no interventions required. No SAEs reported. [630]
Supported by the National Institutes of Health (NIH) (DA017716 and DA016776) and the NIH/National Center for Research Resources (UCSF-	Within-subject double-blind, placebo controlled	12	6/6 (M/F) Average age 24	1.5 mg/kg	Placebo	No AEs of concern were reported, no interventions required. No SAEs reported. [714]



Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
CTSI UL1 RR024131) DA02812; T32 MH020065; T32 GM007281	Mixed; Double-blind within-subject (stress condition) and between-subject (treatment) design 2-session, between- subject, randomized, placebo-controlled, double-blind	26	20/6 (M/F) Average age 24.6; 10 Caucasian, 2 African American, 5 Asian, 9 Other	0.5 mg/kg; 1.0 mg/kg	Placebo (lactose), stress (Trier Stress Test) and no- stress sessions	No AEs of concern were reported, and no interventions required. No SAEs were reported. [615]
DA031796; DA02812		40	Group 1: 10/10 (M/F) Average age 24.9; 55% Caucasian, 5% Black, 25% Asian, 15% Other; Group 2: 10/10 (M/F) Average age 22.4; 55% Caucasian, 5% Black, 15% Asian, 25% Other	1.0 mg/kg	Placebo (dextrose)	No AEs of concern reported, and no interventions required. No SAEs reported. [717]
R01 DA002812; T32 DA007255	Double-blind, 3- session, within- subjects, counter- balanced	36	18/18 (M/F) Average age 24.6; 24 Caucasian, 4 African-American, 1 Asian, 7 Mixed Race	0.75 mg/kg; 1.5 mg/kg	Placebo (lactose)	MDMA increased desire to take drug again over placebo control. No interventions were needed. No SAEs occurred. [29]
Funding from MAPS [not part of IND]	Double blind ascending dose and randomized and placebo controlled within each dose condition; discontinued prematurely due to	4	0/6 (M/F) Age range 29-49; no history of MDMA use, PTSD from sexual assault.	50 mg, 75 mg	Placebo (2 of 6 received placebo only)	No AEs of concern reported, and no interventions required. No SAEs reported. [78]

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
NCT02232789	political/institutional conflicts Randomized, double-blind, crossover, and placebo-controlled	12	12/0 (M/F) Average age 31 years	100 mg (~1.4 mg/kg)	Placebo, 200 mg mephedrone	No AEs of concern reported and no intervention required. No SAEs reported. [718]
2001SGR00407, 2005SGR00032, 2009SGR718, FIS 98/0181 and 01/1336	Randomized, double-blind, crossover, and placebo-controlled, two sessions	10	10/0 (M/F) Average age 24.9	100 mg (~1.4 mg/kg),  50 mg+100 mg 2 h later	Placebo	No AEs of concern reported, and no interventions required. No SAEs reported. [265]
NIDA grant 5R01BA017987-01, DIUE (2009 SGR 718), grant (FIS- RTA RD06/0001/1009), and (MICINN FI09/00355), ISCIII- FIS-CAIBER CAI08/01/0024. fellowship Rio Hortega (FIS CM08/00051).	Open-label, single-dose pharmacokinetic study,	27	15/12 (M/F), Age not specified, recreational users of Ecstasy	1.4 mg/kg (75-100 mg)	N/A	No AEs of concern reported, and no interventions required. No SAEs reported. [588]
NIDA 5R01BA0- 17987-01, MICINN 510900355, FISTRA grant, others; NCT01447472	Open-label, two-session within-subjects design	21	12/9 (M/F) Average age 26.3; Caucasian.	1.5 mg/kg (75-100 mg)	caffeine vs MDMA + caffeine administered 4 h post-MDMA	No AEs of concern were reported, nor interventions required. No SAEs were reported. [571]
R01BA017987-01), MICINN FI09/00355), grant no. RD06/0001/0026),	Open label within-subjects design, two sessions				DXM, vs MDMA + DXM administered 4 h laster	

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
<p>AGAUR; grant no. 2009 SGR 718).NIDA 5R01BA0-17987-01, MICINN 510900355, FISTRA grant, others; NCT01447472 Grants FIS 97/1198, FIS 98/0181, FIS 00/0777, and FIS 01/1336 from Fondo de Investigació n Sanitaria, Madrid, Spain; Grant 2001SGR00407 Generalitat de Catalunya (2001SGR00407), Fondo de Investigació n Sanitaria (98/0181 and 01/1336)</p>	<p>Randomized, double-blind, placebo-controlled crossover Drug interaction study</p>	12	12/0 (M/F) Age not specified	100 mg (~1.4 mg/kg)	Placebo; with and w/out 3 prior days of 20 mg paroxetine	No AEs of concern, and no interventions needed. No SAEs reported. [569]
<p>FIS 98/0181, CIRIT 99-SGR-00242, and PNSD</p>	<p>Randomised, double-blind, cross-over, placebo controlled</p>	10	10/0 (M/F) Age range 21-33; previous experience with psychostimulants, cannabis, or hallucinogens	100 mg day 1+100 mg day 2 (~1.4 mg/kg per day)	Placebo	<p>Diagnostic criteria of isolated systolic hypertension (&gt;140 mmHg) were met by 6 subjects following the first dose of MDMA and 8 subjects following the second dose; mean duration of 1 h (range 0.5-2) following the first dose and 1.4 h (range 0.5-3) following the second dose. Two subjects met diagnostic criteria of sinus tachycardia (&gt;100 beats/minute), both following the second dose of MDMA. Tachycardia lasted between 15 and 30 minutes. No intervention required and no SAEs reported. [577]</p> <p>MDMA produced time-dependent decrease in CD4/CD8 T-cell ratio due to a decrease in the number of CD4 T-helper cells, decrease in functional</p>
<p>FIS 98/0181, CIRIT 99-SGR-00242, and PNSD</p>	<p>Open label within-subjects/time course study</p>	27	27/0 (M/F) Age not specified	100 mg (~1.4 mg/kg), second dose 100 mg Second dose of MDMA administered	None	<p>MDMA produced time-dependent decrease in CD4/CD8 T-cell ratio due to a decrease in the number of CD4 T-helper cells, decrease in functional</p>

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
				4 hours vs. 24 hours post first dose		responsiveness of lymphocytes to mitogenic stimulation, and a simultaneous increase in natural killer cells. Second dose either 4 or 24 hours later accentuated the findings. No SAEs were reported. [614, 649]
Supported in part by grants from Generalitat de Catalunya (2001SGR00407), Fondo de Investigación Sanitaria (98/0181 and 01/1336). FIS 97/1198, CIRIT 1997-SGR-0077, and Plan Nacional sobre Drogas	Randomised, double-blind, cross-over, placebo-controlled trial	10	10/0 (M/F), Age range 21-33; previous experience with psychostimulants, cannabis, or hallucinogens	100 mg day 1+100 mg day 2 (~1.4 mg/kg per day)	Placebo	No AEs of concern were reported, and no interventions were required. No SAEs were reported. [719]
FIS 97/1198, CIRIT 1997-SGR-0077, and Plan Nacional sobre Drogas	double blind, double dummy, randomized crossover, placebo-controlled. 4x4 Latin square. States in paper data presented elsewhere in Pacifici et al. 2001	9	9/0 (M/F) Average age 23	100 mg (~1.4 mg/kg) MDMA + ethanol (0.8 g/kg)	Placebo, ethanol alone (0.8 g/kg)	No AEs of concern, and no interventions required. No SAEs reported. [648, 720]
FIS 97/1198, CIRIT (1997SGR00077), ISCIII 97/4344 and Plan Nacional sobre Drogas.	preliminary phase; study phase: double-blind, randomized, crossover and placebo-controlled	14	14/0 (M/F) Average age 26.5	50 mg (~0.7 mg/kg) 75 mg (~1.1 mg/kg) 125 mg (~1.8 mg/kg) 150 mg (~2.1 mg/kg)	Placebo, 40 mg racemic amphetamine	No AEs of concern reported, and no interventions required. No SAEs reported. [12, 13, 18]

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
R01 DA017987, 2005SGR00032, (FIS-RTA RD06/0001/1009 5 K08 DA00370/DA/NIDA	Controlled open-label drug interaction study (MDMA with dextromethorphan) Double-blind, placebo-controlled within-subject study	15  12	15/0 (M/F) Average age 26; Age range 19-33  6/6 (M/F) Average age 22.3; 10 Caucasian, 1 Asian, 1 Native American	1.5 mg/kg (followed by dextromethor- phan) 1 mg/kg	N/A  Placebo 2 mg/kg d- amphetamine (10 and 20 mg), mCPP (0.5 and 0.75 mg/kg)	No AEs of concern reported, and no interventions required. No SAEs reported. [568]  No AEs of concern were reported, and no interventions were required. No SAEs were reported. [16]
R01 DA- 14874/DA/NIDA	double-blind, 2x2: two sessions at 30 degrees C, two at 18 degrees C, two during MDMA, two during placebo	10	6/4 (M/F) Average age 22.9; 6 White, 3 Black, 1 multiracial	2 mg/kg	Placebo	No AEs of concern were reported, and no interventions were required. No SAEs were reported. [215]
K08 DA00370/DA/NIDA	3 phases (6-session sampling phase, 6- session selection phase, 5-session testing phase), within-subject	8	5/3 (M/F) Average age 25.0; 6 White, 2 Black	1 mg/kg, 1.5 mg/kg	Placebo, 20 mg d- amphetamine, 0.75 mg/kg mCPP	No AEs of concern were reported, and no interventions required. No SAEs were reported. [686]
Joe Young Funds awarded to the Department of Psychiatry and Behavioral Neurosciences by the State of Michigan. R01-DA14874	six-group between- group (one group per MDMA and mCPP dose), placebo- controlled, ascending dose order  Double-blind, placebo controlled, within-subjects; 3 "sessions" consisting of 3 nights in sleep	15  7	8/14 (M/F) Average age 23.6; 20 Caucasian, 1 bi- racial, one Middle Eastern,  5/2 (M/F) Average age 25.3; 6 White, 1 Black	1.1 mg/kg, 1.6 mg/kg, 2.1 mg/kg  2 mg/kg	Placebo, mCPP (17.5, 35, 52.5 mg/70 kg)  Placebo, with 8 or 4 hour time in bed	No AEs of concern were reported, and no interventions required. No SAEs were reported. [633]  No AEs of concern were reported, and no interventions were required. No SAEs were reported. [597]

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
ZonMW 31000062 (Netherlands)	lab [baseline, treatment, recovery night] Double-blind, randomized, placebo-controlled crossover (within-subjects); four conditions, crossing MDMA with THC	16	12/4 (M/F) Average age 21.4	100 mg (~1.4 mg/kg)	Placebo; crossed with placebo or THC	One subject reported "feeling unwell" under the influence of MDMA condition. No other AEs of concern reported, and no interventions required. No SAEs were reported. [ <a href="#">81</a> , <a href="#">684</a> , <a href="#">721</a> , <a href="#">722</a> ]
This research was supported by a grant of ZonMW (31000062)	Double-blind, randomized, placebo-controlled crossover (within-subjects); four conditions	16	9/7 (M/F) Age range 18-29	100 mg (~1.4 mg/kg)	Placebo, crossed with placebo or ethanol	No AEs of concern were reported, and no interventions required. No SAEs were reported. [ <a href="#">637</a> , <a href="#">722-724</a> ]
Not listed	Double-blind, crossover, naturalistic study	12	8/4 (M/F) Age range 21-30	75 mg (~1.1 mg/kg)	Placebo, 0.5 g/kg ethanol	No AEs of concern were reported, and no interventions were required. No SAEs were reported. [ <a href="#">725</a> ]
NIDA (Hart, R01 DA03746)	Double-blind, randomized, placebo-controlled within-subjects	11	9/2 (M/F) Age range 23-39, Average age 29.3	100 mg (~1.4 mg/kg)	Placebo, (20 mg, 40 mg) methamphetamine	No AEs of concern were reported, and no interventions were required. No SAEs were reported. [ <a href="#">39</a> , <a href="#">688</a> ]
EU-project DRUID (TREN-05-FP6TR-S07.61320-518404-DRUID).	double blind, placebo controlled, 4 way crossover (MDMA or placebo x ethanol or placebo	19	10/9 (M/F) Age range 21-40, Average age 30.8	100 mg (~1.4 mg/kg)	Placebo, combined with placebo or ethanol	MDMA showed no significant effects on driving compared with placebo. No AEs of concern were reported, and no interventions were required. No SAEs were reported. [ <a href="#">726</a> ]
Australian Research Council Grant DP0772762	Double-blind, placebo-controlled counterbalanced within-subjects design	61	28/33 (M/F) Average age 25.4	100 mg (~1.4 mg/kg)	Placebo, 0.42 mg/kg methamphetamine	Driving under the influence of MDMA was worse than after both methamphetamine and placebo. No AEs of concern were reported, and no interventions were required. No SAEs were reported. [ <a href="#">727-729</a> ]

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
This research was supported by National Institutes of Health DA017716 and DA016776 and the NIH/National Center for Research Resources UCSF-CTSI UL1 RR024131	Study 1: Randomized, placebo-controlled, double-blind within-subjects study w/ 4 conditions  Study 2: Randomized, placebo-controlled, double-blind within-subjects study w/ 2 conditions	28	Study 1: 8/8 (M/F) Average age 26.6 Study 2: 6/6 (M/F) Average age 28.6	Study 1: 1.5 mg/kg, with / without prazosin  Study 2: 1.5 mg/kg, followed 30 minutes by 20 ml/kg water	Study 1: Placebo, prazosin pretreatment  Study 2: Placebo	Study 1: No AEs of concern reported, no intervention required. No SAEs reported.  Study 2: MDMA acutely exaggerates the hyponatremic effects of water. No AEs of concern reported and no interventions required. No SAEs reported. [ <a href="#">43</a> , <a href="#">626</a> ]
This research was funded by the Intramural Research Program, National Institute on Drug Abuse, NIH. No grant numbers or NCT number listed	Double-blind, placebo-controlled, randomized within-subjects randomized, counterbalanced, and double-blind design  Double-blind, placebo-controlled, randomized within-subjects design	50	33/17 (M/F) Age range 18-35; 73% African-American, 23% Caucasian and 4% unknown/mixed	1.0 mg/kg, 1.6 mg/kg (maximum 150 mg)	Placebo	Significantly lower plasma HMMA AUC <sub>0-3h</sub> in African-American participants after the low dose. The same was found for females. No AEs of concern were reported, and no interventions were required. No SAEs reported. [ <a href="#">558</a> , <a href="#">585</a> , <a href="#">730</a> , <a href="#">731</a> ]
DA05707 and DA017964	Double-blind, randomized, placebo-controlled within subjects Double-blind-randomized counterbalanced (within-subjects) study	9	7/2 (M/F) Age range 18-24	1.0 mg/kg, 1.6 mg/kg (maximum 150 mg)	Placebo	No AEs of concern were reported, and no interventions required. No SAEs reported. [ <a href="#">253</a> , <a href="#">255</a> ]



Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
DA01696, DA12393, DA00053 (R.T.J.), National Institute on Drug Abuse Grants DA00064, DA14528 (J.H.M.), Division of Research Resources, National Institutes of Health Grant 5 M01 RR-00079	Double-blind crossover (within- subjects), ascending dose	8	5/3 (M/F) Age range 24-39, Average age 29	0.5 mg/kg; 1.5 mg/kg	Placebo (lactose)  In Lester et al. 2000, compared cardiac data with ascending doses of dobutamine	No AEs of concern reported, and no interventions required. No SAEs reported. [14, 37]
No grant numbers listed; supported by the Swiss Federal Office of Public Health, Bern, Switzerland, and the Heffter Research Institute.	Randomized, placebo-controlled, within-subjects, (placebo/pindolol, placebo/MDMA)	15	15/0 (M/F) Average age 24.3	1.6 mg/kg	Placebo,  pindolol pretreatment	No information on AEs reported; no SAEs reported. [188, 732]
DA01696, DA12393, DA00053 (R.T.J.), National Institute on Drug Abuse Grants DA00064, DA14528 (J.H.M.), Division of Research Resources, National Institutes of Health Grant 5 M01 RR-00079	Double-blind crossover (within- subjects), ascending dose	8	5/3 (M/F) Age range 24-39, Average age 29	0.5 mg/kg; 1.5 mg/kg	Placebo (lactose),  ascending doses of dobutamine	No AEs of concern reported, and no interventions required. No SAEs reported. [14, 37]
Supported by Heffter Research Institute, no grant numbers	Randomized, double- blind controlled within-subjects	16	10/6 (M/F) Average age 26	1.7 mg/kg	Placebo	No AEs of concern reported, no intervention required. No SAEs reported. [617, 733]

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
Supported by Heffter Research Institute, no grant numbers	(crossover) design, EEG in both Randomized, placebo-controlled within-subjects, pre-administered drug, MDMA	16	12/4 (M/F) Average age 27.4	1.5 mg/kg	Placebo, 40 mg citalopram i.v. pretreatment	No AEs of concern reported, no intervention required. No SAEs reported. [ <a href="#">594</a> , <a href="#">595</a> ]
Supported by Heffter Research Institute, no grant numbers	Randomized, placebo-controlled within-subjects, pre-administered drug, MDMA	14	13/1 (M/F) Average age 26	1.5 mg/kg	Placebo, 50 mg p.o ketanserin pretreatment	No AEs of concern reported, no intervention required. No SAEs reported. [ <a href="#">598</a> ]
Supported by Heffter Research Institute, no grant numbers	Randomized, placebo-controlled within-subjects, pre-administered drug, MDMA)	13	9/4 (M/F) Average age 26	1.5 mg/kg	Placebo, 1.4 mg haloperidol pretreatment	No AEs of concern reported, no intervention required. No SAEs reported. [ <a href="#">604</a> ]
None listed, acknowledges "SBG Medical Science Foundation, Switzerland" and Heffter Research institute	Double-blind, placebo-controlled crossover (within-subjects)	16	13/3 (M/F) Average age 29	1.7 mg/kg	Placebo	One individual showed increased BP of 240/145 SBP/DBP, resolved with no medical intervention needed. Changes in BP significant for SBP, not for DBP but present. [ <a href="#">17</a> , <a href="#">734</a> ]
No grants or NCTs listed	Observational, from psychiatric treatment by Swiss psychiatrists when MDMA treatment allowed	2	1/1 (M/F) Age range 24-40	1.7 mg/kg 1.5 mg/kg	None	No information on AEs of concern reported; no SAEs reported. [ <a href="#">563</a> , <a href="#">564</a> ]
No grants or NCTs listed	Open-label, singledose, also baseline to post-administration	8	8/0 (M/F) Age range 22-32	40 mg (~0.57 mg/kg)	Placebo	No AEs of concern reported, and no interventions required. No SAEs reported. [ <a href="#">154</a> , <a href="#">236</a> , <a href="#">377</a> ]

Funding/grants/ Support	Study design	Sample given MDMA	Demographics	Dose of MDMA HCl	Comparator	Safety findings
DA06863, MH00534, RR00425	Placebo controlled, double-blind study, with two ascending doses MDMA per subject	18	12/6 (M/F) Age range 20-62	0.25 mg/kg to 2.5 mg/kg in 0.25 mg/kg increments; each person received 2 ascending doses	Placebo	No AEs of concern were reported, and no interventions required. No SAEs were reported. [ <a href="#">40</a> , <a href="#">549</a> , <a href="#">735</a> ]
No grants or funding listed	Open label / naturalistic, in context of ongoing psychotherapy	29	Not specified	75-150 mg (~1.1 -2.1 mg/kg), 200 mg (~2.9 mg/kg) half-dose offered later	None	No AEs of concern reported, and no interventions required. No SAEs reported. [ <a href="#">51</a> ]
No grants or funding listed	Open label single administration	21	13/8 (M/F) Age range 20-58	Varied, self-selected, 0.8 mg/lb, average 1.14 mg/lb (app. 2.5 mg/kg)	None	No AEs of concern reported, no interventions required. No SAEs reported. [ <a href="#">36</a> ]
None listed, acknowledges "407 donors from a crowdfunding campaign"	Open label within- subjects design, three sessions	3	1/2 (M/F) Age range 35-45	75 mg (~1.1 mg/kg) or 125 mg (~1.8 mg/kg) with half-dose offered later	None	No AEs of concern reported. No SAEs reported. [ <a href="#">736</a> ]

**Appendix Table 2: Pre-Drug, Peak, and Final Body Temperature (°C) During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored MAA-1**

MDMA HCl Dose	N	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with 1 ° C above Pre-Drug
Placebo	4	36.5 (0.23) 36.1/36.8	36.8 (0.12) 36.6/36.9	36.7 (0.20) 36.4/36.9	0
75 mg	4	36.6 (0.45) 36.2/37.2	37.2 (0.29) 36.9/37.6	37.0 (0.19) 36.7/37.2	0
100 mg	7	36.6 (0.50) 35.9/37.3	37.3 (0.33) 36.7/37.7	37.2 (0.31) 36.6/37.6	2 (28.6)
125 mg	4	37.1 (0.23) 36.8/37.4	37.4 (0.26) 37.2/37.7	37.3 (0.08) 37.2/37.4	0
Open-label (75 mg)	4	36.7 (0.26) 36.4/36.9	37.2 (0.35) 36.7/37.6	37.1 (0.35) 36.7/37.6	0
Open-label (125 mg)	4	36.6 (0.19) 36.4/36.9	37.2 (0.26) 36.8/37.4	36.9 (0.36) 36.4/37.2	0

**Appendix Table 3: Pre-Drug, Peak, and Final Body Temperature (°C) During Dosing Sessions with Placebo or Full MDMA Dose in MAPS-Sponsored MDA-1 Study**

MDMA HCl Dose	N	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with BT 1 ° C above Pre-Drug
Placebo	5	36.4 (0.43) 35.7/36.9	36.9 (0.27) 36.5/37.5	36.4 (0.56) 35.0/37.0	1 (20.0)
125 mg	13	36.3 (0.49) 35.6/37.4	37.3 (0.71) 36.1/39.9	36.9 (0.44) 35.9/37.6	7 (53.8)
Open-label (125 mg)	17	36.3 (0.44) 35.4/37.2	37.3 (0.33) 36.6/38.0	36.9 (0.39) 36.0/37.4	9 (52.9)

**Appendix Table 4: Pre-drug, Peak, and Final Systolic Blood Pressure During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored MAA-1 Study**

MDMA HCl Dose	N	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with SBP Above 180 mm Hg
Placebo	4	131.0 (11.6) 112.0/144.0	142.5 (11.8) 126.0/159.0	126.9 (5.6) 121.0/138.0	0
75 mg	4	117.5 (14.8) 101.0/137.0	136.3 (26.3) 116.0/174.0	122.0 (10.7) 112.0/134.0	0
100 mg	7	113.3 (12.9) 92.0/133.0	121.4 (9.4) 113.0/141.0	114.6 (10.2) 105.0/135.0	0
125 mg	4	114.8 (5.1) 109.0/120.0	123.5 (14.6) 110.0/143.0	114.0 (4.1) 111.0/120.0	0
Open-label (75 mg)	4	124 (11.0) 116.0/140.0	138.8 (17.0) 127.0/164.0	131.8 (17.6) 114.0/156.0	0
Open-label (125 mg)	4	131.0 (3.9) 126.0/135.0	153.0 (17.6) 135.0/170.0	142.8 (19.1) 127.0/170.0	0

**Appendix Table 5: Pre-drug, Peak, and Final Systolic Blood Pressure During Dosing Sessions with Placebo or Full MDMA Dose in MAPS-Sponsored MDA-1 Study**

MDMA HCl Dose	N	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with SBP Above 180 mm Hg
Placebo	5	127.5 (13.34) 102.0/145.0	146.0 (15.53) 126.0/173.0	119.7 (8.71) 106.0/135.0	2 (40.0)
125 mg	13	129.9 (17.94) 91.0/178.0	157.54 (17.05) 127.0/192.0	125.69 (11.45) 103.0/145.0	7 (53.8)
Open-label (125 mg)	17	129.1 (19.13) 78.0/162.0	157.0 (18.64) 119.0/196.0	128.0 (13.8) 106.0/153.0	5 (29.4)

**Appendix Table 6: Pre-drug, Peak, and Final Diastolic Blood Pressure During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored MAA-1 Study**

MDMA HCl Dose	N	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with DBP Above 110 mm Hg
Placebo	4	76.9 (10.0) 64.0/89.0	82.3 (11.2) 72.0/106.0	74.5 (8.6) 62.0/88.0	0
75 mg	4	68.5 (9.3) 61.0/81.0	80.3 (5.3) 73.0/85.0	68.8 (4.6) 64.0/74.0	0
100 mg	7	60.7 (6.3) 52.0/72.0	76.9 (8.4) 62.0/89.0	67.1 (8.5) 59.0/82.0	0
125 mg	4	67.8 (2.2) 66.0/71.0	78.3 (9.0) 69.0/86.0	68.5 (3.4) 64.0/72.0	0
Open-label (75 mg)	4	71.0 (10.8) 62.0/85.0	82.5 (4.7) 77.0/88.0	72.0 (3.5) 69.0/75.0	0
Open-label (125 mg)	4	81.5 (8.3) 70.0/88.0	88.3 (7.6) 79.0/95.0	73.0 (7.6) 62.0/78.0	0

**Appendix Table 7: Pre-drug, Peak, and Final Diastolic Blood Pressure During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored MDA-1 Study**

MDMA HCl Dose	N	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with DBP Above 120 mm Hg
Placebo	5	78.5 (16.49) 4.06/94.0	91.6 (13.40) 72/112	78.4 (11.40) 64/100	1 (20.0)
125 mg	13	78.7 (11.05) 55.0/106.0	93.9 (19.11) 75.0/154.0	73.1 (7.47) 58.0/84.0	4 (30.8)
Open-label (125 mg)	17	81.1 (16.09) 50.0/117.0	94.6 (11.69) 72.0/118.0	77.5 (12.66) 52.0/97.0	2 (11.8)

**Appendix Table 8: Pre-drug, Peak, and Final Heart Rate During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored MAA-1 Study**

MDMA HCl Dose	N	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with HR Above 110 BPM
Placebo	4	57.3 (9.7) 47.0/78.0	75.3 (10.3) 63.0/94.0	67.4 (7.4) 59.0/83.0	0
75 mg	4	68.0 (3.7) 63.0/72.0	87.0 (14.0) 75.0/105.0	73.8 (6.3) 65.0/80.0	0
100 mg	7	70.0 (12.2) 53.0/88.0	89.3 (12.1) 71.0/105.0	79.1 (15.9) 58.0/100.0	0
125 mg	4	78.5 (12.1) 61.0/88.0	95.0 (19.8) 75.0/114.0	89.3 (13.2) 75.0/101.0	1 (25.0)
Open-label (75 mg)	4	58.0 (6.1) 52.0/65.0	71.8 (10.1) 58.0/82.0	66.5 (7.1) 57.0/74.0	0
Open-label (125 mg)	4	64.0 (6.9) 58.0/74.0	87.0 (8.1) 80.0/94.0	70.0 (6.2) 63.0/78.0	0

**Appendix Table 9: Pre-drug, Peak, and Final Heart Rate During Dosing Sessions with Placebo or any MDMA Dose in MAPS-Sponsored MDA-1 Study**

MDMA HCl Dose	N	Pre-drug Mean (SD) Min/Max	Peak Mean (SD) Min/Max	Final Mean (SD) Min/Max	N (%) with HR Above 120 BPM
Placebo	5	69.0 (13.88) 50.0/100.0	81.5 (12.26) 71.0/108.0	71.4 (7.11) 60.0/86.0	0
125 mg	13	69.3 (10.74) 53.0/95.0	105.5 (14.44) 89.0/133.0	92.9 (16.43) 69.0/133.0	6 (46.2)
Open-label (125 mg)	17	70.3 (10.23) 57.0/91.0	106.8 (17.34) 77.0/140.0	87.1 (13.97) 62.0/117.0	6 (35.3)

**Appendix Table 10: Summary of Lifetime and Baseline Positive and Serious Responses on C-SSRS for Study MAA-1**

MDMA HCl Dose		Lifetime <sup>a</sup> N (%)	Pre-drug Exposure <sup>b</sup> N (%)
<b>Social Anxiety in Autistic Adults</b>			
Blinded Placebo	PI	3 (75.0)	0
	SI	0	0
	PB	1 (25.0)	0
	O	4	8
	N	4	4
Blinded Active Doses (75-125 mg)	PI	4 (50.0)	0
	SI	1 (12.5)	0
	PB	1 (12.5)	0
	O	8	16
	N	8	8

PI=Positive Ideation, SI=Serious Ideation, PB=Positive Behavior, O=Observations, N=Number of Participants

<sup>a</sup> Lifetime accounts for all suicidal ideation and behavior prior to study Visit 1, according to participant recall and medical records.

<sup>b</sup> Pre-drug exposure represents measures taken during Preparatory Sessions and before drug administration in dosing session 1.

**Appendix Table 11: C-SSRS Positive and Serious Responses During Dosing Sessions and Integrative Session 1, Day 2 Phone Call, and Day 7 Phone Call Post-Drug for Study MAA-1**

MDMA HCl Dose		Session 1 N (%)					Session 2 N (%)				
		Pre- drug <sup>A</sup>	During- drug <sup>B</sup>	Integrative Session 1	Day 2	Day 7	Pre- drug <sup>a</sup>	During- drug <sup>b</sup>	Integrative Session 1	Day 2	Day 7
<b>Social Anxiety in Autistic Adults</b>											
Blinded	PI	0	0	0	0	0	0	0	0	0	0
Placebo	SI	0	0	0	0	0	0	0	0	0	0
	PB	0	0	0	0	0	0	0	0	0	0
	N	4	4	4	4	3	3	4	4	4	4
Blinded	PI	0	1 (14.3)	1 (12.5)	0	0	0	0	0	0	0
Active Dose (75-125 mg)	SI	0	0	0	0	0	0	0	0	0	0
	PB	0	0	0	0	0	0	0	0	0	0
	N	8	7	8	8	8	6	7	7	7	7
Open-label Stage 2	PI	1 (25.0)	0	0	0	0	0	0	0	0	0
Active Dose (75-125 mg)	SI	0	0	0	0	0	0	0	0	0	0
	PB	0	0	0	0	0	0	0	0	0	0
	N	4	4	4	4	4	3	4	4	4	3

PI=Positive Ideation, SI=Serious Ideation, PB=Positive Behavior, N=Number of Participants

<sup>A</sup> Pre-drug measurement taken day of dosing session prior to drug administration.

<sup>B</sup> During-drug observation measured at dosing session endpoint, approximately 6 hours after drug administration.



**Appendix Table 12: C-SSRS Positive Responses at Endpoints After Treatment for Study MAA-1**

MDMA HCl Dose		Primary/ Secondary Endpoint N (%)	Long-term Follow-up N (%)
<b>Social Anxiety in Autistic Adults</b>			
Blinded Placebo	PI	1 (25.0)	2 (50.0)
	SI	0	0
	PB	0	0
	N	4	4
Blinded Active Doses (75-125 mg)	PI	2 (28.6)	0
	SI	0	0
	PB	0	0
	N	7	7

PI=Positive Ideation, SI=Serious Ideation, PB=Positive Behavior, N=Number of Participants

**Appendix Table 13: Summary of Lifetime and Baseline Positive and Serious Responses on C-SSRS for Study MDA-1**

MDMA HCl Dose		Lifetime <sup>a</sup> N (%)	Pre-drug Exposure <sup>b</sup> N (%)
<b>Anxiety Associated with a Life-threatening Illness</b>			
Blinded Placebo	PI	4 (80.0)	5 (25.0)
	SI	1 (20.0)	0
	PB	0	1 (5.0)
	O	5	20
	N	5	5
Blinded Active Dose (125 mg)	PI	10 (76.9)	0
	SI	0	0
	PB	3 (23.1)	0
	O	13	52
	N	13	13

PI=Positive Ideation, SI=Serious Ideation, PB=Positive Behavior, O=Observations, N=Number of Participants

<sup>a</sup> Lifetime accounts for all suicidal ideation and behavior prior to study Visit 1, according to participant recall and medical records.

<sup>b</sup> Pre-drug exposure represents measures taken during Preparatory Sessions and before drug administration in dosing session 1.

**Appendix Table 14: C-SSRS Positive and Serious Responses During Dosing Sessions and 1-Day Post-Drug for Study MDA-1**

MDMA HCl Dose		Session 1			Session 2			Session 3		
		N (%)			N (%)			N (%)		
		Pre-drug <sup>a</sup>	During-drug <sup>b</sup>	Integration Day 1	Pre-drug <sup>a</sup>	During-drug <sup>b</sup>	Integration Day 1	Pre-drug <sup>a</sup>	During-drug <sup>b</sup>	Integration Day 1
<b>Anxiety Associated with a Life-threatening Illness</b>										
Blinded	PI	0	0	0	0	0	0	---	---	---
Placebo	SI	0	0	0	0	0	0			
	PB	0	0	0	0	0	0			
	N	5	5	5	5	5	5			
Blinded	PI	0	0	0	0	0	0	0	0	0
Active Dose (125 mg)	SI	0	0	0	0	0	0	0	0	0
	PB	0	0	0	0	0	0	0	0	0
	N	13	13	13	13	13	13	11	10	12
Open-label Stage 2	PI	0	0	0	0	0	0	0	0	0
Active Dose (125 mg)	SI	0	0	0	0	0	0	0	0	0
	PB	0	0	0	0	0	0	0	0	0
	N	5	5	5	5	5	5	5	5	5

PI=Positive Ideation, SI=Serious Ideation, PB=Positive Behavior, N=Number of Participants

<sup>a</sup> Pre-drug measurement taken day of dosing session prior to drug administration.

<sup>b</sup> During-drug observation measured at dosing session endpoint, approximately 6 hours after drug administration.

**Appendix Table 15: C-SSRS Positive Responses During Telephone Contact Following Dosing Sessions for Study MDA-1**

MDMA HCl Dose		Session 1		Session 2		Session 3	
		N (%)		N (%)		N (%)	
		Day 2	Day 7	Day 2	Day 7	Day 2	Day 7
<b>Anxiety Associated with a Life-threatening Illness</b>							
Blinded	PI	0	0	0	0	---	---
Placebo	SI	0	0	0	0		
	PB	0	0	0	0		
	N	5	5	5	5		
Blinded	PI	0	0	0	0	0	0
Active Dose (125 mg)	SI	0	0	0	0	0	0
	PB	0	0	0	0	0	0
	N	13	13	13	13	12	12
Open-label	PI	0	0	0	0	0	0
Stage 2 Doses (100-125 mg)	SI	0	0	0	0	0	0
	PB	0	0	0	0	0	0
	N	5	5	5	5	5	5

PI=Positive Ideation, SI=Serious Ideation, PB=Positive Behavior, N=Number of Participants

**Appendix Table 16: C-SSRS Positive Responses at Endpoints After Treatment for Study MDA-1**

MDMA HCl Dose		Primary/ Secondary	End of Stage 1/ End of	Long-term
		Endpoint	Stage 2	Follow-up
		N (%)	N (%)	N (%)
<b>Anxiety Associated with a Life-threatening Illness</b>				
Blinded	PI	0	---	1 (20.0)
Placebo	SI	0		0
	PB	0		0
	N	5		5
Blinded	PI	1 (7.7)	0	0
Active Dose (125 mg)	SI	0	0	0
	PB	0	0	0
	N	13	12	12
Open-label	PI	0	0	---
Stage 2 Doses (100-125 mg)	SI	0	0	
	PB	0	0	
	N	5	5	

PI=Positive Ideation, SI=Serious Ideation, PB=Positive Behavior, N=Number of Participants

**Appendix Table 17: Prevalence of Spontaneously Reported Reactions During Dosing Sessions and Telephone Contact on Day 1-7 After Dosing Sessions in Sponsor-Supported Phase 2 Study MAA-1**

Post-drug MDMA HCl Dose	Day 0 N (%)	Day 1 N (%)	Day 2 N (%)	Day 3 N (%)	Day 4 N (%)	Day 5 N (%)	Day 6 N (%)	Day 7 N (%)
<b>Anxiety</b>								
Placebo (N=4)	1 (25.0)	---	1 (25.0)	---	---	---	---	---
75-125 mg (N=8)	6 (75.0)	1 (12.5)	---	---	---	---	---	---
Open-label (N=4)	1 (25.0)	---	---	---	---	---	---	---
<b>Diarrhea</b>								
Placebo (N=4)	---	---	---	---	---	---	---	---
75-125 mg (N=8)	---	---	---	---	---	---	---	---
Open-label (N=4)	1 (25.0)	---	---	---	---	---	---	---
<b>Difficulty Concentrating</b>								
Placebo (N=4)	1 (25.0)	---	---	---	---	---	---	---
75-125 mg (N=8)	5 (62.5)	1 (12.5)	3 (37.5)	1 (12.5)	---	---	1 (12.5)	---
Open-label (N=4)	2 (50.0)	---	---	---	---	---	---	---
<b>Dizziness</b>								
Placebo (N=4)	1 (25.0)	---	---	---	---	---	1 (25.0)	1 (25.0)
75-125 mg (N=8)	1 (12.5)	---	---	---	---	---	---	---
Open-label (N=4)	---	---	---	---	---	---	---	---
<b>Drowsiness</b>								
Placebo (N=4)	---	---	---	---	---	---	---	---
75-125 mg (N=8)	1 (12.5)	---	---	---	---	---	1 (12.5)	---
Open-label (N=4)	1 (25.0)	---	---	---	---	---	---	---

<b>Post-drug MDMA HCl Dose</b>	<b>Day 0 N (%)</b>	<b>Day 1 N (%)</b>	<b>Day 2 N (%)</b>	<b>Day 3 N (%)</b>	<b>Day 4 N (%)</b>	<b>Day 5 N (%)</b>	<b>Day 6 N (%)</b>	<b>Day 7 N (%)</b>
<b>Dry Mouth</b>								
Placebo (N=4)	---	---	---	---	---	---	---	---
75-125 mg (N=8)	---	---	---	---	---	---	---	---
Open-label (N=4)	---	---	---	---	---	---	---	---
<b>Fatigue</b>								
Placebo (N=4)	1 (25.0)	---	2 (50.0)	---	---	---	---	---
75-125 mg (N=8)	4 (50.0)	3 (37.5)	3 (37.5)	1 (12.5)	---	---	1 (12.5)	---
Open-label (N=4)	---	2 (50.0)	3 (75.0)	---	---	1 (25.0)	1 (25.0)	1 (25.0)
<b>Headache</b>								
Placebo (N=4)	1 (25.0)	1 (25.0)	1 (25.0)	---	---	---	---	---
75-125 mg (N=8)	4 (50.0)	3 (37.5) <sup>A</sup>	2 (25.0)	---	---	3 (37.5)	2 (25.0)	1 (12.5)
Open-label (N=4)	---	1 (25.0)	1 (25.0)	---	---	1 (25.0)	---	---
<b>Heavy Legs</b>								
Placebo (N=4)	---	---	---	---	---	---	---	---
75-125 mg (N=8)	---	---	---	---	---	---	---	---
Open-label (N=4)	---	---	---	---	---	---	---	---
<b>Impaired Gait/Balance</b>								
Placebo (N=4)	---	---	---	---	---	---	---	---
75-125 mg (N=8)	1 (12.5)	---	---	---	---	---	---	---
Open-label (N=4)	---	---	---	---	---	---	---	---
<b>Impaired Judgment</b>								
Placebo (N=4)	---	---	---	---	---	---	---	---

<b>Post-drug MDMA HCl Dose</b>	<b>Day 0 N (%)</b>	<b>Day 1 N (%)</b>	<b>Day 2 N (%)</b>	<b>Day 3 N (%)</b>	<b>Day 4 N (%)</b>	<b>Day 5 N (%)</b>	<b>Day 6 N (%)</b>	<b>Day 7 N (%)</b>
75-125 mg (N=8)	---	---	---	---	---	---	---	---
Open-label (N=4)	---	---	---	---	---	---	---	---
<b>Increased Irritability</b>								
Placebo (N=4)	---	---	1 (25.0)	---	---	---	---	---
75-125 mg (N=8)	1 (12.5)	---	---	---	---	1 (12.5)	---	---
Open-label (N=4)	---	---	---	---	---	---	---	---
<b>Insomnia</b>								
Placebo (N=4)	---	---	---	---	---	---	---	---
75-125 mg (N=8)	---	1 (12.5)	1 (12.5)	1 (12.5)	---	1 (12.5)	1 (12.5)	---
Open-label (N=4)	---	1 (25.0)	1 (25.0)	---	---	---	---	---
<b>Tight Jaw</b>								
Placebo (N=4)	---	---	1 (25.0)	---	---	---	---	1 (25.0)
75-125 mg (N=8)	1 (12.5)	---	---	---	---	---	---	---
Open-label (N=4)	---	1 (25.0)	---	---	---	---	---	---
<b>Lack of Appetite</b>								
Placebo (N=4)	1 (25.0)	---	---	---	---	---	---	---
75-125 mg (N=8)	3 (37.5)	3 (37.5)	1 (12.5)	---	---	---	---	---
Open-label (N=4)	3 (75.0)	---	---	---	---	---	---	---
<b>Low Mood</b>								
Placebo (N=4)	---	---	1 (25.0)	---	---	---	2 (50.0)	1 (25.0)
75-125 mg (N=8)	2 (25.0)	2 (25.0)	4 (50.0)	---	---	1 (12.5)	1 (12.5)	1 (12.5)

<b>Post-drug MDMA HCl Dose</b>	<b>Day 0 N (%)</b>	<b>Day 1 N (%)</b>	<b>Day 2 N (%)</b>	<b>Day 3 N (%)</b>	<b>Day 4 N (%)</b>	<b>Day 5 N (%)</b>	<b>Day 6 N (%)</b>	<b>Day 7 N (%)</b>
Open-label (N=4)	---	1 (25.0)	1 (25.0)	---	---	---	---	1 (25.0)
<b>Muscle Tension</b>								
Placebo (N=4)	1 (25.0)	---	---	---	---	---	---	---
75-125 mg (N=8)	3 (37.5)	---	---	---	---	---	---	---
Open-label (N=4)	2 (50.0)	---	---	---	---	1 (25.0)	---	---
<b>Nausea</b>								
Placebo (N=4)	---	---	---	---	---	---	---	---
75-125 mg (N=8)	---	---	---	---	---	---	---	---
Open-label (N=4)	---	---	---	---	---	---	---	---
<b>Need More Sleep</b>								
Placebo (N=4)	---	1 (25.0)	1 (25.0)	---	---	---	---	---
75-125 mg (N=8)	1 (12.5)	2 (25.0)	---	1 (12.5)	---	---	---	---
Open-label (N=4)	---	3 (75.0)	2 (50.0)	---	---	---	---	---
<b>Nystagmus</b>								
Placebo (N=4)	---	---	---	---	---	---	---	---
75-125 mg (N=8)	---	---	---	---	---	---	---	---
Open-label (N=4)	---	---	---	---	---	---	---	---
<b>Parasthesia</b>								
Placebo (N=4)	---	---	---	---	---	---	---	---
75-125 mg (N=8)	---	1 (12.5)	---	---	---	---	---	---
Open-label (N=4)	1 (25.0)	1 (25.0)	---	---	---	---	---	---
<b>Perspiration</b>								



<b>Post-drug MDMA HCl Dose</b>	<b>Day 0 N (%)</b>	<b>Day 1 N (%)</b>	<b>Day 2 N (%)</b>	<b>Day 3 N (%)</b>	<b>Day 4 N (%)</b>	<b>Day 5 N (%)</b>	<b>Day 6 N (%)</b>	<b>Day 7 N (%)</b>
Placebo (N=4)	1 (25.0)	---	---	---	---	---	---	---
75-125 mg (N=8)	1 (12.5)	---	---	---	---	---	---	---
Open-label (N=4)	2 (50.0)	---	---	---	---	---	---	---
<b>Restlessness</b>								
Placebo (N=4)	1 (25.0)	---	---	---	---	---	---	---
75-125 mg (N=8)	3 (37.5)	---	---	---	---	---	---	---
Open-label (N=4)	1 (25.0)	---	1 (25.0)	---	---	---	---	---
<b>Ruminations</b>								
Placebo (N=4)	---	---	---	---	---	---	1 (25.0)	---
75-125 mg (N=8)	1 (12.5)	---	---	---	---	---	---	---
Open-label (N=4)	2 (50.0)	---	---	---	---	---	---	---
<b>Sensitivity to Cold</b>								
Placebo (N=4)	---	---	---	---	---	---	---	1 (25.0)
75-125 mg (N=8)	4 (50.0)	---	---	---	---	---	---	---
Open-label (N=4)	---	---	---	---	---	---	---	---
<b>Thirst</b>								
Placebo (N=4)	---	---	---	---	---	---	---	---
75-125 mg (N=8)	2 (25.0)	1 (12.5)	---	---	---	---	---	---
Open-label (N=4)	---	---	---	---	---	---	---	---
<b>Weakness</b>								
Placebo (N=4)	1 (25.0)	---	1 (25.0)	---	---	---	---	---
75-125 mg (N=8)	1 (12.5)	1 (12.5)	1 (12.5)	---	---	---	---	---

<b>Post-drug MDMA HCl Dose</b>	<b>Day 0 N (%)</b>	<b>Day 1 N (%)</b>	<b>Day 2 N (%)</b>	<b>Day 3 N (%)</b>	<b>Day 4 N (%)</b>	<b>Day 5 N (%)</b>	<b>Day 6 N (%)</b>	<b>Day 7 N (%)</b>
Open-label (N=4)	---	---	1 (25.0)	---	---	---	---	---

<sup>a</sup>Severe reaction='Headache' on Day 1 in a participant in the active dose group (75-125 mg MDMA HCl)

**Appendix Table 18: Prevalence of Spontaneously Reported Reactions During Dosing Sessions in MDA-1**

Dose	Number of Participants (%) <sup>A</sup>		
	Placebo (N=5)	125 mg MDMA HCl (N=13)	Open-label (N=17)
Anxiety	---	3 (23.1)	2 (11.8)
Diarrhea	---	---	---
Difficulty Concentrating	---	---	---
Dizziness	---	---	---
Drowsiness	---	1 (7.7)	3 (17.6)
Dry Mouth	1 (20.0)	9 (69.2)	8 (47.1)
Fatigue	---	2 (15.4)	5 (29.4)
Headache	1 (20.0)	8 (61.5)	4 (23.5)
Heavy Legs	---	---	---
Impaired Gait/Balance	---	---	1 (5.9)
Impaired Judgment	---	---	---
Increased Irritability	---	---	---
Insomnia	1 (20.0)	2 (15.4)	4 (23.5)
Tight Jaw	1 (20.0)	11 (84.6)	15 (88.2)
Lack of Appetite	---	4 (30.8)	7 (41.2)
Low Mood	---	1 (7.7)	---
Muscle Tension	---	---	---
Nausea	1 (20.0)	3 (23.1)	4 (23.5)
Need More Sleep	---	---	---
Nystagmus	---	1 (7.7)	2 (11.8)
Parasthesia	---	1 (7.7)	1 (5.9)
Perspiration	---	9 (69.2)	7 (41.2)
Restlessness	---	2 (15.4)	2 (11.8)
Ruminations	---	---	---
Sensitivity to Cold	1 (20.0)	2 (15.4)	2 (11.8)
Thirst	2 (40.0)	11 (84.6)	9 (52.9)
Weakness	---	---	1 (5.9)

<sup>A</sup> No severe reactions reported.

**Appendix Table 19: Relative Incidence of Spontaneously Reported Reactions During Telephone Contact on Day 1-7 After Dosing Sessions in MDA-1**

Post-drug MDMA HCl Dose	Day 1 N (%)	Day 2 N (%)	Day 3 N (%)	Day 4 N (%)	Day 5 N (%)	Day 6 N (%)	Day 7 N (%)
<b>Anxiety</b>							
Placebo (N=5)	---	1 (20.0)	2 (40.0)	---	1 (20.0)	---	1 (20.0)
125 mg (N=13)	4 (30.8)	3 (23.1)	4 (30.8)	4 (30.8)	1 (7.7)	2 (15.4)	4 (30.8)
Open-label (N=17)	1 (5.9)	5 (29.4)	5 (29.4)	5 (29.4)	4 (23.5)	5 (29.4)	1 (5.9)
<b>Diarrhea</b>							
Placebo (N=5)	---	---	---	---	---	1 (20.0)	---
125 mg (N=13)	---	---	---	---	---	---	1 (7.7)
Open-label (N=17)	---	1 (5.9) <sup>A</sup>	---	---	1 (5.9)	---	---
<b>Difficulty Concentrating</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	---	1 (7.7)	2 (15.4)	---	---	---	---
Open-label (N=17)	2 (11.8)	3 (17.6)	3 (17.6)	---	---	---	---
<b>Dizziness</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	---	---	---	---	---	---	---
Open-label (N=17)	1 (5.9)	---	---	---	---	---	---
<b>Drowsiness</b>							
Placebo (N=5)	---	---	1 (20.0)	---	---	---	---
125 mg (N=13)	4 (30.8)	---	1 (7.7)	---	---	---	---
Open-label (N=17)	1 (5.9)	2 (11.8)	1 (5.9)	1 (5.9)	---	---	---
<b>Dry Mouth</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	2 (15.4)	1 (7.7)	1 (7.7)	---	---	---	---
Open-label (N=17)	3 (17.6)	2 (11.8)	---	---	---	---	---
<b>Fatigue</b>							
Placebo (N=5)	---	2 (40.0)	1 (20.0)	2 (40.0)	---	---	---
125 mg (N=13)	6 (46.2)	9 (69.2)	12 (92.3)	8 (61.5)	8 (61.5)	6 (46.2)	5 (38.5)
Open-label (N=17)	7 (41.2)	13 (76.5)	10 (58.8)	5 (29.4)	7 (41.2)	2 (11.8)	---
<b>Headache</b>							
Placebo (N=5)	2 (40.0)	1 (20.0)	1 (20.0)	1 (20.0)	---	---	---
125 mg (N=13)	6 (46.2)	4 (30.8)	2 (15.4)	2 (15.4)	---	---	---
Open-label (N=17)	7 (41.2)	5 (29.4)	2 (11.8)	2 (11.8)	2 (11.8)	1 (5.9)	---

<b>Post-drug MDMA HCl Dose</b>	<b>Day 1 N (%)</b>	<b>Day 2 N (%)</b>	<b>Day 3 N (%)</b>	<b>Day 4 N (%)</b>	<b>Day 5 N (%)</b>	<b>Day 6 N (%)</b>	<b>Day 7 N (%)</b>
<b>Heavy Legs</b>							
placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	---	---	---	---	---	---	---
Open-label (N=17)	---	---	---	---	---	---	---
<b>Impaired Gait/Balance</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	---	1 (7.7)	---	---	1 (7.7)	1 (7.7)	---
Open-label (N=17)	1 (5.9)	---	---	---	---	---	---
<b>Impaired Judgment</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	---	---	---	---	---	---	---
Open-label (N=17)	---	---	---	---	---	---	---
<b>Increased Irritability</b>							
Placebo (N=5)	---	---	---	---	1 (20.0)	1 (20.0)	1 (20.0)
125 mg (N=13)	---	---	---	---	1 (7.7)	2 (15.4)	1 (7.7)
Open-label (N=17)	---	---	---	---	---	---	2 (11.8)
<b>Insomnia</b>							
Placebo (N=5)	---	---	2 (40.0)	1 (20.0)	---	---	---
125 mg (N=13)	6 (46.2)	2 (15.4)	2 (15.4)	---	---	---	---
Open-label (N=17)	3 (17.6)	4 (23.5)	1 (5.9)	2 (11.8)	---	2 (11.8)	3 (17.6)
<b>Tight Jaw</b>							
Placebo (N=5)	1 (20.0)	---	---	---	---	---	---
125 mg (N=13)	7 (53.8)	4 (30.8)	3 (23.1)	1 (7.7)	---	---	---
Open-label (N=17)	9 (52.9)	8 (47.1)	4 (23.5)	3 (17.6)	2 (11.8)	1 (5.9)	1 (5.9)
<b>Lack of Appetite</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	2 (15.4)	1 (7.7)	---	1 (7.7)	---	---	---
Open-label (N=17)	---	---	1 (5.9)	---	---	---	---
<b>Low Mood</b>							
Placebo (N=5)	---	1 (20.0)	1 (20.0)	1 (20.0)	3 (60.0)	1 (20.0)	2 (40.0)
125 mg (N=13)	3 (23.1)	5 (38.5)	5 (38.5)	1 (7.7)	3 (23.1)	2 (15.4)	2 (15.4)
Open-label (N=17)	1 (5.9)	5 (29.4)	7 (41.2)	1 (5.9)	5 (29.4)	3 (17.6)	1 (5.9)
<b>Muscle Tension</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	1 (7.7)	1 (7.7)	1 (7.7)	1 (7.7)	---	---	---

<b>Post-drug MDMA HCl Dose</b>	<b>Day 1 N (%)</b>	<b>Day 2 N (%)</b>	<b>Day 3 N (%)</b>	<b>Day 4 N (%)</b>	<b>Day 5 N (%)</b>	<b>Day 6 N (%)</b>	<b>Day 7 N (%)</b>
Open-label (N=17)	1 (5.9)	---	---	2 (11.8)	---	---	---
<b>Nausea</b>							
Placebo (N=5)	1 (20.0)	1 (20.0)	1 (20.0)	1 (20.0)	---	---	---
125 mg (N=13)	2 (15.4)	4 (30.8)	4 (30.8)	2 (15.4)	1 (7.7)	1 (7.7)	1 (7.7)
Open-label (N=17)	2 (11.8)	---	---	---	---	---	---
<b>Need More Sleep</b>							
Placebo (N=5)	1 (20.0)	1 (20.0)	---	---	---	---	1 (20.0)
125 mg (N=13)	5 (38.5)	6 (46.2)	6 (46.2)	2 (15.4)	1 (7.7)	2 (15.4)	---
Open-label (N=17)	1 (5.9)	7 (41.2)	5 (29.4)	2 (11.8)	2 (11.8)	1 (5.9)	1 (5.9)
<b>Nystagmus</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	---	---	---	---	---	---	---
Open-label (N=17)	---	---	---	---	---	---	---
<b>Parasthesia</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	---	1 (7.7)	---	---	---	---	---
Open-label (N=17)	---	---	---	---	---	---	---
<b>Perspiration</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	---	---	---	---	---	---	---
Open-label (N=17)	1 (5.9)	---	---	---	---	---	---
<b>Restlessness</b>							
Placebo (N=5)	---	---	1 (20.0)	---	1 (20.0)	1 (20.0)	1 (20.0)
125 mg (N=13)	1 (7.7)	---	---	---	1 (7.7)	---	---
Open-label (N=17)	---	---	---	1 (5.9)	1 (5.9)	---	---
<b>Ruminations</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	---	---	---	---	---	1 (7.7)	---
Open-label (N=17)	---	---	2 (11.8)	---	---	1 (5.9)	1 (5.9)
<b>Sensitivity to Cold</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	---	1 (7.7)	---	---	---	---	---
Open-label (N=17)	---	---	---	---	---	---	---
<b>Thirst</b>							
Placebo (N=5)	---	---	---	---	---	---	---

<b>Post-drug MDMA HCl Dose</b>	<b>Day 1 N (%)</b>	<b>Day 2 N (%)</b>	<b>Day 3 N (%)</b>	<b>Day 4 N (%)</b>	<b>Day 5 N (%)</b>	<b>Day 6 N (%)</b>	<b>Day 7 N (%)</b>
125 mg (N=13)	2 (15.4)	---	---	---	---	---	---
Open-label (N=17)	2 (11.8)	1 (5.9)	1 (5.9)	---	---	---	---
<b>Weakness</b>							
Placebo (N=5)	---	---	---	---	---	---	---
125 mg (N=13)	1 (7.7)	---	1 (7.7)	---	---	---	---
Open-label (N=17)	---	1 (5.9)	---	---	---	---	---

<sup>A</sup> One severe report of diarrhea on Day 2 contact. All other reactions were mild or moderate.



**Appendix Table 20: Adverse Events by MedDRA (V. 17.1) System Organ Class (SOC) among Autistic Adults in Sponsor-Supported Phase 2 Study of MDMA-Assisted Therapy MAA-1**

SOC	Adverse Event Preferred Term <sup>A</sup>	Blinded Placebo	Blinded 75-125 mg MDMA HCl	Open-label 75-125 mg MDMA HCl	12-month Follow-up
	Participants per dose group	4	8	4	11
	Participants who reported an AE	1	4	3	3
		<b>N (%)</b>	<b>N (%)</b>	<b>N (%)</b>	<b>N (%)</b>
<b>General disorders and administration site conditions</b>					
	Pain	---	---	---	1 (9.0)
	Pyrexia	---	1 (12.5)	---	---
<b>Gastrointestinal disorders</b>					
	Irritable Bowel Syndrome	1 (25.0)	---	---	---
<b>Infections and infestations</b>					
	Nasopharyngitis	---	1 (12.5)	---	1 (9.0)
	Sinusitis	1 (25.0)	---	---	---
	Upper respiratory infection	1 (25.0)	1 (12.5)	1 (25.0)	---
<b>Injury, poisonings, procedural complications</b>					
	Ligament injury	---	1 (12.5)	---	---
	Retinal injury	---	---	---	1 (9.0)
<b>Musculoskeletal and connective tissue disorders</b>					
	Back pain	---	---	1 (25.0)	---
	Myalgia	---	---	1 (25.0)	---
<b>Nervous system disorders</b>					
	Headache	---	1 (12.5)	---	---
	Syncope	---	---	---	1 (9.0)
<b>Psychiatric disorders</b>					
	Anxiety	---	1 (12.5)	---	---
	Depressed mood	---	2 (25.0)	---	---
	Depression	1 (25.0)	1 (12.5)	---	---
	Dissociation	---	---	---	---
	Panic attack	---	1 (12.5)	1 (25.0)	---
	Panic reaction	---	1 (12.5)	---	---
	Psychiatric symptom	---	---	---	---
	Suicidal ideation	1 (25.0)	2 (25.0)	1 (25.0)	---
<b>Reproductive system and breast disorders</b>					
	Dysmenorrhea	---	1 (12.5)	---	---
<b>Respiratory, thoracic, and mediastinal disorders</b>					
	Cough	---	1 (12.5)	1 (25.0)	---
	Oropharyngeal pain	---	---	1 (25.0)	---

<sup>A</sup> Codes derived from MedDRA v17. Only one instance of an individual event per subject after each dosing session and dose is reported. No severe adverse events reported

**Appendix Table 21: Adverse Events<sup>A</sup> by MedDRA (v 17.1) System Organ Class (SOC) among Participants with Anxiety Associated with a Life-threatening Illness in Sponsor Supported Phase 2 Study of MDMA-Assisted Therapy MDA-1**

SOC	Adverse Event Preferred Term	Blinded Placebo	Blinded 125 mg MDMA HCl	Open-label 125 mg MDMA HCl	12-Month Follow-up
Participants per dose group		5	13	17	17
Participants who reported at least 1 AE		2	11	7	9
		N (%)	N (%)	N (%)	N (%)
<b>Cardiac disorders</b>					
	Arrhythmia	---	---	1 (5.9)	---
<b>Gastrointestinal disorders</b>					
	Abdominal discomfort	---	1 (7.7)	---	---
	Abdominal pain	---	1 (7.7)	---	---
	Aphthous stomatitis	1 (20.0)	---	---	---
	Esophageal pain [Oesophageal pain]	---	---	---	---
	Nausea	---	1 (7.7)	---	---
	Oesophageal pain	---	---	1 (5.9)	---
	Diarrhea [Diarhoea]	---	1 (7.7)	---	---
<b>General disorders and administration site conditions</b>					
	Chest pain	1 (20.0)	---	---	---
	Fatigue	---	3 (23.1)	---	---
	Pain	1 (20.0)	1 (7.7)	---	---
<b>Infections and Infestations</b>					
	Influenza	---	2 (15.4)	---	---
	Meningitis	---	---	---	1 (5.9) <sup>B</sup>
	Oral herpes	---	---	1 (5.9)	---
	Post procedural cellulitis	---	---	---	1 (5.9)
	Sepsis	---	---	---	1 (5.9) <sup>B</sup>
	Tinea infection	---	1 (7.7)	---	---
	Upper respiratory tract infection	---	---	1 (5.9)	---
	Viral upper respiratory tract infection	1 (20.0)	---	---	---
<b>Injury, poisoning and procedural complications</b>					
	Contusion	---	2 (15.4)	---	---
	Fall	---	1 (7.7)	---	---
	Skeletal injury	1 (20.0)	---	---	---
	Skin abrasion	---	1 (7.7)	---	---
	Thermal burn	1 (20.0)	---	---	---
	Tooth fracture	---	1 (7.7)	---	---
<b>Investigations</b>					
	Heart rate irregular	---	---	1 (5.9)	---
	Weight decrease	---	1 (7.7)	---	---
<b>Musculoskeletal and connective tissue disorders</b>					
	Arthralgia	---	1 (7.7)	---	---
	Back pain	---	2 (15.4)	---	---
	Intervertebral disc degeneration	---	---	---	1 (5.9)
	Plantar fasciitis	1 (20.0)	---	---	---
	Muscle spasms	1 (20.0)	---	---	---

	Scleroderma	---	---	---	1 (5.9)
	Tenosynovitis stenosaurs	---	1 (7.7)	---	---
Neoplasms benign, malignant and unspecified					
	Chordoma	---	1 (7.7) <sup>B</sup>	---	---
	Intraductal proliferative breast lesion	---	---	---	1 (5.9)
	Invasive ductal breast carcinoma	---	---	---	1 (5.9) <sup>B</sup>
Nervous system disorders					
	Aphasia	---	---	---	1 (5.9) <sup>B</sup>
	Balance disorder	---	1 (7.7)	---	---
	Cerebrovascular accident	---	---	---	1 (5.9) <sup>B</sup>
	Clumsiness	---	1 (7.7)	---	---
	Muscle contractions involuntary	1 (20.0)	---	---	---
	Neuropathy peripheral	1 (20.0)	---	1 (5.9)	1 (5.9)
	Paraesthesia	---	1 (7.7)	---	1 (5.9)
	Sciatica	---	---	---	1 (5.9)
	Sinus headache	---	1 (7.7)	---	---
	Spinal cord paralysis	---	---	---	1 (5.9) <sup>B</sup>
	Tremor	---	---	1 (5.9)	---
Psychiatric disorders					
	Anxiety	---	1 (7.7)	2 (11.8)	---
	Bruxism	---	---	1 (5.9)	---
	Depressed mood	---	1 (7.7)	1 (5.9)	---
	Depression	---	1 (7.7)	---	1 (5.9)
	Dissociation	---	1 (7.7)	---	---
	Drug abuse <sup>C</sup>	---	---	---	1 (5.9)
	Hypomania	---	---	1 (5.9)	---
	Insomnia	1 (20.0)	2 (15.4)	4 (23.5)	---
Renal and urinary disorders					
	Nephrolithiasis	---	1 (7.7)	---	---
Reproductive system and breast disorders					
	Vaginal discharge	---	1 (7.7)	---	---
Respiratory, thoracic and mediastinal disorders					
	Hyperventilation	---	1 (7.7)	---	---
Skin and subcutaneous tissue disorders					
	Alopecia	---	1 (7.7)	---	---
	Pruritis	---	---	1 (5.9)	---
	Urticaria	---	1 (7.7)	1 (5.9)	---
Vascular disorders					
	Hot flush	---	---	1 (5.9)	---
	Lymphoedema	---	---	---	1 (5.9)

<sup>A</sup> Each adverse event reported once per subject per blinded or open-label period.

<sup>B</sup> AEs rated severe. Of the seven AEs rated severe, six AEs occurred in a single individual after cancer recurrence. The participant's last visit was the Primary Endpoint. The subject died prior to LTFU. A second subject experienced a severe AE during the long-term follow-up.

<sup>C</sup> LLT was nondependent use of hallucinogens, not a drug abuse disorder.

**Appendix Table 22: Highlights of MDMA Clinical Pharmacology and Cardiac Safety**

Therapeutic dose and exposure	<p>Maximum proposed clinical dosing regimen: Three divided single-dose exposures spaced approximately a month apart of 80 mg -120 mg initial dose MDMA HCl and 40 mg-60 mg supplemental dose MDMA HCl, administered 1.5 to 2 hours after initial dose. Mean (%CV) C<sub>max</sub> and AUC at the single maximum proposed clinical dose 125 mg MDMA HCl [232]: C<sub>max</sub>: 223.5 ± 38.5 ng/mL (N=136) AUC: 948 ± 172.9 ng*h/mL (N=136) Mean (%CV) C<sub>max</sub> and AUC at the steady state with the maximum proposed clinical dosing regimen: Clinical dosing regimen does not reach steady state, single-dose only with at least 2 weeks washout between doses</p>	
Maximum tolerated dose	NOAEL: 100 mg/kg (p.o.) in rat with single housing	
Maximum dose tested	Single-Dose	150 mg MDMA HCl
	Multiple-Dose	The drug is designed to be given as a divided single-dose on Day 1: Initial dose followed by supplemental dose given 1.5-2.0 hours later. On Day 30 and Day 60, additional single-doses on the same schedule may be given if warranted.
Exposures Achieved at Maximum Tested Dose	Single-Dose	<p>Initial dose 150 mg MDMA HCl (N=2) [18]: <b>MDMA</b> C<sub>max</sub>: 441.9-486.9 ng/mL AUC<sub>0-24</sub>: 5132.8-5232.0 ng*h/mL <b>MDA</b> C<sub>max</sub>: 34.2-31.4 ng/mL AUC<sub>0-24</sub>: 373.9-590.0 ng*h/mL</p>
	Multiple-Dose	<p>Initial dose 50 mg MDMA HCl + Supplemental dose 100 mg MDMA HCl, 2.0 hours later (N=10) [265]: <b>MDMA</b> C<sub>max</sub> +12.8%, AUC<sub>∞</sub> +16.2% <b>MDA</b> C<sub>max</sub>: +25%, AUC<sub>∞</sub> +37.5% <b>HMMA</b> C<sub>max</sub> -38.2%, AUC<sub>∞</sub> -29.8%</p>

<p>Range of linear PK*</p> <p><i>*More PK data was available for 75 mg dose (N=8), which was used as basis for dose normalization [18]</i></p>	<p>MDMA C<sub>max</sub> normalized to 75 mg</p> <p>100 mg (N=2): 1.53 125 mg (N=8): 1.81** 150 mg (N=2): 3.55</p> <p>MDA C<sub>max</sub> normalized to 75 mg</p> <p>100 mg (N=2): 2.35 125 mg (N=8): 1.76 150 mg (N=2): 4.21</p> <p>** This ratio was confirmed in a more recent study with N=29 receiving 75 mg MDMA HCl [232]. 125 mg MDMA HCl (N=110): 1.83</p>	<p>MDMA AUC<sub>0-24</sub> normalized to 75 mg</p> <p>100 mg (N=2): 1.39 125 mg (N=8): 1.97 150 mg (N=2): 3.89</p> <p>MDA AUC<sub>0-24</sub> normalized to 75 mg</p> <p>100 mg (N=2): 1.66 125 mg (N=8): 1.76 150 mg (N=2): 3.94</p>
<p>Accumulation at steady state</p>	<p>Therapeutic use is single-dose, MDMA does not reach steady state</p>	
<p>Metabolites</p>	<p>MDMA metabolism in the liver is saturable in a dose-dependent manner and follows non-linear pharmacokinetics. MDMA is metabolized by <i>N</i>-demethylation to the only active metabolite MDA by several enzymes, including CYP2D6 (&gt;30%), CYP1A2, CYP3A4, CYP2C19, and CYP2B6, followed by COMT. The parent compound and MDA are further <i>O</i>-demethylated to HHMA and HHA, respectively. Both HHMA and HHA are subsequently <i>O</i>-methylated mainly to HMMA and HMA. These four metabolites, particularly HMMA and HMA, are excreted in the urine as conjugated glucuronide or sulfate metabolites.</p>	
<p>Absorption</p>	<p>Absolute/Relative Bioavailability</p>	<p>MDMA has not been studied with I.V. administration in humans.</p>

Distribution	T <sub>max</sub>	T <sub>max</sub> by dose of MDMA HCl administered [18]: <ul style="list-style-type: none"> <li>• <b>Parent MDMA:</b>  75 mg: 1.8 ± 0.4 hours  100 mg: 2-3 hours  125 mg: 2.4 ± 1.0 hours  150 mg: 1.5-2 hours</li> <li>• <b>Active Metabolite MDA:</b>  75 mg: 5.1 ± 2.6 hours  100 mg: 4-6 hours  125 mg: 7.1 ± 2.8 hours  150 mg: 4-10 hours</li> </ul>
	Vd/F or Vd	Vd/F by dose of MDMA administered [253]: 1.0 mg/kg MDMA HCl (43-106 mg): 5.5 ± 1.1 L/kg 1.6 mg/kg MDMA HCl (69-150 mg): 5.5 ± 1.3 L/kg
	% bound	51% Bound at a concentration of 200ng/mL [560]
Elimination	Route	<ul style="list-style-type: none"> <li>• Primary route hepatic, 50% to 75% metabolized</li> <li>• Renal clearance 8% to 11%</li> </ul> <p>All metabolites of MDMA in urine were detected as glucuronide and sulfate conjugates.</p> <p>After 1.0 mg/kg MDMA HCl, the majority was excreted in urine as the inactive metabolites HMMA sulfate (13%), followed by DHMA 3-sulfate (9%), and HMMA glucuronide (5%), and only 8% as the parent compound MDMA [253].</p> <p>After 1.6 mg/kg MDMA HCl, the majority was excreted in urine as the inactive metabolites HMMA sulfate (10%), followed by DHMA 3-sulfate (9%), and HMMA glucuronide (4%), and only 11% as the parent compound MDMA. Studies examining metabolism of 100 mg MDMA HCl reported similar excretion values [253].</p>
	Terminal t <sub>1/2</sub>	Terminal t <sub>1/2</sub> by dose of MDMA HCl administered [253]: <ul style="list-style-type: none"> <li>• <b>Parent MDMA:</b>  1.0 mg/kg (43 mg-106 mg): 6.9 ± 3.4 h  1.6 mg/kg (69 mg-150 mg): 8.1 ± 2.1 h</li> <li>• <b>Active Metabolite MDA:</b>  1.0 mg/kg (43 mg-106 mg): 10.6 ± 4.3 h  1.6 mg/kg (69 mg-150 mg): 12.3 ± 3.7 h</li> </ul>

Intrinsic Factors	CL/F or CL	<p>Renal CL by dose of MDMA HCl administered [18]:            75 mg: 12.8 ± 5.6 L/h            100 mg: 20.4-12.3 L/h            125 mg: 13.0 ± 5.4 L/h            150 mg: 5.2-11.3 L/h</p> <p>CL/F by dose of MDMA HCl administered [253]:            1.0 mg/kg (43 mg-106 mg): 0.62 ± 0.19 L/h/kg            1.6 mg/kg (69 mg-150 mg): 0.48 ± 0.11 L/h/kg</p>
	Age	<p>Pediatric PK will be tested after initial NDA            No information is available on effect of age on exposure, but from a mechanistic point of view, the enzymes responsible for metabolism of MDMA are not known to be affected by age.</p>
	Sex	In a pooled study analysis, sex was not predictive of plasma concentration once corrected for body weight [570].
	Race	<p>PK parameters by dose of MDMA administered [253]:            1.0 mg/kg (43 mg-106 mg) MDMA HCl:            MDMA C<sub>max</sub>: +22% in Blacks vs. Europeans            MDMA AUC: +19% in Blacks vs. Europeans            MDA C<sub>max</sub>: +9.3% in Blacks vs. Europeans            1.6 mg/kg (69-150 mg) MDMA:            MDMA C<sub>max</sub>: +21% in Blacks vs. Europeans            MDMA AUC: +8% in Blacks vs. Europeans            MDA C<sub>max</sub>: +1.4% in Blacks vs. Europeans</p>
	Hepatic & Renal Impairment	<p>CYP2D6 poor vs. extensive metabolizers [586]:            MDMA C<sub>max</sub> +15%            MDA C<sub>max</sub> +50%            HMMA C<sub>max</sub> -50-70%</p> <p>A PK study in subjects with moderate hepatic impairment is planned as post-marketing Phase 4 study (MPKH). Due to &lt;20% renal clearance of the parent compound, a renal impairment PK study is not planned.</p>



Extrinsic Factors	Drug interactions	<p>Paroxetine (N=7), CYP2D6 inhibitor, metabolized by CYP2D6&gt;&gt;CYP3A4&gt;CYP1A2&gt;CYP2C19&gt;CYP3A5 [591].</p> <p><b>MDMA</b> C<sub>max</sub> +17% AUC<sub>0-27</sub> +23%</p> <p><b>MDA</b> C<sub>max</sub> +17% AUC<sub>0-27</sub> +16%</p> <p>Bupropion (N=16) CYP2D6 and CYP2B6 inhibitor, metabolize [592]<sup>[06]</sup>.</p> <p><b>MDMA</b> C<sub>max</sub> +14% AUC<sub>0-24</sub> +33% t<sub>1/2</sub> +24%</p> <p><b>MDA</b> C<sub>max</sub> -15% AUC<sub>0-24</sub> -12%</p> <p>30 mg Dextromethorphan (N=12), metabolized by CYP2D6&gt;&gt; CYP3A4&gt; CYP2B6. Co-administered with 1.5 mg/kg MDMA HCl [569].</p> <p><b>Dextromethorphan</b> C<sub>max</sub> +87.9% AUC<sub>0-8</sub> +89.1%</p> <p><b>Dextrophan</b> C<sub>max</sub> -93.0% AUC<sub>0-8</sub> -90.4%</p> <p><b>3-methoximorphinan</b> C<sub>max</sub> +72.2% AUC<sub>0-8</sub> +64.6%</p> <p><b>Hydroxymorphinan-3-ol</b> C<sub>max</sub> -87.2% AUC<sub>0-8</sub> -86.7%</p>
-------------------	-------------------	--

		<p>Methylphenidate (N=16), metabolized by CYP2D6 [557]</p> <p><b>MDMA</b> C<sub>max</sub> -3.5% AUC<sub>0-24</sub> +3.2%</p> <p><b>MDA</b> C<sub>max</sub> -3.6% AUC<sub>0-24</sub> -3.4%</p> <p><b>Methylphenidate</b> C<sub>max</sub> +&lt;0.1% AUC<sub>0-24</sub> -&lt;0.1%</p>
Expected High Clinical Exposure Scenario	Food Effects	<p>Has not been studied</p> <p>Metabolism of MDMA is complex, with 50-75% of the parent compound being metabolized. Major enzymes involved in metabolism of MDMA include: CYP2D6 (&gt;30%)&gt; CYP1A2&gt;CYP3A4&gt;CYP2C19&gt; CYP2B6. Active doses of MDMA HCl (75 mg -125 mg) reversibly inhibit CYP2D6 and decrease CYP3A4 activity, with CYP2D6 activity normalizing after 10 days post-drug. Compensatory metabolic mechanisms have been demonstrated when CYP2D6 is inhibited, such as an increase in CYP1A2 activity by 20-40% [571].</p> <p>In the therapeutic dose range of 75-125 mg MDMA HCl, a concentration-dependent effect is observed. Studying higher doses of MDMA in healthy subjects poses both safety and ethical concerns due to the Schedule 1 controlled substance status of MDMA. Although elevation of blood pressure and heart rate has been observed, these cases have not been accompanied by clinical signs and symptoms of end organ effects of hypertension (e.g., chest pain, shortness of breath, neurological deficit or confusion) and have not been considered clinically significant AEs.</p> <p>The worst-case scenario would be strong inhibition of both CYP2D6, CYP2B6, and CYP1A2 combined with administration of an initial dose of 125 mg MDMA HCl followed by a supplemental half-dose 1.5-2.0 hours later. Based on the exposure observed with CYP2D6/CYP2B6 inhibition by Bupropion with a C<sub>max</sub> elevation of +14% and AUC elevation of +33%, combined with a C<sub>max</sub> elevation of +12.8% and AUC elevation of +16.2% with a supplemental dose, the increase in exposure is estimated to be C<sub>max</sub> +26.8% of MDMA and AUC +49.2% of MDMA. If CYP1A2 is additionally inhibited, a conservative estimate would be to double the exposure estimate for a C<sub>max</sub> elevation of +53% and AUC could be elevated up to +75%.</p> <p>125 mg MDMA HCl: If an estimated 60% of metabolism is shut down, moderate hepatic impairment would double the AUC to be equivalent to 250 mg MDMA HCl. PK exposure to single-doses above 150 mg MDMA HCl remain untested to date. PK studies planned to be conducted will cover a therapeutic dose of 120 mg MDMA HCl, with a maximum dosage strength of 60 mg MDMA HCl capsules. In MAPS-sponsored clinical trials, MDMA is only administered under the supervision of trained and qualified healthcare professionals in a controlled setting.</p>

Preclinical Cardiac Safety	<p><b><i>In vitro</i> nonclinical data:</b> The sponsor has completed an appropriately controlled, <i>in vitro</i> IKr Assay (commonly referred to as a human Ether-à-go-go-Related Gene (hERG) assay) per ICH S7A and S7B. Final results from the cell patch clamp measure found an IC<sub>50</sub> of 206 μM and a Hill coefficient of 1.1 for MDMA at near-physiologic temperature (33°C), with a 170-fold ratio over the expected unbound MDMA plasma concentration in clinical exposure at 2 mg/kg p.o. [218]. These results demonstrate that MDMA has minimal risk of QTc prolongation or Torsade de Pointes (TdP), which is one of the most critical types of arrhythmia associated with sudden death.</p> <p><b><i>In vivo</i> nonclinical data:</b> The sponsor has completed an <i>in vivo</i> cardiovascular substudy as a part of the GLP Extended Single-Dose Neurotoxicology study administering beagle dogs with 0,2,4, 9/12 mg/kg p.o. MDMA (with correction factor for HCl salt) once weekly for 4 weeks (Study 2884-002). The dog is commonly used to investigate cardiac electrophysiology in a manner that will extrapolate to humans in terms of which cardiac ion channels contribute to cardiac repolarization and to the duration of the action potential. All animals in all groups received an electrocardiographic (ECG) examination pretest, and all survivors predose and 1-2 hours postdose on Day 1 and prior to terminal necropsy (study days 2 and 27). Standard ECGs (10 Lead) were recorded at 50 mm/sec. The RR, PR, and QT intervals, and QRS duration were measured and recorded using an appropriate lead. The Principal Investigator for electrocardiographic analysis interpreted the electrocardiograms. Heart rate was calculated from the number of ECG complexes in 10 seconds. QTc was calculated using Van de Water's correction. There was no effect of the oral administration of MDMA on qualitative or quantitative ECG parameters in this study.</p>
----------------------------	--

Clinical Cardiac Safety	Cumulative Known Exposure to MDMA in MAPS-Sponsored Clinical Trials						
	Study	Phase	Country	Study Population	Planned Enrollment	Participant Exposure to MDMA	Participant Exposure to Placebo
	MP-1	2	US	PTSD	21	22 <sup>A</sup>	8
	MP-2	2	Switzerland	PTSD	12	14	-
	MP-3	2	Israel	PTSD	12	5	-
	MP-4	2	Canada	PTSD	12	6	2
	MP-8	2	US	PTSD	24	26	-
	MP-9	2	Israel	PTSD	10	10	-
	MP-12	2	US	PTSD	23	28	-
	MP1-E2	2	US	PTSD	3 <sup>B</sup>	3 <sup>B</sup>	-
	MT-1	1	US	Healthy Volunteer	120	96 <sup>C</sup>	96
	MAA-1	2	US	Autistics with Social Anxiety	12	12	4
	MDA-1	2	US	Anxiety Related to Life-threatening Illness	18	18	5
	MPVA-1	1/2	US	PTSD and Concerned Significant Other	20	12	-
	MPVA-4	1	US	Healthy Volunteer	30	17	17
	MP16	2	US	PTSD	60	33	-
	MP17	2	Canada	PTSD	5	4	-
	MP18	2	EEA	PTSD	40	4	-
	MAPP1	3	US/Canada/Israel	PTSD	100	46	44
	MAPP2	3	US/Canada/Israel	PTSD	100	Blinded; 41 total <sup>D</sup>	
	MAPPUSX	2	US/Canada/Israel	PTSD	100	5	-
	Total				719	358	176

*(Based on final data for completed studies and preliminary data for ongoing studies)*

- **2 sponsored Phase 3 studies in patients (N=51):** initial doses ranging from 84 mg to 100 mg MDMA <sup>E</sup> with supplemental dose of 34 mg to 50 mg MDMA 1.5-2 hours after initial dose. Number of exposures: 3 single-dose dosing sessions. MAPP2 is excluded as it is ongoing and blinded.
- **15 sponsored Phase 2 studies in patients (N=194):** initial doses ranging from 21 mg, 25 mg, 34 mg, 64 mg, 68 mg, 84 mg, 100 mg, 106 mg, to 128 mg MDMA with supplemental half-dose 1.5-2 hours after initial dose. Participants randomized to 21 mg to 64 mg MDMA group in blinded Phase 2 studies had open-label cross over to active dose (84 mg to 106 mg MDMA). Number of exposures: 1 to 6 single-dose dosing sessions (1-3 blinded, 2-3 open-label exposures).
- **2 sponsored Phase 1 studies in healthy volunteers (N=113):** initial doses ranging from 84 mg to 106 mg MDMA with supplemental dose 1.5-2 hours after initial dose. Number of exposures: 1 to 2 single-dose dosing sessions.
- **78 investigator-initiated Phase 1 and Phase 2 studies (N=1441),** doses ranging from 0.25 mg/kg to 3.1 mg/kg MDMA HC1 (17.5-217 mg based on 70 kg standard weight assumption). Number of exposures: At least 1.

**Cardiac Safety Events in MAPS Sponsored Clinical Trials**

The following cardiac safety events have been observed in the MDMA group in MAPS Sponsored Phase 2 and 3 clinical trials to date. Adverse events resolved without treatment.

- *QT prolongation:* none reported
- *Syncope (postural):* 1 blinded PTSD participant receiving active dose (64 mg to 106 mg MDMA) and 3 open-label PTSD participants receiving active dose (68 mg to 128 mg MDMA) experienced this AE.
- *Syncope (non-postural):* none reported
- *Seizures:* none reported
- *Exacerbation of ventricular extrasystoles:* 1 blinded PTSD participant receiving active dose (106 mg MDMA) experienced this AE. Participant had one PVC at baseline EKG prior to exposure and a history of PVCs. Observed during fifth exposure, duration 1 day, reported to sponsor as expected SAR based on hospitalization for observation and further assessment.
- *Ventricular tachycardia:* none reported
- *Sinus tachycardia:* 1 blinded PTSD participant receiving active dose MDMA in study MP-1 experienced this AE. Reported 12 days post second exposure, duration 54 days.
- *Palpitations:* 6 Phase 2 open-label PTSD participants receiving active dose (68 mg to 128 mg MDMA), 4 Phase 3 blinded PTSD participants receiving active dose (68 mg to 100 mg MDMA), and 1 Phase 2 open-label PTSD participant receiving active dose (68 mg to 100 mg MDMA) experienced this AE.
- *Ventricular fibrillation:* none reported
- *Flutter:* none reported
- *Torsade de pointes:* none reported
- *Sudden deaths:* none reported

	<p><b>In the Phase 2 study MP-8, participants with controlled hypertension</b> (kept normal with medication) were allowed entry into the study if they passed a nuclear stress test and carotid ultrasound in addition to normal EKG at screening. A total of 4 controlled hypertension subjects were enrolled and treated (25 mg MDMA N=1, 64 mg MDMA N=1, 106 mg MDMA N=2). Subjects receiving 64 mg and 106 mg MDMA experienced transient systolic blood pressure (SBP) above 160 mmHg in 75% (3 of 4) of participants during blinded sessions with 64 mg to 106 mg MDMA and in 67% (2 of 3) participants receiving 84 mg to 106 mg MDMA during open-label sessions. No increase in SBP &gt;160 mmHg occurred after administration of 25 mg MDMA. Among these 4 subjects, peak SBP during blinded MDMA exposure was 131 mmHg with 25 mg MDMA, 179 mmHg with 64 mg MDMA and 177 mmHg with 106 mg MDMA. During the open-label crossover with 84 mg to 106 mg MDMA, the peak SBP during exposure was 193 mmHg. The maximum systolic blood pressure for these 7 participants with controlled hypertension was 193 mmHg, which occurred during an open-label session. The baseline values and elevations after MDMA appear higher in this sub-group than the overall sample but any meaningful comparison is limited by the sample size. None of the participants with controlled hypertension experienced AEs of the cardiovascular system and SBP returned to baseline or near-baseline levels at final session reading without any additional medication.</p> <p><b>In the Phase 3 placebo-controlled study MAPP1, participants with controlled hypertension</b> (kept normal with medication) were allowed entry into the study if they passed a nuclear stress test and carotid ultrasound in addition to normal EKG at screening. There were 7 participants with a medical history of controlled hypertension (n = 3 MDMA), of these three MDMA participants one had transient systolic BP &gt; 180 mmHg post-dosing at the first and second dosing session (increase in systolic BP &gt; 40 mmHg compared to pre-dose measurement) and another one of these had a transient diastolic BP &gt; 110 mmHg post-dosing at the second dosing session (increase in diastolic BP &gt; 25 mmHg compared to pre-dose measurement). None of the MDMA participants with controlled hypertension experienced AEs of the cardiovascular systems. Systolic BP and diastolic BP returned to baseline or near-baseline levels at final session reading without any additional medication or intervention.</p>
--	--

<sup>A</sup> In MP-1, participants received either MDMA or an inactive placebo, but participants who took the option of continuing to the open-label crossover Stage 2 then received active dose MDMA as well (only one participant chose not to continue to Stage 2 in MP-1, due to a strong and sustained placebo response)

<sup>B</sup> In MP1-E2, participants were previously enrolled in MP-1. These participants were not counted again in the final summation.

<sup>C</sup> The MT-1 study uses a blinded full crossover design, with placebo administered in one session and MDMA in another session.

<sup>D</sup> The ongoing MAPP2 study has a blinded 1:1 allocation. The combined blinded exposures were not added to either total for MDMA or placebo.

<sup>E</sup> Values in sponsor-supported studies reflect the active MDMA free-base weight, not the total MDMA HCl weight. See [Appendix Table 23: MDMA Salt to Active Moiety Conversion](#) Chart.

**Appendix Table 23: MDMA Salt to Active Moiety Conversion Chart**

The molecular weight (MW) of MDMA as an anhydrous HCl salt (229.70 g/mol) and the MW of MDMA as a base (193.25 g/mol) were used to convert the mg of MDMA HCl to mg of MDMA (active moiety), rounded to the nearest mg, per capsule. In studies where multiple capsules were administered, the converted amount per capsule was multiplied.

<b># of Capsules of each Dose MDMA HCl (mg)</b>	<b>MDMA HCl (mg)</b>	<b>MDMA (mg)</b>
	12.5	11
	15	13
	25	21
	30	25
	37.5	32
	40	34
	50	42
	60	50
	62.5	53
2 x 37.5	75	64
2 x 40	80	68
2 x 50	100	84
3 x 37.5	112.5	96
2 x 60	120	100
2 x 62.5	125	106
4 x 37.5	150	128
2 x 60 + 40	160	134
3 x 60	180	150
3 x 62.5	187.5	159
6 x 37.5	225	192



## References

1. Yehuda, R., et al., *Post-traumatic stress disorder*. Nat Rev Dis Primers, 2015. **1**: p. 15057.
2. Shalev, A., I. Liberzon, and C. Marmar, *Post-Traumatic Stress Disorder*. N Engl J Med, 2017. **376**(25): p. 2459-2469.
3. Stefanovics, E.A., M.N. Potenza, and R.H. Pietrzak, *PTSD and obesity in U.S. military veterans: Prevalence, health burden, and suicidality*. Psychiatry Res, 2020. **291**: p. 113242.
4. Dorrington, S., et al., *Trauma, post-traumatic stress disorder and psychiatric disorders in a middle-income setting: prevalence and comorbidity*. Br J Psychiatry, 2014. **205**(5): p. 383-9.
5. Tarrier, N. and L. Gregg, *Suicide risk in civilian PTSD patients--predictors of suicidal ideation, planning and attempts*. Soc Psychiatry Psychiatr Epidemiol, 2004. **39**(8): p. 655-61.
6. Cipriani, A., et al., *Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis*. Psychol Med, 2018. **48**(12): p. 1975-1984.
7. Lee, D.J., et al., *Psychotherapy Versus Pharmacotherapy for Posttraumatic Stress Disorder: Systemic Review and Meta-Analyses to Determine First-Line Treatments*. Depress Anxiety, 2016. **33**(9): p. 792-806.
8. Steenkamp, M.M., et al., *Psychotherapy for Military-Related PTSD: A Review of Randomized Clinical Trials*. JAMA, 2015. **314**(5): p. 489-500.
9. Bradley, R., et al., *A multidimensional meta-analysis of psychotherapy for PTSD*. Am J Psychiatry, 2005. **162**(2): p. 214-27.
10. Brady, K., et al., *Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial*. JAMA, 2000. **283**(14): p. 1837-44.
11. Kolbrich, E.A., et al., *Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration*. J Clin Psychopharmacol, 2008. **28**(4): p. 432-40.
12. Cami, J., et al., *Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects*. J Clin Psychopharmacol, 2000. **20**(4): p. 455-66.
13. Mas, M., et al., *Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans*. J Pharmacol Exp Ther, 1999. **290**(1): p. 136-45.
14. Harris, D.S., et al., *Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans*. Psychopharmacology (Berl), 2002. **162**(4): p. 396-405.

15. Liechti, M.E., A. Gamma, and F.X. Vollenweider, *Gender differences in the subjective effects of MDMA*. *Psychopharmacology (Berl)*, 2001. **154**(2): p. 161-8.
16. Tancer, M. and C.E. Johanson, *Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP*. *Drug Alcohol Depend*, 2003. **72**(1): p. 33-44.
17. Vollenweider, F.X., et al., *Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers*. *Neuropsychopharmacology*, 1998. **19**(4): p. 241-51.
18. de la Torre, R., et al., *Non-linear pharmacokinetics of MDMA ('ecstasy') in humans*. *Br J Clin Pharmacol*, 2000. **49**(2): p. 104-9.
19. Marks, D.M., C.U. Pae, and A.A. Patkar, *Triple reuptake inhibitors: a premise and promise*. *Psychiatry Investig*, 2008. **5**(3): p. 142-7.
20. Millan, M.J., *Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs*. *Neurotherapeutics*, 2009. **6**(1): p. 53-77.
21. Han, D.D. and H.H. Gu, *Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs*. *BMC Pharmacol*, 2006. **6**: p. 6.
22. Liechti, M.E. and F.X. Vollenweider, *Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies*. *Hum Psychopharmacol*, 2001. **16**(8): p. 589-598.
23. Murnane, K.S., et al., *Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys*. *J Pharmacol Exp Ther*, 2010. **334**(2): p. 642-50.
24. Setola, V., et al., *3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro*. *Mol Pharmacol*, 2003. **63**(6): p. 1223-9.
25. Simmler, L.D., et al., *Monoamine transporter and receptor interaction profiles of a new series of designer cathinones*. *Neuropharmacology*, 2014. **79**: p. 152-60.
26. Carhart-Harris, R.L., et al., *The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories*. *Int J Neuropsychopharmacol*, 2014. **17**(4): p. 527-40.
27. Bedi, G., et al., *A window into the intoxicated mind? Speech as an index of psychoactive drug effects*. *Neuropsychopharmacology*, 2014. **39**(10): p. 2340-8.
28. Wardle, M.C., M.G. Kirkpatrick, and H. de Wit, *'Ecstasy' as a social drug: MDMA preferentially affects responses to emotional stimuli with social content*. *Soc Cogn Affect Neurosci*, 2014. **9**(8): p. 1076-81.
29. Wardle, M.C. and H. de Wit, *MDMA alters emotional processing and facilitates positive social interaction*. *Psychopharmacology (Berl)*, 2014. **231**(21): p. 4219-29.

30. Mitchell, J.M., et al., *MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study*. Nat Med, 2021. **27**(6): p. 1025-1033.
31. Mithoefer, M.C., et al., *MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials*. Psychopharmacology (Berl), 2019. **236**(9): p. 2735-2745.
32. Feduccia, A.A., et al., *Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline*. Frontiers in Psychiatry, 2019. **10**: p. 1-7.
33. Jerome, L., et al., *Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials*. Psychopharmacology (Berl), 2020.
34. Danforth, A., *Findings from a collective case study of the MDMA/Ecstasy experiences of adults on the autism spectrum: Transcripts from Psychedelic Science 2013*. MAPS Bulletin, 2013. **23**(3): p. 30-35.
35. Danforth, A.L., *Embracing Neurodiversity in Psychedelic Science: A Mixed-Methods Inquiry into the MDMA Experiences of Autistic Adults*. J Psychoactive Drugs, 2019: p. 1-9.
36. Downing, J., *The psychological and physiological effects of MDMA on normal volunteers*. J Psychoactive Drugs, 1986. **18**(4): p. 335-40.
37. Lester, S.J., et al., *Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial*. Ann Intern Med, 2000. **133**(12): p. 969-73.
38. Bedi, G., et al., *Effects of MDMA on sociability and neural response to social threat and social reward*. Psychopharmacology (Berl), 2009. **207**(1): p. 73-83.
39. Kirkpatrick, M.G., et al., *A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans*. Psychopharmacology (Berl), 2012. **219**(1): p. 109-22.
40. Grob, C., *MDMA research: preliminary investigations with human subjects*. Int J Drug Policy, 1998. **9**(2): p. 119-124.
41. Mithoefer, M.C., et al., *The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study*. J Psychopharmacol, 2011. **25**(4): p. 439-52.
42. Oehen, P., et al., *A randomized, controlled pilot study of MDMA (+/- 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)*. J Psychopharmacol, 2013. **27**(1): p. 40-52.
43. Baggott, M.J., et al., *MDMA Impairs Response to Water Intake in Healthy Volunteers*. Adv Pharmacol Sci, 2016. **2016**: p. 2175896.

44. Pacifici, R., et al., [*Immunomodulator properties of ecstasy (MDMA)*]. *Ann Ist Super Sanita*, 2000. **36**(1): p. 69-75.
45. Freudenmann, R.W., F. Oxler, and S. Bernschneider-Reif, *The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents*. *Addiction*, 2006. **101**(9): p. 1241-5.
46. Shulgin, A. and A. Shulgin, *Pihkal: A Chemical Love Story*. 1st ed. 1991, Berkeley, CA: Transform Press. 1-978.
47. Anderson, G.M.d., et al., *Absolute configuration and psychotomimetic activity*. *NIDA Res Monogr*, 1978. **22**: p. 8-15.
48. Shulgin, A.T. and D.E. Nichols, *Characterization of three new psychotomimetics*, in *The Pharmacology of Hallucinogens*, R.C. Stillman and R.E. Willette, Editors. 1978, Pergamon: New York.
49. Rudnick, G. and S.C. Wall, *The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release*. *Proc Natl Acad Sci U S A*, 1992. **89**(5): p. 1817-21.
50. O'Neil, M.J., *The Merck Index: An Encyclopedia of chemicals, drugs and biologicals*. *Merck Research Laboratories, Merck and Co. Inc*, Whitehouse station, New Jersey, 2006. **319**.
51. Greer, G. and R. Tolbert, *Subjective reports of the effects of MDMA in a clinical setting*. *J Psychoactive Drugs*, 1986. **18**(4): p. 319-27.
52. Hysek, C.M., et al., *MDMA enhances emotional empathy and prosocial behavior*. *Soc Cogn Affect Neurosci*, 2014. **9**(11): p. 1645-52.
53. Kirkpatrick, M.G., et al., *Effects of MDMA and Intranasal oxytocin on social and emotional processing*. *Neuropsychopharmacology*, 2014. **39**(7): p. 1654-63.
54. Adamson, S., *Through the gateway of the heart: Accounts of experiences With MDMA and other empathogenic substances*. 1985, San Francisco CA: Four Trees Publications.
55. Grinspoon, L. and J.B. Bakalar, *Can drugs be used to enhance the psychotherapeutic process?* *Am J Psychother*, 1986. **40**(3): p. 393-404.
56. Nichols, D.E., *Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens*. *J Psychoactive Drugs*, 1986. **18**(4): p. 305-13.
57. Greer, G. and R.J. Strassman, *Information on "Ecstasy"*. *Am J Psychiatry*, 1985. **142**(11): p. 1391.
58. Greer, G.R. and R. Tolbert, *A method of conducting therapeutic sessions with MDMA*. *J Psychoactive Drugs*, 1998. **30**(4): p. 371-379.
59. Metzner, R. and S. Adamson, *Using MDMA in healing, psychotherapy and spiritual practice*, in *Ecstasy, A Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA.*, J. Holland, Editor. 2001, Inner Traditions: Rochester VT. p. 182-207.

60. Greer, G. and R. Tolbert, *The therapeutic use of MDMA.*, in *Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA.*, S.J. Peroutka, Editor. 1990, Kluwer Academic: Boston, MA. p. 21-35.
61. Beck, J. and M. Rosenbaum, *Pursuit of Ecstasy: The MDMA Experience.* 1994, Albany, NY: SUNY Press.
62. US Department of Health and Human Services, S.A.a.M.H.S.A., Center for Behavioral Health Statistics and Quality, *National Survey on Drug Use and Health (NSDUH-2016-DS0001)*. 2018: Retrieved from <https://datafiles.samhsa.gov/>.
63. Europol, E.M.C.f.D.a.D.A.a., *EU Drug Markets Report 2019.* 2019, Publications Office of the European Union: Luxembourg.
64. Drug Enforcement Agency, *Scheduling of Controlled Substances: Scheduling of 3,4-methylenedioxymethamphetamine (MDMA) into Schedule I of the Controlled Substances Act: Remand*, DEA, Editor. 1988, Federal Register: Washington, DC. p. 5156-5160.
65. Lawn, J.C., *On the Matter of MDMA Scheduling*, in *Docket No. 84-48*, Drug\_Enforcement\_Administration, Editor. 1986: Washington, DC.
66. Henry, J.A., K.J. Jeffreys, and S. Dawling, *Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")*. *Lancet*, 1992. **340**(8816): p. 384-7.
67. Cohen, R.S. and J. Cocores, *Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA: "Ecstasy")*. *Prog Neuropsychopharmacol Biol Psychiatry*, 1997. **21**(4): p. 727-34.
68. Williamson, S., et al., *Adverse effects of stimulant drugs in a community sample of drug users*. *Drug Alcohol Depend*, 1997. **44**(2-3): p. 87-94.
69. Krystal, J.H., et al., *Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function?* *Am J Drug Alcohol Abuse*, 1992. **18**(3): p. 331-41.
70. McCann, U.D., et al., *Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans*. *Neuropsychopharmacology*, 1994. **10**(2): p. 129-38.
71. McCann, U.D., et al., *Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study*. *Psychopharmacology (Berl)*, 1999. **143**(4): p. 417-25.
72. Parrott, A.C. and J. Lasky, *Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance*. *Psychopharmacology (Berl)*, 1998. **139**(3): p. 261-8.
73. Ricaurte, G.A., et al., *Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy')*. *Toxicol Lett*, 2000. **112-113**: p. 143-6.

74. Baumann, M.H., et al., *Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat*. Drug Metab Dispos, 2009. **37**(11): p. 2163-70.
75. Biezonski, D.K. and J.S. Meyer, *The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis*. Curr Neuropharmacol, 2011. **9**(1): p. 84-90.
76. Gouzoulis-Mayfrank, E. and J. Daumann, *The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview*. J Psychopharmacol, 2006. **20**(2): p. 188-93.
77. Rogers, G., et al., *The harmful health effects of recreational ecstasy: a systematic review of observational evidence*. Health Technol Assess, 2009. **13**(6): p. iii-iv, ix-xii, 1-315.
78. Bouso, J.C., et al., *MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder*. J Psychoactive Drugs, 2008. **40**(3): p. 225-36.
79. Mithoefer, M.C., et al., *Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study*. J Psychopharmacol, 2013. **27**(1): p. 28-39.
80. Bedi, G., D. Hyman, and H. de Wit, *Is ecstasy an "empathogen"? Effects of +/-3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others*. Biol Psychiatry, 2010. **68**(12): p. 1134-40.
81. Dumont, G.J., et al., *Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration*. Soc Neurosci, 2009. **4**(4): p. 359-66.
82. Farre, M., et al., *Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics*. J Pharmacol Exp Ther, 2007. **323**(3): p. 954-62.
83. Hysek, C.M., G. Domes, and M.E. Liechti, *MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions*. Psychopharmacology (Berl), 2012. **222**(2): p. 293-302.
84. van Wel, J.H., et al., *Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT(2) and 5-HT(1) Receptors*. PLoS One, 2012. **7**(7): p. e40187.
85. Wagner, A.C., et al., *Combining Cognitive-Behavioral Conjoint Therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA): A Case Example*. J Psychoactive Drugs, 2019: p. 1-8.
86. Wang, J.B., et al., *Scaling Up: Multisite Open-Label Clinical Trials of MDMA-Assisted Therapy for Severe Posttraumatic Stress Disorder*. Journal of Humanistic Psychology, 2021: p. 00221678211023663.
87. Feduccia, A.A., J. Holland, and M.C. Mithoefer, *Progress and promise for the MDMA drug development program*. Psychopharmacology (Berl), 2018. **235**(2): p. 561-571.

88. Maples-Keller, J.L., et al., *A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults*. *J Psychopharmacol*, 2022: p. 2698811211069124.
89. Danforth, A.L., et al., *Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study*. *Psychopharmacology (Berl)*, 2018. **235**(11): p. 3137-3148.
90. Wolfson, P.E., et al., *MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study*. *Sci Rep*, 2020. **10**(1): p. 20442.
91. Lyon, R.A., R.A. Glennon, and M. Titeler, *3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors*. *Psychopharmacology (Berl)*, 1986. **88**(4): p. 525-6.
92. Shulgin, A.T., *The background and chemistry of MDMA*. *J Psychoactive Drugs*, 1986. **18**(4): p. 291-304.
93. Navarro, M., et al., *Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH*. *Clin Chem*, 2001. **47**(10): p. 1788-95.
94. Nair, J.B., et al., *Fully Validated, Multi-Kilogram cGMP Synthesis of MDMA*. *ACS Omega*, 2022. **7**(1): p. 900-907.
95. Hardman, H.F., C.O. Haavik, and M.H. Seevers, *Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals*. *Toxicol Appl Pharmacol*, 1973. **25**(2): p. 299-309.
96. Gardani, M., R.N. Blance, and S.M. Biello, *MDMA alters the response of the mammalian circadian clock in hamsters: effects on re-entrainment and triazolam-induced phase shifts*. *Brain Res*, 2005. **1046**(1-2): p. 105-15.
97. Mechan, A., et al., *Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons*. *Neuropsychopharmacology*, 2006. **31**(2): p. 339-50.
98. Wang, X., et al., *(+/-)-3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane*. *J Pharmacol Exp Ther*, 2005. **314**(3): p. 1002-12.
99. Frith, C.H., et al., *Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat*. *Fundam Appl Toxicol*, 1987. **9**(1): p. 110-9.
100. Frith, C.H. and W. Slikker, *28-Day Oral Toxicity of Methylenedioxymethamphetamine hydrochloride in rats: Protocol # EMD-SC-002*. 1985, MAPS: Unpublished.
101. Johnson, M.P., A.J. Hoffman, and D.E. Nichols, *Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices*. *Eur J Pharmacol*, 1986. **132**(2-3): p. 269-76.



102. Cole, J.C. and H.R. Sumnall, *The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA)*. *Neurosci Biobehav Rev*, 2003. **27**(3): p. 199-217.
103. Zsilla, G., et al., *3,4-Methylenedioxymethamphetamine, mephedrone, and beta-phenylethylamine release dopamine from the cytoplasm by means of transporters and keep the concentration high and constant by blocking reuptake*. *Eur J Pharmacol*, 2018. **837**: p. 72-80.
104. Fitzgerald, J.L. and J.J. Reid, *Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices*. *Eur J Pharmacol*, 1990. **191**(2): p. 217-20.
105. Kankaanpaa, A., et al., *The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens*. *Pharmacol Biochem Behav*, 1998. **59**(4): p. 1003-9.
106. Verrico, C.D., G.M. Miller, and B.K. Madras, *MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment*. *Psychopharmacology (Berl)*, 2007. **189**(4): p. 489-503.
107. Cozzi, N.V., et al., *Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines*. *Eur J Pharmacol*, 1999. **381**(1): p. 63-9.
108. Partilla, J.S., et al., *Interaction of amphetamines and related compounds at the vesicular monoamine transporter*. *J Pharmacol Exp Ther*, 2006. **319**(1): p. 237-46.
109. Bogen, I.L., et al., *Short- and long-term effects of MDMA ("ecstasy") on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo*. *Neurochem Int*, 2003. **43**(4-5): p. 393-400.
110. Gu, X.F. and E.C. Azmitia, *Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons*. *Eur J Pharmacol*, 1993. **235**(1): p. 51-7.
111. Leonardi, E.T. and E.C. Azmitia, *MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac)*. *Neuropsychopharmacology*, 1994. **10**(4): p. 231-8.
112. Pilgrim, J.L., et al., *Serotonin toxicity involving MDMA (ecstasy) and moclobemide*. *Forensic Sci Int*, 2012. **215**(1-3): p. 184-8.
113. Vuori, E., et al., *Death following ingestion of MDMA (ecstasy) and moclobemide*. *Addiction*, 2003. **98**(3): p. 365-8.
114. Slikker, W., Jr., et al., *Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate*. *Neurotoxicology*, 1989. **10**(3): p. 529-42.
115. Mlinar, B. and R. Corradetti, *Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT<sub>1B</sub> receptors located on CA1 pyramidal neurons*. *Eur J Neurosci*, 2003. **18**(6): p. 1559-71.

116. Rothman, R.B. and M.H. Baumann, *Monoamine transporters and psychostimulant drugs*. Eur J Pharmacol, 2003. **479**(1-3): p. 23-40.
117. Gudelsky, G.A. and B.K. Yamamoto, *Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons*. Pharmacol Biochem Behav, 2008. **90**(2): p. 198-207.
118. Feduccia, A.A., N. Kongovi, and C.L. Duvauchelle, *Heat increases MDMA-enhanced NAcc 5-HT and body temperature, but not MDMA self-administration*. Eur Neuropsychopharmacol, 2010. **20**(12): p. 884-94.
119. Yamamoto, B.K. and L.J. Spanos, *The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat*. Eur J Pharmacol, 1988. **148**(2): p. 195-203.
120. Shankaran, M. and G.A. Gudelsky, *Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin*. Pharmacol Biochem Behav, 1998. **61**(4): p. 361-6.
121. Bradbury, S., et al., *Acquisition of MDMA self-administration: pharmacokinetic factors and MDMA-induced serotonin release*. Addict Biol, 2014. **19**(5): p. 874-84.
122. Lazenka, M.F., et al., *Sex differences in abuse-related neurochemical and behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats*. Pharmacol Biochem Behav, 2017. **152**: p. 52-60.
123. Acquas, E., et al., *Intravenous administration of ecstasy (3,4-methylenedioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo*. Eur J Pharmacol, 2001. **418**(3): p. 207-11.
124. Nair, S.G. and G.A. Gudelsky, *3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat*. Psychopharmacology (Berl), 2006. **184**(2): p. 182-9.
125. Battaglia, G., et al., *Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites*. Eur J Pharmacol, 1988. **149**(1-2): p. 159-63.
126. Jones, D.C., S.S. Lau, and T.J. Monks, *Thioether metabolites of 3,4-methylenedioxymethamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells*. J Pharmacol Exp Ther, 2004. **311**(1): p. 298-306.
127. PDSP, *MDMA receptor binding profiles from Psychoactive Drug Screening Program Database Contract # NO1MH32004 (NIMH PDSP), with data accessed between November 12 and November 14, 2007*. 2007, National Institute of Mental Health.
128. Giannaccini, G., et al., *Short-term effects of 3,4-methylen-dioxy-metamphetamine (MDMA) on 5-HT(1A) receptors in the rat hippocampus*. Neurochem Int, 2007. **51**(8): p. 496-506.
129. Brunner, D. and R. Hen, *Insights into the neurobiology of impulsive behavior from serotonin receptor knockout mice*. Ann N Y Acad Sci, 1997. **836**: p. 81-105.

130. Graeff, F.G., et al., *Role of 5-HT in stress, anxiety, and depression*. Pharmacol Biochem Behav, 1996. **54**(1): p. 129-41.
131. Glennon, R.A. and R. Young, *MDMA stimulus generalization to the 5-HT(1A) serotonin agonist 8-hydroxy-2- (di-n-propylamino)tetralin*. 2000. **66**(3): p. 483-488.
132. Glennon, R.A., et al., *N-Methyl-1-(4-methoxyphenyl)-2-aminopropane (PMMA) and N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) produce non-identical discriminative stimuli in rats*. Pharmacol Biochem Behav, 2007. **86**(3): p. 477-84.
133. Schechter, M.D., *Discriminative profile of MDMA*. Pharmacol Biochem Behav, 1986. **24**(6): p. 1533-7.
134. Webster, J.I., D.N. Harper, and S. Schenk, *Generalization of serotonin and dopamine ligands to the discriminative stimulus effects of +/-3,4-methylenedioxymethamphetamine*. Behav Pharmacol, 2017. **28**(4): p. 245-254.
135. Schenk, S. and Q. Highgate, *Dopamine and serotonin antagonists fail to alter the discriminative stimulus properties of +/-methylenedioxymethamphetamine*. Behav Pharmacol, 2019. **30**(4): p. 327-334.
136. Nair, S.G. and G.A. Gudelsky, *3,4-Methylenedioxymethamphetamine (MDMA) enhances the release of acetylcholine by 5-HT4 and D1 receptor mechanisms in the rat prefrontal cortex*. Synapse, 2005. **58**(4): p. 229-35.
137. Kuteykin-Teplyakov, K. and R. Maldonado, *Looking for prosocial genes: ITRAQ analysis of proteins involved in MDMA-induced sociability in mice*. Eur Neuropsychopharmacol, 2014. **24**(11): p. 1773-83.
138. Belmer, A., et al., *Positive regulation of raphe serotonin neurons by serotonin 2B receptors*. Neuropsychopharmacology, 2018. **43**(7): p. 1623-1632.
139. Bankson, M.G. and B.K. Yamamoto, *Serotonin-GABA interactions modulate MDMA-induced mesolimbic dopamine release*. J Neurochem, 2004. **91**(4): p. 852-9.
140. Cordero-Erausquin, M., et al., *Nicotinic receptor function: new perspectives from knockout mice*. Trends Pharmacol Sci, 2000. **21**(6): p. 211-7.
141. Llabres, S., et al., *Molecular basis of the selective binding of MDMA enantiomers to the alpha4beta2 nicotinic receptor subtype: synthesis, pharmacological evaluation and mechanistic studies*. Eur J Med Chem, 2014. **81**: p. 35-46.
142. Jorgensen, H., et al., *Serotonin receptors involved in vasopressin and oxytocin secretion*. J Neuroendocrinol, 2003. **15**(3): p. 242-9.
143. Forsling, M.L., et al., *The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus*. Br J Pharmacol, 2002. **135**(3): p. 649-56.
144. Thompson, M.R., et al., *A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy")*. Neuroscience, 2007. **146**(2): p. 509-14.

145. Morley, K.C., J.C. Arnold, and I.S. McGregor, *Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat*. *Prog Neuropsychopharmacol Biol Psychiatry*, 2005. **29**(5): p. 648-57.
146. Broadbear, J.H., et al., *Oxytocinergic regulation of endogenous as well as drug-induced mood*. *Pharmacol Biochem Behav*, 2014. **119**: p. 61-71.
147. Pettie, M., et al., *A genetic deletion of the serotonin transporter differentially influences the behavioural effects of MDMA*. *J Psychopharmacol*, 2019. **33**(3): p. 355-363.
148. Ferraz de Paula, V., et al., *Methylenedioxymethamphetamine (Ecstasy) Decreases Neutrophil Activity and Alters Leukocyte Distribution in Bone Marrow, Spleen and Blood*. *Neuroimmunomodulation*, 2009. **16**(3): p. 191-200.
149. Nash, J.F., Jr., H.Y. Meltzer, and G.A. Gudelsky, *Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine*. *J Pharmacol Exp Ther*, 1988. **245**(3): p. 873-9.
150. Connor, T.J., J.P. Kelly, and B.E. Leonard, *An assessment of the acute effects of the serotonin releasers methylenedioxymethamphetamine, methylenedioxyamphetamine and fenfluramine on immunity in rats*. *Immunopharmacology*, 2000. **46**(3): p. 223-35.
151. Murnane, K.S., et al., *The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study*. *Horm Behav*, 2012. **61**(2): p. 181-90.
152. Tiangco, D.A., et al., *3,4-Methylenedioxymethamphetamine activates nuclear factor-kappaB, increases intracellular calcium, and modulates gene transcription in rat heart cells*. *Cardiovasc Toxicol*, 2005. **5**(3): p. 301-10.
153. Schindler, C.W., et al., *Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats*. *Br J Pharmacol*, 2014. **171**(1): p. 83-91.
154. Fallon, J.K., et al., *Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release*. *Ann N Y Acad Sci*, 2002. **965**: p. 399-409.
155. Fonsart, J., et al., *Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA)*. *Toxicol Appl Pharmacol*, 2009. **241**(3): p. 339-47.
156. Malpass, A., et al., *Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats*. *Pharmacol Biochem Behav*, 1999. **64**(1): p. 29-34.
157. Palenicek, T., et al., *Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats*. *Physiol Behav*, 2005. **86**(4): p. 546-53.
158. Davis, W.M., H.T. Hatoum, and I.W. Waters, *Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevance to hazards of MDMA (Ecstasy) abuse*. *Alcohol Drug Res*, 1987. **7**(3): p. 123-34.

159. Fantegrossi, W.E., et al., *Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice.* Psychopharmacology (Berl), 2003. **166**(3): p. 202-11.
160. Mahmood, I. and J.D. Balian, *Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species.* Life Sci, 1996. **59**(7): p. 579-85.
161. Fantegrossi, W.E., et al., *Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice.* Psychopharmacology (Berl), 2004. **173**(3-4): p. 270-7.
162. Meyer, J.S., et al., *Neural effects of MDMA as determined by functional magnetic resonance imaging and magnetic resonance spectroscopy in awake marmoset monkeys.* Ann N Y Acad Sci, 2006. **1074**: p. 365-76.
163. Molliver, M.E., et al., *Neurotoxicity of MDMA and related compounds: anatomic studies.* Ann N Y Acad Sci, 1990. **600**: p. 649-61; discussion 661-4.
164. O'Callaghan, J.P. and D.B. Miller, *Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse.* J Pharmacol Exp Ther, 1994. **270**(2): p. 741-51.
165. Sabol, K.E., et al., *Amphetamine analogs have differential effects on DRL 36-s schedule performance.* Psychopharmacology (Berl), 1995. **121**(1): p. 57-65.
166. Miller, D.B. and J.P. O'Callaghan, *Neurotoxicity of d-amphetamine in the C57BL/6J and CD-1 mouse. Interactions with stress and the adrenal system.* Ann N Y Acad Sci, 1996. **801**: p. 148-67.
167. Collins, S.A., G.A. Gudelsky, and B.K. Yamamoto, *MDMA-induced loss of parvalbumin interneurons within the dentate gyrus is mediated by 5HT2A and NMDA receptors.* Eur J Pharmacol, 2015. **761**: p. 95-100.
168. Ma, K.H., et al., *Effects of dextromethorphan on MDMA-induced serotonergic aberration in the brains of non-human primates using [(123)I]-ADAM/SPECT.* Sci Rep, 2016. **6**: p. 38695.
169. Karimi, S., M. Jahanshahi, and M.J. Golalipour, *The Effect of MDMA-Induced Anxiety on Neuronal Apoptosis in Adult Male Rats' Hippocampus.* Folia Biol (Praha), 2014. **60**(4): p. 187-91.
170. Isbister, G.K. and N.A. Buckley, *The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment.* Clin Neuropharmacol, 2005. **28**(5): p. 205-14.
171. Gillman, P.K., *Ecstasy, serotonin syndrome and the treatment of hyperpyrexia.* Med J Aust, 1997. **167**(2): p. 109, 111.
172. Mueller, P.D. and W.S. Korey, *Death by "ecstasy": the serotonin syndrome?* Ann Emerg Med, 1998. **32**(3 Pt 1): p. 377-80.

173. Dutta, R.R., M.A. Taffe, and C.D. Mandyam, *Chronic administration of amphetamines disturbs development of neural progenitor cells in young adult nonhuman primates*. *Prog Neuropsychopharmacol Biol Psychiatry*, 2018. **85**: p. 46-53.
174. Frith, C.H. and W. Slikker, *28-Day Oral Toxicity of Methylenedioxymethamphetamine hydrochloride in dogs: Protocol # EMD-SC-001*. 1985: Unpublished: MAPS [As Earth Metabolic Design Laboratories].
175. Selken, J. and D.E. Nichols, *Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in rats*. *Pharmacol Biochem Behav*, 2007. **86**(4): p. 622-30.
176. Fletcher, P.J., J. Sinyard, and G.A. Higgins, *The effects of the 5-HT(2C) receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists*. *Psychopharmacology (Berl)*, 2006. **187**(4): p. 515-25.
177. Crean, R.D., et al., *Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques*. *Neuroscience*, 2006. **142**(2): p. 515-25.
178. Bhattacharya, S.K., A. Bhattacharya, and S. Ghosal, *Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy): an experimental study*. *Biogenic Amines*, 1998. **7**: p. 217-237.
179. Ho, Y.J., et al., *Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat*. *Behav Brain Res*, 2004. **149**(2): p. 135-44.
180. Budzynska, B., et al., *Acute behavioral effects of co-administration of mephedrone and MDMA in mice*. *Pharmacol Rep*, 2017. **69**(2): p. 199-205.
181. Mechan, A.O., et al., *A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field*. *Psychopharmacology (Berl)*, 2002. **159**(2): p. 167-75.
182. Gurtman, C.G., et al., *Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion*. *Eur J Pharmacol*, 2002. **446**(1-3): p. 89-96.
183. Clemens, K.J., et al., *MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat*. *Psychopharmacology (Berl)*, 2004. **173**(3-4): p. 318-25.
184. Ando, R.D., et al., *Partial lesion of the serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances acute MDMA-induced social behaviour on the social interaction test*. *Neuropharmacology*, 2006. **50**(7): p. 884-96.
185. Garcia-Pardo, M.P., et al., *Cognitive and behavioural effects induced by social stress plus MDMA administration in mice*. *Behav Brain Res*, 2017. **319**: p. 63-72.
186. Thompson, M.R., G.E. Hunt, and I.S. McGregor, *Neural correlates of MDMA ("Ecstasy")-induced social interaction in rats*. *Soc Neurosci*, 2009. **4**(1): p. 60-72.

187. Hunt, G.E., et al., *MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635*. *Brain Res Bull*, 2011. **86**(1-2): p. 65-73.
188. Hasler, F., et al., *Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA*. *J Psychopharmacol*, 2009. **23**(8): p. 923-35.
189. Hysek, C.M., F.X. Vollenweider, and M.E. Liechti, *Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy)*. *Emerg Med J*, 2010. **27**(8): p. 586-9.
190. van Wel, J.H., et al., *Blockade of 5-HT(2) Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment*. *Neuropsychopharmacology*, 2011. **36**(9): p. 1932-9.
191. Liester, M.B., et al., *Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use*. *J Nerv Ment Dis*, 1992. **180**(6): p. 345-52; discussion 353-4.
192. Peroutka, S.J., H. Newman, and H. Harris, *Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users*. *Neuropsychopharmacology*, 1988. **1**(4): p. 273-7.
193. Solowij, N., W. Hall, and N. Lee, *Recreational MDMA use in Sydney: a profile of 'Ecstasy' users and their experiences with the drug*. *Br J Addict*, 1992. **87**(8): p. 1161-72.
194. Pitts, E.G., et al., *3,4-Methylenedioxymethamphetamine Increases Affiliative Behaviors in Squirrel Monkeys in a Serotonin 2A Receptor-Dependent Manner*. *Neuropsychopharmacology*, 2017.
195. Edsinger, E. and G. Dolen, *A Conserved Role for Serotonergic Neurotransmission in Mediating Social Behavior in Octopus*. *Curr Biol*, 2018. **28**(19): p. 3136-3142 e4.
196. Stewart, A., et al., *Behavioral effects of MDMA ('ecstasy') on adult zebrafish*. *Behav Pharmacol*, 2011. **22**(3): p. 275-80.
197. Taffe, M.A., et al., *Functional consequences of repeated (+/-)3,4-methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys*. *Neuropsychopharmacology*, 2001. **24**(3): p. 230-9.
198. Goodwin, A.K. and L.E. Baker, *A three-choice discrimination procedure dissociates the discriminative stimulus effects of d-amphetamine and (+/-)-MDMA in rats*. *Exp Clin Psychopharmacol*, 2000. **8**(3): p. 415-23.
199. Goodwin, A.K., et al., *Behavioral effects and pharmacokinetics of (+/-)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) after intragastric administration to baboons*. *J Pharmacol Exp Ther*, 2013. **345**(3): p. 342-53.
200. Plaza-Zabala, A., et al., *Effects of repeated MDMA administration on the motivation for palatable food and extinction of operant responding in mice*. *Psychopharmacology (Berl)*, 2010. **208**(4): p. 563-73.
201. Mohr, D., et al., *Acute and long-term effect of MDMA on startle reflex and prepulse inhibition in rats*. *Behav Pharmacol*, 2007. **18**: p. S14-S14.

202. Arrue, A., F.M. Gomez, and M.T. Giralt, *Effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') on the jaw-opening reflex and on the alpha-adrenoceptors which regulate this reflex in the anesthetized rat.* Eur J Oral Sci, 2004. **112**(2): p. 127-33.
203. Gordon, C.J., *Thermophysiological responses to hyperthermic drugs: extrapolating from rodent to human.* Prog Brain Res, 2007. **162**: p. 63-79.
204. Reveron, M.E., E.Y. Maier, and C.L. Duvauchelle, *Experience-dependent changes in temperature and behavioral activity induced by MDMA.* Physiol Behav, 2006. **89**(3): p. 358-63.
205. Concheiro, M., et al., *Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat.* Drug Metab Dispos, 2014. **42**(1): p. 119-25.
206. Musolino, S.T., et al., *Improved method for optical fiber temperature probe implantation in brains of free-moving rats.* J Neurosci Methods, 2019. **313**: p. 24-28.
207. Kiyatkin, E.A., et al., *Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use.* J Neurosci, 2014. **34**(23): p. 7754-62.
208. Dafters, R.I., *Effect of ambient temperature on hyperthermia and hyperkinesia induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats.* Psychopharmacology (Berl), 1994. **114**(3): p. 505-8.
209. Malberg, J.E. and L.S. Seiden, *Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat.* J Neurosci, 1998. **18**(13): p. 5086-94.
210. Feio-Azevedo, R., et al., *Aged rats are more vulnerable than adolescents to "ecstasy"-induced toxicity.* Arch Toxicol, 2018. **92**(7): p. 2275-2295.
211. Gordon, C.J., et al., *Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat.* Pharmacol Biochem Behav, 1991. **38**(2): p. 339-44.
212. Pedersen, N.P. and W.W. Blessing, *Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits.* J Neurosci, 2001. **21**(21): p. 8648-54.
213. Von Huben, S.N., et al., *Impact of ambient temperature on hyperthermia induced by (+/-)3,4-methylenedioxymethamphetamine in rhesus macaques.* Neuropsychopharmacology, 2007. **32**(3): p. 673-81.
214. Bowyer, J.F., et al., *Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations.* Neurotoxicology, 2003. **24**(3): p. 379-90.
215. Freedman, R.R., C.E. Johanson, and M.E. Tancer, *Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.* Psychopharmacology (Berl), 2005. **183**(2): p. 248-56.



216. Crean, R.D., S.A. Davis, and M.A. Taffe, *Oral administration of (+/-)3,4-methylenedioxymethamphetamine and (+)methamphetamine alters temperature and activity in rhesus macaques*. *Pharmacol Biochem Behav*, 2007. **87**(1): p. 11-9.
217. Banks, M.L., et al., *Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermoregulation and pharmacokinetics in male monkeys*. *Drug Metab Dispos*, 2007. **35**(10): p. 1840-5.
218. De La Torre, R., et al., *Non-linear pharmacokinetics of MDMA ('ecstasy') in humans: Non-linear pharmacokinetics of MDMA*. *British Journal of Clinical Pharmacology*, 2002. **49**(2): p. 104-109.
219. Abbas, R., et al., *A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects*. *Clin Pharmacol Drug Dev*, 2020. **9**(3): p. 307-320.
220. Otsuka, Y., *Paroxetine-induced QTc prolongation*. *J Gen Fam Med*, 2017. **18**(6): p. 442-445.
221. Vandeputte, C. and J.R. Docherty, *Vascular actions of 3,4-methylenedioxymethamphetamine in alpha(2A/D)- adrenoceptor knockout mice*. *Eur J Pharmacol*, 2002. **457**(1): p. 45-9.
222. Bexis, S. and J.R. Docherty, *Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors*. *Br J Pharmacol*, 2006. **147**(8): p. 926-34.
223. Bexis, S. and J.R. Docherty, *Role of alpha2A-adrenoceptors in the effects of MDMA on body temperature in the mouse*. *Br J Pharmacol*, 2005. **146**(1): p. 1-6.
224. Quinn, S.T., et al., *Blockade of noradrenaline transport abolishes 4-methylthioamphetamine-induced contraction of the rat aorta in vitro*. *Auton Autacoid Pharmacol*, 2006. **26**(4): p. 335-44.
225. Hysek, C.M., et al., *Effects of the alpha(2)-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers*. *J Pharmacol Exp Ther*, 2012. **340**(2): p. 286-94.
226. Hysek, C.M. and M.E. Liechti, *Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex*. *Psychopharmacology (Berl)*, 2012. **224**(3): p. 363-76.
227. Hysek, C.M., et al., *Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans: Lost in translation*. *Br J Pharmacol*, 2013. **170**(6): p. 1273-5.
228. Hysek, C.M., et al., *Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study*. *PLoS One*, 2012. **7**(5): p. e36476.
229. Fonseca, D.A., et al., *Hyperthermia Severely Affects the Vascular Effects of MDMA and Metabolites in the Human Internal Mammary Artery In Vitro*. *Cardiovasc Toxicol*, 2017. **17**(4): p. 405-416.

230. van der Schier, R., et al., *Opioid-induced respiratory depression: reversal by non-opioid drugs*. F1000Prime Rep, 2014. **6**: p. 79.
231. Goad, P.T., *Acute and subacute oral toxicity study of MDMA in rats (protocol number: EMD-AT-001, 1985)* 1986: Unpublished; MAPS [Earth Metabolic Design Laboratories].
232. Vizeli, P. and M.E. Liechti, *Safety pharmacology of acute MDMA administration in healthy subjects*. J Psychopharmacol, 2017. **31**(5): p. 576-588.
233. Farah, R. and R. Farah, *Ecstasy (3,4-methylenedioxymethamphetamine)-induced inappropriate antidiuretic hormone secretion*. Pediatr Emerg Care, 2008. **24**(9): p. 615-7.
234. Esposito, P., et al., *The syndrome of inappropriate antidiuresis: pathophysiology, clinical management and new therapeutic options*. Nephron Clin Pract, 2011. **119**(1): p. c62-73; discussion c73.
235. Laycock, J., *Introduction to vasopressin*. Perspectives on vasopressin. London: World Scientific Publishing Company, Imperial College Press, 2010: p. 1-16.
236. Forsling, M., et al., *Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine ("ecstasy"): is metabolism a contributory factor?* J Pharm Pharmacol, 2001. **53**(10): p. 1357-63.
237. Tasker, J.G., et al., *Cell biology of oxytocin and vasopressin cells*, in *Hormones, brain and behavior*, Pfaff D.W., et al., Editors. 2002, Academic Press: London. p. 811-842.
238. Burbach, J., L. Young, and J. Russell, *Oxytocin: synthesis, secretion, and reproductive functions*. Knobil and Neill's physiology of reproduction, 2006. **2**: p. 3055-3128.
239. Hargreaves, G.A., et al., *High ambient temperature increases 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")-induced Fos expression in a region-specific manner*. Neuroscience, 2007. **145**(2): p. 764-74.
240. Stanley, N., A. Salem, and R.J. Irvine, *The effects of co-administration of 3,4-methylenedioxymethamphetamine ("ecstasy") or para-methoxyamphetamine and moclobemide at elevated ambient temperatures on striatal 5-HT, body temperature and behavior in rats*. Neuroscience, 2007. **146**(1): p. 321-9.
241. McNamara, R., et al., *Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love")*. Neuropharmacology, 2006. **50**(1): p. 69-80.
242. Kasai, M., et al., *The effects of mirtazapine and fluoxetine on hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats*. Neurosci Lett, 2011. **499**(1): p. 24-7.
243. Thompson, M.R., et al., *Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats*. Neuropsychopharmacology, 2004. **29**(4): p. 694-704.
244. Upreti, V.V. and N.D. Eddington, *Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat*. J Pharm Sci, 2008. **97**(4): p. 1593-605.

245. Mueller, M., et al., *Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses.* J Pharmacol Exp Ther, 2008. **327**(1): p. 38-44.
246. Mueller, M., et al., *Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.* J Pharmacol Exp Ther, 2011. **338**(1): p. 310-7.
247. De Letter, E.A., et al., *Is vitreous humour useful for the interpretation of 3,4-methylenedioxymethamphetamine (MDMA) blood levels? Experimental approach with rabbits.* Int J Legal Med, 2000. **114**(1-2): p. 29-35.
248. Wan Aasim, W.R., S.C. Tan, and S.H. Gan, *Interspecies In Vitro Evaluation of Stereoselective Protein Binding for 3,4-Methylenedioxymethamphetamine.* Journal of Chemistry, 2017. **2017**: p. 8103726.
249. Scheidweiler, K.B., et al., *(+/-)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice.* J Anal Toxicol, 2011. **35**(7): p. 470-80.
250. Campbell, N.G., et al., *MDMA administration to pregnant Sprague-Dawley rats results in its passage to the fetal compartment.* Neurotoxicol Teratol, 2006. **28**(4): p. 459-65.
251. Williams, M.T., et al., *Absorption and clearance of +/-3,4-methylenedioxymethamphetamine from the plasma of neonatal rats.* Neurotoxicol Teratol, 2004. **26**(6): p. 849-56.
252. de la Torre, R. and M. Farre, *Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans.* Trends Pharmacol Sci, 2004. **25**(10): p. 505-8.
253. Kolbrich, E.A., et al., *Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.* Ther Drug Monit, 2008. **30**(3): p. 320-32.
254. Fantegrossi, W.E., et al., *Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations.* J Pharmacol Exp Ther, 2009. **329**(3): p. 1006-15.
255. Mueller, M., et al., *Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans.* Ther Drug Monit, 2009. **31**(3): p. 367-73.
256. Valtier, S., C.F. Phelix, and J.T. Cody, *Analysis of MDMA and its metabolites in urine and plasma following a neurotoxic dose of MDMA.* J Anal Toxicol, 2007. **31**(3): p. 138-43.
257. Jamali, B., et al., *Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.* Drug Metab Pers Ther, 2017. **32**(3): p. 137-145.
258. Kuwayama, K., et al., *Interaction of 3,4-methylenedioxymethamphetamine and methamphetamine during metabolism by in vitro human metabolic enzymes and in rats.* J Forensic Sci, 2012. **57**(4): p. 1008-13.

259. Moon, K.H., et al., *Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated mitochondrial dysfunction in rat liver*. Proteomics, 2008. **8**(18): p. 3906-18.
260. Bonkale, W.L. and M.C. Austin, *3,4-Methylenedioxymethamphetamine induces differential regulation of tryptophan hydroxylase 2 protein and mRNA levels in the rat dorsal raphe nucleus*. Neuroscience, 2008. **155**(1): p. 270-6.
261. Schenk, S., et al., *Effects of repeated exposure to MDMA on 5HT1a autoreceptor function: behavioral and neurochemical responses to 8-OHDPAT*. Psychopharmacology (Berl), 2013. **227**(2): p. 355-61.
262. Adori, C., et al., *Recovery and aging of serotonergic fibers after single and intermittent MDMA treatment in Dark Agouti rat*. J Comp Neurol, 2011. **519**(12): p. 2353-78.
263. Mueller, M., et al., *Single oral doses of (+/-) 3,4-methylenedioxymethamphetamine ('Ecstasy') produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations*. Int J Neuropsychopharmacol, 2013. **16**(4): p. 791-801.
264. de la Torre, R., et al., *MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?* Front Genet, 2012. **3**: p. 235.
265. Peiro, A.M., et al., *Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart*. Psychopharmacology (Berl), 2013. **225**(4): p. 883-93.
266. Klingler, W., et al., *3,4-Methylenedioxymethamphetamine (ecstasy) activates skeletal muscle nicotinic acetylcholine receptors*. J Pharmacol Exp Ther, 2005. **314**(3): p. 1267-73.
267. St Omer, V.E., et al., *Behavioral and neurochemical effects of prenatal methylenedioxymethamphetamine (MDMA) exposure in rats*. Neurotoxicol Teratol, 1991. **13**(1): p. 13-20.
268. Plessinger, M.A., *Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy*. Obstet Gynecol Clin North Am, 1998. **25**(1): p. 119-38.
269. Connor, T.J., et al., *Methylenedioxymethamphetamine (MDMA; Ecstasy) suppresses IL-1beta and TNF-alpha secretion following an in vivo lipopolysaccharide challenge*. Life Sci, 2000. **67**(13): p. 1601-12.
270. Pennock, J.W., et al., *3,4-Methylenedioxymethamphetamine increases susceptibility to genital herpes simplex virus infection in mice*. J Infect Dis, 2009. **200**(8): p. 1247-50.
271. Liu, X., et al., *3,4-Methylenedioxymethamphetamine causes cytotoxicity on 661W cells through inducing macrophage polarization*. Cutan Ocul Toxicol, 2018. **37**(2): p. 143-150.
272. de Paula, V.F., et al., *Methylenedioxymethamphetamine (Ecstasy) decreases neutrophil activity and alters leukocyte distribution in bone marrow, spleen and blood*. Neuroimmunomodulation, 2009. **16**(3): p. 191-200.

273. Boyle, N.T. and T.J. Connor, *MDMA ("Ecstasy") suppresses the innate IFN-gamma response in vivo: a critical role for the anti-inflammatory cytokine IL-10*. *Eur J Pharmacol*, 2007. **572**(2-3): p. 228-38.
274. Stankevicius, D., et al., *3,4-methylenedioxymethamphetamine (ecstasy) decreases inflammation and airway reactivity in a murine model of asthma*. *Neuroimmunomodulation*, 2012. **19**(4): p. 209-19.
275. Fernandez-Castillo, N., et al., *Active and passive MDMA ('ecstasy') intake induces differential transcriptional changes in the mouse brain*. *Genes Brain Behav*, 2012. **11**(1): p. 38-51.
276. Passos, I.C., et al., *Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression*. *Lancet Psychiatry*, 2015. **2**(11): p. 1002-12.
277. Miller, C.A. and J.D. Sweatt, *Covalent modification of DNA regulates memory formation*. *Neuron*, 2007. **53**(6): p. 857-69.
278. Unternaehrer, E., et al., *Childhood maternal care is associated with DNA methylation of the genes for brain-derived neurotrophic factor (BDNF) and oxytocin receptor (OXTR) in peripheral blood cells in adult men and women*. *Stress*, 2015. **18**(4): p. 451-61.
279. Curry, D.W., et al., *Sensitization to the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA)*. *Neuropharmacology*, 2019.
280. Nardou, R., et al., *Oxytocin-dependent reopening of a social reward learning critical period with MDMA*. *Nature*, 2019. **569**(7754): p. 116-120.
281. Ly, C., et al., *Psychedelics Promote Structural and Functional Neural Plasticity*. *Cell Rep*, 2018. **23**(11): p. 3170-3182.
282. Young, M.B., et al., *3,4-Methylenedioxymethamphetamine facilitates fear extinction learning*. *Transl Psychiatry*, 2015. **5**: p. e634.
283. Budzynska, B., et al., *Acute MDMA and Nicotine Co-administration: Behavioral Effects and Oxidative Stress Processes in Mice*. *Front Behav Neurosci*, 2018. **12**: p. 149.
284. Hake, H.S., et al., *3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats*. *Physiol Behav*, 2019. **199**: p. 343-350.
285. Peng, W., et al., *Synaptotagmin I and IV are differentially regulated in the brain by the recreational drug 3,4-methylenedioxymethamphetamine (MDMA)*. *Brain Res Mol Brain Res*, 2002. **108**(1-2): p. 94-101.
286. Petschner, P., et al., *Downregulation of the Vitamin D Receptor Regulated Gene Set in the Hippocampus After MDMA Treatment*. *Front Pharmacol*, 2018. **9**: p. 1373.
287. Petschner, P., et al., *Gene expression analysis indicates reduced memory and cognitive functions in the hippocampus and increase in synaptic reorganization in the frontal cortex 3 weeks after MDMA administration in Dark Agouti rats*. *BMC Genomics*, 2018. **19**(1): p. 580.

288. Pompei, P., et al., *Preprotachykinin A gene expression after administration of 3,4-methylene dioxymethamphetamine (Ecstasy)*. Eur J Pharmacol, 2002. **450**(3): p. 245.
289. Sprague, J.E., et al. *Effects of antisense oligonucleotide alteration of MAO-B gene expression on MDMA-induced serotonergic neurotoxicity*. in *Society for Neuroscience*. 1999. Miami, FL.
290. Thiriet, N., et al., *Analysis of ecstasy (MDMA)-induced transcriptional responses in the rat cortex*. Faseb J, 2002. **16**(14): p. 1887-94.
291. Martinez-Turrillas, R., et al., *Differential effects of 3,4-methylenedioxyamphetamine (MDMA, "ecstasy") on BDNF mRNA expression in rat frontal cortex and hippocampus*. Neurosci Lett, 2006. **402**(1-2): p. 126-30.
292. Sandrini, M., et al., *Causal role of prefrontal cortex in strengthening of episodic memories through reconsolidation*. Curr Biol, 2013. **23**(21): p. 2181-4.
293. Llado-Pelfort, L., et al., *5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons*. Cereb Cortex, 2012. **22**(7): p. 1487-97.
294. Karpova, N.N., *Role of BDNF epigenetics in activity-dependent neuronal plasticity*. Neuropharmacology, 2014. **76 Pt C**: p. 709-18.
295. Biezonski, D.K. and J.S. Meyer, *Effects of 3,4-methylenedioxyamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity*. J Neurochem, 2010. **112**(4): p. 951-62.
296. Kindlundh-Hogberg, A.M., P. Svenningsson, and H.B. Schioth, *Quantitative mapping shows that serotonin rather than dopamine receptor mRNA expressions are affected after repeated intermittent administration of MDMA in rat brain*. Neuropharmacology, 2006. **51**(4): p. 838-47.
297. Salzman, J., et al., *Analysis of transcriptional responses in the mouse dorsal striatum following acute 3,4-methylenedioxyamphetamine (ecstasy): identification of extracellular signal-regulated kinase-controlled genes*. Neuroscience, 2006. **137**(2): p. 473-82.
298. Yubero-Lahoz, S., et al., *Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake*. Psychopharmacology (Berl), 2015. **232**(11): p. 1921-9.
299. Fantegrossi, W.E., et al., *Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys*. Neuropsychopharmacology, 2004. **29**(7): p. 1270-81.
300. Highgate, Q. and S. Schenk, *Comparison of the effects of abstinence on MDMA and cocaine self-administration in rats*. Psychopharmacology (Berl), 2018. **235**(11): p. 3233-3241.

301. Schenk, S., et al., *Development, maintenance and temporal pattern of self-administration maintained by ecstasy (MDMA) in rats*. *Psychopharmacology (Berl)*, 2003. **169**(1): p. 21-7.
302. Trigo, J.M., et al., *A reliable model of intravenous MDMA self-administration in naive mice*. *Psychopharmacology (Berl)*, 2006. **184**(2): p. 212-20.
303. Oberlender, R. and D.E. Nichols, *Drug discrimination studies with MDMA and amphetamine*. *Psychopharmacology (Berl)*, 1988. **95**(1): p. 71-6.
304. Lile, J.A., J.T. Ross, and M.A. Nader, *A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") with cocaine in rhesus monkeys*. *Drug Alcohol Depend*, 2005. **78**(2): p. 135-40.
305. Wang, Z. and W.L. Woolverton, *Estimating the relative reinforcing strength of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine*. *Psychopharmacology (Berl)*, 2007. **189**(4): p. 483-8.
306. Robledo, P., et al., *Study of the behavioural responses related to the potential addictive properties of MDMA in mice*. *Naunyn Schmiedebergs Arch Pharmacol*, 2004. **369**(3): p. 338-49.
307. Glennon, R.A., *Arylalkylamine drugs of abuse: an overview of drug discrimination studies*. *Pharmacol Biochem Behav*, 1999. **64**(2): p. 251-6.
308. Goodwin, A.K., D.M. Pynnonen, and L.E. Baker, *Serotonergic-dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination*. *Pharmacol Biochem Behav*, 2003. **74**(4): p. 987-95.
309. Schenk, S. and Q. Highgate, *Dopamine and serotonin antagonists fail to alter the discriminative stimulus properties of +/-methylenedioxymethamphetamine*. *Behav Pharmacol*, 2018.
310. Smith, D.A., B.E. Blough, and M.L. Banks, *Cocaine-like discriminative stimulus effects of amphetamine, cathinone, methamphetamine, and their 3,4-methylenedioxy analogs in male rhesus monkeys*. *Psychopharmacology (Berl)*, 2017. **234**(1): p. 117-127.
311. Gaston, T.R., Rasmussen, G. T., *Identification of 3,4-methylenedioxy-n-methylamphetamine;*. *Microgram*, 1972. **5**: p. 60-63.
312. Stolaroff, M., *The Secret Chief Revealed: Conversations with a pioneer of the underground therapy movement*. 2004, Sarasota FL: Multidisciplinary Association for Psychedelic Studies.
313. Carlson, R.G., et al., *Drug use practices among MDMA/ecstasy users in Ohio: a latent class analysis*. *Drug Alcohol Depend*, 2005. **79**(2): p. 167-79.
314. Sumnall, H.R., J.C. Cole, and L. Jerome, *The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy*. *J Psychopharmacol*, 2006. **20**(5): p. 670-82.

315. Cole, J.C. and H.R. Sumnall, *Altered states: the clinical effects of Ecstasy*. Pharmacol Ther, 2003. **98**(1): p. 35-58.
316. Baggott, M., et al., *Chemical analysis of ecstasy pills*. Jama, 2000. **284**(17): p. 2190.
317. Cole, J.C., et al., *The content of ecstasy tablets: implications for the study of their long-term effects*. Addiction, 2002. **97**(12): p. 1531-6.
318. Tanner-Smith, E.E., *Pharmacological content of tablets sold as "ecstasy": results from an online testing service*. Drug Alcohol Depend, 2006. **83**(3): p. 247-54.
319. Brunt, T.M., et al., *Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project*. Drug Test Anal, 2017. **9**(2): p. 188-198.
320. Halpern, J.H., et al., *Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs*. Addiction, 2011. **106**(4): p. 777-86.
321. Baggott, M.J., *Preventing problems in Ecstasy users: reduce use to reduce harm*. J Psychoactive Drugs, 2002. **34**(2): p. 145-62.
322. Gore, S.M., *Fatal uncertainty: death-rate from use of ecstasy or heroin*. Lancet, 1999. **354**(9186): p. 1265-6.
323. United Nations Office on Drugs and Crime, *World Drug Report*. 2020, United Nations Office on Drugs and Crime: New York, NY.
324. Green, A.R., E. O'Shea, and M.I. Colado, *A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response*. Eur J Pharmacol, 2004. **500**(1-3): p. 3-13.
325. Liechti, M.E., I. Kunz, and H. Kupferschmidt, *Acute medical problems due to Ecstasy use. Case-series of emergency department visits*. Swiss Med Wkly, 2005. **135**(43-44): p. 652-7.
326. Rosenson, J., et al., *Patterns of ecstasy-associated hyponatremia in California*. Ann Emerg Med, 2007. **49**(2): p. 164-71, 171 e1.
327. Henry, J.A. and J.G. Rella, *Medical risks associated with MDMA use*, in *Ecstasy: A Complete Guide*, J. Holland, Editor. 2001, Inner Traditions: Rochester, VT. p. 71-86.
328. Hall, A.P. and J.A. Henry, *Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management*. Br J Anaesth, 2006. **96**(6): p. 678-85.
329. Cregg, M.T. and J.A. Tracey, *Ecstasy abuse in Ireland*. Ir Med J, 1993. **86**(4): p. 118-20.
330. Williams, H., et al., *"Saturday night fever": ecstasy related problems in a London accident and emergency department*. J Accid Emerg Med, 1998. **15**(5): p. 322-6.
331. Armenian, P., et al., *Multiple MDMA (Ecstasy) overdoses at a rave event: a case series*. J Intensive Care Med, 2013. **28**(4): p. 252-8.



332. CDC, *Ecstasy overdoses at a New Year's Eve rave--Los Angeles, California, 2010*. MMWR Morb Mortal Wkly Rep, 2010. **59**(22): p. 677-81.
333. Angeliq, F., et al., *Postmortem Hyperthermia: Two Case Reports and a Review of the Literature*. Am J Forensic Med Pathol, 2018. **39**(4): p. 364-366.
334. Gowing, L.R., et al., *The health effects of ecstasy: a literature review*. Drug Alcohol Rev, 2002. **21**(1): p. 53-63.
335. Grunau, B.E., M.O. Wiens, and M. Greidanus, *Dantrolene for the treatment of MDMA toxicity*. CJEM, 2010. **12**(5): p. 457-9.
336. Russell, T., et al., *Ecstasy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene*. Anaesthesia, 2012. **67**(9): p. 1021-4.
337. Shah, H.V., G.H. Irvine, and M. Bradley, *Rhabdomyolysis of the masseter muscle: case report*. Br J Oral Maxillofac Surg, 2008. **46**(2): p. 138-40.
338. Davies, O., et al., *Full recovery after severe serotonin syndrome, severe rhabdomyolysis, multi-organ failure and disseminated intravascular coagulopathy from MDMA*. Heart Lung, 2014. **43**(2): p. 117-9.
339. Hall, A.P., et al., *An unusual case of Ecstasy poisoning*. Intensive Care Med, 1996. **22**(7): p. 670-1.
340. Logan, A.S., et al., *Survival following 'Ecstasy' ingestion with a peak temperature of 42 degrees C*. Anaesthesia, 1993. **48**(11): p. 1017-8.
341. Singarajah, C. and N.G. Lavies, *An overdose of ecstasy. A role for dantrolene*. Anaesthesia, 1992. **47**(8): p. 686-7.
342. Bedford Russell, A.R., R.H. Schwartz, and S. Dawling, *Accidental ingestion of 'Ecstasy' (3,4-methylenedioxymethylamphetamine)*. Arch Dis Child, 1992. **67**(9): p. 1114-5.
343. Nimmo, S.M., et al., *Drug-induced hyperthermia*. Anaesthesia, 1993. **48**(10): p. 892-5.
344. Murthy, B.V., R.G. Wilkes, and N.B. Roberts, *Creatine kinase isoform changes following Ecstasy overdose*. Anaesth Intensive Care, 1997. **25**(2): p. 156-9.
345. Ramcharan, S., et al., *Survival after massive ecstasy overdose*. J Toxicol Clin Toxicol, 1998. **36**(7): p. 727-31.
346. Screatton, G.R., et al., *Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse*. Lancet, 1992. **339**(8794): p. 677-8.
347. Montgomery, H. and S. Myerson, *3,4-methylenedioxymethamphetamine (MDMA, or "ecstasy") and associated hypoglycemia*. Am J Emerg Med, 1997. **15**(2): p. 218.
348. Williams, A. and R. Unwin, *Prolonged elevation of serum creatine kinase (CK) without renal failure after ingestion of ecstasy*. Nephrol Dial Transplant, 1997. **12**(2): p. 361-2.

349. Hayner, G.N. and H. McKinney, *MDMA. The dark side of ecstasy*. J Psychoactive Drugs, 1986. **18**(4): p. 341-7.
350. Jahns, F.P., A. Pineau Mitchell, and G. Auzinger, *Too Hot to Handle: A Case Report of Extreme Pyrexia After MDMA Ingestion*. Ther Hypothermia Temp Manag, 2018.
351. Ghaffari-Rafi, A., et al., *Protracted hyperthermia and delayed rhabdomyolysis in ecstasy toxicity: A case report*. Medicine (Baltimore), 2020. **99**(41): p. e21842.
352. Toth, A.R. and T. Varga, *Myocardium and striated muscle damage caused by licit or illicit drugs*. Leg Med (Tokyo), 2009. **11 Suppl 1**: p. S484-7.
353. Vanden Eede, H., et al., *Rhabdomyolysis in MDMA intoxication: a rapid and underestimated killer. "Clean" Ecstasy, a safe party drug?* J Emerg Med, 2012. **42**(6): p. 655-8.
354. Lang, J., et al., *Fatal Ecstasy-induced malignant hyperthermia with rhabdomyolysis. A case report*. Romanian Journal of Legal Medicine, 2016. **24**(3): p. 212-215.
355. Milroy, C.M., J.C. Clark, and A.R. Forrest, *Pathology of deaths associated with "ecstasy" and "eve" misuse*. J Clin Pathol, 1996. **49**(2): p. 149-53.
356. Sadeghian, S., et al., *Two ecstasy-induced myocardial infarctions during a three month period in a young man*. Arch Iran Med, 2007. **10**(3): p. 409-12.
357. Diffley, M., et al., *Catecholaminergic polymorphic ventricular tachycardia found in an adolescent after a methylenedioxymethamphetamine and marijuana-induced cardiac arrest*. Crit Care Med, 2012. **40**(7): p. 2223-6.
358. Hoggett, K., D. McCoubrie, and D.M. Fatovich, *Ecstasy-induced acute coronary syndrome: something to rave about*. Emerg Med Australas, 2012. **24**(3): p. 339-42.
359. Moller, M., et al., *Ecstasy-induced myocardial infarction in a teenager: rare complication of a widely used illicit drug*. Clin Res Cardiol, 2010. **99**(12): p. 849-51.
360. Kapoor, A. and K.S. Jackson, *Seizures presenting in pregnancy: eclampsia or something else?* J Obstet Gynaecol, 2013. **33**(6): p. 630-1.
361. Okunoye, G.O. and P. Dutton, *Acute myocardial infarction in pregnancy following unlicensed use of methylenedioxymethamphetamine ('Ecstasy')*. Scott Med J, 2013. **58**(3): p. e4-6.
362. Montastruc, F., et al., *Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy')*. Br J Clin Pharmacol, 2012. **74**(3): p. 547-8.
363. Mizia-Stec, K., et al., *Severe dilated cardiomyopathy as a consequence of Ecstasy intake*. Cardiovasc Pathol, 2008. **17**(4): p. 250-3.
364. Dagli, C. and I. Duman, *Successful Use of Early Therapeutic Hypothermia in an MDMA and Amphetamine Intoxication-Induced Out-of-Hospital Cardiac Arrest: A Case Report*. J Emerg Med, 2020. **59**(3): p. e89-e92.

365. Hua, Y.S., et al., *Contraction band necrosis in two ecstasy abusers: a latent lethal lesion associated with ecstasy*. *Am J Forensic Med Pathol*, 2009. **30**(3): p. 295-7.
366. Sano, R., et al., *A fatal case of myocardial damage due to misuse of the "designer drug" MDMA*. *Leg Med (Tokyo)*, 2009. **11**(6): p. 294-7.
367. Dowling, G.P., E.T.d. McDonough, and R.O. Bost, *'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA*. *Jama*, 1987. **257**(12): p. 1615-7.
368. Suarez, R.V. and R. Riemersma, *"Ecstasy" and sudden cardiac death*. *Am J Forensic Med Pathol*, 1988. **9**(4): p. 339-41.
369. Lora-Tamayo, C., T. Tena, and A. Rodriguez, *Amphetamine derivative related deaths*. *Forensic Sci Int*, 1997. **85**(2): p. 149-57.
370. Bingham, C., et al., *Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxyamphetamine ('ecstasy')*. *Nephrol Dial Transplant*, 1998. **13**(10): p. 2654-5.
371. Castro, A.L., et al., *MDMA Intoxication in a Potential Organ Donor with Cardiac Arrest*. *J Anal Toxicol*, 2020. **44**(8): p. 923-926.
372. Ghatol, A. and A. Kazory, *Ecstasy-associated acute severe hyponatremia and cerebral edema: a role for osmotic diuresis?* *J Emerg Med*, 2012. **42**(6): p. e137-40.
373. Beuerle, J.R. and F. Barrueto, Jr., *Neurogenic bladder and chronic urinary retention associated with MDMA abuse*. *J Med Toxicol*, 2008. **4**(2): p. 106-8.
374. Bryden, A.A., P.J. Rothwell, and P.H. O'Reilly, *Urinary retention with misuse of "ecstasy"*. *BMJ*, 1995. **310**(6978): p. 504.
375. Delgado, J.H., et al., *Acute, transient urinary retention from combined ecstasy and methamphetamine use*. *J Emerg Med*, 2004. **26**(2): p. 173-5.
376. Holden, R. and M.A. Jackson, *Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA)*. *Lancet*, 1996. **347**(9007): p. 1052.
377. Henry, J.A., et al., *Low-dose MDMA ("ecstasy") induces vasopressin secretion*. *Lancet*, 1998. **351**(9118): p. 1784.
378. Gomez-Balaguer, M., et al., *Syndrome of inappropriate antidiuretic hormone secretion and "designer drugs" (ecstasy)*. *J Pediatr Endocrinol Metab*, 2000. **13**(4): p. 437-8.
379. Hegadoren, K.M., G.B. Baker, and M. Bourin, *3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans*. *Neurosci Biobehav Rev*, 1999. **23**(4): p. 539-53.
380. Woodrow, G., P. Harnden, and J.H. Turney, *Acute renal failure due to accelerated hypertension following ingestion of 3,4-methylenedioxyamphetamine ('ecstasy')*. *Nephrol Dial Transplant*, 1995. **10**(3): p. 399-400.
381. Cadier, M.A. and J.A. Clarke, *Ecstasy and Whizz at a rave resulting in a major burn plus complications*. *Burns*, 1993. **19**(3): p. 239-40.

382. Fahal, I.H., et al., *Acute renal failure after ecstasy*. *Bmj*, 1992. **305**(6844): p. 29.
383. Maxwell, D.L., M.I. Polkey, and J.A. Henry, *Hyponatraemia and catatonic stupor after taking "ecstasy"*. *Bmj*, 1993. **307**(6916): p. 1399.
384. Satchell, S.C. and M. Connaughton, *Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion*. *Br J Hosp Med*, 1994. **51**(9): p. 495.
385. Thakkar, A., et al., *A Case of MDMA-Associated Cerebral and Pulmonary Edema Requiring ECMO*. *Case Rep Crit Care*, 2017. **2017**: p. 6417012.
386. Claffey, C., *A 26-year-old woman with sudden onset cerebral edema*. *J Emerg Nurs*, 2011. **37**(1): p. 55-6.
387. Gritti, P., et al., *Are we aware of ecstasy effects?* *Intern Emerg Med*, 2009. **4**(2): p. 175-7.
388. Parr, M.J., H.M. Low, and P. Botterill, *Hyponatraemia and death after "ecstasy" ingestion*. *Med J Aust*, 1997. **166**(3): p. 136-7.
389. O'Connor, A., et al., *Death from hyponatraemia-induced cerebral oedema associated with MDMA ("Ecstasy") use*. *N Z Med J*, 1999. **112**(1091): p. 255-6.
390. Dar, K.J. and M.E. McBrien, *MDMA induced hyperthermia: report of a fatality and review of current therapy*. *Intensive Care Med*, 1996. **22**(9): p. 995-6.
391. Gilbert, J.D. and R.W. Byard, *Fatal Diabetic Ketoacidosis-A Potential Complication of MDMA (Ecstasy) Use*. *J Forensic Sci*, 2018. **63**(3): p. 939-941.
392. Mikula, T., J. Kozłowska, and A. Wiercinska-Drapalo, *Alcohol and ecstasy (MDMA-3,4-methylenedioxymethamphetamine) overdose as a reason for acute hepatitis with gall bladder inflammation*. *Drug Alcohol Rev*, 2009. **28**(6): p. 685.
393. Payance, A., et al., *Severe chronic hepatitis secondary to prolonged use of ecstasy and cocaine*. *Clin Res Hepatol Gastroenterol*, 2013. **37**(5): p. e109-13.
394. Nadkarni, G.N., et al., *Serotonin syndrome, disseminated intravascular coagulation, and hepatitis after a single ingestion of MDMA in an Asian woman*. *Am J Ther*, 2014. **21**(4): p. e117-9.
395. Colak, Y., et al., *Ecstasy induced fatal hepatic failure*. *J Gastrointestin Liver Dis*, 2011. **20**(2): p. 215-6.
396. Chadwick, I.S., et al., *Ecstasy, 3-4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia*. *J R Soc Med*, 1991. **84**(6): p. 371.
397. Campkin, N.J. and U.M. Davies, *Treatment of 'ecstasy' overdose with dantrolene*. *Anaesthesia*, 1993. **48**(1): p. 82-3.
398. Fineschi, V. and A. Masti, *Fatal poisoning by MDMA (ecstasy) and MDEA: a case report*. *Int J Legal Med*, 1996. **108**(5): p. 272-5.

399. Wollner, K., et al., *[Death after the intake of amphetamine/ecstasy: two case reports]*. Arch Kriminol, 2015. **235**(1-2): p. 53-61.
400. Clark, A.D. and N. Butt, *Ecstasy-induced very severe aplastic anaemia complicated by invasive pulmonary mucormycosis treated with allogeneic peripheral blood progenitor cell transplant*. Clin Lab Haematol, 1997. **19**(4): p. 279-81.
401. Marsh, J.C., et al., *Aplastic anaemia following exposure to 3,4-methylenedioxymethamphetamine ('Ecstasy')*. Br J Haematol, 1994. **88**(2): p. 281-5.
402. Richman, J. and A. Ferber, *Severe aplastic anemia with hot pockets following daily Ecstasy ingestion*. Am J Hematol, 2008. **83**(4): p. 321-2.
403. Gomez-Fernandez, C., et al., *Facial eruption related to snorting Ecstasy*. Eur J Dermatol, 2010. **20**(6): p. 853-4.
404. Schroder, A.S., H. Andresen-Streichert, and S. Anders, *Swollen Lips After a Night of Partying-An Allergic Reaction to Ecstasy?* J Forensic Sci, 2019.
405. Del Bano, F., A. Supervia, and F. Escolano, *Angioedema by MDMA mediated by bradykinin. Role of icatibant acetate*. Med Clin (Barc), 2021. **156**(2): p. 99-100.
406. Sauvageau, A., *Death from a possible anaphylactic reaction to ecstasy*. Clin Toxicol (Phila), 2008. **46**(2): p. 156.
407. Kahn, D.E., N. Ferraro, and R.J. Benveniste, *3 cases of primary intracranial hemorrhage associated with "Molly", a purified form of 3,4-methylenedioxymethamphetamine (MDMA)*. J Neurol Sci, 2012. **323**(1-2): p. 257-60.
408. Kaku, D.A. and D.H. Lowenstein, *Emergence of recreational drug abuse as a major risk factor for stroke in young adults*. Ann Intern Med, 1990. **113**(11): p. 821-7.
409. Hughes, J.C., M. McCabe, and R.J. Evans, *Intracranial haemorrhage associated with ingestion of 'ecstasy'*. Arch Emerg Med, 1993. **10**(4): p. 372-4.
410. De Smet, K., et al., *Bilateral globus pallidus infarcts in ecstasy use*. JBR-BTR, 2011. **94**(2): p. 93.
411. Gardner, H., et al., *Acute hippocampal sclerosis following ecstasy ingestion*. Neurology, 2009. **73**(7): p. 567-9.
412. Nifosi, F., et al., *Hippocampal remodelling after MDMA neurotoxicity: a single case study*. World J Biol Psychiatry, 2009. **10**(4 Pt 3): p. 961-8.
413. Ruis, C., et al., *Cognitive disorders after sporadic ecstasy use? A case report*. Neurocase, 2014.
414. Bruggemann, N., et al., *Acute amnesic syndrome due to MDMA exposure*. J Neurol, 2016. **263**(5): p. 1022-1023.
415. Spatt, J., B. Glawar, and B. Mamoli, *A pure amnesic syndrome after MDMA ("ecstasy") ingestion*. J Neurol Neurosurg Psychiatry, 1997. **62**(4): p. 418-9.

416. Squier, M.V., et al., *Death after ecstasy ingestion: neuropathological findings*. J Neurol Neurosurg Psychiatry, 1995. **58**(6): p. 756.
417. Ginat, D.T., *MRI of toxic leukoencephalopathy syndrome associated with methylenedioxyamphetamine*. Neurology, 2015. **84**(7): p. 757.
418. Hauw, F., et al., *Isolated persistent acute global amnesia after acute abuse of 3,4-methylenedioxy-methamphetamine (MDMA)*. J Neurol Sci, 2018. **386**: p. 36-38.
419. Brand, H.S., S.N. Dun, and A.V. Nieuw Amerongen, *Ecstasy (MDMA) and oral health*. Br Dent J, 2008. **204**(2): p. 77-81.
420. Duxbury, A.J., *Ecstasy--dental implications*. Br Dent J, 1993. **175**(1): p. 38.
421. Nixon, P.J., C.C. Youngson, and A. Beese, *Tooth surface loss: does recreational drug use contribute?* Clin Oral Investig, 2002. **6**(2): p. 128-30.
422. Marchesi, C., M. Tonna, and C. Maggini, *Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse*. World J Biol Psychiatry, 2009. **10**(4 Pt 2): p. 599-602.
423. Potash, M.N., K.A. Gordon, and K.L. Conrad, *Persistent Psychosis and Medical Complications After a Single Ingestion of MDMA "Ecstasy": A Case Report and Review of the Literature*. Psychiatry (Edgmont), 2009. **6**(7): p. 40-4.
424. Tabatabaei, S.A., M. Soleimani, and A. Khodabandeh, *A case of autoenucleation associated with a contralateral field defect*. Orbit, 2011. **30**(3): p. 165-8.
425. Mutlu, H., et al., *'Ecstasy'(MDMA)-induced pneumomediastinum and epidural pneumatosis*. Diagn Interv Radiol, 2005. **11**(3): p. 150-1.
426. Onwudike, M., *Ecstasy induced retropharyngeal emphysema*. J Accid Emerg Med, 1996. **13**(5): p. 359-61.
427. Pittman, J.A. and J.C. Pounsford, *Spontaneous pneumomediastinum and Ecstasy abuse*. J Accid Emerg Med, 1997. **14**(5): p. 335-6.
428. Quin, G.I., G.M. McCarthy, and D.K. Harries, *Spontaneous pneumomediastinum and ecstasy abuse*. J Accid Emerg Med, 1999. **16**(5): p. 382.
429. Gungadeen, A. and J. Moor, *Extensive subcutaneous emphysema and pneumomediastinum after ecstasy ingestion*. Case Rep Otolaryngol, 2013. **2013**: p. 795867.
430. Clause, A.L., et al., *Spontaneous pneumomediastinum and epidural pneumatosis after oral ecstasy consumption*. Acta Clin Belg, 2014. **69**(2): p. 146-8.
431. Peters, N.F., R. Gosselin, and K.L. Verstraete, *A rare case of diffuse alveolar hemorrhage following oral amphetamine intake*. JBR-BTR, 2014. **97**(1): p. 42-3.
432. Barrett, P.J., *'Ecstasy' misuse--overdose or normal dose?* Anaesthesia, 1993. **48**(1): p. 83.

433. Van den Kerckhove, E., et al., *Airway Necrosis and Barotrauma after Ecstasy Inhalation*. *Am J Respir Crit Care Med*, 2017. **196**(1): p. 105-106.
434. O'Neill, D. and J.K. Dart, *Methylenedioxyamphetamine ('Ecstasy') associated keratopathy*. *Eye*, 1993. **7**(Pt 6): p. 805-6.
435. Schroeder, B. and S. Brieden, *Bilateral sixth nerve palsy associated with MDMA ('ecstasy') abuse*. *Am J Ophthalmol*, 2000. **129**(3): p. 408-9.
436. Schifano, F., et al., *Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002*. *Hum Psychopharmacol*, 2003. **18**(7): p. 519-24.
437. Nadesan, K., C. Kumari, and M. Afiq, *Dancing to death: A case of heat stroke*. *J Forensic Leg Med*, 2017. **50**: p. 1-5.
438. Escalante, F.A., F. Del Bano, and A. Supervia, *MDMA-induced angioedema treated with icatibant*. *Clin Toxicol (Phila)*, 2015. **53**(10): p. 1148-9.
439. Zaami, S., et al., *Myocardial bridging and ecstasy: A fatal combination involving a 22-year-old male*. *Int J Cardiol*, 2016. **220**: p. 835-6.
440. Nedahl, M., S.S. Johansen, and K. Linnet, *Postmortem Brain-Blood Ratios of Amphetamine, Cocaine, Ephedrine, MDMA and Methylphenidate*. *J Anal Toxicol*, 2019. **43**(5): p. 378-384.
441. Cohen, I.V., et al., *Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database*. *Sci Rep*, 2021. **11**(1): p. 5997.
442. Roxburgh, A., et al., *Trends in MDMA-related mortality across four countries*. *Addiction*, 2021.
443. Parrott, A.C., *MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans*. *Drug Alcohol Depend*, 2012. **121**(1-2): p. 1-9.
444. Greene, S.L., et al., *Multiple toxicity from 3,4-methylenedioxymethamphetamine ('ecstasy')*. *Am J Emerg Med*, 2003. **21**(2): p. 121-4.
445. Dafters, R.I., *Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing*. *Physiol Behav*, 1995. **58**(5): p. 877-82.
446. Docherty, J.R. and A.R. Green, *The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives*. *Br J Pharmacol*, 2010. **160**(5): p. 1029-44.
447. Martin, T.L., D.A. Chiasson, and S.J. Kish, *Does hyperthyroidism increase risk of death due to the ingestion of ecstasy?* *J Forensic Sci*, 2007. **52**(4): p. 951-3.
448. Sprague, J.E., et al., *Roles of norepinephrine, free Fatty acids, thyroid status, and skeletal muscle uncoupling protein 3 expression in sympathomimetic-induced thermogenesis*. *J Pharmacol Exp Ther*, 2007. **320**(1): p. 274-80.

449. Doyle, A.J., et al., *N-Methyl-3,4-methylenedioxymethamphetamine (MDMA)-related coagulopathy and rhabdomyolysis: A case series and literature review*. Res Pract Thromb Haemost, 2020. **4**(5): p. 829-834.
450. Lang, C.N., et al., *Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study*. Intensive Care Med Exp, 2020. **8**(1): p. 21.
451. Peck, J., et al., *Adolescent With Acute Liver Failure in the Setting of Ethanol, Cocaine, and Ecstasy Ingestion Treated With a Molecular Adsorbent Recirculating System*. Cureus, 2020. **12**(8): p. e9699.
452. Perez, J.A., Jr., E.L. Arsura, and S. Strategos, *Methamphetamine-related stroke: four cases*. J Emerg Med, 1999. **17**(3): p. 469-71.
453. Rothwell, P.M. and R. Grant, *Cerebral venous sinus thrombosis induced by 'ecstasy'*. J Neurol Neurosurg Psychiatry, 1993. **56**(9): p. 1035.
454. Gledhill, J.A., et al., *Subarachnoid haemorrhage associated with MDMA abuse [letter]*. J Neurol Neurosurg Psychiatry, 1993. **56**(9): p. 1036-7.
455. Manchanda, S. and M.J. Connolly, *Cerebral infarction in association with Ecstasy abuse*. Postgrad Med J, 1993. **69**(817): p. 874-5.
456. Selmi, F., et al., *Intracerebral haemorrhage due to amphetamine abuse: report of two cases with underlying arteriovenous malformations*. Br J Neurosurg, 1995. **9**(1): p. 93-6.
457. Ho, M.P., J.L. Tsai, and Y.K. Wong, *Subarachnoid hemorrhage and death following coingestion of MDMA with other drugs*. J Chin Med Assoc, 2004. **67**(12): p. 640-3.
458. Johnson, J., et al., *Posterior spinal artery aneurysm rupture after 'Ecstasy' abuse*. J Neurointerv Surg, 2014.
459. Finley, J.J.t., M.A. Konstam, and J.E. Udelson, *Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia*. Circulation, 2008. **118**(4): p. 410-21.
460. Bolignano, D., et al., *Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology*. Clin Chem Lab Med, 2014. **52**(10): p. 1447-56.
461. Droogmans, S., et al., *Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease*. Am J Cardiol, 2007. **100**(9): p. 1442-5.
462. Bonsignore, A., et al., *MDMA Induced Cardio-toxicity and Pathological Myocardial Effects: A Systematic Review of Experimental Data and Autopsy Findings*. Cardiovasc Toxicol, 2019. **19**(6): p. 493-499.
463. Aitchison, K.J., et al., *Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT*. J Psychopharmacol, 2012. **26**(3): p. 408-18.
464. Henry, J.A. and I.R. Hill, *Fatal interaction between ritonavir and MDMA*. Lancet, 1998. **352**(9142): p. 1751-2.



465. Baggott, M., L. Jerome, and R. Stuart, *3,4-Methylenedioxymethamphetamine (MDMA); A review of the English-language scientific and medical literature: , in First Edition of Investigator's Brochure for MDMA*. 2001, Multidisciplinary Association for Psychedelic Studies.
466. Brvar, M., et al., *Polydipsia as another mechanism of hyponatremia after 'ecstasy' (3,4 methylendioxyamphetamine) ingestion*. Eur J Emerg Med, 2004. **11**(5): p. 302-4.
467. Corona, G., et al., *Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis*. PLoS One, 2013. **8**(12): p. e80451.
468. Wolff, K., et al., *Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population*. J Psychopharmacol, 2006. **20**(3): p. 400-10.
469. Ayus, J.C., S.G. Achinger, and A. Arief, *Brain cell volume regulation in hyponatremia: role of sex, age, vasopressin, and hypoxia*. Am J Physiol Renal Physiol, 2008. **295**(3): p. F619-24.
470. Lien, Y.H. and J.I. Shapiro, *Hyponatremia: clinical diagnosis and management*. Am J Med, 2007. **120**(8): p. 653-8.
471. Stoiser, B., et al., *Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure*. Eur J Clin Invest, 2006. **36**(11): p. 771-8.
472. Morgenthaler, N.G., *Copeptin: a biomarker of cardiovascular and renal function*. Congest Heart Fail, 2010. **16 Suppl 1**: p. S37-44.
473. Yalta, K., et al., *Copeptin and cardiovascular disease: a review of a novel neurohormone*. Int J Cardiol, 2013. **167**(5): p. 1750-9.
474. McGuire, P.K., H. Cope, and T.A. Fahy, *Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('Ecstasy')*. Br J Psychiatry, 1994. **165**(3): p. 391-5.
475. Huizink, A.C., et al., *Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study*. Bmj, 2006. **332**(7545): p. 825-8.
476. MacInnes, N., S.L. Handley, and G.F. Harding, *Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms*. J Psychopharmacol, 2001. **15**(3): p. 181-6.
477. Parrott, A.C., E. Sisk, and J.J. Turner, *Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users*. Drug Alcohol Depend, 2000. **60**(1): p. 105-10.
478. Sumnall, H.R. and J.C. Cole, *Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis*. J Psychopharmacol, 2005. **19**(1): p. 84-92.
479. Milani, R.M., et al., *Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users*. Addict Behav, 2004. **29**(5): p. 965-71.

480. Sumnall, H.R., G.F. Wagstaff, and J.C. Cole, *Self-reported psychopathology in polydrug users*. *J Psychopharmacol*, 2004. **18**(1): p. 75-82.
481. Medina, K.L. and P.K. Shear, *Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use*. *Drug Alcohol Depend*, 2007. **87**(2-3): p. 303-11.
482. Fisk, J.E., et al., *Modelling the adverse effects associated with ecstasy use*. *Addiction*, 2011. **106**(4): p. 798-805.
483. Scott, L.A., et al., *The impact of comorbid cannabis and methamphetamine use on mental health among regular ecstasy users*. *Addict Behav*, 2012. **37**(9): p. 1058-62.
484. Daumann, J., et al., *Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation*. *Psychopharmacology (Berl)*, 2004. **173**(3-4): p. 398-404.
485. Rougemont-Bucking, A., et al., *Comparing Mental Health across Distinct Groups of Users of Psychedelics, MDMA, Psychostimulants, and Cannabis*. *J Psychoactive Drugs*, 2019: p. 1-11.
486. Whitaker-Azmitia, P.M. and T.A. Aronson, *"Ecstasy" (MDMA)-induced panic*. *Am J Psychiatry*, 1989. **146**(1): p. 119.
487. McCann, U.D. and G.A. Ricaurte, *Lasting neuropsychiatric sequelae of (+-)-methylenedioxymethamphetamine ('ecstasy') in recreational users*. *J Clin Psychopharmacol*, 1991. **11**(5): p. 302-5.
488. Pallanti, S. and D. Mazzi, *MDMA (Ecstasy) precipitation of panic disorder*. *Biol Psychiatry*, 1992. **32**(1): p. 91-5.
489. McCann, U.D. and G.A. Ricaurte, *MDMA ("ecstasy") and panic disorder: induction by a single dose*. *Biol Psychiatry*, 1992. **32**(10): p. 950-3.
490. Carlyle, M., et al., *Greater empathy in MDMA users*. *J Psychopharmacol*, 2019: p. 269881119826594.
491. Allott, K., et al., *Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users*. *J Psychopharmacol*, 2008.
492. Wetherell, M.A. and C. Montgomery, *Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users*. *Psychopharmacology (Berl)*, 2014. **231**(7): p. 1365-75.
493. Frokjaer, V.G., et al., *In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users*. *Int J Neuropsychopharmacol*, 2014. **17**(8): p. 1119-28.
494. George, A.M., S. Olesen, and R.J. Tait, *Ecstasy use and depression: a 4-year longitudinal study among an Australian general community sample*. *Psychopharmacology (Berl)*, 2013. **229**(4): p. 713-21.

495. Thomasius, R., et al., *Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective*. J Psychopharmacol, 2006. **20**(2): p. 211-25.
496. Abad, S., et al., *MDMA enhances hippocampal-dependent learning and memory under restrictive conditions, and modifies hippocampal spine density*. Psychopharmacology (Berl), 2014. **231**(5): p. 863-74.
497. Semple, D.M., et al., *Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users*. Br J Psychiatry, 1999. **175**: p. 63-9.
498. Gouzoulis-Mayfrank, E. and J. Daumann, *Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?* Addiction, 2006. **101**(3): p. 348-61.
499. Buchert, R., et al., *A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters*. Am J Psychiatry, 2004. **161**(7): p. 1181-9.
500. Gouzoulis-Mayfrank, E., et al., *Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users*. Prog Neuropsychopharmacol Biol Psychiatry, 2003. **27**(5): p. 819-27.
501. Halpern, J.H., et al., *Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs*. Drug Alcohol Depend, 2004. **75**(2): p. 135-47.
502. Thomasius, R., et al., *Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users*. Psychopharmacology (Berl), 2003. **167**(1): p. 85-96.
503. Szigeti, B., et al., *Are ecstasy induced serotonergic alterations overestimated for the majority of users?* J Psychopharmacol, 2018. **32**(7): p. 741-748.
504. Daumann, J., Jr., et al., *Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study*. Biol Psychiatry, 2004. **56**(5): p. 349-55.
505. Gouzoulis-Mayfrank, E., et al., *Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use*. Drug Alcohol Depend, 2005. **78**(3): p. 317-23.
506. Buchert, R., et al., *Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users*. Eur J Nucl Med Mol Imaging, 2006. **33**(2): p. 188-99.
507. Bosch, O.G., et al., *Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users*. PLoS One, 2013. **8**(4): p. e61234.
508. Taurah, L., C. Chandler, and G. Sanders, *Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)*. Psychopharmacology (Berl), 2014. **231**(4): p. 737-51.

509. Smithies, V., et al., *Dysfunctional overnight memory consolidation in ecstasy users*. *J Psychopharmacol*, 2014. **28**(8): p. 751-62.
510. Laws, K.R. and J. Kokkalis, *Ecstasy (MDMA) and memory function: a meta-analytic update*. *Hum Psychopharmacol*, 2007.
511. Zakzanis, K.K., Z. Campbell, and D. Jovanovski, *The neuropsychology of ecstasy (MDMA) use: a quantitative review*. *Hum Psychopharmacol*, 2007. **22**(7): p. 427-35.
512. Schilt, T., et al., *Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study*. *Arch Gen Psychiatry*, 2007. **64**(6): p. 728-36.
513. Jager, G., et al., *Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study*. *Psychopharmacology (Berl)*, 2007. **193**(3): p. 403-14.
514. White, C., J. Brown, and M. Edwards, *Alterations to global but not local motion processing in long-term ecstasy (MDMA) users*. *Psychopharmacology (Berl)*, 2014.
515. Amoroso, T., *The spurious relationship between ecstasy use and neurocognitive deficits: A Bradford Hill review*. *Int J Drug Policy*, 2019. **64**: p. 47-53.
516. Bedi, G. and J. Redman, *Metamemory in recreational ecstasy polydrug users: what do self-reports of memory failures mean?* *J Psychopharmacol*, 2008.
517. Bedi, G. and J. Redman, *Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds*. *Psychol Med*, 2008. **38**(9): p. 1319-30.
518. Hanson, K.L. and M. Luciana, *Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor*. *J Clin Exp Neuropsychol*, 2010. **32**(4): p. 337-49.
519. Raj, V., et al., *MDMA (ecstasy) use is associated with reduced BOLD signal change during semantic recognition in abstinent human polydrug users: a preliminary fMRI study*. *J Psychopharmacol*, 2010. **24**(2): p. 187-201.
520. Roiser, J.P., R.D. Rogers, and B.J. Sahakian, *Neuropsychological function in ecstasy users: a study controlling for polydrug use*. *Psychopharmacology (Berl)*, 2007. **189**(4): p. 505-16.
521. Roberts, C.A., et al., *Differences in prefrontal blood oxygenation during an acute multitasking stressor in ecstasy polydrug users*. *Psychol Med*, 2015. **45**(2): p. 395-406.
522. Blagrove, M., et al., *Procedural and declarative memory task performance, and the memory consolidation function of sleep, in recent and abstinent ecstasy/MDMA users*. *J Psychopharmacol*, 2011. **25**(4): p. 465-77.
523. Kish, S.J., et al., *Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[<sup>11</sup>C]DASB and structural brain imaging study*. *Brain*, 2010. **133**(Pt 6): p. 1779-97.
524. Montgomery, C. and J.E. Fisk, *Ecstasy-related deficits in the updating component of executive processes*. *Hum Psychopharmacol*, 2008.

525. McCann, U.D., et al., *Sleep deprivation differentially impairs cognitive performance in abstinent methylenedioxymethamphetamine ("ecstasy") users*. J Neurosci, 2009. **29**(44): p. 14050-6.
526. Hadjiefthymoulou, F., et al., *Everyday and prospective memory deficits in ecstasy/polydrug users*. J Psychopharmacol, 2011. **25**(4): p. 453-64.
527. van Holst, R.J. and T. Schilt, *Drug-related decrease in neuropsychological functions of abstinent drug users*. Curr Drug Abuse Rev, 2011. **4**(1): p. 42-56.
528. Cuyas, E., et al., *The Influence of Genetic and Environmental Factors among MDMA Users in Cognitive Performance*. PLoS One, 2011. **6**(11): p. e27206.
529. Jager, G., et al., *Assessment of cognitive brain function in ecstasy users and contributions of other drugs of abuse: results from an FMRI study*. Neuropsychopharmacology, 2008. **33**(2): p. 247-58.
530. Indlekofer, F., et al., *Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol*. J Psychopharmacol, 2009. **23**(5): p. 495-509.
531. Schilt, T., et al., *Long-term neuropsychological effects of ecstasy in middle-aged ecstasy/polydrug users*. Psychopharmacology (Berl), 2010. **207**(4): p. 583-91.
532. Murphy, P.N., et al., *The effects of 'ecstasy' (MDMA) on visuospatial memory performance: findings from a systematic review with meta-analyses*. Hum Psychopharmacol, 2012. **27**(2): p. 113-38.
533. Wagner, D., et al., *A prospective study of learning, memory, and executive function in new MDMA users*. Addiction, 2013. **108**(1): p. 136-45.
534. Wagner, D., et al., *Learning, Memory, and Executive Function in New MDMA Users: A 2-Year Follow-Up Study*. Front Neurosci, 2015. **9**: p. 445.
535. Price, J.S., P. Shear, and K.M. Lisdahl, *Ecstasy exposure & gender: examining components of verbal memory functioning*. PLoS One, 2014. **9**(12): p. e115645.
536. Kuypers, K.P.C., et al., *Verbal memory impairment in polydrug Ecstasy users: A clinical perspective*. PLoS One, 2016. **11**(2): p. e0149438. .
537. Wareing, M., et al., *Verbal working memory deficits in current and previous users of MDMA*. Hum Psychopharmacol, 2004. **19**(4): p. 225-34.
538. von Geusau, N.A., et al., *Impaired executive function in male MDMA ("ecstasy") users*. Psychopharmacology (Berl), 2004. **175**(3): p. 331-41.
539. Murphy, P.N., et al., *Executive working memory deficits in abstinent ecstasy/MDMA users: a critical review*. Neuropsychobiology, 2009. **60**(3-4): p. 159-75.
540. Hoshi, R., et al., *Neurocognitive function in current and ex-users of ecstasy in comparison to both matched polydrug-using controls and drug-naïve controls*. Psychopharmacology (Berl), 2007. **194**(3): p. 371-9.

541. Morgan, M.J., *Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity*. *Neuropsychopharmacology*, 1998. **19**(4): p. 252-64.
542. Quednow, B.B., et al., *Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy")*. *Psychopharmacology (Berl)*, 2007. **189**(4): p. 517-30.
543. Morgan, M.J., et al., *Elevated impulsivity and impaired decision-making in abstinent Ecstasy (MDMA) users compared to polydrug and drug-naive controls*. *Neuropsychopharmacology*, 2006. **31**(7): p. 1562-73.
544. Schilt, T., et al., *Decision making as a predictor of first ecstasy use: a prospective study*. *Psychopharmacology (Berl)*, 2009. **203**(3): p. 519-27.
545. Pirona, A. and M.J. Morgan, *An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users*. *J Psychopharmacol*, 2010. **24**(2): p. 175-85.
546. Hanson, K.L., M. Luciana, and K. Sullwold, *Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users*. *Drug Alcohol Depend*, 2008. **96**(1-2): p. 99-110.
547. Betzler, F., L. Viohl, and N. Romanczuk-Seiferth, *Decision-making in chronic ecstasy users: a systematic review*. *Eur J Neurosci*, 2017. **45**(1): p. 34-44.
548. Richard, J., et al., *The Stimulating Nature of Gambling Behaviors: Relationships Between Stimulant Use and Gambling Among Adolescents*. *J Gambl Stud*, 2019. **35**(1): p. 47-62.
549. Grob, C.S., et al., *Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations*. *Behav Brain Res*, 1996. **73**(1-2): p. 103-7.
550. Mithoefer, M.C., et al., *3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial*. *Lancet Psychiatry*, 2018. **5**(6): p. 486-497.
551. Ot'alora, G.M., et al., *3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial*. *J Psychopharmacol*, 2018. **32**(12): p. 1295-1307
552. Wagner, A.C., et al., *Combining Cognitive-Behavioral Conjoint Therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA): A Case Example*. *J Psychoactive Drugs*, 2019. **51**(2): p. 166-173.
553. Wolfson, P., et al., *MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses*. Submitted for Publication, 2020.
554. Kirkpatrick, M.G., et al., *MDMA effects consistent across laboratories*. *Psychopharmacology (Berl)*, 2014. **231**(19): p. 3899-905.
555. de la Torre, R., et al., *Pharmacology of MDMA in humans*. *Ann N Y Acad Sci*, 2000. **914**: p. 225-37.

556. Dumont, G.J. and R.J. Verkes, *A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers*. J Psychopharmacol, 2006. **20**(2): p. 176-87.
557. Hysek, C.M., et al., *Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination*. Int J Neuropsychopharmacol, 2014. **17**(3): p. 371-81.
558. Desrosiers, N.A., et al., *Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration*. Anal Bioanal Chem, 2013. **405**(12): p. 4067-76.
559. Zhang, L., et al., *Predicting drug-drug interactions: an FDA perspective*. The AAPS journal, 2009. **11**(2): p. 300-306.
560. Wan Aasim, W.R., S.C. Tan, and S.H. Gan, *Interspecies In Vitro Evaluation of Stereoselective Protein Binding for 3, 4-Methylenedioxymethamphetamine*. Journal of Chemistry, 2017. **2017**.
561. de la Torre, R., et al., *Clinical pharmacokinetics of amphetamine and related substances: monitoring in conventional and non-conventional matrices*. Clin Pharmacokinet, 2004. **43**(3): p. 157-85.
562. de Boer, D., et al., *Gas chromatographic/mass spectrometric assay for profiling the enantiomers of 3,4-methylenedioxymethamphetamine and its chiral metabolites using positive chemical ionization ion trap mass spectrometry*. J Mass Spectrom, 1997. **32**(11): p. 1236-46.
563. Helmlin, H.J., et al., *Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS*. J Anal Toxicol, 1996. **20**(6): p. 432-40.
564. Lanz, M., R. Brenneisen, and W. Thormann, *Enantioselective determination of 3,4-methylene-dioxymethamphetamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis*. Electrophoresis, 1997. **18**(6): p. 1035-43.
565. Ortuno, J., et al., *Quantification of 3,4-methylenedioxymetamphetamine and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorus detection*. J Chromatogr B Biomed Sci Appl, 1999. **723**(1-2): p. 221-32.
566. Helmlin, H.J. and R. Brenneisen, *Determination of psychotropic phenylalkylamine derivatives in biological matrices by high-performance liquid chromatography with photodiode-array detection*. J Chromatogr, 1992. **593**(1-2): p. 87-94.
567. Yang, J., et al., *Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA*. J Psychopharmacol, 2006. **20**(6): p. 842-9.
568. O'Mathuna, B., et al., *The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans*. J Clin Psychopharmacol, 2008. **28**(5): p. 523-9.

569. Yubero-Lahoz, S., et al., *Sex Differences in 3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy)-Induced Cytochrome P450 2D6 Inhibition in Humans*. Clin Pharmacokinet, 2011. **50**(5): p. 319-29.
570. Studerus, E., et al., *Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies*. J Psychopharmacol, 2021: p. 269881121998322.
571. Yubero-Lahoz, S., et al., *Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug*. Drug Metab Pharmacokinet, 2012. **27**(6): p. 605-13.
572. Fallon, J.K., et al., *Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans [published erratum appears in Clin Chem 1999 Sep;45(9):1585]*. Clin Chem, 1999. **45**(7): p. 1058-69.
573. Schwaninger, A.E., et al., *Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration*. Clin Chem, 2011. **57**(12): p. 1748-56.
574. Steuer, A.E., et al., *Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans*. PLoS One, 2016. **11**(3): p. e0150955.
575. Farre, M., et al., *Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart*. Eur Neuropsychopharmacol, 2015. **25**(10): p. 1637-49.
576. Ramamoorthy, S. and R.D. Blakely, *Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants*. Science, 1999. **285**(5428): p. 763-766.
577. Farre, M., et al., *Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics*. Psychopharmacology (Berl), 2004. **173**(3-4): p. 364-75.
578. Pizarro, N., et al., *Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine)*. Drug Metab Dispos, 2004. **32**(9): p. 1001-7.
579. Pizarro, N., et al., *Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites by gas chromatography/mass spectrometry*. Rapid Commun Mass Spectrom, 2003. **17**(4): p. 330-6.
580. Pizarro, N., et al., *Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis*. J Anal Toxicol, 2002. **26**(3): p. 157-65.
581. Segura, M., et al., *3,4-Dihydroxymethamphetamine (HHMA). A Major in Vivo 3,4-methylenedioxymethamphetamine (MDMA) Metabolite in Humans*. Chem Res Toxicol, 2001. **14**(9): p. 1203-1208.
582. Steuer, A.E., et al., *Development and validation of an LC-MS/MS method after chiral derivatization for the simultaneous stereoselective determination of methylenedioxy-*



- methamphetamine (MDMA) and its phase I and II metabolites in human blood plasma.* Drug Test Anal, 2015. **7**(7): p. 592-602.
583. Steuer, A.E., et al., *Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans.* Drug Metab Dispos, 2015. **43**(12): p. 1864-71.
584. de la Torre, R., et al., *Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.* Ther Drug Monit, 2004. **26**(2): p. 137-44.
585. Abraham, T.T., et al., *Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.* J Anal Toxicol, 2009. **33**(8): p. 439-46.
586. Vizeli, P., et al., *Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects.* Eur Neuropsychopharmacol, 2017. **27**(3): p. 232-238.
587. Rodgers, J.T., et al., *Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): functional heterogeneity of the enzyme and the reversibility of its inactivation.* Biochem Pharmacol, 2018.
588. Pardo-Lozano, R., et al., *Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT).* PLoS One, 2012. **7**(10): p. e47599.
589. Vizeli, P., H.E. Meyer Zu Schwabedissen, and M.E. Liechti, *Role of serotonin transporter and receptor gene variations in the acute effects of MDMA in healthy subjects.* ACS Chem Neurosci, 2018.
590. Vizeli, P. and M.E. Liechti, *Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects.* PLoS One, 2018. **13**(6): p. e0199384.
591. Segura, M., et al., *Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.* Clin Pharmacokinet, 2005. **44**(6): p. 649-60.
592. Schmid, Y., et al., *Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects.* J Pharmacol Exp Ther, 2015. **353**(1): p. 102-11.
593. Steuer, A.E., et al., *Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine.* Toxicol Lett, 2016. **243**: p. 48-55.
594. Liechti, M.E., et al., *Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram.* Neuropsychopharmacology, 2000. **22**(5): p. 513-21.
595. Liechti, M.E. and F.X. Vollenweider, *The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.* J Psychopharmacol, 2000. **14**(3): p. 269-74.

596. Pacifici, R., et al., *Paroxetine inhibits acute effects of 3,4-methylenedioxymethamphetamine on the immune system in humans*. *J Pharmacol Exp Ther*, 2004. **309**(1): p. 285-92.
597. Tancer, M. and C.E. Johanson, *The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans*. *Psychopharmacology (Berl)*, 2007. **189**(4): p. 565-73.
598. Liechti, M.E., et al., *Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans*. *Neuropsychopharmacology*, 2000. **23**(4): p. 396-404.
599. Dipasquale, O., et al., *Receptor-Enriched Analysis of functional connectivity by targets (REACT): A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA*. *Neuroimage*, 2019.
600. Hysek, C.M., et al., *The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans*. *Clin Pharmacol Ther*, 2011. **90**(2): p. 246-55.
601. Simmler, L.D., C.M. Hysek, and M.E. Liechti, *Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects*. *J Clin Endocrinol Metab*, 2011. **96**(9): p. 2844-50.
602. Holze, F., et al., *Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects*. *Neuropsychopharmacology*, 2020. **45**(3): p. 462-471.
603. Moron, J.A., et al., *Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines*. *J Neurosci*, 2002. **22**(2): p. 389-95.
604. Liechti, M.E. and F.X. Vollenweider, *Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans*. *Eur Neuropsychopharmacol*, 2000. **10**(4): p. 289-95.
605. Schmid, Y., et al., *Differential effects of MDMA and methylphenidate on social cognition*. *J Psychopharmacol*, 2014. **28**(9): p. 847-56.
606. Bershad, A.K., et al., *Effects of acute doses of prosocial drugs methamphetamine and alcohol on plasma oxytocin levels*. *J Clin Psychopharmacol*, 2015. **35**(3): p. 308-12.
607. Kirkpatrick, M.G., et al., *Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans*. *Psychoneuroendocrinology*, 2014. **46**: p. 23-31.
608. Kuypers, K.P., et al., *Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies*. *J Psychopharmacol*, 2017. **31**(5): p. 589-598.
609. Kuypers, K.P., et al., *No Evidence that MDMA-Induced Enhancement of Emotional Empathy Is Related to Peripheral Oxytocin Levels or 5-HT1a Receptor Activation*. *PLoS One*, 2014. **9**(6): p. e100719.

610. Boxler, M.I., et al., *Human Metabolome Changes after a Single Dose of 3,4-Methylenedioxymethamphetamine (MDMA) with Special Focus on Steroid Metabolism and Inflammation Processes*. J Proteome Res, 2018. **17**(8): p. 2900-2907.
611. Grob, C., *Unpublished data on human study of psychological and physiological effects of MDMA*. 2001.
612. Kuypers, K.P., et al., *Inhibition of MDMA-induced increase in cortisol does not prevent acute impairment of verbal memory*. Br J Pharmacol, 2013. **168**(3): p. 607-17.
613. Seibert, J., et al., *Acute effects of 3,4-methylenedioxymethamphetamine and methylphenidate on circulating steroid levels in healthy subjects*. Neuroendocrinology, 2014. **100**(1): p. 17-25.
614. Pacifici, R., et al., *Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings*. Ann N Y Acad Sci, 2002. **965**: p. 421-33.
615. Bershad, A.K., M.A. Miller, and H. de Wit, *MDMA does not alter responses to the Trier Social Stress Test in humans*. Psychopharmacology (Berl), 2017. **234**(14): p. 2159-2166.
616. Walpolá, I.C., et al., *Altered Insula Connectivity under MDMA*. Neuropsychopharmacology, 2017. **42**(11): p. 2152-2162.
617. Gamma, A., et al., *3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans*. Neuropsychopharmacology, 2000. **23**(4): p. 388-95.
618. Phelps, E.A., et al., *Activation of the left amygdala to a cognitive representation of fear*. Nat Neurosci, 2001. **4**(4): p. 437-41.
619. Ramaekers, J.G., et al., *Involvement of inferior parietal lobules in prospective memory impairment during acute MDMA (ecstasy) intoxication: an event-related fMRI study*. Neuropsychopharmacology, 2009. **34**(7): p. 1641-8.
620. Kuypers, K.P., et al., *MDMA intoxication and verbal memory performance: a placebo-controlled pharmac-MRI study*. J Psychopharmacol, 2011. **25**(8): p. 1053-61.
621. Carhart-Harris, R.L., et al., *The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity*. Biol Psychiatry, 2015. **78**(8): p. 554-62.
622. Bosker, W.M., et al., *Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss*. Psychopharmacology (Berl), 2010. **209**(1): p. 69-76.
623. Wagner, M.T., et al., *Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy*. J Psychopharmacol, 2017. **31**(8): p. 967-974.
624. Erritzoe, D., et al., *Effects of psilocybin therapy on personality structure*. Acta Psychiatr Scand, 2018. **138**(5): p. 368-378.

625. Maclean, K.A., M.W. Johnson, and R.R. Griffiths, *Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness*. *J Psychopharmacol*, 2011. **25**(11): p. 1453-61.
626. Baggott, M.J., et al., *3,4-Methylenedioxyamphetamine (MDMA, 'Ecstasy') and Prazosin Interactions in Humans.*, in *70th Annual Meeting of the College on Problems of Drug Dependence*. 2008: San Juan, Puerto Rico.
627. Kuypers, K.P.C., et al., *MDMA-induced indifference to negative sounds is mediated by the 5-HT<sub>2A</sub> receptor*. *Psychopharmacology (Berl)*, 2018. **235**(2): p. 481-490.
628. Gabay, A.S., et al., *MDMA Increases Cooperation and Recruitment of Social Brain Areas When Playing Trustworthy Players in an Iterated Prisoner's Dilemma*. *J Neurosci*, 2019. **39**(2): p. 307-320.
629. Schmidt, A., et al., *Acute Effects of Methylphenidate, Modafinil, and MDMA on Negative Emotion Processing*. *Int J Neuropsychopharmacol*, 2018. **21**(4): p. 345-354.
630. Kirkpatrick, M.G. and H. de Wit, *MDMA: a social drug in a social context*. *Psychopharmacology (Berl)*, 2015. **232**(6): p. 1155-63.
631. Kirkpatrick, M., et al., *Prosocial effects of MDMA: A measure of generosity*. *J Psychopharmacol*, 2015. **29**(6): p. 661-8.
632. Frye, C.G., et al., *MDMA decreases the effects of simulated social rejection*. *Pharmacol Biochem Behav*, 2014. **117**: p. 1-6.
633. Tancer, M.E. and C.E. Johanson, *The subjective effects of MDMA and mCPP in moderate MDMA users*. *Drug Alcohol Depend*, 2001. **65**(1): p. 97-101.
634. Baggott, M.J., et al., *Intimate insight: MDMA changes how people talk about significant others*. *J Psychopharmacol*, 2015. **29**(6): p. 669-77.
635. Corey, V.R., V.D. Pisano, and J.H. Halpern, *Effects of 3,4-Methylenedioxyamphetamine on Patient Utterances in a Psychotherapeutic Setting*. *J Nerv Ment Dis*, 2016.
636. Lamers, C.T., et al., *Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance*. *J Psychopharmacol*, 2003. **17**(4): p. 379-87.
637. Spronk, D.B., et al., *The acute effects of MDMA and ethanol administration on electrophysiological correlates of performance monitoring in healthy volunteers*. *Psychopharmacology (Berl)*, 2014. **231**(14): p. 2877-88.
638. Bosker, W.M., et al., *MDMA (ecstasy) effects on actual driving performance before and after sleep deprivation, as function of dose and concentration in blood and oral fluid*. *Psychopharmacology (Berl)*, 2012. **222**(3): p. 367-76.
639. Kuypers, K.P. and J.G. Ramaekers, *Transient memory impairment after acute dose of 75mg 3,4-Methylene-dioxyamphetamine*. *J Psychopharmacol*, 2005. **19**(6): p. 633-9.

640. Ramaekers, J.G. and K.P. Kuypers, *Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on behavioral measures of impulsivity: alone and in combination with alcohol*. *Neuropsychopharmacology*, 2006. **31**(5): p. 1048-55.
641. Kuypers, K.P., N. Samyn, and J.G. Ramaekers, *MDMA and alcohol effects, combined and alone, on objective and subjective measures of actual driving performance and psychomotor function*. *Psychopharmacology (Berl)*, 2006. **187**(4): p. 467-75.
642. Kuypers, K.P. and J.G. Ramaekers, *Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected*. *Psychopharmacology (Berl)*, 2007. **189**(4): p. 557-63.
643. Ramaekers, J.G., K.P. Kuypers, and N. Samyn, *Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal*. *Addiction*, 2006. **101**(11): p. 1614-21.
644. Clark, C.M., et al., *Acute effects of MDMA on autonomic cardiac activity and their relation to subjective prosocial and stimulant effects*. *Psychophysiology*, 2015. **52**(3): p. 429-35.
645. Sessa, B., et al., *First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder*. *J Psychopharmacol*, 2021: p. 269881121991792.
646. Pacifici, R., et al., *Immunomodulating activity of MDMA*. *Ann N Y Acad Sci*, 2000. **914**: p. 215-24.
647. Pacifici, R., et al., *Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study*. *Life Sci*, 1999. **65**(26): p. L309-16.
648. Pacifici, R., et al., *Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans*. *J Pharmacol Exp Ther*, 2001. **296**(1): p. 207-15.
649. Pacifici, R., et al., *Effects of repeated doses of MDMA ("ecstasy") on cell-mediated immune response in humans*. *Life Sci*, 2001. **69**(24): p. 2931-41.
650. McElhatton, P.R., et al., *Congenital anomalies after prenatal ecstasy exposure [letter]*. *Lancet*, 1999. **354**(9188): p. 1441-2.
651. Bateman, D.N., et al., *A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England*. *Eur J Clin Pharmacol*, 2004. **60**(9): p. 635-41.
652. Ho, E., L. Karimi-Tabesh, and G. Koren, *Characteristics of pregnant women who use Ecstasy (3, 4- methylenedioxymethamphetamine)*. *Neurotoxicol Teratol*, 2001. **23**(6): p. 561-7.
653. Singer, L.T., et al., *Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy*. *Neurotoxicol Teratol*, 2012. **34**(3): p. 303-10.

654. Singer, L.T., et al., *Motor delays in MDMA (ecstasy) exposed infants persist to 2years*. Neurotoxicol Teratol, 2016.
655. Huxster, J.K., A. Pirona, and M.J. Morgan, *The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans*. J Psychopharmacol, 2006. **20**(2): p. 281-90.
656. Wagner, M.T., et al., *Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy*. J Psychopharmacol, 2017: p. 269881117711712.
657. Neff, K., *The Development and validation of a scale to measure self-compassion*. Self and Identity, 2003. **2**: p. 223-250.
658. Blake, D.D., et al., *A clinician rating scale for assessing current and lifetime PTSD: the CAPS-1*. Behav Ther, 1990. **13**: p. 187-188.
659. Nagy, L.M., et al., *Open prospective trial of fluoxetine for posttraumatic stress disorder*. J Clin Psychopharmacol, 1993. **13**(2): p. 107-13.
660. Weathers, F.W., *Clinician-Administered PTSD Scale (CAPS): Technical Manual*. 2004, Los Angeles, CA: Western Psychological Services.
661. Weathers, F.W., et al., *The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and Initial Psychometric Evaluation in Military Veterans*. Psychol Assess, 2017.
662. Hexel, M. and G. Sonneck, *Somatoform symptoms, anxiety, and depression in the context of traumatic life experiences by comparing participants with and without psychiatric diagnoses*. Psychopathology, 2002. **35**(5): p. 303-12.
663. Afari, N., et al., *Psychological trauma and functional somatic syndromes: a systematic review and meta-analysis*. Psychosom Med, 2014. **76**(1): p. 2-1.
664. Pietrzak, R.H., et al., *Psychiatric comorbidity of full and partial posttraumatic stress disorder among older adults in the United States: results from wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions*. Am J Geriatr Psychiatry, 2012. **20**(5): p. 380-90.
665. Baker, D.G., et al., *Relationship between posttraumatic stress disorder and self-reported physical symptoms in Persian Gulf War veterans*. Arch Intern Med, 1997. **157**(18): p. 2076-8.
666. Hoge, C.W., et al., *Association of posttraumatic stress disorder with somatic symptoms, health care visits, and absenteeism among Iraq war veterans*. Am J Psychiatry, 2007. **164**(1): p. 150-3.
667. Gouzoulis-Mayfrank, E., et al., *Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study*. Psychopharmacology (Berl), 1999. **142**(1): p. 41-50.
668. Song, H., et al., *Stress related disorders and subsequent risk of life threatening infections: population based sibling controlled cohort study*. BMJ, 2019. **367**: p. 15784.

669. Jiang, X., et al., *Stress Impairs 5-HT(2A) Receptor-Mediated Serotonergic Facilitation of GABA Release in Juvenile Rat Basolateral Amygdala*. *Neuropsychopharmacology*, 2009. **34**(2): p. 410-23.
670. Gradus, J.L., et al., *Posttraumatic stress disorder and completed suicide*. *Am J Epidemiol*, 2010. **171**(6): p. 721-7.
671. Conner, K.R., et al., *Posttraumatic stress disorder and suicide in 5.9 million individuals receiving care in the veterans health administration health system*. *J Affect Disord*, 2014. **166**: p. 1-5.
672. US Food and Drug Administration, *Guidance for industry: suicidal ideation and behavior: prospective assessment of occurrence in clinical trials*. Silver Springs, MD: US Food and Drug Administration Available at: <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm315156.htm>. Accessed October, 2012. **5**: p. 2012.
673. Nilsson, M.E., et al., *Columbia Suicide Severity Rating Scale Scoring and Data Analysis Guide*, in *CSSRS Scoring Version 2.0*. 2013: [http://www.cssrs.columbia.edu/documents/ScoringandDataAnalysisGuide\\_Feb2013.pdf](http://www.cssrs.columbia.edu/documents/ScoringandDataAnalysisGuide_Feb2013.pdf). p. 1-13.
674. Stone, T.E., C. Swanson, and M.D. Feldman, *Venlafaxine discontinuation syndrome and suicidal ideation: a case series*. *J Clin Psychopharmacol*, 2007. **27**(1): p. 94-5.
675. Tint, A., P.M. Haddad, and I.M. Anderson, *The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study*. *J Psychopharmacol*, 2008. **22**(3): p. 330-2.
676. Valuck, R.J., H.D. Orton, and A.M. Libby, *Antidepressant discontinuation and risk of suicide attempt: a retrospective, nested case-control study*. *J Clin Psychiatry*, 2009. **70**(8): p. 1069-77.
677. Young, M.B., et al., *Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)*. *Psychopharmacology (Berl)*, 2017.
678. Feduccia, A.A. and M.C. Mithoefer, *MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?* *Prog Neuropsychopharmacol Biol Psychiatry*, 2018. **84**(Pt A): p. 221-228.
679. Randolph, C., et al., *The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity*. *J Clin Exp Neuropsychol*, 1998. **20**(3): p. 310-9.
680. Gronwall, D.M., *Paced auditory serial-addition task: a measure of recovery from concussion*. *Percept Mot Skills*, 1977. **44**(2): p. 367-73.
681. Roman, D.D., et al., *Extended norms for the paced auditory serial addition task*. *Clin Neuropsychol*, 1991. **5**(1): p. 33-40.

682. Kamilar-Britt, P. and G. Bedi, *The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals*. *Neurosci Biobehav Rev*, 2015. **57**: p. 433-46.
683. Bershad, A.K., et al., *The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?* *J Psychopharmacol*, 2016. **30**(12): p. 1248-1258.
684. Dumont, G.J., et al., *Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans*. *Clin Pharmacol Ther*, 2009. **86**(2): p. 160-6.
685. Hysek, C.M., et al., *alpha(1)-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans*. *J Clin Psychopharmacol*, 2013. **33**(5): p. 658-66.
686. Johanson, C.E., et al., *Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo*. *Drug Alcohol Depend*, 2006. **81**(1): p. 27-36.
687. Schmid, Y., et al., *Effects of methylphenidate and MDMA on appraisal of erotic stimuli and intimate relationships*. *Eur Neuropsychopharmacol*, 2015. **25**(1): p. 17-25.
688. Marrone, G.F., et al., *Amphetamine analogs methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) differentially affect speech*. *Psychopharmacology (Berl)*, 2010. **208**(2): p. 169-77.
689. Davis, A.K. and H. Rosenberg, *The prevalence, intensity, and assessment of craving for MDMA/ecstasy in recreational users*. *J Psychoactive Drugs*, 2014. **46**(2): p. 154-61.
690. Degenhardt, L., R. Bruno, and L. Topp, *Is ecstasy a drug of dependence?* *Drug Alcohol Depend*, 2010. **107**(1): p. 1-10.
691. Cottler, L.B., et al., *Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria*. *Hum Psychopharmacol*, 2001. **16**(8): p. 599-606.
692. Topp, L., et al., *Ecstasy use in Australia: patterns of use and associated harm*. *Drug Alcohol Depend*, 1999. **55**(1-2): p. 105-15.
693. Verheyden, S.L., J.A. Henry, and H.V. Curran, *Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users*. *Hum Psychopharmacol*, 2003. **18**(7): p. 507-17.
694. Meyer, J.S., *3,4-methylenedioxymethamphetamine (MDMA): current perspectives*. *Subst Abuse Rehabil*, 2013. **4**: p. 83-99.
695. Cottler, L.B., K.S. Leung, and A.B. Abdallah, *Test-re-test reliability of DSM-IV adopted criteria for 3,4-methylenedioxymethamphetamine (MDMA) abuse and dependence: a cross-national study*. *Addiction*, 2009. **104**(10): p. 1679-90.
696. Topp L.J., H. W.D., and H. J., *Is there a dependence syndrome for ecstasy?* 1997, Randwick, NSW: National Drug & Alcohol Research Centre.



697. von Sydow, K., et al., *Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults-a transient phenomenon? Results from a longitudinal community study.* Drug Alcohol Depend, 2002. **66**(2): p. 147-59.
698. Powers, W.J., et al., *Guidelines for the early management of patients With acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association.* Stroke, 2019. **50**(12): p. e344-e418.
699. Searchfield, G.D., et al., *A proof-of-principle study of the short-term effects of 3,4-methylenedioxymethamphetamine (MDMA) on tinnitus and neural connectivity.* Int J Neurosci, 2020: p. 1-12.
700. Sessa, B., et al., *First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants.* BMJ Case Rep, 2019. **12**(7).
701. de Wit, H. and A.K. Bershad, *MDMA enhances pleasantness of affective touch.* Neuropsychopharmacology, 2020. **45**(1): p. 217-239.
702. Bershad, A.K., et al., *Effects of MDMA on attention to positive social cues and pleasantness of affective touch.* Neuropsychopharmacology, 2019. **44**(10): p. 1698-1705.
703. Gabay, A.S., et al., *Psilocybin and MDMA reduce costly punishment in the Ultimatum Game.* Sci Rep, 2018. **8**(1): p. 8236.
704. Borissova, A., et al., *Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment.* J Psychopharmacol, 2020: p. 269881120926673.
705. Roseman, L., et al., *The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers.* Front Hum Neurosci, 2014. **8**: p. 204.
706. Dolder, P.C., et al., *Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects.* Psychopharmacology (Berl), 2018. **235**(2): p. 467-479.
707. Schmidt, A., et al., *Comparative Effects of Methylphenidate, Modafinil, and MDMA on Response Inhibition Neural Networks in Healthy Subjects.* Int J Neuropsychopharmacol, 2017. **20**(9): p. 712-720.
708. Boxler, M.I., et al., *First Time View on Human Metabolome Changes after a Single Intake of 3,4-Methylenedioxymethamphetamine in Healthy Placebo-Controlled Subjects.* J Proteome Res, 2017. **16**(9): p. 3310-3320.
709. van Heugten-Van der Kloet, D., et al., *MDMA, cannabis, and cocaine produce acute dissociative symptoms.* Psychiatry Res, 2015. **228**(3): p. 907-12.
710. Kuypers, K.P., M. Wingen, and J.G. Ramaekers, *Memory and mood during the night and in the morning after repeated evening doses of MDMA.* J Psychopharmacol, 2008. **22**(8): p. 895-903.

711. Kuypers, K.P., et al., *Acute effects of nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the night*. *Psychopharmacology (Berl)*, 2007. **192**(1): p. 111-9.
712. de Sousa Fernandes Perna, E.B., et al., *Memory and mood during MDMA intoxication, with and without memantine pretreatment*. *Neuropharmacology*, 2014. **87**: p. 198-205.
713. Haijen, E., et al., *Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication*. *Psychopharmacology (Berl)*, 2018. **235**(3): p. 709-717.
714. Baggott, M.J., et al., *Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting*. *J Psychopharmacol*, 2016. **30**(4): p. 378-87.
715. Francis, S.M., et al., *Urinary and plasma oxytocin changes in response to MDMA or intranasal oxytocin administration*. *Psychoneuroendocrinology*, 2016. **74**: p. 92-100.
716. Agurto, C., et al., *Detection of acute 3,4-methylenedioxymethamphetamine (MDMA) effects across protocols using automated natural language processing*. *Neuropsychopharmacology*, 2020. **45**(5): p. 823-832.
717. Doss, M.K., et al., *MDMA Impairs Both the Encoding and Retrieval of Emotional Recollections*. *Neuropsychopharmacology*, 2018. **43**(4): p. 791-800.
718. Papaseit, E., et al., *Human Pharmacology of Mephedrone in Comparison with MDMA*. *Neuropsychopharmacology*, 2016. **41**(11): p. 2704-13.
719. de la Torre, R., et al., *MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers*. *Eur J Clin Pharmacol*, 2005. **61**(7): p. 551-4.
720. Hernandez-Lopez, C., et al., *3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics*. *J Pharmacol Exp Ther*, 2002. **300**(1): p. 236-44.
721. Lansbergen, M.M., et al., *Acute effects of MDMA (3,4-methylenedioxymethamphetamine) on EEG oscillations: alone and in combination with ethanol or THC (delta-9-tetrahydrocannabinol)*. *Psychopharmacology (Berl)*, 2011. **213**(4): p. 745-56.
722. Dumont, G.J., et al., *Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers*. *J Psychopharmacol*, 2010. **24**(2): p. 155-64.
723. Dumont, G.J., et al., *Acute neuropsychological effects of MDMA and ethanol (co-) administration in healthy volunteers*. *Psychopharmacology (Berl)*, 2008. **197**(3): p. 465-74.
724. Dumont, G.J., et al., *Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology*. *J Psychopharmacol*, 2010. **24**(2): p. 165-74.
725. Samyn, N., et al., *Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions*. *Forensic Sci Int*, 2002. **128**(1-2): p. 90.

726. Veldstra, J.L., et al., *Effects of alcohol (BAC 0.5 per thousand) and ecstasy (MDMA 100 mg) on simulated driving performance and traffic safety*. *Psychopharmacology (Berl)*, 2012. **222**(3): p. 377-90.
727. Parrott, A.C., et al., *MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study*. *Psychopharmacology (Berl)*, 2011.
728. Stough, C., et al., *The acute effects of 3,4-methylenedioxymethamphetamine and d-methamphetamine on human cognitive functioning*. *Psychopharmacology (Berl)*, 2012. **220**(4): p. 799-807.
729. Stough, C., et al., *The acute effects of 3,4-methylenedioxymethamphetamine and methamphetamine on driving: A simulator study*. *Accid Anal Prev*, 2012. **45**(2): p. 493-7.
730. Hartman, R.L., et al., *3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration*. *Anal Bioanal Chem*, 2014. **406**(2): p. 587-99.
731. Schwaninger, A.E., et al., *Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans*. *Biochem Pharmacol*, 2012. **83**(1): p. 131-8.
732. Ludewig, S., et al., *No lasting effects of moderate doses of MDMA (Ecstasy) on memory performance and mood states in health humans*. *Biol Psychiatry*, 2003. **52 (Suppl)** . p. 205S.
733. Frei, E., et al., *Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA)*. *Hum Brain Mapp*, 2001. **14**(3): p. 152-65.
734. Vollenweider, F.X., et al., *Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans*. *Psychopharmacology (Berl)*, 1999. **143**(4): p. 365-72.
735. Chang, L., et al., *Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study*. *Psychiatry Res*, 2000. **98**(1): p. 15-28.
736. Jardim, A.V., et al., *3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil*. *Braz J Psychiatry*, 2020.